SYNTHETIC MULTIVALENT MOLECULES
SYNTHETIC MULTIVALENT MOLECULES Concepts and Biomedical Applications
SEOK-KI CHOI
A ...
44 downloads
1804 Views
6MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
SYNTHETIC MULTIVALENT MOLECULES
SYNTHETIC MULTIVALENT MOLECULES Concepts and Biomedical Applications
SEOK-KI CHOI
A JOHN WILEY & SONS, INC., PUBLICATION
Copyright 6 2004 by John Wiley & Sons, Inc. All rights reserved. Published by John Wiley & Sons, Inc., Hoboken, New Jersey. Published simultaneously in Canada. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, 978-646-8600, fax 978-750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best e¤orts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. For general information on our other products and services please contact our Customer Care Department within the U.S. at 877-762-2974, outside the U.S. at 317-572-3993 or fax 317-5724002. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print, however, may not be available in electronic format. Library of Congress Cataloging-in-Publication Data: Choi, Seok-ki, 1964– Synthetic multivalent molecules : concepts and biomedical applications / Seok-ki Choi. p. cm. Includes index. ISBN 0-471-56347-1 (cloth) 1. Multivalent molecules—Synthesis. 2. Multivalent molecules—Design. 3. Multivalent molecules—Physiological e¤ect. I. Title. RS431.M84 C48 2004 615 0 .31—dc22 2003020808 Printed in the United States of America 10 9 8 7 6 5 4 3 2 1
CONTENTS
Preface
xix
Notes for Organization and Classification
xxi
Abbreviations 1
Introduction
xxiii 1
1.1 Nomenclature and Definitions, 1 1.1.1 Valency, 1 1.1.2 Linkers, 3 1.1.3 Sca¤olds, 4 1.1.4 Ligand Density, 7 1.1.5 Homo- and Heterovalent Molecules, 7 1.2 Mechanistic Aspects of Multivalent Interaction, 9 1.2.1 A‰nity Constant and Avidity, 9 1.2.2 Thermodynamics, 12 1.2.3 Kinetics, 18 1.2.4 Steric E¤ects, 19 1.3 Biological Roles of Multivalent Ligands, 20 2
Multivalent Molecules Applied to Viral Targets
23
2.1 Influenza Virus, 23 2.1.1 Hemagglutinin, 23 2.1.1.1 Divalent Sialic Acid, 23 2.1.1.2 Tetravalent Sialoside, 26 2.1.1.3 Dendrimers Presenting Sialosides, 26 v
vi
CONTENTS
2.1.1.4 2.1.1.5
2.2
2.3 2.4 2.5
Sialic Acid Displayed in Liposomes, 29 Polymerized Liposome Presenting Sialic Acid, 32 2.1.1.6 Sialic Acid in Langmuir–Blodget Monolayers, 35 2.1.1.7 Sialic Acid Presented on Biopolymer Surfaces, 36 2.1.1.8 Poly(acrylamide) Presenting Sialosides, 36 2.1.1.9 Poly(acrylic acid) Presenting Sialosides, 37 2.1.1.10 Poly(acrylamide) Presenting C-Sialosides, 37 2.1.1.11 Postmodification of Activated Polymers, 38 2.1.1.12 Modes of Action of Polymeric Sialosides, 39 2.1.1.13 OPTCOL Assay, 40 2.1.1.14 ter-Poly(acrylic acid) Presenting Sialosides, 41 2.1.1.15 Poly(glutamic acid) Presenting Lysogangliosides, 42 2.1.1.16 Poly(glutamic acid) Bearing Sialic Acid– Containing Trisaccharides, 42 2.1.1.17 Poly(acrylamide) Bearing Sialic Acid Linked at the C4 Position, 44 2.1.1.18 Poly(acrylamide) Tethering 9-OAcetylsialosides, 45 2.1.1.19 Neoglycoprotein Displaying Sialic Acids, 45 2.1.1.20 Natural b-Inhibitors, 47 2.1.2 Neuraminidase, 47 2.1.2.1 Poly(glutamic acid) Presenting NA Inhibitors, 48 Human Immunodeficiency Virus, 49 2.2.1 HIV-1 Protease, 49 2.2.1.1 Divalent Terminal Peptides, 50 2.2.2 HIV-1 Reverse Transcriptase, 51 2.2.2.1 Heterodimers Composed of NRTI and NNRTI, 51 2.2.3 Glycoprotein 120 (gp120) on Viral Surfaces, 53 2.2.3.1 Neoglycoprotein-Displaying CD4 Peptide, 55 2.2.3.2 Galactosyl Ceramide Immobilized on Viral Surfaces, 55 2.2.3.3 Multivalent Anions, 57 2.2.3.4 Bivalent Antagonists of CXCR4, 59 2.2.4 Surface Carbohydrates on HIV, 60 2.2.4.1 Oligomannose Sugars Present on gp120, 60 2.2.4.2 Modes of CVN Recognition, 62 Rotavirus, 63 Polyoma Virus, 64 Picorna Virus, 65
CONTENTS
vii
2.6 Respiratory Syncytial Virus, 66 2.7 Dengue Virus, 67 2.8 Nucleic Acids of Viruses, 68 2.8.1 RNA–Protein Interactions, 68 2.8.1.1 Neomycin B Linked to Acridine, 69 2.8.1.2 Neamine Linked to Pyrene–Carboxylic Acid, 69 2.8.2 RNA–Enzyme Interactions, 70 2.8.3 Binders to the Minor Groove of Viral DNA, 71 2.8.3.1 Hairpin-Shaped Polyamide Dimers, 71 2.8.3.2 H-Shaped Polyamide Dimers, 73 2.8.3.3 Naturally Occurring Dimers, 74 2.9 Synthetic Multivalent Vaccines, 77 2.9.1 Peptide-Based Anti-influenza Vaccines, 77 2.9.2 Gp41-Based Anti-HIV Vaccine, 78 2.9.3 Peptide-Based Anti-FMDV Vaccines, 78 3
Multivalent Molecules Applied to Bacterial Targets 3.1 Targets in Bacterial Cell Membranes, 79 3.1.1 d-Ala-d-Ala Peptide Precursors, 79 3.1.1.1 Mode of Action by Antibiotics of the Vancomycin Class, 79 3.1.1.2 Dimerization of Glycopeptide Antibiotics, 82 3.1.1.3 Di- and Trivalent Vancomycin, 84 3.1.1.4 Cyclic Dimers of Eremomycin, 96 3.1.1.5 Polyvalent Vancomycin Constructs, 97 3.1.1.6 Heterobivalent Vancomycin Constructs, 99 3.1.1.7 Multivalent Vancomycin Mimics, 103 3.1.1.8 Catalytic Vancomycin Mimics, 104 3.1.1.9 Presentation of Glycopeptide Molecules on Bacterial Surfaces, 105 3.1.2 Lipid A, 108 3.1.2.1 Cholate-Based Polymyxin Mimics, 108 3.1.2.2 ter-Cyclopentane–Based Polymyxin Mimics, 109 3.1.2.3 Natural Multivalent Molecules Bound to Lipid A, 110 3.1.3 Helicobacter pylori Adhesin Receptor, 112 3.1.3.1 Synthetic Multivalent Inhibitors of H. pylori, 112 3.1.4 Streptococcus suis Hemagglutinin, 117 3.1.5 Escherichia coli FimH Adhesin, 117 3.1.5.1 Physical Forces Involved in Bacterium–Cell Adhesion, 118
79
viii
CONTENTS
3.1.5.2 Polyvalent Inhibitors of E. coli Adhesin, 119 3.1.5.3 Presentation of Mannosides on Gold Nanoparticles, 119 3.1.6 E. coli Chemoreceptors, 120 3.1.6.1 Polyvalent Galactosides as an E. coli Chemoattractant, 121 3.1.6.2 Polyvalent Glucosides in the Chemotaxis of Gram-Positive Bacteria, 124 3.1.7 Nonbacterial Lectins, 124 3.1.8 Staphylococcus aureus E¿ux Pumps, 125 3.2 Bacterial Toxins, 126 3.2.1 Heat-Labile Enterotoxins, 126 3.2.1.1 Pentavalent Galactosides, 127 3.2.1.2 Multivalent Inhibitors Displayed on a Solid Support, 128 3.2.2 Cholera Toxin, 129 3.2.2.1 Galactoside-Presenting Pentavalent Inhibitors, 130 3.2.2.2 Mode of Action of Pentavalent Galactosides, 133 3.2.2.3 Dendrimer-Based Multivalent Lactosides, 133 3.2.2.4 Polymerized Liposomes Incorporating GM1 , 133 3.2.2.5 Liposomes Presenting Fluorescent GM1 , 136 3.2.3 Shigalike Toxin, 136 3.2.3.1 Bivalent Pk Trisaccharides, 136 3.2.3.2 Decavalent Pk Ligands, 137 3.2.3.3 Polyvalent Polymeric Pk Ligands, 139 3.2.3.4 Multivalent Presentation of P1 on a Solid Support, 140 3.2.4 Verotoxin, 141 3.2.5 Bacillus anthracis Anthrax Toxin, 141 3.2.5.1 Polyvalent Peptide Inhibitors, 142 3.3 Bacterial Enzymes, 143 3.3.1 Transpeptidases, 143 3.3.1.1 Divalent Substrates, 143 3.3.1.2 Multivalent b-Lactams, 143 3.3.2 E. coli Pyrophosphokinase, 146 3.3.3 Protein Tyrosine Phosphatase, 147 3.3.4 DNA Gyrase, 147 3.3.5 Dihydrofolate Reductase, 148 3.3.6 Sialidase (Neuraminidase), 150 3.3.7 NAD Synthetase, 151 3.4 Bacterial Nucleic Acids, 152 3.4.1 Ribosomal RNA, 152
CONTENTS
ix
3.4.1.1 Divalent Aminoglycosides, 152 3.4.1.2 Divalent Aminoglycoside Bound to a Dimerized A-Site, 153 3.4.1.3 Polyvalent Polymeric Amikacin Derivatives, 154 3.5 Multivalent Molecules as Synthetic Vaccines, 155 3.5.1 Synthetic Shigella Vaccines, 155 3.5.2 Synthetic Mycobacterium Vaccines, 155 3.5.3 Carbohydrate Vaccines against Leishmaniasis, 156 3.5.4 Capsular Polysialic Acid Presented on Liposomes, 157 3.5.5 Multivalent Carbohydrate Antigens from Streptococcus, 158 3.6 Fungal Cells, 160 3.6.1 Covalent Dimer of Amphotericin B, 160 4
Multivalent Molecules Applied to Cellular Targets 4.1 Carbohydrate-Recognition Receptors on Cell Surfaces, 162 4.1.1 Hepatic Mannose/N-Acetylgalactosamine-4-SO4 Receptors, 162 4.1.1.1 Glycoprotein-Based Multivalent Ligands, 162 4.1.2 Hepatic Asialoglycoprotein Receptors, 164 4.1.2.1 Triantennary Galactosides, 164 4.1.2.2 Lysine-Based Multivalent NAcetylgalactosides, 164 4.1.2.3 Trivalent Galactoside–Cholesterol Conjugates, 165 4.1.2.4 Trivalent Galactosides for Cell-Specific DNA Delivery, 168 4.1.2.5 Multivalent Binding and Intracellular Tra‰cking, 169 4.1.3 Mannose-Binding Proteins, 169 4.1.3.1 Bivalent Mannosides, 171 4.1.3.2 Mannose-Presenting Neoglycoproteins, 172 4.1.3.3 GlcNAc-Presenting Polymer, 172 4.1.3.4 Mannoside Mimics, 173 4.1.4 Mannose 6-Phosphate Receptor (Insulinlike Growth Factor II), 174 4.1.4.1 Neoglycoprotein-Based Mannose-6Phosphate, 175 4.1.4.2 Biotin/Avidin-Based Tetravalent Mannose6-Phospate, 176 4.1.5 Galectins, 177
162
x
CONTENTS
4.1.6 4.1.7
4.1.8 4.1.9
4.1.10
4.1.11 4.1.12
4.1.13
4.1.14
4.1.15
4.1.5.1 Glycodendrimer, 177 Sialoadhesin CD22, 179 Dendritic Cell–Specific ICAM-3–Grabbing Nonintegrin, 180 4.1.7.1 Mannoside Clusters on Peptide and Protein Sca¤olds, 180 4.1.7.2 Lewis Saccharide–Presenting Dendrimers, 181 Spermatogenesis, 181 Sperm–Egg Interactions, 182 4.1.9.1 Bindin, 182 4.1.9.2 b-1,4-Galactosyltransferase, 183 4.1.9.3 Fertilin b, 183 4.1.9.4 XL35 Lectin, 183 Fucose-Binding Receptor on Cancer Cells, 184 4.1.10.1 Fucose–Batracylin Conjugate Based on Neoglycoprotein, 184 4.1.10.2 Liposomes That Display GM3 –lac Ceramide, 185 Fibroblast Growth Factors, 186 Carbohydrate–Carbohydrate Interactions at Cell Surfaces, 186 4.1.12.1 Gg3 –GM3 Interaction, 186 4.1.12.2 Aggregation Factors of Marine Sponges, 187 4.1.12.3 Le x –Le x Interaction, 188 E-Selectin, 188 4.1.13.1 Divalent Sialyl Lewis x, 189 4.1.13.2 Trivalent Sialyl Lewis x Constructs, 189 4.1.13.3 Neoglycoproteins Displaying Sialyl Lewis x Ligands, 191 4.1.13.4 Liposomes Displaying Sialyl Lewis x, 192 4.1.13.5 Polyvalent Polymeric Sialyl Lewis x, 195 4.1.13.6 Sialyl Le x –Binding Multivalent Receptors, 198 L-Selectin, 198 4.1.14.1 Divalent Sulfated Lactoside, 200 4.1.14.2 Neoglycopolymers Presenting Sialyl Le x , 201 4.1.14.3 Poly(acrylamide) Sca¤olds That Present Sulfated Le x , 203 4.1.14.4 Poly(lactosamine) Sca¤olds That Present SLe x , 203 P-Selectin, 204 4.1.15.1 Sialyl Lewis x-RGD Conjugates, 205
CONTENTS
Copolymers Presenting Sialyl Le a Residues and Sulfated Tyrosines, 205 4.1.15.3 Neoglycopolymers Presenting Sulfated Galactosides, 206 4.1.15.4 Polymerized Liposomes Presenting Mimetics of Sialyl Lewis x, 206 4.1.16 Lectins, 209 4.1.16.1 Oligovalent Mannosides Binding to Con A, 209 4.1.16.2 Trivalent Mannosides on a Rigid Sca¤old, 209 4.1.16.3 Bifunctional Multivalent Glycosides Binding to Con A, 211 4.1.16.4 Heptavalent Mannosides Linked to bCyclodextrin, 211 4.1.16.5 Mannosides Displayed on a Benzene- or Peptide-Based Dendrimer, 211 4.1.16.6 Poly(oxanorbornene) Presenting Glucosides, 215 4.1.16.7 Poly(norbornene) Derivatives Bearing Two Types of Ligands, 217 4.1.16.8 Glycopolymer-Mediated Cell–Cell Adhesion, 217 4.1.16.9 Mannosides Displayed on Self-Assembled Monolayers, 218 4.1.16.10 Multivalent Galactosides Binding to Bauhinia purpurea Lectin, 218 4.1.16.11 Dendritic Sialosides Binding to Limax flavus Lectin, 219 4.1.16.12 Dendritic GlcNAc Binding to Wheat Germ Agglutinin, 220 4.1.16.13 Cyclodextrin-Based Multivalent Glucosides Binding to Pisum sativum Lectin, 222 4.1.16.14 Oligovalent Mannosides Binding to Dioclea grandiflora Lectin, 223 4.1.16.15 Polymeric Polyvalent Lactosides Binding to Psophocarpus tetragonolobus Lectin, 225 4.1.16.16 Resin-Displayed Multivalent Galactosides Binding to RCA Lectin, 225 4.1.16.17 Liposome-Based Multivalent Galactosides Binding to RCA Lectin, 226 4.1.16.18 Multivalent Display of Saccharides on Microtiter Well Surfaces, 227 4.2 Peptide and Hormone Recognition Receptors on Cell Surfaces, 228 4.1.15.2
xi
xii
CONTENTS
4.2.1
CD14 Glycoprotein, 228 4.2.1.1 Poly(acrylamide) Displaying Muramyl Dipeptides, 228 4.2.2 Major Histocompatibility Complex, 229 4.2.2.1 MHC Peptides Tethered to a Peptide Sca¤old, 229 4.2.3 Integrins, 231 4.2.3.1 Poly(norbornene) Presenting RGD and PHSRN Sequences, 231 4.2.3.2 GRGDS Displayed on Polystyrene Beads, 232 4.2.3.3 RGD Peptides Presented on SAMs, 233 4.2.3.4 Polymeric Nanoparticles Displaying av b3 Antagonist, 233 4.2.3.5 Divalent Antagonist of Integrin av b3 , 234 4.2.4 Immunoglobulin, 235 4.2.4.1 Pentavalent Peptides, 236 4.2.5 Estrogen Receptors, 236 4.3 Ligand-Mediated Receptor Dimerization, 236 4.3.1 Chemical Inducers of Dimerization, 236 4.3.1.1 Natural Heterodimerizers, 237 4.3.1.2 FK506 Dimer (FK1012), 238 4.3.1.3 FK506 Mimetics and CIDs, 239 4.3.1.4 Cyclosporin Dimer, 240 4.3.1.5 Heterodimeric CIDs Composed of FK506 and Cyclosporin, 241 4.3.1.6 Heterodimeric CIDs Composed of FK506 and SH2 Ligands, 241 4.3.1.7 Bivalent Ligands Binding to FKBP, 245 4.3.1.8 Rapamycin-Mediated Association of Inteins, 245 4.3.2 Cytokine Receptors, 246 4.3.2.1 Divalent EPO Mimetics, 247 4.3.2.2 Divalent Peptide Antagonists of IL-5, 247 4.3.2.3 Dimeric Mimetics of G-CSF, 247 4.3.2.4 Dimeric Mimetics of NT-3, 249 4.3.3 Vitamin D3 Receptors, 250 4.4 Enzymes, 250 4.4.1 Acetylcholinesterase, 250 4.4.1.1 Tetrahydroacridine Dimer, 250 4.4.1.2 Huperzine Dimer, 252 4.4.1.3 Surface Anchoring, 252 4.4.2 Matrix Metalloproteinases, 252 4.4.3 Tryptase, 253
CONTENTS
4.4.3.1
Bivalent Inhibitors Tethered to Cyclodextrin, 254 4.4.3.2 Bivalent Inhibitors Tethered to Diketopiperazine, 255 4.4.3.3 Benzamidine-Based Divalent Inhibitors, 255 4.4.4 Proteasomes, 256 4.4.4.1 Multivalent Nature of Proteasomes, 256 4.4.4.2 PEG-Linked Tripeptide Dimers, 257 4.4.5 Protein Kinase C, 258 4.4.5.1 Divalent Nature of Protein Kinase C, 258 4.4.5.2 Phorbol Dimers, 258 4.4.6 Syk Protein Tyrosine Kinase, 259 4.4.7 Protein Tyrosine Phosphatases, 259 4.4.7.1 Phosphophenol Dimers, 259 4.4.7.2 Divalent Tetronic Acids, 261 4.4.8 Human Leukocyte Elastase, 261 4.4.9 Thrombin, 261 4.4.10 Glucoamylase, 262 4.4.10.1 Acarbose Linked to b-Cyclodextrin, 262 4.4.11 Glycosyltransferase, 264 4.4.11.1 Divalent Inhibitors of a1,3-Galactosyltransferase, 264 4.4.11.2 Divalent Inhibitors of b1,4-Galactosyltransferase, 264 4.4.11.3 Divalent Inhibitors of a1,2-Fucosyltransferase, 266 4.4.11.4 Divalent Inhibitors of Sialyltransferase, 266 4.4.12 Riboflavin Synthase, 267 4.4.12.1 Lumazine Dimers, 267 4.4.13 Lactate Dehydrogenase, 267 4.4.13.1 Enzyme Oligomerization, 267 4.4.13.2 Cyclodextrin Dimers, 268 4.4.14 Zinc-Dependent Enzymes, 269 4.4.14.1 Histone Deacetylase, 269 4.4.14.2 Carbonic Anhydrase, 270 4.5 G-Protein-Coupled Receptors, 270 4.5.1 b-Adrenergic Receptors, 270 4.5.1.1 Divalent Ligands of b-AR, 271 4.5.1.2 Isoproterenol Presented on Polypeptides, 272 4.5.1.3 Practolol Dimers, 272 4.5.1.4 Propranolol Dimers, 272 4.5.1.5 Alprenolol Displayed on Dextran, 273 4.5.2 a-Adrenergic Receptors, 274
xiii
xiv
CONTENTS
4.5.2.1 Prazocin Dimers, 274 4.5.2.2 Yohimbine Dimers, 275 4.5.3 Opioid Receptors, 275 4.5.3.1 Oxymorphamine Dimers, 276 4.5.3.2 Bivalent Bridging, 276 4.5.4 Serotonin Receptors, 277 4.5.4.1 Carboxamidoindole Dimers, 278 4.5.4.2 Sumatriptan Dimer, 278 4.5.4.3 Divalent SERT Inhibitors, 278 4.5.4.4 Serotonin Displayed on Nanocrystals, 280 4.5.5 Muscarinic Acetylcholine Receptors, 280 4.5.5.1 Quinnuclidine Dimers, 280 4.5.6 Melanocortin-1 Receptor, 281 4.5.6.1 Divalent a-MSH Peptides, 281 4.6 Ion Channels, 282 4.6.1 Cyclic Nucleotide-Gated Channels, 282 4.6.1.1 Cyclic Nucleotides, 282 4.6.1.2 PEG-Linked cGMP Dimers, 282 4.6.2 IP3 -Gated Calcium Channels, 283 4.6.2.1 PEG-Linked IP3 Dimers, 283 4.6.3 Potassium Channels, 284 4.6.3.1 Bisquinolinium, 284 4.6.4 Nicotinic Acetylcholine Receptor, 285 4.6.4.1 Succinyldicholine, 285 4.7 Nucleic Acids, 286 4.7.1 DNA Intercalators, 286 4.7.1.1 Antraquinone Linked to an Aminosugar, 286 4.7.1.2 Daunorubicin Dimer, 287 4.7.1.3 Bisacridine, 288 4.7.1.4 Naphthalimide Dimers, 290 4.7.2 Minor Groove Binders, 291 4.7.2.1 Calicheamicin-Based Dimers, 291 4.7.2.2 Mitomycin Dimers, 292 4.7.2.3 Cyclopropa[c]pyrrolo [3,2-e]indole Dimers, 293 4.7.2.4 Pyrrolo[2,1-c][1,4]benzodiazepine Dimers, 294 4.7.2.5 PBD-Containing Heterodimers, 295 4.7.2.6 DNA-Binding Polyamides, 295 4.7.2.7 H-Shaped Polyamide Dimers, 296 4.7.2.8 Hairpin-Shaped Polyamide Dimers, 297 4.7.2.9 Hairpin-Shaped Extended Polyamides, 299 4.7.2.10 Ring-Shaped Polyamide Dimers, 299 4.7.2.11 Tetravalent Polyamides, 299
CONTENTS
xv
4.7.2.12
Polyamide–DNA Alkylator Conjugates, 299 4.7.2.13 Polyamides Linked to Camptothecin, 300 4.7.2.14 Polyamides Linked to Transcription Activators, 301 4.7.3 Divalent Recognition at Abasic Sites, 303 4.7.3.1 Adenine Tethered to Acridine, 304 4.7.4 Divalent Binding to Guanine–Guanine Pairs, 304 4.7.4.1 Naphthyridine Dimers, 304 4.7.5 Basic Leucine Zipper Proteins, 304 4.7.5.1 bZIP-Derived Peptide Dimers, 304 4.7.5.2 Divalent bZIP Moieties Linked to Chiral Templates, 305 4.7.5.3 Divalent bZIP Moieties Tethered to an Azobenzene Sca¤old, 305 4.8 Antibodies, 306 4.8.1 Anticancer Vaccines, 306 4.8.1.1 Tumor Cell Marker, 306 4.8.1.2 Globo-H Presented on Keyhole Limpet Hemocyanin, 307 4.8.1.3 GM3 Presented on Bovine Serum Albumin, 309 4.8.1.4 GM2 Presented on KLH, 310 4.8.1.5 TN Clusters Presented on KLH, 310 4.8.1.6 TF -Presenting Dendrimers, 312 4.8.1.7 Neoglycoproteins Presenting Multiple Tumor-Associated Antigens, 312 4.8.2 Surface Epitopes Not Related to Cancer, 313 4.8.3 Miscellaneous Epitopes, 314 4.9 Cell Surface Engineering, 315 4.9.1 Metabolic Incorporation of Unnatural Carbohydrate Antigens, 315 4.9.1.1 N-Butanoylsialic Acid, 316 4.9.1.2 N-Levulinoyl Neuraminic Acid, 316 4.9.1.3 Azidoacetyl Neuraminic Acid, 319 4.9.2 (Bio)chemical Modification of Cell Surface Antigens, 320 5
Chemical Synthesis of Multivalent Molecules 5.1 Selected Synthetic Methods for Multimerization, 321 5.1.1 Summary of Linker Chemistry, 321 5.1.2 Polymerization, 323 5.1.3 Self-Assembly, 325 5.1.4 Solid-Phase Synthesis, 325
321
xvi
CONTENTS
5.2 Combinatorial Chemistry, 325 5.2.1 Structure-Biased Combinatorial Synthesis, 325 5.2.1.1 Hetrodimeric Inhibitors of Picorna Virus, 325 5.2.1.2 Polyvalent Inhibitors of Influenza Virus, 327 5.2.1.3 Heterodimeric Inhibitors of NAD Synthetase, 328 5.2.1.4 Disulfide-Linked Heterodimers, 328 5.2.2 Target-Guided Combinatorial Synthesis, 330 5.2.2.1 FK-506 Binding Protein, 330 5.2.2.2 Caspase, 331 5.2.2.3 c-Src Kinase, 332 5.2.2.4 Acetylcholine Esterase, 333 5.2.2.5 Carbonic Anhydrase, 334 5.2.2.6 Kallikrein, 334 5.2.3 Dynamic Combinatorial Synthesis, 334 5.2.3.1 Disulfide Exchange, 336 5.2.3.2 Olefin Metathesis, 336 5.2.3.3 Transition Metal Complexes, 337 Appendix Table 1. Table 2. Table 3. Table 4. Table 5. Table 6. Table 7. Table 8. Table 9. Table 10. Table 11. Table 12. Table 13. Table 14.
339 Divalent Ligands Linked to Enzymes in Human Immunodeficiency Virus (HIV), 339 Multivalent Ligands Linked to gp120 Surface Receptors in Human Immunodeficiency Virus, 340 Multivalent Ligands Linked to Surface Receptors on Viruses, 341 Multivalent Receptors Targeting Multivalent Ligands in Bacterial Cell Walls, 343 Multivalent Ligands Targeting Bacterial Receptors in Membrane Surfaces, 344 Multivalent Ligands Linked to Bacterial Toxins, 345 Multivalent Molecules Targeting Bacterial Enzymes, 346 Multivalent Ligands Targeting Carbohydrate-Recognition Receptors on Cellular Surfaces, 347 Multivalent Ligands Targeting NoncarbohydrateRecognition Receptors on Cellular Surfaces, 350 Multivalent Ligands Linked to Selectins on Cell Surfaces, 352 Multivalent Ligands Linked to Lectins, 354 Multivalent Ligands Linked to Cellular Enzymes, 357 Multivalent Ligands Linked to G-Protein-Coupled Receptors (GPCRs), 359 Multivalent Ion Channel–Binding Molecules, 360
CONTENTS
xvii
Table 15. Homo- and Heterodivalent Chemical Inducers of Dimerization (CIDs), 361 Table 16. Multivalent Ligands Linked to Nucleic Acids, 362 Table 17. Synthetic Multivalent Antigens, 365 Table 18. Multivalent Ligands Displayed on Self-Assembled Monolayer (SAM) Made of Alkanethiolate on Gold, 367 Table 19. (Bio)chemical Modification of Cell Surface Antigens, 368 Table 20. Multivalent Targets, 369 References
371
Index
409
PREFACE
This book presents basic and advanced principles underlying the multivalent interactions that are prevalent in biological systems. To illustrate important or complex concepts, the book provides up-to-date examples of synthetic multivalent molecules, their design, and their biological benefits. Functional roles displayed by such molecules of both natural and synthetic origin are well documented in biology, where they exert unique and crucial activities at a level not readily achievable by monovalent molecules. The concept of multivalent design is now accepted as an e¤ective strategy—in particular, for designing ligands, inhibitors, and drugs that influence biological systems potently and selectively. Over the past 15 years, diverse diciplines have generated a growing interest in the biomedical application of multivalent design. The goal of this book is to share the findings in this exciting area of research by providing a systematic summary of experimentally tested case studies of multivalency. I believe that a single book serves best to collect such scattered research material in one place and to discuss it in a consistent and introductory format. The book focuses on practical examples of synthetic multivalent molecules reported broadly in the literature. It consists of five chapters. In Chapter 1 I introduce the multivalent molecule and its structural elements, describe the mechanistic basis that accounts for the benefits of multivalent interaction, and provide a short summary of biological functions displayed by multivalent molecules. In Chapters 2 to 4 I provide practical examples derived from biological targets in viral, bacterial, and mammalian cells, respectively. In each chapter I review in a similar format the design concept, synthesis, and biological activity of multivalent molecules: in particular, those of synthetic origin. xix
xx
PREFACE
Typically, the chapter format begins with a brief description of a target from a structural and functional viewpoint to provide a rationale for multivalent design, followed by the main discussion. In Chapter 5 I summarize various aspects of synthetic methods used in the synthesis of multivalent molecules, and I conclude with a summary of combinatorial approaches developed in the library design of multivalent molecules. The book ends with an appendix that presents tabular summaries of both examples treated in this book and untreated. The targets selected for discussion are comprehensive but, of course, do not purport to be a complete list. The book is written for a broad community of audiences, comprising educators, graduate students, and professional researchers in academia and the (bio)pharmaceutical industry, particularly those who perform interdisciplinary research in organic chemistry, chemical biology, biological chemistry, medicinal chemistry, pharmacology, and medicine. Specifically, it would be most valuable as a reference book for those scientists interested in finding new ideas and developments in areas of receptor–ligand interaction, carbohydrate-based medicines, enzyme inhibitors, toxin inhibitors, DNA(RNA)–drug association, antibiotics, antiviral agents, anti-inflammatory drugs, and anticancer therapeutics. It is my pleasure to express great gratitude to Professor Koji Nakanishi of Columbia University, who introduced me to the importance of multidisciplinary bioorganic studies and encouraged this publication. I am also indebted to Professor George M. Whitesides of Harvard University and sincerely appreciate his directing me to continue research in multivalency. In 1996, Professor Whitesides and several colleagues, including Professor John Gri‰n of Stanford University, Dr. Mathai Mammen of Harvard, and James Tananbaum of Sierra Ventures, founded Advanced Medicine, Inc. to develop opportunities in multivalent drug research and development. I joined Advanced Medicine in 1997 to help further develop ideas in multivalent drug design. Today, Advanced Medicine has evolved into a vibrant pharmaceutical company, Theravance, Inc., under the guidance of our Chairman, Roy Vagelos (former CEO of Merck Pharmaceuticals), and current CEO, Rick Winningham. I am indebted to my colleagues at Theravance for ongoing collaborations in medicinal chemistry. In particular, I am sincerely thankful to Dr. Ed Moran, Dr. Thomas Jenkins, and Dr. Mathai Mammen for their editorial assistance with this manuscript. I am also very grateful to Professor Fred Brewer at Albert Einstein College of Medicine and Dr. Obadiah Plante at Ancora Pharmaceuticals for their valuable comments during the review process. Publication of this book would not have been possible without the support and patience of Hyun-Joo, Gilbert, and other family members. Finally, I wish to thank the editors and sta¤ members at John Wiley & Sons, particularly Jonathan T. Rose, for their e¤orts to complete this project smoothly and in a timely manner. Palo Alto, California
Seok-Ki Choi
NOTES FOR ORGANIZATION AND CLASSIFICATION
Given diverse aspects of classification related to multivalent ligands and inhibitors, I wish to provide a road map to the structure and organization of this book. Its main contents consist of three chapters that are divided according to the origin of targets: viruses (2), bacteria (3), or mammalian cells (4). Within this division, materials are grouped further on the basis of target class and structural composition of multivalent molecules. Therefore, typical headings of each chapter start with an organism (e.g., influenza virus), proceed to a description of a target under a certain class (receptor: hemagglutinin), followed by a discussion of a group of multivalent molecules (e.g., divalent, trivalent, polyvalent, . . . , sialic acid). Under such a format, multivalent ligands from the same class can be reviewed collectively and comparatively as to their design concept, synthesis, and biological activity. A short outline of each chapter is given below. Chapter 2 covers multivalent examples from viral targets such as influenza virus and the human immunodeficiency virus (HIV). Several classes of multivalent inhibitors targeting viral surface proteins (influenza hemagglutinin), enzymes (influenza neuraminidase, HIV-protease), and nucleic acids (as intercalators and as binders at minor or minor groove) are presented. The chapter ends with a summary of synthetic multivalent antigens that are designed to mimic the surface of influenza, HIV, or foot-and-mouth disease virus. Chapter 3 focuses on bacterial cells, a pathogenic system that proves to be well validated for a multivalent approach. This chapter provides ample examples of multivalent inhibitors that display enhanced activity against a wide range of receptors or ligands expressed on a bacterial surface (d-ala-d-ala, lipid A, adhesins), toxins (cholera, anthrax), enzymes (transpeptidase), and nucleic acids (ribosomal RNA). xxi
xxii
NOTES FOR ORGANIZATION AND CLASSIFICATION
Chapter 4 treats multivalent molecules that inhibit or modulate mammalian cells. The list of tested macromolecular targets is extensive. Selected examples include surface receptors (hepatic asialoglycoprotein receptor, selectins), enzymes (acetylcholine esterase), G-protein-coupled receptors (opioid receptor), and ion channels (cyclicnucleotide-gated channel). Applications in nucleic acid are demonstrated by a daunorubicin dimer acting as a DNA intercalator, and a hairpin-shaped polyamide dimer acting as a minor groove binder. In addition, several types of synthetic vaccines are illustrated, including multivalent globoH presented on protein carrier as the one mimicking cancer cell surface. Discussion of such diverse cellular targets should help to better understand multivalent concepts and applications in drug development. Finally, the organization of the book aims for easy access to and concise comparison of multivalent molecules for a given receptor. However, readers might be interested in looking at the features of multivalent molecules organized from di¤erent aspects regardless of their target families, functions, or cellular origins. In a sense, it might be useful to compare multivalent design methods within a broadly defined boundary based on target location (membrane-bound versus soluble) and target valency (divalent, trivalent, . . . , multivalent). The nature of assembly of multivalent sites is considered to be important as well, such that targeting to a single-subunit multivalent receptor can be distinguished from a multisubunit receptor complex composed of either identical subunits (homo) or di¤erent subunits (hetero). To complement such interesting features, a table (Table 20) is given in the appendix as a cross-reference to present such information for major targets: for example, whether they are membrane-bound, soluble, homo-trivalent, or hetero-divalent. Readers are advised to utilize these additional aspects of classification when selecting materials.
ABBREVIATIONS
ACE AChE Ala AmB b-AR ASGP-R AT-III AZT BChE BSA bZIP CA-II Caspase-3 CD Ce¤ cGMP CID CNG Con A CPMV CRD CsA
a‰nity capillary electrophoresis acetylcholine esterase alanine amphotericin B b-adrenergic receptor asialoglycoprotein receptor antithrombin III azidothymidine butyrylcholinesterase bovine serum albumin basic leucine zipper protein carbonic anhydrase II cysteine aspartyl protease-3 cyclodextrin e¤ective local concentration cyclic guanosine monophosphate chemical inducer of dimerization cyclic nucleotide-gated (CNG) concanavalin A cowpea mosaic virus carbohydrate-recognition domain cyclosporin A xxiii
xxiv
ABBREVIATIONS
CTB CVN DC-SIGN DHFR DLS EC EGFR ELAM-1 ELISA EPO-R ERK FGF FKBP FMDV FRAP Gal Gal cer GalNAc GalTase G-CSF GGBP Glc Glc cer GlcNAc GlyCAM-1 gp120 GPCR GPI HA HAI HIV HLE HMPA HPPK HT IC50 ICAM-3 IgG
cholera toxin B subunit cyanovirin-N dendritic cell–specific ICAM-3 grabbing nonintegrin dihydrofolate reductase dynamic light scattering e¤ective concentration epidermal growth factor receptor endothelial leukocyte adhesion molecule-1 enzyme-linked immunosorbent assay erythropoietin receptor extracellular regulated kinase fibroblast growth factor FK506-binding protein foot-and-mouth disease virus FKBP-12-rapamycin-associated protein galactose galactosylceramide N-acetylgalactoside galactosyltransferase granulocyte-colony-stimulating factor glucose–galactose binding protein glucose glucosylceramide N-acetylglucosamine glycosylated cell adhesion molecule-1 glycoprotein 120 G-protein-coupled receptor glycosylphosphatidylinositol hemagglutinin hemagglutination inhibition human immunodeficiency virus human leukocyte elastase N-(2-hydroxypropyl)polymetharylamide 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase 5-hydroxytryptamine or serotonin concentration at 50% inhibition intracellular adhesion molecule-3 immunoglobulin G
ABBREVIATIONS
IgM IL-5 IP3 ITC JCP Ka Kd Ki K HAI i Km ko¤ kon KLH Lac cer L–B LDL Leb Lex LPS mAChR Man MBP MDR MHC MIC MMP a-MSH MTX NA nACh-R NAD NeuAc NNRTI NRTI NT-3 PA pA pAA
immunoglobulin M interleukin-5 inositol 1,4,5-triphosphate isothermal titration calorimetry jelly coat glycoprotein association constant dissociation constant inhibition constant hemagglutination inhibition constant Michaelis constant rate of dissociation rate of association keyhole limpet hemocyanin lactosylceramide Langmuir–Blodgett low-density lipoprotein Lewis b Lewis x lipopolysaccharide muscarinic acetylcholine receptor mannose mannose-binding protein multidrug resistance major histocompatibility complex receptor minimal inhibition concentration matrix metalloproteinase a-melanocyte-stimulating hormone methotrexate neuraminidase nicotinic acetylcholine receptor nicotine adenine dinucleotide N-acetylneuraminic acid (sialic acid) non-nucleoside-based reverse transcriptase inhibitor nucleoside-based reverse transcriptase inhibitor neurotrophin 3 protective antigen poly(acrylamide) poly(acrylic acid)
xxv
xxvi
ABBREVIATIONS
PAMAM PBP PEG PKC PNA pNAS PSA PSGL-1 PTPase RCA RGD RNase S ROMP RRE RSV RT SA SAM SIV SLea SLex SLT SNP SPR SSRI TAR VHR VP VRE VSE WGA ZP
poly(amide amine) penicillin-binding protein poly(ethylene glycol) protein kinase C peptide nucleic acid poly(N-acryloyloxysuccinimide) poly-a2,8-sialic acid P-selectin glycoprotein ligand-1 protein tyrosine phosphatase Ricinus communis agglutinin Arg-Gly-Asp ribonuclease S ring-opening metathesis polymerization rev-response element respiratory syncytial virus reverse transcriptase sialic acid self-assembled monolayer simian immunodeficiency virus sialyl Lewis a sialyl Lewis x Shigalike toxin single-nucleotide polymorphism surface plasma resonance selective serotonin reuptake inhibitor transactivator-response RNA element vaccinia VH1–related phosphatase viral protein vancomycin-resistant enterococci vancomycin-susceptible enterococci wheat germ agglutinin zona pellulcida
1 INTRODUCTION
1.1 1.1.1
NOMENCLATURE AND DEFINITIONS Valency
According to Mammen et al. [1], the valency of a molecule, or that of a biological entity such as a cell, virus, or bacterium, represents the number of separate structural units of the same or a similar type that are connected to the molecule or entity. Thus, if a molecule presents two tethered, identical copies of binding elements, such as a ligand, it is classified as a divalent molecule (ligand). Schematic examples are provided in Figure 1.1 to describe the concept of valency in the context of receptor and ligand interaction. For example, divalent binding occurs when a divalent ligand associates with a divalent receptor through the simultaneous interaction established between two receptor–ligand pairs. Similarly, multivalent or polyvalent interactions are defined as specific simultaneous associations of multiple ligands present on a molecular construct or biological surface that bind to multiple receptors presented on a complementary entity. The classification of multivalent molecules presented above is simply based on the structural aspects of molecules, such as the number of structurally identical ligands per multivalent construct; hence, the term structural valency is used to classify such molecules. However, not all ligands present on a multivalent molecule are involved in interactions with a multivalent receptor displaying
Synthetic Multivalent Molecules: Concepts and Biomedical Applications, By Seok-Ki Choi ISBN 0-471-56347-1 Copyright 6 2004 John Wiley & Sons, Inc.
1
2
INTRODUCTION
monovalent ligand
monovalent receptor
divalent ligand
divalent receptor
divalent association
n multivalent receptor
multivalent association
n multivalent ligand
trivalent ligand (structural valency)
trivalent receptor
monovalent association
n
divalent association (functional valency)
Figure 1.1 Definitions of structural and functional valence as illustrated in monovalent, divalent, and multivalent (polyvalent) interaction.
multiple sites, and a certain portion of the tethered ligands are functionally inactive (Figure 1.1). Thus, for a particular multivalent receptor–ligand association, the valency of a multivalent ligand is not necessarily equivalent to its structural valency. This property is described by Dam et al. [2] as functional valency. The concept of functional valency is of significant interest; however, it has been explored in only a limited number of studies. In this book the valency of a multivalent molecule normally refers to structural valency unless its functional valency is available otherwise. Multivalent interactions are now understood to be a ubiquitous strategy that has evolved in nature for a wide range of functions, including selective recognition of multivalent antigens by antibodies [3] (e.g., bivalent anti-DNP IgG [4], decavalent IgM, bivalent anticardiolipin antibody binding to b2 glycoprotein I lipoprotein [5]), neutrophil adhesion and rolling on the surface of an activated endothelial cell [6], and the tight adsorption of a virus particle or bacterium to a host cell surface [7–9] (Figure 1.2). These multivalent interactions are more potent and selective over the analogous monovalent interaction and are therefore only weakly inhibited by most monovalent ligands, especially when the binding cleft for the monovalent ligand is shallow. When designing inhibitor molecules to interfere with multivalent interactions, the most e¤ective strategy is to use multivalent molecules. Such multivalent molecules proved to be highly potent inhibitors: in particular, against surface– surface interaction as observed in virus–cell and cell–cell adhesion (Figure 1.2) [10,11].
NOMENCLATURE AND DEFINITIONS
3
IgG
antigenic surface virus (bacterium)
multivalent ligand
multivalent ligand
cell surface
cell multivalent ligand
cell surface
Figure 1.2 Representative examples of natural multivalent interactions and their synthetic multivalent inhibitors.
1.1.2
Linkers
The synthesis of multivalent molecules is performed by tethering multiple copies of a ligand or binding element with a linker. A linker provides not only a covalent connection but also appropriate spacing between tethered ligands such that multiple receptor–ligand pairs interact simultaneously without being forced to mismatch. A linker used for a multivalent molecule has to be stable chemically, biochemically, and enzymatically. In contrast, many linkers used in bioconjugate molecules, such as those designed into prodrugs or delivery tools [12], must be chemically or enzymatically labile in order to provide the release of monovalent drugs at a certain stage or site after delivery into a biological system. In addition, the use of linker in prodrugs is not intended for modulation of binding activity of prodrugs such that covalently attached ligands from prodrugs may not bind to its receptor in either monovalent or multivalent fashion until its ligands are released free. The linker must be at least a neutral contributor to biological activity, so as not to interfere with the intrinsic activity of the tethered ligand. In some cases, the linker may even contribute favorably provided that productive contacts are made between the linker and the target surface.
4
INTRODUCTION
In this book, the terms linkers and spacers are used interchangeably. A linker needs to be designed taking a number of factors into account, such as linker length between connected ligands, conformational property (i.e., flexible, rigid), and the nature of linker functional groups (e.g., amide, ether, amine). As long as the linker is long enough to allow bivalent occupation of tethered ligands at receptor sites, a rigid linker contributes more favorably to tight association than does a flexible one, as predicted from considering the conformational entropy of linkers, examined by Mammen et al. [13]. This is because a large number of linker configurations existing in the unbound state are going to a single configuration in the bound state, a thermodynamic feature associated with an entropic cost. Therefore, the larger the initial number of configurations, the greater this cost. A very important assumption, however, is that the rigid linker orients the ligands such that multivalent binding is possible. With this assumption, an unsaturated or aryl-incorporated linker, for example, experiences a lower conformational entropic cost upon association than does a saturated or thioether-containing flexible linker. Amide- and ether-based linkers provide an intermediate flexibility. However, the entropic e¤ect is often accompanied by an enthalpic contribution to the free energy of binding since the linker itself is able to participate in interaction with the receptor, or to contribute via a hydrophobic e¤ect by favorable transfer from an aqueous medium to a hydrophobic receptor domain. The experimental verification of such linker variation is discussed in later chapters. 1.1.3
Sca¤olds
Covalent linkage is a term generally associated with a sca¤olding or framework that serves as a molecular anchoring system where multiple chemically reactive sites are expressed as handles for ligand attachment. The valency and shape of a sca¤old exert a significant influence on the binding and functional ability of multivalent molecules that comprise such a sca¤old. Numerous classes of scaffold are commonly used in the design of multivalent molecules, as shown in Figure 1.3. Molecules of low valency (e.g., di- and trivalent molecules) are designed using a one-dimensional linear or branched chain. Examples include oligo(glycine)-spaced divalent sialoside as an influenza inhibitor [14], alkanespaced divalent sLe x as an E-selectin inhibitor [15], and Tris-linked trivalent lactoside as a ligand to the asialoglycoprotein receptor [16]. In addition to linear sca¤olding, multivalent molecules may also be built on a rigid and preorganized sca¤old that is well defined in structure, orientation, and conformation. Such a rigid system presents a known number of preassembled attachment sites that enables one to achieve the proper positioning between attached ligands. Rigid sca¤olds are found in diverse classes of molecular systems, ranging from small molecules [17] such as benzene and glucose, to macrocycles such as azacrown ether, to round molecules such as cyclodextrin and calix[n]arene. For example, azacrown ether proves to be an e¤ec-
NOMENCLATURE AND DEFINITIONS one-dimensional linear scaffold
5
rigid scaffold
scaffold linker ligand glucose benzene
branched scaffold
calixarene azacrown ether cyclodextrin macrocycle transition metal complex
flexible chain scaffold
polymer peptoid
multiantennary dendrimer (tree-like)
two- and three-dimensional surface scaffold
globular protein dendrimer latex bead nanocrystal (Au, Cd/Se)
micelle liposome self-assembled monolayer (Au) surface (silica, polystyrene, carbon nanotube)
Figure 1.3 Shape and size of various sca¤olds used in multivalent presentation.
tive framework for the activity of galactoside-presenting pentavalent ligands, which bind cholera toxin B pentamer very tightly [18]. Calix[n]arene consists of four (n ¼ 4), six (n ¼ 6), or eight (n ¼ 8) phenol units joined to form a vaselike structure (calix ¼ ‘‘vase’’ in Greek). Another well-known rigid system includes cyclodextrin, a cyclic oligosaccharide composed of six, seven, or eight a-d-glucose units, thus forming a-, b-, and g-cyclodextrin, respectively [19]. Sca¤olds such as cyclodextrin and calix[n]arene o¤er multiple repeats of a hydroxyl functional group located around the circumference of the narrow (primary) or the wide (secondary) face. These hydroxyl groups are readily derivatized for tethering ligands such as those based on carbohydrates [20–24]. The application of such rigid sca¤olds is represented by a heptavalent galactoside anchored on the primary face of b-cyclodextrin [25] and a tetravalent sialoside displayed on calix[4]arene. The surfaces of naturally occurring glycoproteins present multiple types of
6
INTRODUCTION
complex carbohydrates clustered in di- and triantennary configurations [26]. Such branched sca¤olds resemble a treelike structure that is classified as a dendrimer [27,28]. Compared to these natural glycodendrimerlike molecules, synthetic dendrimers o¤er templates that are more compact, with dense branching. Synthetic dendrimers allow the multivalent display of ligands in a medium range of valency (10- to <100-mer), thus filling the gap formed between relatively low valency (2- to 10-mer) and high valency (>100-mer in a polymer) [29–32]. Depending on branching pattern and core structure, some dendrimers adopt a large spherical or pseudospherical structure, whereas others take on the shape of a half sphere. For example, a hexadecavalent sialoside that strongly inhibits the adhesion of influenza virus to red blood cells is designed on the template of an oligo(lysine)-derived half-spherical dendrimer [33]. The synthesis of multivalent molecules designed on a polymer backbone is readily achieved by polymerizing a ligand monomer or by modifying a preformed polymer by conjugating it with the ligand [34]. A polymer sca¤old provides a high-valency (>100-mer) system that is di‰cult to construct by using repeated connections of linear and branched sca¤olding. Polymeric polyvalent molecules are highly e¤ective in interfering with multivalent interactions, in particular those involving interactions of complementary micrometer-scale surfaces. This high level of interfering activity is attributed primarily to tight binding of one surface, but also partially to a steric e¤ect, a second mode of action observed in certain multivalent systems [35]. This steric occlusion involves blocking the complementary surfaces from approaching one another due to the presence of the interfering ligand, even if that ligand is incompletely bound to one surface. Typical examples of polymeric polyvalent ligands are based on a flexible framework that includes poly(acrylamide). For instance, the sialic acid present in amide side chains of poly(acrylamide) acts as a potent inhibitor of virus–cell adhesion [36]. Other polyvalent examples are based on conformationally rigid sca¤olds, such as polymers of unsaturated framework prepared by ring-opening metathesis polymerization. A specific example of the latter class includes polymeric mannoside, which provides multiple copies of mannoside as an inhibitor of lectin-mediated hemagglutination [37]. Unlike the natural peptide backbone, peptoid is made of synthetic a-amino peptide units in which the side chains are linked at the amide nitrogen rather than at the a-carbon. The resulting tertiary amide both removes a hydrogen bond critical to secondary structure and introduces a second stable rotomer of the amide bond. Both e¤ects are probably responsible for the unique properties that distinguish peptoids from a peptide sca¤old. An example peptoid-based multivalent molecule is illustrated by an N-substituted oligo(glycine) presenting multiple copies of lactoside or mannoside as side chains [38]. Several classes of sca¤old mimic a two-dimensional plane or three-dimensional spherical surface, as shown in Figure 1.3. First, globular proteins such as human albumin constitute a type of adaptable sca¤old because they contain reactive functional groups such as lysine, which are useful for amide coupling, and tyrosine, which is reactive to diazonium molecule for diazo coupling [39].
NOMENCLATURE AND DEFINITIONS
7
These proteins are soluble in water and lack intrinsic glycosylation, thus permitting neoglycoprotein preparation. Self-assembled monolayers (SAMs) on gold comprise a two-dimensional planar surface that enables the presentation of multivalent molecules. This system mimics a cell surface in some aspects, but it lacks lateral mobility as observed in a cell surface. Sugar-displaying SAMs have been designed to study multivalent sugar–lectin interactions [40,41]. Similar systems may be used to model the surface for bacterium–mammalian cell adhesion [42,43]. Liposomes and vesicles allow multivalent display on a spherical surface and are commonly used to simulate cells. In such a system, lateral motion is permitted and allows a multivalent display to ‘‘adapt’’ to a complementary surface, much as may occur in cellular systems. The utility of liposomes and vesicles is demonstrated by several examples, including sialyl ganglioside displayed on a liposome as a potent inhibitor of influenza virus [44], and d-Ala-d-Ala peptide ligand presented on micelles to mimic bacterial cell surfaces [45]. Multivalent display on a larger round surface is possible by using nanometer-sized spheres made of latex, silica, or gold. For instance, polystyrene beads are available for derivatization with 6-sulfo sLe x as a selectin ligand to produce multivalent nanoparticles that can e¤ectively inhibit selectin-mediated attachment of a human embryo to the uterine wall [46]. 1.1.4
Ligand Density
Two or more di¤erent types of molecules can be presented simultaneously, in multiple copies, on the surface of a liposome or on the side chains of a polymer. By varying, for instance, the proportions of bioactive ligand and inactive residues, it is possible to change the biological activity of such molecules. The properties of such molecules are described in terms of surface density or ligand density for liposomes and polymers, respectively. For polyvalent polymers, ligand density is defined as the number of attached ligands relative to the total number of side chains per polymer molecule. For liposomes bearing ligands, the surface density is defined as the average number of ligands relative to the total number of functional groups, including ligands, exposed on the surface of a liposome particle. Pertinent examples are illustrated using multivalent sialic acid, shown as either poly(acrylamide) [47] or liposome [48] in Figure 1.4. Ligand density constitutes a critical factor to be considered when designing multivalent molecules because it broadly a¤ects ligand distribution, interligand distance, and the shape and conformation of the polymer. All of these properties help to modulate the biological activity of multivalent molecules. 1.1.5
Homo- and Heterovalent Molecules
Multivalent interactions can refer to the simultaneous association occurring between multiple, identical pairs of receptor and ligand; such interactions are homovalent. In contrast, multivalent interactions can occur between more than
8
INTRODUCTION poly(SA-co-acrylamide)
O R
n O O O O O O O R NH R R R NH R
OHOH AcHN HO HO
(R = NH2) O
OH
OH
HO O CO2O
HN
HN O
HN O
HN O
HN O
O HO
OH
HN O
HO NHAc OH OH O
OHHO
CO2O HN
O
N H -O2C HO
O
O OH
HO AcHN OH
-O2C HO
OH
HN OH N
O
liposome
O
OH
O
OH
HO AcHN OH spacing
Side-chain density of sialic acid (χSA)
Surface density of sialic acid (χSA)
= [SA]/ [acrylamide]total = 2/8 = 0.25 or 25%
= [SA]/ [amide]total = 2/10 = 0.20 or 20%
Figure 1.4 Definition of ligand density in polymer- and liposome-based multivalent molecules.
one kind of receptor and ligand; such interactions are heterovalent. As with homovalent interactions, formation of multiple ligand–receptor pairs should contribute to the increased association strength of the entire complex. Figure 1.5 illustrates the functionally bivalent association between a heterobivalent ligand and a heterobivalent receptor. Structurally, a heterodimeric molecule closely resembles a bifunctional molecule, as the latter is also composed of two di¤erent ligands tethered through a linker. However, a bifunctional molecule is designed to bind in a monovalent manner to two distinct target receptors widely separated or located in a di¤erent compartment of a cell.
homobivalent association
heterobivalent association
bifunctional molecule
monovalent association
Figure 1.5 Representation of homovalent and heterovalent interaction.
MECHANISTIC ASPECTS OF MULTIVALENT INTERACTION
9
monovalent association Ka
mono
+ ∆G1mono = -RTln(Kamono) multivalent association Kamulti + n
n
n
∆GNmulti = -RTln(Kamulti) where N = (n + 2)
Figure 1.6 Comparison of thermodynamic parameters of association in monovalent and multivalent interaction.
1.2 1.2.1
MECHANISTIC ASPECTS OF MULTIVALENT INTERACTION A‰nity Constant and Avidity
Multivalent and monovalent interactions di¤er fundamentally in their respective definitions and calculations of association strength [1]. For a monovalent system composed of a receptor and a ligand, the a‰nity constant (Ka ) is the binding strength for a monovalent complex (Figure 1.6). This term is related to the free energy of association (DG mono ) by the Gibbs equation below. In a multivalent interaction between two entities presenting N tethered ligands and N tethered receptors, the association constant is defined as avidity (Kamulti ). This constant is a collective association constant that takes into consideration multiple interactions between two multivalent entities, and it is related to the free energy of binding calculated as for monovalent binding: DG mono ¼ RT ln(Kamono ) DGNmulti ¼ RT ln(Kamulti ) In estimating cooperativity in multivalent association, the free energy of multivalent binding (DGNmulti ) can be related to that of N monovalent associations: that is, N DG mono , given N independent receptor–ligand interactions. The ratio between the two indicates the degree of cooperativity, where the cooperativity coe‰cient (a) is defined as follows: a ¼ degree of cooperativity ¼
DGNmulti N DG mono
Depending on the magnitude of a, multivalent interaction is positively cooperative or synergistic (a > 1), noncooperative or additive (a ¼ 1), or negatively cooperative (a < 1). The term cooperativity is often used in biological systems
10
INTRODUCTION
as with the hemoglobin tetramer–oxygen interaction, which shows positive cooperativity [49]. However, the term is rarely used in multivalent systems, partly because few multivalent systems have been shown to demonstrate positive cooperativity. Moreover, multivalent interaction can be much tighter than monovalent binding, regardless of the size of the cooperativity constant. In practical terms, the contribution of a multivalent association is often expressed by the ratio (b) of multivalent avidity to monovalent a‰nity constant, introduced by Mammen et al. [1] (Figure 1.6): b¼
Kamulti Kamono
Thus, b represents the enhancement factor, a term that reflects the strength of a multivalent association relative to the monovalent association. The di¤erence between a and b is illustrated by a trivalent system based on a vancomycin receptor and a d-Ala-d-Ala ligand (Figure 1.7) [50]. Vancomycin is an antibiotic belonging to the glycopeptide class of receptors. Antibiotics in
Vancomycin (R)
Trivalent Receptor (R 3)
OHNH2 OH O HO H3C CH3O
H Vancomycin N
OH O O
HN
O HO H N
O NH
O
O H O N
N H N H
O
O
Cl H N
O
Cl
N O
H
OH O
O
CH3 NH
N H
N
H CONH2
CH3 CH3
O Vancomycin
OH OH
NH
HO Nα-Ac-Lys-D-Ala-D-Ala HN
O
Trivalent Ligand (L 3)
Nα-Ac-Lys-D-Ala-D-Ala
O
H N
O NH
O
N NH H
H3C
CH3 H N O
O OCH3
O Nα-Ac-Lys-D-Ala-D-Ala (L)
R
+
L
R•L
Kdmono ≈ 1.6 x 10-6 M; ∆G = -33 kJ/mol
R3
+
L3
R3•L3
Kdtri ≈ 4 x 10-17 M; ∆G = -94 kJ/mol
Figure 1.7 Interaction of a trivalent vancomycin with a trivalent d-Ala-d-Ala ligand.
MECHANISTIC ASPECTS OF MULTIVALENT INTERACTION
11
this class target bacterial cell walls by binding to the d-Ala-Ala peptide precursor. In a monovalent system, vancomycin associates with d-Ala-d-Ala ligand with a dissociation constant (Kd ) value of 1:6 106 M (DG mono ¼ 33 kJ/mol). In a trivalent system composed of trivalent vancomycin and trivalent d-Ala-d-Ala designed by Rao et al. at Harvard [50], the receptor–ligand association is extremely tight, with a Kd value of 4 1017 M (DG tri ¼ 94 kJ/ mol). The avidity of the trivalent complex is much higher than the a‰nity of the monovalent interaction. Based on the value of the cooperativity constant [a ¼ 94 ð3 33Þ ¼ 0:95], this trivalent interaction is still negatively cooperative, although it is exceptionally tight. In terms of binding enhancement (b), the trivalent interaction leads to about a 4 10 10 -fold increase in binding strength relative to that of the corresponding monovalent interaction. In fact, the binding strength is 25 times higher than that of the avidin–biotin system—one of the strongest monovalent interactions in biological systems—thus clearly demonstrating the practical value of multivalency for designing a high-a‰nity system. Gargano et al. at Syracuse [51] proposed a simplified model that can be used in correlating the strength of multivalent association with that of monovalent association. This model makes it possible to estimate the multivalent enhancement factor (b) (Figure 1.8). The model is, however, designed under highly simplified conditions of multivalent systems that are not likely to fit real systems. The conditions include (1) equivalent binding sites on the multivalent receptor as a homobivalent system, (2) noncooperativity (a ¼ 1) such that first binding at one site is thermodynamically identical to second binding at neighboring site, (3) a flexible linker of optimal length to ensure bivalent association, and (4) no linker–receptor interaction, to avoid extra thermodynamic considerations. Because of such limiting conditions, this model should be used for
Kmono Eqn A
+ Kdi
Eqn B
+
K1 Eqn 1
Eqn 2
K2
K2 ≈ Kmono
+
K3 Eqn 3
K1 ≈ 4Kmono
+
+
K3 ≈ 10-2/2 M
Figure 1.8 Theoretical model used for deriving an equation that would make it possible to estimate di(multi)valent association constant.
12
INTRODUCTION
estimating the b term rather than predicting it accurately. It is illustrated by a simple divalent binding model composed of a dimeric receptor and a dimeric ligand, as described in Figure 1.8. This model suggests that the bivalent association constant (K di ) is expressed as three related association constants: K1 , K2 , and K3 . Each equilibrium constant is derived based on certain approximations, such as the number of possible permutations assumed in receptor–ligand site association in Eqn 1 in the figure (K1 ¼ 4K mono ), monovalent binding in Eqn 2 (K2 ¼ K mono ), and e¤ective local concentration (Ce¤ ) of bound divalent ligand in Eqn 3 (K3 A Ce¤ ¼ 102 /2 M, where two tethered ˚ apart [52]). An overall divalent association constant, which ligands are 30 A provides an estimate of the factor of divalent enhancement, is obtained as a product of the three equilibrium constants: K di ¼ K1 K2 K3 ¼ 2 102 (K mono ) 2 b¼
K di ¼ 2 102 (K mono ) K mono
This type of prediction is generalized to the multivalent association constant in a higher-order system as follows: K multi ¼ F (s 102 ) n1 (K mono ) n where n is the valency number, F is a statistical factor defined by the sys˚ )]. An application is illustrated by tem, and s ¼ 30/[interreceptor distance (A k a monovalent P trisaccharide ligand, which binds to pentavalent Shiga toxin (AB5 ) with a Ka value of 1 10 3 M 1 . If this monovalent ligand is converted to a polyvalent ligand that carries P k trisaccharide as side chains of poly(acrylamide), a binding constant(K penta ) can be estimated for the multivalent interaction with the toxin pentamer as follows: K penta (M 1 ) A 1(1 102 ) 51 (K mono ) 5 ¼ 108 (10 3 ) 5 ¼ 10 7 where F ¼ 1 and s ¼ 1. The predicted value is close to the experimental value of the binding constant, K penta A 1:2 10 7 M 1 , obtained from a cell-based assay [51]. This theoretical equation for calculating K multi indicates that the strength of the multivalent association increases exponentially as a function of valency. It also predicts that the intrinsic a‰nity of a monovalent system contributes significantly to the strength of multivalent association and that the intrinsic a‰nity is especially important in cases of low valency, such as for a bivalent or trivalent ligand. 1.2.2
Thermodynamics
The thermodynamic basis of multivalent interactions has been investigated by numerous groups of researchers [1,2]. Mammen et al. have provided a particu-
MECHANISTIC ASPECTS OF MULTIVALENT INTERACTION
13
larly thorough description in their review article [1], and the following discussion borrows ideas from this review. To elucidate the thermodynamic basis of multivalent interactions, it is easiest to start by examining a simple, bivalent system. A bivalent association (Eqn B, Figure 1.8) can be compared with a monovalent association (Eqn A) under certain limiting conditions, as defined in Figure 1.8. The free energy of binding (DG) in a receptor–ligand association is made up of enthalpic (DH ) and entropic (DS ) components, in which the monovalent association is linked to the standard relationships between three thermodynamic parameters (DG mono , DH mono , and DS mono ), which are expressed as follows: DG mono ¼ DH mono T DS mono DS mono A DS mono (translational) þ DS mono (rotational) In the equations above, the total entropy change involved is derived from changes primarily in the translational and rotational entropies of the receptor and ligand upon association. The equation represents a qualitative summation. It assumes that the translational and rotational entropies make the greatest contribution and that other possible contributions, such as from the conformational, vibrational, and solvation entropies, are relatively insignificant (i.e., vibrational entropy of a water molecule is about 3000-fold smaller than its rotational or translational entropy) and too complicated to be treated here. For a bivalent association, the free energy of binding (DG di ) is expressed similarly, using standard equations that relate thermodynamic components in qualitative terms: DG di ¼ DH di T DS di DH di A 2DH mono DS di A DS mono (translational) þ DS mono (rotational) þ DS di (conformational‚ linker) where the association of a discrete ligand of a bivalent molecule with each of the bivalent sites is assumed to occur in an unstrained and independent manner. Under such binding conditions, the bivalent enthalpy change is equal to twice the enthalpy of monovalent binding. The change of entropy in the bivalent association is considered to consist of three components. The first two terms are equal to translational and rotational components from monovalent association. Such an estimation is based on certain limited considerations: (1) translational and rotational entropies of divalent and monovalent particles are equal because these entropies are only weakly dependent on mass and size; and (2) in both bivalent and monovalent associations, two particles associate and become one particle, resulting in the net loss of the free translation and rotation
14
INTRODUCTION
of a single particle. The third component results from a change in conformational entropy. This component takes into consideration the conformational entropy that is contributed by the change in entropy of the linker upon association. For a simple estimation of the thermodynamic advantages of a multivalent system, the free energies of association can be compared between two ideal systems. One is a multivalent system in which one multivalent receptor, with n sites, binds to one multivalent ligand, also with n sites, to become one perfectly matched multivalent complex. The second system is represented by n independent pairs of monovalent complexes composed of n copies of the monovalent ligand and n copies of the monovalent receptor. Thus, the free energy of association for each system is given collectively as follows: nDG mono ¼ nDH mono nT DS mono DG multi (n) ¼ DH multi (n) T DS multi (n) A nDH mono T DS mono T DS multi (n) (conformational‚ linker) Subtracting the two equations provides a free-energy di¤erence between the two systems: DDG ¼ DG multi (n) nDG mono ¼ (n 1)T DS mono T DS multi (n) Therefore, if the multivalent association is tighter than the monovalent association, it is due largely to the entropic contribution of monovalent binding (DS mono < 0). This comparison suggests that multivalent binding is favored because it su¤ers a relatively smaller entropy loss. In practical examples reported in the literature, the thermodynamic benefits of a multivalent system are estimated from a comparison with one pair of a monovalent system rather than with n pairs of a monovalent complex as a group. As an example, the free energy of bivalent association is compared with that of monovalent association, where the di¤erence between DG di and DG mono can be approximated by two terms, the enthalpy of monovalent binding and the conformational entropy. Such a relationship is extended similarly to a multivalent system: DG di ¼ 2DH mono T DS mono T DS di (conformational‚ linker) DG di DG mono ¼ DH mono T DS di (conformational‚ linker) DG multi (n) DG mono ¼ (n 1)DH mono T DS multi (conformational‚ linker) Based on this estimation, a negative value of the free-energy di¤erence (DDG ¼ DG multi DG mono ) represents multivalently enhanced binding. There-
MECHANISTIC ASPECTS OF MULTIVALENT INTERACTION
15
fore, the enthalpy term contributes significantly and positively to the free energy of the multivalent association, whereas the conformational entropy causes a negative e¤ect because it is often associated with loss of conformational entropy of a linker upon receptor–ligand association. Such an enthalpy contribution has also been noted in ditopic binding of the cyclodextrin receptor dimer by Breslow et al. at Columbia [19]. In summarizing this section, thermodynamic aspect suggests that the enhancement factor (b ¼ eDDG/RT ) becomes greater in a system that involves a higher valency number (n), a tighter monovalent association (more negative DH mono ), and a rigid linker (a lower degree of conformational entropy loss), unless the linker interacts directly with the receptor. The thermodynamic basis of a tight multivalent association is illustrated by an experimental system (Figure 1.7) that is based on the association of a trivalent vancomycin molecule to a trivalent d-Ala-d-Ala molecule [50]. The trivalent binding results in a favorable value of DG tri (94 kJ/mol), which is dissected to enthalpic and entropic contributions (DH tri ¼ 167 kJ/mol; T DS tri ¼ 73 kJ/mol). It is a highly favored process compared with the association of monovalent vancomycin and d-Ala-d-Ala, which leads to a DG mono value of 33 kJ/mol, where DH mono is composed of DH mono (50.2 kJ/mol) and T DS mono (17.2 kJ/mol). Thus, in this system, DH tri has a value that is slightly more negative than three times the value of DH mono and thus is a major, driving factor for tight association. On the other hand, the absolute value of T DS tri is larger than that of T DS mono by 56 kJ/mol, which might be related to the loss in conformational entropy of trivalent complex, including the entropic loss contributed by linker. Clearly, favorable enthalpy makes a strong contribution to the very tight association of the trivalent system (K dtri ¼ 4 1011 M ). The thermodynamic basis for benefits of multivalent ligand–receptor association can be influenced by the system itself. For example, a multivalent ligand can interact with either a multivalent receptor presenting multiple connected sites (such as trivalent vancomycin and trivalent d-Ala-d-Ala) or unconnected multiple receptor sites. A series of studies performed by Dam et al. at Albert Einstein School of Medicine [2,53,54] provide important insights underlying the thermodynamics of multivalent binding of the latter class. Their studies are based on the association of concanavalin A dimer (Con A at pH 5.2) and divalent trimannoside cluster (Figure 1.9). The trimannoside dimer can form a soluble, one-dimensional cross-linked complex with Con A, with a divalent association constant (Kadi ) of 2:5 10 6 M 1 , which is about sixfold tighter than that of trimannoside monomer to Con A (Kamono ¼ 3:9 10 5 M 1 ). Such a slight enhancement in bivalent binding can be attributed to a combination of two separate, sequential association events where a trimannoside dimer cross-links to two lectins with a distinct binding a‰nity (first association: K a1 ¼ 1:6 10 7 M 1 ; second association: K a2 ¼ 8:8 10 5 M 1 ). Therefore, the first association is 18-fold tighter than the second one, which translates into
16
INTRODUCTION Binding parameters to concanavalin A (Con A)
Ka = 6.2 x 105 M-1 ∆G = -7.9 kcal/mol
HO HO HO
O HOO HO HO HO
First ligand association Ka1 = 1.6 x 107 M-1 ∆G1 = -9.8 kcal/mol
OH O
HO HO HO
O OH
Trimannoside monomer
OR
OH O O HO O
HO HO HO
OH O
O OH
OH O O O NH NH S
Second ligand association Ka2 = 8.8 x 105 M-1 ∆G2 = -8.1 kcal/mol
HO HO HO
OH O
NH O HOO
HO HO HO
CO2R
S
O OH
OH O
NH O
O Trimannoside dimer
Figure 1.9 Thermodynamic binding parameters in divalent trimannoside–lectin interaction.
a more negative value for the free energy of binding (DG1 ¼ 9:8 kcal/mol; DG2 ¼ 8:1 kcal/mol), indicating negative cooperativity generated on bivalent association. The two separate association events display similar enthalpies of binding (DH1 ¼ 12:5 kcal/mol; DH2 ¼ 12:3 kcal/mol), whereas the first association shows a more favorable entropy of binding (T DS1 ¼ 2:7 kcal/mol) than the second (T DS1 ¼ 4:2 kcal/mol), or binding of a trimannoside monomer to a lectin molecule (T DS ¼ 5:2 kcal/mol). This class of bivalent ligand– lectin association represents a multivalent system driven by entropy. Therefore, in the thermodynamic basis of binding, this system is clearly distinguished from a previous enthalpy-driven vancomycin/d-Ala-d-Ala system where a trivalent receptor presents three connected sites. Drug–DNA interactions represent another well-studied multivalent ligand– receptor system [55]. This type of system is exemplified by the association of hydroxyrubicin and daunorubicin to double-stranded DNA (Figure 1.10). Hydroxyrubicin is an anthracycline antibiotic composed of two parts. The first part is an adriamycinone moiety that intercalates into nucleotide bases. The second part is an attached sugar moiety that is able to bind at a DNA minor groove. Chaires et al. [56] reported that the free energy of binding (DG) of hydroxyrubicin to DNA is 7.0 kcal/mol, while that of adriamycinone is 5.7 kcal/mol. The higher a‰nity of hydroxyrubicin is attributable to the bivalent mode of interaction (intercalation plus minor groove recognition) compared to the monovalent mode of interaction (intercalation only) by adriamycinone.
MECHANISTIC ASPECTS OF MULTIVALENT INTERACTION
17
base sugar
intercalator
phosphate
divalent association ∆Gdi minor groove binder
multivalent association ∆Gmulti
monovalent association
intercalator
∆Gmono
covalent dimer
I∆Gmulti I > I∆Gdi I > I∆Gmono I
O
OH
O
O
OH
OH
OH H3 CO
H3CO
Hydroxyrubicin (∆G = -7.0 kcal/mol )
OH
O
O
OH
O OH
OH
O OH O H3C O OH OH
O
O
H3CO
O OH O H3C O OH NH2
O OH O H3 C O OH NH
Daunorubicin HN OH O CH
3
OH
O
OH O
OCH3
OH HO H3CO
O
OH OH O
Adriamycinone (∆G = -5.5 kcal/mol )
Figure 1.10
OH O
Daunorubicin dimer
Mode of DNA binding displayed by daunorubicin and its dimer.
The involvement of multivalency in drug–DNA interactions is illustrated more dramatically by daunorubicin, a close analog of hydroxyrubicin. A daunorubicin dimer binds tightly to DNA with an association constant Ka of 2:7 10 11 M 1 (DG ¼ 15 kcal/mol), which is 16,000-fold greater than that of daunorubicin (DG ¼ 10 kcal/mol) [57]. This greatly enhanced a‰nity comes mostly from a large enthalpy contribution (DH ¼ 30 kcal/mol; T DS ¼ 15 kcal/mol) compared to daunorubicin (DH ¼ 11 kcal/mol; T DS ¼ 1 kcal/ mol). The favorable enthalpy displayed by the daunorubicin dimer, which is close to three times that of the daunorubicin monomer, serves as a major driving force enabling the otherwise unfavorable entropic cost arising from multi-
18
INTRODUCTION kon Kd = koff/kon
+ koff
+
kon
kondi
koff
koffdi
Figure 1.11 Comparison of association kinetics in monovalent and bivalent systems.
valent drug–DNA interaction to be overcome. This example illustrates the important role of enthalpy in the association of a multivalent ligand with a multivalent receptor. In summary the thermodynamic basis of multivalent association can be driven by enthalpy or entropy and depends on the nature of multivalent system as discussed with the three examples above, involving vancomycin, lectin, and DNA.
1.2.3
Kinetics
The thermodynamic aspects of multivalent receptor–ligand interactions are highlighted by enhanced binding a‰nity. These aspects are, however, inseparably related with the kinetic features of multivalent binding, which is characterized by a decrease in the rate of dissociation of the two interacting entities. The kinetic aspects of bivalent association are shown schematically in Figure 1.11, in which a bivalent ligand occupies two binding sites present on a divalent receptor. The dissociation of a bound dimer occurs in two stages, so that its di dissociation rate (ko¤ ) at the second site can be compared theoretically with the rate of dissociation (ko¤ ) of a bound monovalent ligand, as suggested by Kramer and Karpen [52]:
di ¼ ko¤
2ko¤ K d Ce¤ þ K d
where Ce¤ refers to the e¤ective local concentration of a ligand unit at the second site and Kd refers to the dissociation constant of the monovalent ligand. The e¤ective concentration of a bound divalent ligand is calculated from the volume of the molecular hemisphere, with a radius of r equal to the length of the linker:
Ce¤ ¼
1000 NA 23 pr 3
MECHANISTIC ASPECTS OF MULTIVALENT INTERACTION
19
where NA is Avogadro’s number. The e¤ective concentration is closely associated with e¤ective molarity as a kinetic parameter commonly used in enzymatic or intramolecular reactions where e¤ective molarity contributes to rate acceleration relative to bimolecular reaction as investigated by Page and Jencks [58] and others. Thus, the rate of dissociation at the second site, di ko¤ , is defined as a linear function of the monovalent dissociation rate ko¤ multiplied by both a statistical factor of 2 (because dissociation can occur at either of two sites) and the probability K d =(Ce¤ þ K d ) that the second site is not occupied. Approximating the divalent dissociation rate is illustrated by the interaction of a bivalent cyclic guanosinemonophosphate (cGMP) tethered with a variable poly(ethylene glycol) spacer of molecular weight 2000 kDa. The spacer includes a cyclic nucleotide-gated channel which presents four cGMP sites distributed equally on four subunits comprising the channel [52]. With a linker length of ˚ , this bivalent ligand binds the tetrameric channel receptor with a K ddi val39 A ue of about 5 nM, which represents 600-fold tighter binding than that of the cGMP monomer (K d A 3 mM ). Assuming that the first site is occupied by a bivalent cGMP, the e¤ective concentration of cGMP at the second site is calculated to be 13.4 mM, which is much higher than the monovalent dissociation di constant (K d A 3 mM ). Under such circumstances, ko¤ at the second site is predicted to be about 1700-fold slower than ko¤ by monovalent cGMP. Thus, the decrease in dissociation rate is linked to the enhanced binding a‰nity of bivalent cGMP. Another good example of a slow dissociation rate by multivalent species involves a trivalent system composed of vancomycin and d-Ala-d-Ala (Figure 1.7). Compared to a monovalent system of vancomycin and d-Ala-d-Ala peptide (K d ¼ 1:6 10 6 M; kon ¼ 9:3 10 6 M 1 /s; ko¤ ¼ 14:88 s1 ), this trivalent system shows an exceptionally low dissociation constant Kd of 4 1017 M, tri and ko¤ is estimated to be 3 109 s1 [50]. Thus, for any trivalent receptorligand with a very tight association, a slower rate of dissociation can be inferred. 1.2.4
Steric E¤ects
As discussed, to design any multivalent ligand intended to target a cell surface receptor, the linker is an important factor to consider. In addition to its normal role as a spacer for bridging, it is implicated in the occurrence of undesired steric e¤ects caused by the size of receptor and the incompatible ligand spacing of multivalent ligands [59]. This unfavorable e¤ect is illustrated in Figure 1.12, where the interligand distance (LL ) is smaller than the distance between adjacent receptor sites (LR ). Under these circumstances, a certain fraction of unbound ligand units of a multivalent ligand are no longer available for receptor binding because these units are either obstructed directly by a bound receptor or they are excluded sterically by adjacent bound receptors.
20
INTRODUCTION optimal spacing: LR = LL LL
LR
cell surface receptor
short spacing: LR > LL LL
Figure 1.12 Definition of steric e¤ect in multivalent receptor–ligand complexation.
sterically hindered, and unavailable for receptor binding
Hlavacek et al. [59] proposed a theoretical model defining the steric e¤ect in a multivalent system that makes it possible to predict the relationship between the fraction of available ligand units and the fraction of bound receptor sites. It is illustrated using a linear multivalent ligand with a valency of 200 under arbitrary conditions where the number of ligand units covered by or in contact with bound receptor is 3 (LR > LL ; Figure 1.12). This model predicts that if the fraction of bound receptor sites by such a multivalent ligand is 5% (i.e., there are 10 bound ligands), about 75% of ligand units are still available for receptor binding. If the fraction of bound receptors increases to 10% (20 bound ligands), the fraction of ligand units available for receptor binding decreases to 50%. Therefore, a moderate increase in the fraction of bound receptor sites leads to a much greater degree of steric hindrance. In contrast, where linker spacing exceeds the optimal length between receptor sites, such that LL > LR , unbound ligand units are not covered or excluded sterically by bound receptors but instead are possibly available for receptor binding. However, the increase in linker length accounts for the decrease in e¤ective local concentration of the ligand, and thus leads to a weaker contribution to multivalent binding.
1.3
BIOLOGICAL ROLES OF MULTIVALENT LIGANDS
In biological systems, multivalent binding provides a broad range of benefits and unique roles that are not achievable with monovalent interactions. Here, we introduce selected features of multivalency benefits; detailed coverage is left for upcoming chapters. First, multivalent interaction is collectively much tighter than monovalent interaction. There are numerous examples of multivalent ligands that bind more strongly to their respective multivalent receptors,
BIOLOGICAL ROLES OF MULTIVALENT LIGANDS
21
as demonstrated in a diverse array of targets, including molecules as diverse as cell surface receptors, enzymes, G-protein-coupled receptors, ion channels, lectins, toxins, and nucleic acids found in cells and pathogens (viruses, bacteria). Notable examples include multivalent sialic acid molecules that bind to the hemagglutinin receptor on the surface of the influenza virus, where the multivalent enhancement factor ranges from 10 to 10 6 , depending on the degree of valency and type of sca¤old [60]. High-a‰nity multivalent ligands that target surface receptors show great potential as e¤ective inhibitors of surface–surface interactions, including cell–cell and cell–pathogen interactions, that occur in biological systems. Second, multivalent interactions can enhance receptor selectivity, as demonstrated by studies using multivalent ligands that bind to lectins [61], acetylcholine esterase [62], monoamine transporters [63], and serotonin receptors [64]. Third, multivalent interactions induce receptor clustering on the cell surface, as illustrated by bacterial galactoside-sensing receptors [65] and galactosyl transferase receptors on the surface of sperm [66,67]. Fourth, multivalent interactions provide a strategy for controlling signal transduction pathways within cells, as represented by the FK506 dimer, a prototype member of chemical inducers of dimerzation (CID) [68–70] and by the polyamide dimer as an artificial transcription factor [71]. Numerous excellent review articles deal with potential applications and characteristics of multivalent ligand–receptor interactions. The principles and biomedical applications of polyvalent interactions are discussed systematically by Mammen et al. [1]. The thermodynamic basis of multivalent binding is evaluated with respect to lectin–carbohydrate interaction by Brewer [54] and with respect to drug–DNA interaction by Chaires [55]. Classical examples of multivalent interactions, known as the cluster e¤ect, are described by Lee and Lee [26] in the context of carbohydrate–protein (C-type lectin and animal lectin) interaction, and multivalent selectin inhibitors are reviewed by Simanek et al. [72]. The mechanism of action by dimers of the FK506 class and its biomedical uses are reviewed by Crabtree and Schreiber [68]. Accounts by Roy [29] and Kiessling and Pohl [60] deal with chemical and biological aspects of multivalent neoglycoconjugates, and those by Yarema and Bertozzi [73] and Bertozzi and Kiessling [74] describe the novel roles played by multivalent carbohydrates in a chemical approach to glycobiology. Polyamide dimers are treated as highly selective DNA binders and their use in transcriptional control is described by Dervan and Bu¨rli [75] and Wemmer and Dervan [76]. The need for polyvalency when designing drugs to prevent pathogen–cell adhesion is described by Matrosovich [77]. Examples of multivalent drug candidates are documented in several therapeutic areas by Wright and Usher [11], while focused reviews include that of the use of multivalent glycan mimics as antiinfectives by Mulvey et al. [78], and rational design of a multivalent inhibitor of bacterial toxin by Fan and Merritt [79]. The role of noncovalent dimerzation of vancomycin in its antibiotic action is reviewed by Williams [80]. Cyclodextrin is a molecule that plays a dual role: Its hydrophobic cavity serves as a receptor,
22
INTRODUCTION
and multiple hydroxyl groups on its rims serve as handles for ligand attachment. Breslow et al. [19] reviewed the chelate e¤ect observed in ditopic binding of covalent cyclodextrin dimer. Fulton and Stoddart [21] discuss neoglycoconjugates designed on a multivalent sca¤old composed of cyclodextrin and calix[n]arene. Finally, the use of protein- and synthetic polymer-based polyvalent carbohydrates is reviewed by Bovin and Gabius [39].
2 MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
2.1 2.1.1
INFLUENZA VIRUS Hemagglutinin
Influenza virus initiates mammalian cell infection by adhering to the cell surface (Figure 2.1) [81]. This viral adhesion is mediated by the binding of viral surface protein–hemagglutinin (HA) to sialic acid (i.e., N-acetylneuraminic acid), which is presented on cell surfaces [82,83]. The hemagglutinin is expressed as clusters of trimers on the surface of influenza viruses A and B, in ˚ apart from each other, as suggested by lowwhich the trimers are 105 to 109 A angle neutron-scattering experiments (Figure 2.1) [84,85]. The virus–cell association is very tight and involves multivalent interactions among multiple pairs of HA trimer and sialic acid ligand. In contrast, the association of monovalent sialoside to a HA trimer shows very weak binding (K d @ 2 mM ). 2.1.1.1 Divalent Sialic Acid. Glick and Knowles [86] tested the notion of multivalent recognition by designing sialic acid–based inhibitors that target influenza virus. Their multivalent design led to the synthesis of two classes of bivalent sialosides, 1 and 2 (Figure 2.2). In these two related molecular classes, two sialic acids are tethered to each end of a xylyl-based sca¤old either an oligo(glycine) or poly(ethylene glycol) linker of varying length. These dimers were biologically active with an ability to bind hemagglutinin target and to in-
Synthetic Multivalent Molecules: Concepts and Biomedical Applications, By Seok-Ki Choi ISBN 0-471-56347-1 Copyright 6 2004 John Wiley & Sons, Inc.
23
24
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
Influenza virus
Hemagglutinin (HA) trimer
Sialic acid
cell membrane
glycolipid
glycoprotein
HA trimer
105 Å
46 Å Sialic acid-binding site
Figure 2.1 Adhesion of influenza virus to mammalian cell via multivalent binding of viral hemagglutinin (HA) trimers to multiple sialic acids expressed on cell surfaces and the estimated distance between sialic acid–recognition sites located within a hemagglutinin trimer and neighboring HA trimers.
1 (n = 0 to 4)
HO OH
HO OH
CO2AcHN
O OH OH
OMe
CO2AcHN
α-O-Methyl Sialoside
O OH OH
O
O N H
O
H N O
H N n
NH n
O O
OH OH NHAc O CO2OH OH
Span ~27 to 57 Å
HO OH CO2AcHN
O OH OH
O
O N H
O
O
2 (n = 1 to 3) H N
H N n
O
O
O
O
O n
N H O
O CO2-
OH OH NHAc OH OH
Span ~49 to 65 Å
Figure 2.2 Bivalent sialosides linked with oligo(glycine) or poly(ethylene glycol) spacer.
INFLUENZA VIRUS
25
hibit influenza-cell adhesion. Specific a‰nity of the sialoside dimer to ligand recognition sites located within a hemagglutinin trimer was studied by using nuclear magnetic resonance (NMR) titration. These experiments were typically carried out in a virus-free system where binding was tested with a nonmembrane-bound, aqueous-soluble form of hemagglutinin (bromelain released form). For example, bivalent sialosides such as 1 (n ¼ 4) and 2 (n ¼ 1 to 3) showed a dissociation constant of 2.8 mM, which is identical to that of monovalent methyl sialoside. The similar binding a‰nities of the monovalent and bivalent species strongly suggest that the dimers bind monovalently. This result is somewhat surprising and unclear since some of the dimers have spacer ˚ —enough to span the distance of about 46 A ˚ required to lengths up to 65 A bridge to ligand sites within an HA trimer. Although dimeric sialosides (1 and 2) show virtually no increase in a‰nity to soluble HA trimer over the monovalent molecule, they are capable of inhibiting the adhesion of influenza virus (X-31) to chick red blood cells as measured in the hemagglutination inhibition (HAI) assay. In this assay, these same bivalent ligands show enhanced inhibitory activity, which is about 6- to 100-fold larger than that of methyl sialoside (K iHAI ¼ 2:5 mM ). With a specific, extended ˚ , two dimers, 1 (n ¼ 4) and 2 (n ¼ 2), display optilinker length of about 57 A mal binding with an inhibition constant K iHAI of 25 and 125 mM, respectively. In this assay, dimeric sialosides are likely to display certain mode(s) of action distinct from simple monovalent binding. One possibility is the involvement of bivalent binding, where sialic acid dimers tethered with a long spacer are able to bridge hemagglutinin trimers, which are clustered in multiple copies on the viral surface. Such binding should be able to discourage virus–cell adhesion, perhaps through tighter association. Natural sialic acids, as found in glycoproteins and glycolipids, are presented structurally as terminal sugars and in a multivalent format derived from complex carbohydrate clusters. Sabesan et al. [87,88] studied a series of bivalent sialoside-containing carbohydrate clusters as ligands that bind influenza virus in a bivalent mode (Figures 2.3 and 2.4). Each of the sialoside clusters (3 to 5) present two units of NeuAc-a2,6-Gal-b1,4-GlcNAc-b1 anchored on a galactoside sca¤old. They are arranged in specific orientations at positions 2,4-, 3,6-, and 4,6- on the galactoside. Depending on the relative orientation, the distance ˚ at positions 3,6 between two sialosides in each cluster varies from about 9 A ˚ and 4,6 to about 19 A at positions 2,4. These heptasaccharides serve as inhibitors of influenza virus A adsorption to resialylated human erythrocytes in the hemagglutination inhibition assay. For instance, dimers 4 and 5, which ˚ , show 10- and 8.4-fold increased posess a sialoside-to-sialoside distance of 9 A inhibitory activity, respectively, over that of the monomer control, methyl a˚, sialoside (K i ¼ 1:9 mM ). By contrast, 3, with an end-to-end distance of 19 A shows the same inhibitory activity as the monomer (K i ¼ 1:3 mM ). Thus, a ˚ supports optimal activity. At such a distance, a ligand separation of about 9 A divalent sialoside cluster is more likely to bind intramolecularly to the closest ligand recognition sites present on a hemagglutinin trimer rather than to bridge
26
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS HO OH AcHN HO
CO2OH O HO HO O
O HO O
HO
NHAc
HO HO
~19 Å (2,4-orientation)
AcHN O HO HO
-O2C O
O
HO OH AcHN OH HO
HO OO
-O2C O O HO AcHN OO HO HO HO HO HO
~9 Å (3,6-orientation)
HO HO
NHAc OH O O O O OH HO AcHN O O HO OO
HO OH AcHN OH HO
OH
-O2C O
-O2C O
O
HO OH AcHN OH HO
O HO
OCH3
3
OCH3
4
OCH3
5
O
OH
O
HO HO
O O O
OH
HO HO
~9 Å (4,6-orientation)
O
OH
OH HO O O NHAc O O O AcHN O OH
HO OO OH
O
-O2C
O
OH O O
O
OH
O HO OH OHHO
HO HO AcHN OH
Figure 2.3 Structure of three types of heptasaccharide clusters displaying di¤erently oriented bivalent sialosides.
two sites located on adjacent hemagglutinin trimers, which would require ˚. spanning a distance of more than 55 A 2.1.1.2 Tetravalent Sialoside. Tuzikov et al. [89] reported a tetravalent sialic acid designed on the sca¤old of an antennary structure, C[aCH2 NHCOCH2 NHa] 4 . This structure forms noncovalent oligomers as a consequence of selfassembly mediated by intermolecular hydrogen bonding. This tetrameric sialoside inhibits influenza virus–cell adhesion 1000-fold more e¤ectively than does monovalent sialoside. 2.1.1.3 Dendrimers Presenting Sialosides. Multivalent molecules designed with hyperbranched fractal structures, such as dendrimers, mimic natural mul-
INFLUENZA VIRUS OH O O
HO
OBz O O OBz
OH O O
O
O
OH OH
HO
i,ii
OCH3
OH
iv,v
OCH3
HO HO
O
OH
27
iii
OCH3 O
OTBDMS
NHAc OH O O O O OH HO AcHN O
OCH3 O
O HO HO
vi
OH HO HO
OH
NHAc OH O O O O OH HO AcHN O
HO OO
OCH3
vii
O
O
OH HO
HO OO
OH
HO HO
OH
HO HO
-O2C O O HO AcHN OO OH OH HO HO HO HO HO
-O2C
AcHN OH
NHAc OH O O O O OH HO AcHN O O
O
HO OO
HO OH HO
OH
O
OCH3 O
4 OH
reagents and conditions: i) n-Bu2SnO, benzene, Et4NBr, allyl bromide; ii) TBDMSCl, DMF; iii) PhCOCl, pyridine; Ir(COD)-[Ph2Me]2PF6, THF; 10% HgCl2, 90% aqueous acetone; iv) 2-deoxy-3,4,6-tri-O-acetyl-2-phthalimido-α,β-D-glucopyranosyl bromide, AgOTf, collidine, CH3NO2; v) NaOMe, MeOH; H2NNH2, MeOH; Ac2O, pyridine; NaOMe, MeOH; vi) UDPgalactose, bovine galactosyltransferase; vii) CMP-NeuAc, 2,6-sialyltransferase
Figure 2.4 Chemoenzymatic synthesis of divalent sialoside cluster.
tiantennary ligands present on glycoproteins. Roy et al. [90] reported the synthesis of dendritic a-thiosialosides as inhibitors of influenza A virus. These molecules consist of a-thiosialosides located on the tips of hyperbranched arms that emanate from an oligo(lysine)-based dendrimer (Figure 2.5). Examples of such sialic acid–presenting dendrimers include a simple divalent ligand (5; first-generation dendrimer) to a dense hexadecavalent dendrimer (8; fourthgeneration dendrimer). These dendrimers can block the adsorption of influenza virus A (strain X-31) to mammalian cells. Compared to sialic acid monomers, the dendrimers show enhanced inhibitory activity in virus-mediated hemagglutination of chick red blood cells: K iHAI ¼ 625 mM (5), 313 mM (6), 156 mM (7), and 19 mM (8). These activities are 5- to 158-fold greater than that displayed by methyl sialoside monomers (K iHAI ¼ 3 mM ). Moreover, higher valency leads to greater antiviral activity. Thus, these dendritic clustered sialosides belong to a class of e¤ective multivalent inhibitors of influenza virus.
28
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
AcHN HO
OH OH
AcHN HO
OH OH
HO HO O CO2O CO2OH S AcHN S OH OH OH O NH HO O AcHN OH O HO O OH CO2- NH HO AcHN O CO2- HN O S HO HO HN S O NH O HO O CO2NH NH O O O S O NH HN NH HN OH OH O O O O N AcHN HN H HN O HN HO O CO2NH O O HO S NH O NH O HN O O NH O N H HN O HO O OH OH O
5 (1st generation) 6 (2nd generation)
AcHN HO
HO
OH OH
O
S
CO2-
HO NHAc OH HO OH O S CO2-
O NH
O
HN O HO NHAc NH O OH HO OH HO HO NHAc O NH O HN OH O S CO2O O S CO - OH HO O 2 NHAc HO HN NH NH O OH HN O S HN O O O HN O CO2- OH O NH NH O HN HO HO HN O O O H NHAc S O O HN N N H N O CO2- OH N NH H O N O H H H OH N O N O H O H HN OH OH N S O HN N O NHAc O H CO2O O OH OH HN NH O (3rd generation) O HN S OH O OH -O2C NHAc HOHO
OH OH
HO O CO2S
7
AcHN HO
AcHN HO HO
OH OH
AcHN HO
OH OH AcHN S O AcHN OH O NH HO CO2O HO OH HO OH S O HO O CO2- NH HO AcHN O HN O HO O S CO NH CO 2 O 2 HN HO O NH S S O NH O O HO NHAc HO NHAc HN OH NH O O NH HO OH O OH HO HO O OH NH O O O OH HO NHAc HN HN AcHN O HO O NH N CO2- O S CO2OH HO S O CO2HN O O H HN O OH HO NHAc HO S CO O HN HO S NH O 2 O O NH O NH O OH HN O S HN O NH O NH O HN CO2- OH O HO OH NH HN HN O HN O NH O NH NH O CO2O O HN O AcHN H O O O O N HO HN S N HO HN N H NH H O NH H O N HO OH O HO HO N O O O H CO2- H O O HN O O NHAc S O N O H N NHH AcHN O HN N N N N N OH OH S CO2- OH O H O O NH H H HN HN O H OH O H HN O H N O O N HO -O2C H O O N N HO H O S O OH N S O NH OH O H AcHN O OH OH NHAc -O2C OH OH
O
CO2-
HO
O OH
HO HO
8 (4th generation)
Figure 2.5 Lysine-cored dendritic sialosides: first to fourth generations.
A representative synthesis of dendrimer 8 in the solid phase is shown in Figure 2.6. The majority of synthetic e¤orts lie in the construction of the dendritic l-lysine core anchored through b-alanyl spacer to poly[styrene-co-4(hydroxymethyl)phenoxymethyl]resin, also known as Wang resin. The sialoside derivative is tethered to each of the glycine ends of dendritic arms through an a-thio linkage, which, unlike the a-O-linkage, is strongly resistant to hydrolytic cleavage catalyzed by viral sialidase (neuraminidase).
INFLUENZA VIRUS OAc
AcO
AcO
AcHN
O OAcOAc
OAc
AcO
i
Cl
CO2Me AcHN
CO2Me
O OAcOAc
CO2Me AcHN
SAc
H2N
OAc
ii O OAcOAc
SH
NeuAc-SH
O Wang resin (polymer support)
29
O O
H N
Cl
O N H
O AcO
O Lys8-Lys4-Lys2-Lys
N H
16
O
O
iii-vi O
OAc CO2Me
O AcHN AcO OAc HO
H N
O
H N
S
O N H
O
H N
N H
16
O
O
O Lys8-Lys4-Lys2-Lys
O O
vii
OH CO2H
O AcHN HO OH
H N
S O
O N H
H N O
O
O Lys8-Lys4-Lys2-Lys 16
N H
OH
8
viii-x
reagents and conditions: i) AcSNa, Bu4NHSO4, EtOAc, Na2CO3, 25oC, 30 min (66%); ii) NaOMe, MeOH, -40oC, 5 min, then H+ resin; iii) N α,N ε-di-fmoc-L-Lys-OBt, DMF; iv) 20% piperidine; v) repeat steps–iii,iv– three more cycles; vi) ClCH2CO-Gly-Gly-OBt, DMF; vii) NeuAc-SH, 1% Et3N, DMF, 16 h, 25oC, viii) 95% aq. TFA, 1.5 h (66-99%); ix) NaOMe, MeOH, 1 h; x) 0.05 M NaOH, 2 h, 25oC, then H+ resin
Figure 2.6 Solid-phase synthesis of fourth-generation dendritic sialoside as an inhibitor of influenza virus.
A sialoside-presenting glycodendrimer with 16 sialoside residues (9) is prepared using a di¤erent strategy, as reported by Zanini and Roy [91]. This strategy is based on a solution-phase method that utilizes 3,3 0 -imino(propylamine) as a building block for the dendrimer core (Figure 2.7). Further, Reuter et al. [92] reported a unique class of polymer-based dendritic sialosides that are composed of dendrimer (9) linked in multiple copies to a polymer sca¤old. The resulting dendritic polymers are potent inhibitors of influenza hemagglutinin, with their activity dependent on the shape and valency of the dendritic polymers. For example, a comb-branched dendrigraft polymer shows enhancement in inhibitory activity up to 50,000-fold relative to monomeric sialoside. 2.1.1.4 Sialic Acid Displayed in Liposomes. Liposomes closely mimic natural cell membranes in shape, surface topology, and chemical functionality [3]. Liposomes o¤er several advantages when used as a multivalent sca¤old: (1) liposomes can present multiple copies of ligands on their surface; (2) as with a fluid bilayer, liposomes allow lateral movement of surface ligands, which aids in optimizing the strength of multivalent binding to the receptor; and (3) the lipid bilayer tends to limit ligand motion to a two-dimensional plane rather than a three-dimensional space, leading to a relatively minimal loss of translational and rotational entropy change upon multivalent association. The utility of liposomes as sca¤olds in multivalent design was demonstrated
30
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
iii
CbzHN O N H H N N O
N
O OH
O N H H N N O
N
O OtBu
N
CbzHN
CbzHN
O N OH
CbzHN
CbzHN
i
H2N
O N OtBu
H2N
CbzHN O N H H N N O N
CbzHN CbzHN
N
O OtBu
CbzHN H2N N
CbzHN
H2N
ii
H2N H2N
CbzHN CbzHN NHCbz NHCbz CbzHN NHCbz CbzHN N NHCbz CbzHN N NHCbz O N O N HN CbzHN N O O NH NHCbz NH N HN O O CbzHN NHCbz HN NH N N N H H CbzHN N N O NH N NHCbz N O NH HN OHN N O O O N N
ii, iv,v,vi,vii
O AcO OAc
NH HN O
CO2Me O SH AcHN AcO OAc
N BuO
NeuAc (Ac4)-SH
t
O
OH AcHN OH OHHO OH AcHN OH HO OH HO NHAc HO NHAc HO O CO2- O CO2HO HO O OH OH OH S HO OH AcHN OH S OH COHO 2O HO S O O OHOH O NH NH CO2- HO NHAc HO O CO2S CO2- S O AcHN HO O NH O OH S HO O OH O CO2NH N NH HO S NH O CO2-HOHO NHAc O S O HO OH NH N OH HN O NH N O AcHN O S CO - OH O HO N O 2 O CO2HO H NH HN O NH S NH N HO HO NHAc N HO OH O S O CO2- HO N O N AcHN OH N O O CO2- OH N H NH HO S O N HO NHO H HO HO N O O N N NHAc NH S O H N HO OH H H -O2C N O O CO2- OH N N N H O S N HN O OH AcHN OHN HN O N O OH OH O O OH N N S H OH N OH N H -O C O NHAc HO N O 2 HO -O2C H O S O HO HO AcHN OH OH AcHN HO
9 reagents and conditions: i) DIC, HOBt (42-82%); ii) H2, 10% Pd/C (97%); iii) 30% TFA (96%); iv) (ClCH2CO)2O (91%); v) NeuAc-SH, 1% Et3N, DMSO; vi) NaOMe, MeOH; vii) 0.05 M NaOH
Figure 2.7 Solution-phase synthesis of PAMAM-based dendritic sialoside.
i
31
INFLUENZA VIRUS 10
HO OH CO2AcHN
O OH OH
H N
O
O
O
H N
N O NH H O S
S
CH3
CH3
11 CO2-
O OH OH
O
O
O
NMe2
HO OH AcHN
H N
O
H N
O
O
H N O
O
O O S
CH3
N NH H
CH3
NMe2
HO OH
OH CO2OH O AcHN O O O OH OH HO HO AcHN
OH OH OH O OO O HO HO HO
O OH O HN O
p
OH
CH3
p < 8, q > 1
Ganglioside G2 q
CH3
Figure 2.8 Structure of sialic acid–presenting synthetic and natural lipids.
initially by Whitesides et al. [44], who designed liposome-based multivalent sialic acids as potent inhibitors of influenza virus. The liposomes are made of lipids that terminate in sialic acid residues and that contain either synthetic (10) or natural ganglioside G2 , as shown in Figures 2.8 and 2.9. When examined in the influenza virus–induced agglutination assay, such liposomes inhibit hemagglutination with extreme potency, as illustrated by those containing 10. These molecules show an HAI activity or K iHAI value of 20 nM when calculated on the basis of total sialic acid groups contained in this multivalent system. Such activity represents a 100-fold enhancement compared to the activity (K iHAI @ 200 mM ) of a monomer control (11) which is a close analog of 10 but is incapable of being incorporated into liposome. The lipid 10 is also more active than methyl sialoside monomer by a factor of 10 4 . This level of potent activity is observed from liposomes displaying sialic acid in the density range 2.5 to 18% mole fraction. This optimum range of sialic acid surface density correlates well with earlier measurements by Haywood [93] in which a liposome preparation containing 3% bovine ganglioside acted as a potent inhibitor of Sendai virus in the HAI assay. Thus, liposomes provide a very e¤ective multivalent system, particularly when designing inhibitors against the adsorption of influenza virus to mammalian cells. Liposomes play a valuable role as a model surface for studying the fusion of viruses and cell membranes and understanding the mechanism of viral invasion. To this end, Alford et al. [94] prepared liposomes presenting on their surfaces either ganglioside (GD1a ) or glycoporin, a membrane-bound protein
32
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS OH OH
AcHN HO HO O
CO2-
AcHN HO
O
OH OH
HO O O
CO2O OH
HO
10 NH
Ganglioside G2
O HO O OH
O
AcHN O
Me2N
O OH O OH HO
NH
O O S N H
O HO O OH O HN
O
HO NH
S
n
O O OH NH
n
Membrane
Figure 2.9 Membrane-bound form of sialic acid–presenting lipid.
commonly found on red blood cells. Glycoporin is heavily glycosylated with multiple sialic acid molecules. The glycoporin-bearing liposomes adhere to hemagglutinin-expressing cells through specific interactions involving hemagglutinin and sialic acid, with two or more copies of hemagglutinin trimer required at the fusion site [95]. 2.1.1.5 Polymerized Liposome Presenting Sialic Acid. Despite the fact that liposomes serve as an excellent sca¤old to mimic natural cell membranes, liposomes are potentially unstable and can disassemble reversibly to their lipid monomers. To overcome such an undesired property a multivalent sca¤olding strategy was developed by a group of researchers at the University of California–Berkeley led by Bednarski [96–98]. It is based on the use of polymerized liposomes. Covalently cross-linked lipid bilayers are constructed using synthetic lipid molecules containing a diacetylene functionality in the middle of a lipid chain while presenting a desired ligand, such as sialic acid, on their polar termini. A typical synthesis is illustrated by the two-step preparation of a polymerized liposome made of lipids 12 and 13: (1) sonication of an aqueous suspension of two sialic acid–derivatized lipids mixed at a certain molar ratio; (2) ultraviolet irradiation at 254 nm of the prepared liposome to cross-link lipids assembled in close proximity (Figure 2.10). The resulting polymerized liposome is stable, due to the nature of the poly(diacetylene) structure. It appears ellip-
INFLUENZA VIRUS OHOH CO2-O AcHN
O OH OH
12
O O
N H
N H
3
13
O HO
N H
+
i) sonication (liposome) ii) hν, 254 nm (cross-linking)
AcHN HO
OH OH
HO O CO2-
OHOH AcHN HO
O
HO
HN
O CO2HO O
CO2HN
HN
HO NHAc OH OH O
O
OHOH AcHN HO
CO2-O O
aqueous layer
N H
HO
33
HN O
HO HO NHAc O OH CO2- OH
polymerized liposome
O HO
N H
OHOH CO2-O AcHN
O OH OH
O O
N H
N H
3
O HO
N H O
HO
N H
OHOH CO2-O AcHN
O OH OH
poly(diacetylene)
O N H
O 3
N H
Figure 2.10 Structure of polymerized liposome presenting sialosides.
soidal in shape, is about 40 nm in length, and is about 15 nm in width. This sialyl-presenting liposome polymer is biologically active, demonstrated by its ability to adhere to influenza virus as assessed using the erythrocyte agglutination assay. Its activity depends largely on the surface density of sialic acid, which is defined as 12 o (12 þ 13). Liposomes presenting sialoside at a surface density between 5 and 10% are among the most e¤ective inhibitors of influenza virus, with K iHAI values of 0.57 and 0.33 mM, respectively. By contrast, poly-
34
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS OH OH
AcHN HO HO O HO OH AcHN HO O CO2HO O
CO2-
HO
O HN HN
HO NHAc OH OH O CO2-
O
HN
Blue color (λmax = 626 nm)
HN
polydiacetylene liposome
O
HO HO NHAc O OH CO2- OH
Influenza virus
virus
Red color (λmax = ~550 nm)
polydiacetylene liposome
Hemagglutinin Sialic acid
Figure 2.11 Colorimetric detection of influenza virus by use of polymerized liposome which contains poly(diacetylene) framework that makes it possible to elicit hypersensitive responses to molecular recognition events occurring on surfaces.
merized liposomes displaying a sialyl surface density outside the range 5 to 10% are virtually inactive, even at 10-fold higher concentration. The best activity by the polymerized liposome represents a 30,000-fold increase in potency over a-O-allyl sialoside as a comparable monomer. In one biological application, polymerized liposomes serve as a colorimetric sensor to detect pathogens. This optical application is made possible through the unique properties of the poly(diacetylene) molecules in the internal framework of the liposome (Figure 2.11) [96,97]. The conjugated backbone, with its alternating double and triple bonds, gives rise to intense absorption in the visible light range. The wavelength absorbed by the poly(diacetylene) backbone changes in response to molecular and environmental perturbations such as ligand–receptor binding on the surface, temperature, pH, solvent, and mechanical stress. For example, a polymerized liposome displaying sialic acid (12) at 5% density shows a deep blue color in the unperturbed state. When influenza virus adsorbs to the surface of the liposome through multivalent, specific recognition, the liposome solution changes immediately to a red color (Figure 2.11). The transition is visible and readily quantified by visible absorption spectroscopy. In summary, polymerized liposomes comprise an e¤ective multi-
INFLUENZA VIRUS
35
valent sca¤old for mimicking the cell surface, and they can serve as optical sensors that respond to multivalent binding. 2.1.1.6 Sialic Acid in Langmuir–Blodget Monolayers. Another application of functionalized poly(diacetylene) lipids is to use the Langmuir–Blodgett (LB) technique to form thin films on a solid support (Figure 2.12) [98]. Illustrated in Figure 2.12 is the preparation of an LB film monolayer that displays on its surface a poly(diacetylene) layer consisting of 5% sialic acid. Multivalent presentation of such biological ligands on a glass support in combination with poly(diacetylene) thin film enables this system to be used as an optical probe
OH OH
AcHN HO HO O
OH OH
AcHN HO HO O
CO2-
Multivalent ligands for recognition of pathogen
CO2-
O
O
NH
NH
O
O
O
O
HN
O
HN
OH
OH
OH
O
O
HN
O
HN
O HN
OH
OH
O
O
HN
O
HN
O
Polydiacetylene backbone as optical sensor
Monolayer support
glass support
Figure 2.12 Polymerized bilayer assembly on a glass support where the bottom monolayer of octadecylsiloxane is attached to a solid surface through siloxane linkage.
36
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
for detecting specific pathogens [99]. For example, a film with a blue color and a maximum absorption at 630 nm might shift to a red color with a maximum absorption of 540 nm upon exposure to influenza virus. This virus–biosurface recognition is reversible and specific, since it is based on the interaction of a hemaggultinin–sialic acid pair. Such a color shift can be impeded by specific inhibitors of viral HA activity, such as a-O-methyl sialoside. By extension, this application of the LB technique may enable the rapid screening of potential drug candidates. 2.1.1.7 Sialic Acid Presented on Biopolymer Surfaces. Displaying sialic acid in a multivalent manner is also possible on the surfaces of biomaterials. Takemoto et al. [100] demonstrated such an approach by covalently immobilizing fetuin—a glycoprotein that contains sialic acid—to the surface of a carboxymethylated dextran sensor chip. The ligand-presenting chip is coupled with surface plasma resonance (SPR) spectroscopy to study multivalent ligand– receptor recognition. This setup can be used to determine dissociation constants under flow conditions. For example, this approach was used to determine the dissociation constant between sialic acid–presenting biosurfaces and soluble hemagglutinin clusters (such as influenza virus A (X-31) rosettes, which contain 6 to 10 hemagglutinin trimers per rosette [101]). The interaction, which mimics the association of virus and cell, leads to an equilibrium Kd value of 1 107 M derived from on and o¤ rate constants (ka ¼ 2 10 3 M 1 /s; kd ¼ 2 104 s1 ). This multivalent binding is four orders of magnitude tighter than the monovalent interaction between an X-31 rosette and sialic acid and is attributable to a slower o¤-rate. 2.1.1.8 Poly(acrylamide) Presenting Sialosides. Mammen et al. [34], Spaltenstein and Whitesides [36], and Lees et al. [47] have demonstrated the practical use of synthetic polymers as multivalent sca¤olds to present bioactive ligands. The utility of such polymeric sca¤olding is illustrated by poly(acrylamide), which is prepared conveniently by free-radical polymerization of acrylamide monomers. For example, copolymerization of a mixture of monomers composed of unsubstituted acrylamide and sialic acid–containing acrylamide (14) yields poly(14-co-acrylamide), which presents multiple copies of sialosides as the side chains of poly(acrylamide) (Figure 2.13). This method is also convenient for preparing a series of polymeric, polyvalent molecules with a range of side-chain densities. Thus, copolymerization at various ratios of 14 to acrylamide monomer leads to the generation of a series of poly(14-co-acrylamide) displaying sialoside density in a range between 0 and 0.9 [side-chain density ¼ wsialic acid ¼ [14] o ([14] þ [acrylamide])]. These sialoside-containing copolymers are highly e¤ective in inhibiting the hemagglutination of red blood cells by influenza virus X-31. In particular, copolymers with wsialic acid of 0.2 to 0.5 are the most e¤ective inhibitors, showing a K iHAI value of about 2 107 M (calculated on a sialoside basis). The polyvalent polymer is more e¤ective than methyl a-sialoside monomer by a factor of about 10 4 to 10 5 . This example
INFLUENZA VIRUS OAc
AcO
HO
Cl AcHN
O OAc OAc
i,ii
HO 14
AcHN
CO2Me
AcHN
CO2O OH OH
O
O
O
O
NHCbz
iii,iv
CO2O OH OH
HN OH
O CO2O
v
H N
OH
NH2 O
O OH OH
CO2O OH OH
O
AcHN
AcHN
OH
OH
HO
HO
37
poly(14-co-acrylamide) (χSA = [14]/ [acrylamide] = 0.2)
O O
HN O
O O O O NH2 NH2 NH2 NH2 HO AcHN
NH2 O
O O
O O O HN NH2 NH2 NH2
OH
O
n O O NH2 NH2
O CO2-
O OH OH
O
reagents and conditions : i) HO(CH2)4O(CH2)3NHCbz, Ag-salicylate, benzene, 25oC, 3 days; ii) 1 M NaOH, 25oC, 12 h; iii) H2, 5% Pd/C, MeOH, 25oC, 6 h; iv) N-(acryloyloxy)succinimide, Et3N, H2O, 25oC, 12 h; v) CH2=CHCONH2, 4,4'-azobis(4-cyanopentanoic acid), hν (365 nm), 25oC, 5 h.
Figure 2.13
Synthesis of poly(acrylamide) presenting a-O-sialoside as a side chain.
demonstrates the e¤ectiveness and practicality of using multivalent polymers for designing influenza virus inhibitors. 2.1.1.9 Poly(acrylic acid) Presenting Sialosides. Matrosovich et al. [102] and Dikusar et al. [103] described a synthetic polymeric sialoside, poly(15-co-acrylic acid), whose polymer framework is based on poly(acrylic acid) (Figure 2.14). The polymer displays multiple copies of sialoside via amide side chains as well as a high density of negative charges along the polymer backbone. This polymeric sialoside e¤ectively inhibits hemagglutination, with a K iHAI value of 1.8 mM. 2.1.1.10 Poly(acrylamide) Presenting C-Sialosides. The a-O-sialoside–based inhibitors of influenza virus are designed by using a natural a-O-linkage. Accordingly, these molecules are chemically labile, particularly at acidic pH. They are also substrates of viral neuraminidase—a glycosidase that is present on the surface of the virus—and are susceptible to O-glycosidic cleavage, leading to the removal of sialoside ligands emanating from the polyvalent framework [104,105]. Paulsen and Matschulat [106], Nagy and Bednarski [107], and Lee and Lee [108] solved that issue by preparing C-glycosidic sialoside moieties
38
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
O X
O X
O X
O X
X
OH
HO
n O
O
+
O
X = p-nitrophenoxy
AcHN
i) 15
CO2O OH OH
O
O N H
15
NO2
ii) NaOH, H2O NH2
OH
HO AcHN
CO2O OH OH
O NH O
OH O
HN
OH O
O
Poly(15-co-acrylacid) HN O
O
O O O O OH OH OH OH
O O O HN OH OH OH O
NH -O2C
HO O HO OH AcHN OH
O
O
n O O OH OH
NH -O2C
O HO O HO OH AcHN OH
Figure 2.14 Synthesis of poly(acrylic acid) presenting sialoside as an amide side chain.
where the C-linkage is stable to chemical and enzymatic cleavage. The synthesis of such polymeric sialosides begins with the preparation of an N-acryloyloxy derivative (16) of a-C-sialic acid (NeuAc), followed by its copolymerization with acrylamide monomer (Figure 2.15). This method makes it possible to generate copolymers incorporating C-glycosidic NeuAc moieties as side chains with wNeuAc values of about 0.01 to 0.8 [109]. Biologically, the C-glycosidic copolymers are as e¤ective as O-glycosidic copolymers in inhibiting the agglutination of erythrocytes by influenza virus. For example, the optimal K iHAI values for O-glycosidic and C-glycosidic polymers are 0.2 and 0.4 mM, respectively, at side-chain densities ( wNeuAc ) of 0.3 to 0.4. The monomeric a-C-allyl sialic acid is a weak inhibitor of hemagglutination in the HAI assay, with a K iHAI value between 2.5 and 5 mM. 2.1.1.11 Postmodification of Activated Polymers. Making polyvalent sialoside polymers via copolymerization may introduce uncontrollable variables that influence the structure of resulting polymer molecules: (1) uneven distribution of sialoside chains along the polymer backbone, (2) polydispersity—heterogeneity in polymer size, and (3) tacticity—the orientation and stereochemistry of the side chains. Such variables are likely to be generated by di¤erent rates of polymerization among di¤erently substituted acrylamide monomers. Mammen et al. [34] developed a di¤erent approach to control the incorporation of such variables in polyvalent polymers. Their appraoch is based on a postmodification method, which relies on the use of activated polymers, such as poly(Nacryloyloxysuccinimide), that have reactive NHS esters as side chains (Figure
39
INFLUENZA VIRUS
AcO
OAc
AcHN
O OAc OAc
OH
HO
Cl
i,ii CO2Me
AcHN
OH
HO CO2H
iii,iv
AcHN
O OH OH
CO2O OH OH
O S
(and β-allyl isomer)
N H
16
OH OH AcHN HO
O
poly(16-co-acrylamide) χSA = [16] ÷ { [acrylamide] + [16]} = 0.2
CO2-
HO S v
NH2 O HN
HO HO AcHN
-O2C O OH OH
S
NH O
O O O O NH2 NH2 NH2 NH2 HO HO AcHN
NH2 O
O
O O O HN NH2 NH2 NH2 -O2C
O
n O O NH2 NH2
S
O OH OH
reagents and conditions: i) CH2=CHCH2SiMe3, BF3Et2O; ii) NaOH, 25oC, 12 h; iii) aminoethanethiol hydrochloride, 4,4'-azobis(4-cyanopentanoic acid), hν (365 nm); iv) N-(acryloyloxy)succinimide, Et3N, MeOH; v) CH2=CHCONH2, 4,4'-azobis(4-cyanopentanoic acid), hν (365 nm), H2O.
Figure 2.15 chain.
Synthesis of poly(acrylammide) presenting a-C-sialoside as an amide side
2.16). These activated polymers react with amines, and sequential addition of two di¤erent amines yields di¤erently functionalized polyvalent terpolymers. Sialoside-presenting polymers prepared by the postmodification method are potent inhibitors of influenza-caused hemagglutination of chick red blood cells. For example, poly(17-co-acrylamide) at a side-chain density of 35% shows the lowest K iHAI (0.3 nM) among the polyvalent sialosides of various side-chain densities. Based on an enzyme-linked immunosorbent assay (ELISA), this polymeric sialoside binds influenza virus very tightly, with a K iELISA value < 3 nM [110]. The inhibitory activity of poly(17-co-acrylamide) is influenced mostly by the density or mole fraction of the sialoside side chains, and potent activities are observed from polymers presenting densities in the range 20 to 80%. Other factors a¤ecting the activity of polyvalent molecules include molecular weight (Mp ) and polymer chain length (N, the number of monomer units per polymer molecule). The impact of such factors is linearly proportional to the activity if they lie in the range Mp 10 to 1000 kDa and N 100 to 40,000. Polymeric sialosides prepared by the postmodification method are significantly more e¤ective (up to 100-fold) than are their corresponding polymers obtained from copolymerization. 2.1.1.12 Modes of Action of Polymeric Sialosides. Poly(17-co-acrylamide) inhibits influenza virus adhesion through tight association of the polymer to the
40
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS O O
HO
i N O
O O
R
O R
O R
O R
NHS
n O
+
AcHN
R (R = NHS)
OH CO2O OH OH
S
NH2
17
poly(NAS)
N-Acryloyloxysuccinimide (NAS) HO OH AcHN HO
CO2O OH
poly(17-co-acrylamide) χSA = [17] ÷ {[17] + [acrylamide]} = 0.2
S NH O
ii,iii
n O O O O O O O NH NH NH2 NH2 NH2 NH2 NH 2 2
O O O O NH2 NH2 NH2 NH2 HO HO AcHN
-O2C O
S
OH OH reagents and conditions: i) azoisobutyronitrile (AIBN), benzene, 60oC, 24 h; ii) 17, Et3N, DMF, rt, 20 h, then 65oC, 6 h; iii) NH4OH, rt, 12 h.
Figure 2.16 Synthetic method that makes it possible to derive polyvalent copolymer from preactivated polymer.
surface of the virus and, as shown with monomeric inhibitors of influenza neuraminidase (NA), through steric stabilization of the virus (Figure 2.17). The ability of the polymer to inhibit hemagglutination is enhanced by a factor of 2 to 20 when assayed in the presence of Neu2en-NH2 , which is known as a potent and selective neuraminidase inhibitor [35]. For example, the K iHAI of poly(17-co-acrylamide) at wsialic acid of 100% is 200 nM in the absence of neuraminidase inhibitor, but decreases 20-fold, to 10 nM, in the presence of 0.5 mM Neu2en-NH2 . The neuraminidase inhibitor is a selective inhibitor of neuraminidase (K i ¼ 50 nM ) and only a poor inhibitor of hemagglutinin with K iHAI > 50 mM. Therefore, the neuraminidase inhibitor does not contribute directly to the inhibition of virus–cell adsorption. Instead, the enhanced activity results from competitive displacement of sialoside ligands bound at the neuraminidase site by the neuraminidase inhibitor. Through this displacement mechanism and the resulting steric stabilization of virus particles, the bound polymer backbone expands and becomes more e¤ective in preventing virus–cell interactions. 2.1.1.13 OPTCOL Assay. The HAI assay is of limited application when measuring exceptionally high activity, such as that of polyvalent polymeric inhibitors. The lowest measurable value of K iHAI in the assay is approximately equal to the minimal usable concentration of viral hemagglutinin, or the minimum concentration of hemagglutinin necessary to cause agglutination (esti-
INFLUENZA VIRUS
41
NA Influenza virus
HA NA inhibitor
Sialic acid
polymeric polyvalent inhibitor (tight association; steric blocking)
enhanced steric effect
NA inhibitor Inhibition of virus-cell adhesion Sialic acid
cell membrane
HO OH H O AcHN HO NH2
CO2H
Neu2en-NH2 Ki (NA) = 50 nM
Figure 2.17 Summary the modes of action displayed by polymeric polyvalent sialoside as an inhibitor of influenza virus.
mated to be 1 nM). Under such assumptions, all inhibitors with a K i < 1 nM therefore appear to be equally e¤ective and are indistinguishable in HAI assay. Other methods are necessary to determine potent inhibitory activity accurately and precisely. Mammen et al. at Harvard and the National Institute of Standards and Technology [111] developed a new bioassay based on an optical tweezer called OPTCOL (optically controlled collision). In this assay, the probability of adhesion of a single erythrocyte to a single virus-coated microsphere is evaluated in the presence of inhibitor. The technique makes it possible to distinguish the inhibition activity of the best polyvalent inhibitors prepared by the postmodification method. For example, poly(17-co-acrylamide) at an wSA value of 35% shows an inhibition constant K iOPTCOL value of 35 pM and a K iHAI value of 0.3 nM. 2.1.1.14 ter-Poly(acrylic acid) Presenting Sialosides. A primary mode of action of polyvalent sialosides can be attributed to specific multivalent interactions between silaoside and its receptor (hemagglutinin or neuraminidase) on the surface of influenza virus. Introducing a second, nonsialoside functionality to the side chains of the polymer provides an additional binding motif, perhaps through nonspecific binding of nonsialoside functional groups to the receptor. For example, hydrophobic groups, which are incorporated as side chains into the backbone of poly(acrylamide) or poly(acrylic acid) molecules displaying
42
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
O NH
HO OH
O O O O OH OH OH OH
n
poly(SA-co-acrylic acid) [χSA = 0.1]
CO2Na H 3C
O
S
O
HN
OH OH
O NH
HO OH HN O
O
O O O O OH OH OH NH
n
CO2H
CO2Na H3C
18
19 poly(SA-co-acrylic acid)(naphthylalanine) [χSA = 0.1; χNA = 0.12]
S
OH OH
Figure 2.18 Structure of poly(SA-co-acrylic acid) presenting side chains composed of sialoside and l-naphthylalanine.
sialoside groups, enhance the activity of the polymers in inhibiting virus-caused hemagglutination [112]. One such example is poly(SA-co-acrylic acid) (l-naphthylalanine), 19 (Figure 2.18). This terpolymer shows a potent HAI activity with a K iHAI value of 0.5 nM, an activity about 1000 times higher than that of the corresponding copolymer, poly(SA-co-acrylic acid), 18. As demonstrated by this example, the second functionality can dramatically improve HAI activity and should be considered when designing polymeric polyvalent ligands. 2.1.1.15 Poly(glutamic acid) Presenting Lyso-gangliosides. Kamitakahara et al. [113] conducted an important test of the hypothesis that incorporation of hydrophobic groups in a polymeric sialoside might contribute to enhanced binding as well as disruption of viral adhesion ability. The study is based on a unique polyvalent sialoside, which presents lyso-ganglioside (GM3 ) as amide side chains linked to a sca¤old of poly(glutamic acid) (degree of polymerization ¼ 540). In this polymer, the ganglioside serves as a source of sialic acid as well as providing long, hydrophobic alkyl chains (Figure 2.19). The polymeric, polyvalent ganglioside 20 shows potent inhibition activity with an IC50 value of 1:9 1012 M against influenza virus A in ELISA. It is about 103 -fold more potent than a corresponding monomer such as lyso-GM3 21 or GM3 , and about 105 -fold more potent than sialyllactose. The nanomolar activities of lysoGM3 and GM3 relative to sialyllactose can be attributed to their ability to form aggregates in aqueous solution, mimicking liposomes or micelles, both of which serve as a multivalent sca¤old. 2.1.1.16 Poly(glutamic acid) Bearing Sialic Acid–Containing Trisaccharides. Totani et al. [114] reported the chemoenzymatic synthesis of glycopolymers composed of poly(glutamic acid) bearing side chains of sialic acid–containing
43
INFLUENZA VIRUS 20 Poly(Glu)(Lyso-GM3) HO OH NaO2C H 3C
O
O
HN
OH OH O OH
OH OH
O
OH O O OH O
O HO
OH CH3 NH H N
Lysoganglioside GM3
O
HN O
O
OH OH O OH
OH OH
O HO
OH O O OH
m = 4; n = 270 O
O
OH C13H27
+
NH-Fmoc 5 eq
O
HN O
O
OH OH O OH
OH OH
O HO
OH O O OH O
C13H27 NH H N
NH-Fmoc
H 3C
HN O
O OH OH
O
OH OH O OH
O HO
OH O O OH O
OH
O
NH2
H N
H 3C C13H27
NH H N
N F B N F H3C
N F B N F H 3C
CH3
OH
O
HO OH NaO2C
H N O
NH2
HO OH NaO2C H3C
O
O
21 Lysoganglioside GM3
i
CH3
n
N
HO OH NaO2C H 3C
O m
O
NaO
Fluorescent tag (BODIPY-C3)
ONa N H
O
O
NH
O
H N
H 3C
N F B N F H3C
O
O SuO
ii
N F B N F H3C
CH3
O
OSu O
O
O N H
N
n O m O
O 20 iii
CH3
reagents and conditions: i) Et3N, MeOH, DMF, ~100%; ii) piperidine, DMF, 34%; iii) DMF, MeOH, then NaOH.
Figure 2.19 Synthesis of polyvalent lysoganglioside constructed on the backbone of poly(glutamic acid).
44
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
trisaccharide. They utilized a2,3- and a2,6-sialyltransferase in the synthesis in order to incorporate sialic acid in a regiospecific manner, thus producing molecules such as NeuAc-a2,6-Gal-b1,4-G1cNAc or NeuAc-a2,3-Gal-b1,4GlcNAc. The polyvalent glycopolymer displaying NeuAc-a2,6-Gal-b1,4GlcNAc shows significant inhibitory activity against infection by influenza viruses A and B in a cell protection assay. Such activity is enhanced upon increasing the molecular weight of the polymer and the density of sialic acid. 2.1.1.17 Poly(acrylamide) Bearing Sialic Acid Linked at the C4 Position. The most common site for introducing a linker to sialic acid is the C2 position; however, an alternative attachment site can be utilized including the 4-N substituent of sialic acid (22). Wu et al. [115] reported the synthesis of polymeric polyvalent sialic acid based on such linkage sites (Figure 2.20). The resulting polyvalent molecules weakly inhibit the influenza-caused agglutination of red blood cells, with a K iHAI value of around 106 M per sialic acid. This example shows that the attachment via C2 position may be preferred to 4-N position, although attachment through either position leads to polyvalent sialosides more potent than a monovalent sialoside.
poly(NAS)
O
O NHS
N
O O
O R
O R
O R
HO
n O
OH
CO2AcHN O S HO HN O
+
R
(R = NHS)
HN
NH4OH NH2
22 OH OH AcHN HO HN HN
O CO2O
S poly(22-co-acrylamide) (χSA = [22]/{[22] + [acrylamide]} = 0.25) NH O n O O O O O O NH2 NH2 NH2 NH NH2 NH2
O O O NH2 NH2 NH2
S
-O2C O
O
NH
NH
HO HO
OH NHAc
Figure 2.20 Synthesis of poly(acrylamide) presenting multiple copies of 4-N-linked sialoside.
INFLUENZA VIRUS AcO OAc
AcO OAc
AcO OAc
Cl H3C
O
HN O
CO2Me i
CO2Me
H 3C
OAc OAc
O
HN O
NO2
S
CO2Me
ii,iii H 3C
OAc OAc
CO2H H 3C
O
HN O
NH
S
O
H3C
O
vii
O H3C H 3C
O
O
OH OH
O O O O O NH NH2 NH2 NH2 NH2
O OH NaO2C HN
O
HN
n
O
S
OAc OAc
NH O
O O O O O NH NH2 NH2 NH2 NH2
HO OH NaO2C
vi
OH OH
HN O
HO OH iv,v
45
S
n
23 poly(SA-co-acrylylamide) [χSA = 0.1]
24 poly(9-O-acetyl-SA-co-acrylamide) [χSA = 0.1]
S
OH OH
reagents and conditions: i) 4-NO2C6H4SH, n-Bu4NHSO4, 1 M NaOH, CH2Cl2, 25oC; ii) NH4HCO2, 10% Pd/C, then SnCl2, EtOH, reflux; iii) CH2=CHCOCl, Et3N, CH2Cl2; iv) NaOMe; v) 0.1 M NaOH; vi) CH2=CHCONH2, (NH4)2S2O8; vii) MeC(OMe)3, TsOH
Figure 2.21 Synthesis of poly(acrylamide) presenting 9-O-acetylsialic acid as an amide side chain.
2.1.1.18 Poly(acrylamide) Tethering 9-O-Acetylsialosides. Unlike influenza viruses A and B, influenza virus C produces a hemagglutinin that recognizes 9O-acetyl-N-acetylneuraminic acid (9-O-acetylsialic acid) as a ligand determinant [116]. Roy et al. [117] reported the synthesis of a polyvalent sialoside (24) based on 9-O-acetylsialic acid as an inhibitor of influenza virus C (Figure 2.21). This polyvalent sialoside is designed on the backbone of poly(acrylamide) by tethering multiple copies of 9-O-acetylsialoside as side chains. In the HAI assay using murine erythrocytes, 24 inhibits influenza virus C at a concentration of 3.3 mM. Such activity is attributed to the specific binding of 24 to the influenza virus C as demonstrated in the microtiter plate assay. The binding ability of 24 is remarkable relative to an analogous polymer prepared from des-9-Oacetylsialic acid (23), which does not show any binding to the virus. This 9-Oacetylated glycopolymer (24) is found to be a poor substrate of 9-O-acetylsialic acid esterase, a hydrolytic enzyme located on the surface of influenza C. Thus, this type of polymeric sialoside represents an esterase-resistant polyvalent inhibitor. 2.1.1.19 Neoglycoprotein Displaying Sialic Acids. A variety of nonspecific molecules present in human and animal sera can inhibit the interaction of influenza virus and sialosides on cell surfaces [118,119]. Most natural inhibitors are glycoproteins that present multiple copies of sialosides on a protein surface.
46
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
Such natural inhibitors include bovine mucin (K i ¼ 20 mM ), fetuin (K i ¼ 8 mM ), human and bovine a2 M (K i ¼ 1 to 3 mM ), guinea pig a2 M (K i ¼ 50 nM ), and equine a2 M (K i ¼ 10 nM ) [34]. Hanaoka et al. [120] reported that a natural defense molecule known as g-inhibitor is a2 -macroglobulin, whose antiviral activity is attributed to the presence of multiple copies of sialosides displayed on the macromolecule. The proposed mechanism of action by such glycoproteins involves multivalent binding of its sialosides to influenza hemagglutinin. The term neoglycoproteins commonly refers to synthetic protein derivatives with multiple copies of carbohydrate ligands on the surface of a protein scaffold. They are prepared chemically or enzymatically by conjugating multiple ligands to a sugar-free protein, such as serum albumin (human or bovine), through the formation of an amide bond or via reductive amination. Modified BSA 26 is a typical neoglycoprotein (Figure 2.22). It displays up to 58 copies of sialyl-containing heptasaccharide 25 covalently attached to bovine serum albumin through amide linkages [88]. This neoglycoprotein inhibits the adhesion of influenza virus to human erythrocytes with an activity higher than that of divalent heptasaccharide 25, used as control. A second example of a synthetic glycoprotein is the neoglycoprotein 27, reported by Roy et al. [121] shown in Figure 2.23. It can display up to 23 copies
HO
OH Divalent heptasaccharide (25)
AcHN HO
CO2-
O HO
HO
Lysine
O NHAc O O
OHO O
HO HO
OH
HO OO
HO OH AcHN OH HO
OH
-O2C O
OH
Bovine serum albumin (BSA)
OH
HO
OH
AcHN HO
CO2-
O HO
EDC
HO
O NHAc O O
OHO O
HO HO
HO HO
OH
HO OO
HO OH HO
OH
O
H N
OH O O
O
OH AcHN O O
O
-O2C
AcHN OH
Figure 2.22
NH2 n = 58
H2N
+
O
OH AcHN O O
O
HO HO
OH O O
26 OH
Structure of sialic acid–presenting neoglycoprotein.
n
INFLUENZA VIRUS OAc
AcO AcHN
O OAc OAc
iv
O OAc OAc
OH
O AcHN OH OH
v
CO2H O
O H
HO
ii,iii
CO2Me
AcHN
CO2Me
HO
OAc
AcO
i
Cl
AcHN
O
HO AcHN
OH CO2H O OH OH
OH CO2H O OH OH
O
47
O
BSA H N n = 23
27 reagents and conditions: i) CH2=CHCH2OH, silver salicylate; ii) NaOMe, MeOH; iii) 0.1 M NaOH; iv) O3, then Me2S; v) bovine serum albumin, NaCNBH3, phosphate buffer, pH 7.0, 37oC.
Figure 2.23 Synthesis of neoglycoprotein conjugate via coupling of reductive amination.
of sialic acid per protein molecule, coupled through reductive amination to the e-amino residue of lysine. This multivalent sialylated protein e¤ectively inhibits the adsorption of influenza virus to chicken red blood cells [122]. 2.1.1.20 Natural b-Inhibitors. A di¤erent naturally occurring class of hemagglutinin inhibitors exhibits a unique mode of action relative to the a2 macroglobulins. Called b-inhibitors, they belong to a class of proteins found in normal bovine and mouse sera. Unlike the role played by a2 -macroglobulins (g-inhibitor) as a multivalent ligand, b-inhibitors do not target sialic acid– binding sites on hemagglutinin but instead, act as lectin receptors that can selectively recognize mannoside-containing ligands. For example, a viral hemagglutinin (X-31) monomer expresses on its surface a mannoside-containing oligosaccharide attached at Asn-165. The oligosaccharide is located proximally toward sialic acid-recognition sites on a neighboring hemagglutinin (Figure 2.24). Anders et al. [123] suggest that b-inhibitor binds to such mannoside residues on the tip of hemagglutinin molecules and sterically blocks access of the hemagglutinin site to sialic acid on the cell surface, thereby indirectly inhibiting virus–cell adhesion.
2.1.2
Neuraminidase
A second major protein located on the surface of influenza, neuraminidase (NA), exists as a tetrameric cluster with a surface density of 50 copies of tertamer per virion particle. Because of its critical role in viral pathogenicity, NA is the target of many drugs, including marketed drugs, such as zanamivir and oseltamavir, and other discovery-stage inhibitors [124–126]. The topological features of NA make it an attractive target for a multivalent approach.
48
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS inhibitor
HO OH AcHN O O OH AcHN HO
HO
HA1
HO
O O OH OH
OHO O HO
OH HO O O HO
sialic acid-site
OH O O
HO NHAc O O OH
NHAc OH OH
O OH O OH OH
O OH O Asn-165
sialic acid-site
Leu-226
HA2
HA3
O O HO
steric hindrance
OH OHO O HO OH OHO O OH HO O
O NHAc OH
HO NHAc HO
Figure 2.24 Anti-influenza activity by a b-inhibitor.
2.1.2.1 Poly(glutamic acid) Presenting NA Inhibitors. Honda et al. [127] reported the first class of polyvalent inhibitors that target influenza neuraminidase, designed on the basis of a derivative of zanamivir (Figure 2.25). A monomer ligand, 28—a 7-O-alkyl ether derivative—shows an inhibitory activity against sialidase, with an IC50 value of 22 nM, which is close to that of zanamivir (IC50 ¼ 11 to 29 nM ) [128]. Linking multiple copies of 28 to activated poly(glutamic acid) leads to the polymeric polyvalent molecules 29 and 30, in which the side-chain density of the inhibitor is controlled by varying the ratio of 28 to the reactive ester of activated poly(glutamic acid). In a solutionphase enzyme assay, 29 and 30 are active against sialidase, with IC50 values of 114 and 161 nM, respectively, although such activities are five- to sevenfold lower than that of a monomer control (28). However, in a plaque reduction assay that measures the extent to which influenza virus can replicate, the values of IC50 are 66 pM (29) and 72 pM (30). In contrast, unsubstituted poly(glutamic acid) is inactive. These activities represent 76- to 83-fold enhancement relative to 28. The mode of action by these polymers probably involves tight binding of the polymeric inhibitor to viral surfaces by binding multiple neuraminidase molecules simultaneously.
HUMAN IMMUNODEFICIENCY VIRUS OHO
OHOH H O
AcHN
CO2H
AcHN
OH HN H2N
O
NH
ONa
Oseltamivir
O
N H O
i
NH
O
O
H N
ii,iii m
OBt
O
NH2 O
H N O
(CH2)n O
OH HN H 2N
OBt
N H
activated poly(Glu)
O
AcHN
O O
poly(Glu) Mr = 50 - 70 kDa
OHO
OBt
H N
m ONa
CO2H
28 (n = 2,5)
O
H N
NH2
OH HN H 2N
O
H N
O
AcHN
CO2H
ONa
O O
O H 2N
Zanamivir
O
(CH2)n
H
49
NH
N H
CO2H
O
H N
N H O
m NH2
29 (n = 2; χNeu2en = 10%) 30 (n = 5; χNeu2en = 10%)
reagents and conditions: i) EDC, HOBt; ii) 28, pyridine; iii) aq. NH3; then dialysis against water.
Figure 2.25 Synthesis of polyvalent inhibitor that targets influenza neuraminidase.
2.2 2.2.1
HUMAN IMMUNODEFICIENCY VIRUS HIV-1 Protease
The enzymes and structural proteins of human immunodeficiency virus type 1 (HIV-1) play critical roles in producing mature and infectious virion particles [129]. These diverse proteins are first produced in the form of large precursor proteins encoded by the virus. They are subsequently generated after proteolytic cleavage of the precursor proteins by HIV-1 protease. This protease is active enzymatically only as a homodimer [130]. A principal driving force underlying the dimerization of HIV-1 protease is the favorable peptide–peptide association between the N- and C-terminal portions of the protease, which generates a four-stranded b-sheet (Figure 2.26). The homodimeric HIV-1 protease forms a stable complex with Kd values ranging from 39 pM to 440 nM [131,132]. The homodimeric complex contains a substrate-binding pocket that serves as a catalytic reaction site.
50
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS divalent peptide
N-terminal peptide
C-terminal peptide HIV-1 protease monomer (inactive)
HIV-1 protease dimer (active)
protease/divalent peptide complex (inactive)
Figure 2.26 HIV-1 protease dimerization and its inhibition by divalent interfacial peptide.
2.2.1.1 Divalent Terminal Peptides. One multivalent strategy for inhibiting HIV protease is to induce interference at the stage of self-dimerization by disrupting the dimeric peptide interface (Figure 2.26). Monomeric peptides with sequences corresponding to the N- and C-terminuses of HIV-1 protease have been reported that can block protease activity, perhaps by inhibiting enzyme dimerization [133–135]. This approach was elaborated by Babe et al. [136], who designed a contiguous, divalent peptide composed of either N- or Cterminal sequences of HIV-1 protease tethered with a tri(glycine) peptide ˚ long. Examples of such dimers linker. The linker was approximately 3.5 A include [HN-Pro-Gln-Ile-Thr-Leu]-(Gly)3 -[Cys-Thr-Leu-Asn-Phe-OH] and [H2 N-Met-Ser-Leu-Asn-Leu]-(Gly)3 -[Met-Ser-Leu-Asn-Leu-OH], both of which can inhibit HIV-1 protease. In a comparable approach, Zutshi et al. [137] reports cross-linked peptides from the N- and C-termini of the protease as potent inhibitors of HIV-1 protease (Figure 2.27). These divalent peptides are designed based on monomeric peptide sequences which show optimum inhibitory activity: N-terminus sequence ¼ H2 N-Ser-Thr-Leu-Asn-Phe-OH; C-terminus sequence ¼ HN-ProGln-Ile-Thr-Leu-Trp-OH [138]. Two identical (C-terminus) or di¤erent (N- and C-terminus) peptides are linked through aliphatic chains of C12 to C16 as an amide bond to a¤ord homodimers or heterodimers, respectively. The long, ˚ , which is equal to the disflexible alkyl chain is intended to span about 10 A tance separating the N-terminal ends in a dimeric form of the protease (Figure 2.26). In a standard enzyme assay, a series of heterodivalent peptides (31; n ¼ 10 to 16) show antiprotease activities that correlate with the length of the alkane spacer. The linker for optimal activity is observed at (CH2 )14 , with an IC50 value of 2.0 mM. Deleting one amino acid residue from the original sequence of C-terminus (32) or N-terminus (33) reduces the inhibitory activity about threefold, while removing two amino acids simultaneously (34) leads to an inactive peptide. A homodivalent molecule (35), which presents two Cterminal ends is also active, although it is less potent than the corresponding heterodivalent molecule (31; n ¼ 12).
HUMAN IMMUNODEFICIENCY VIRUS
O
N-Pro-Gln-Ile-Thr-Leu-Trp-OH
(CH2)n O
O
N-Pro-Gln-Ile-Thr-Leu-X-OH O
O
NH-Ser-Thr-Leu-Asn-Phe-OH
(CH2)12
(CH2)12
NH-Ser-Thr-Leu-Asn-Phe-OH
NH-Ser-Thr-Leu-Asn-Y-OH
O
NH-Ser-Thr-Leu-Asn-Phe-OH
32 (X = Trp; Y = bond) 33 (X = bond; Y = Phe) 34 (X = Y = bond)
31 (n = 10 to 16)
O
HN-Pro-Gln-Ile-Thr-Leu-Trp-OH +
51
N
O
O (CH2)10
O
35
O O
+
N
H2N-Ser-Thr-Leu-Asn-Phe-OH
O
O
O DIEA, DMSO 60oC, 24 h (~5% )
N-Pro-Gln-Ile-Thr-Leu-Trp-OH
(CH2)10 O
31
NH-Ser-Thr-Leu-Asn-Phe-OH
Figure 2.27 Structure of divalent interfacial peptides and their representative synthesis.
Homodivalent peptides tethered to a conformationally constrained, aromatic sca¤old inhibit the dimerization of HIV-1 protease [139]. Dimers of this class are shown in Figure 2.28, and their inhibitory activities depend largely on their peptide sequence. For example, in an enzyme assay, dimers 36 and 37 block protease activity with IC50 values of 4.2 and 2 mM, respectively. Such activity is attributed to their ability to form a complex with the enzyme at micromolar concentration, therefore preventing assembly of enzyme dimer. Removing one peptide from an active dimer inactivates the molecule, pointing to the importance of divalent association. 2.2.2
HIV-1 Reverse Transcriptase
An HIV-specific type 1 polymerase, HIV-1 reverse transcriptase (RT), catalyzes the synthesis of double-stranded DNA from the template of viral RNA [140]. Inhibitors of the enzyme include 20 ,30 -dideoxynucleoside analogs such as AZT and ddC (Figure 2.29), which are classified as nucleoside-based RT inhibitors (NRTIs). NRTIs competitively block the catalytic activity of RT. A second class of enzyme inhibitors comprises the nonnucleoside-based RT inhibitors (NNRTTs) such as HEPT. Unlike NRTIs, NNRTIs inhibit RT through a noncompetitive mechanism, occupying a hydrophobic pocket located proximal to the enzyme’s catalytic site and interfering sterically with reverse transcriptase activity. 2.2.2.1 Heterodimers Composed of NRTI and NNRTI. Pontikis et al. [141] prepared divalent inhibitors of RT by tethering one molecule of NRTI to an NNRTI molecule through a flexible linker. Such dimers are designed to occupy the distinct but proximal catalytic (NRTI) and NNRTI sites simultaneously. Examples of the dimers are shown in Figure 2.29 along with their representa-
52
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS O Peptide 1
N H
O Scaffold
Peptide 2
O
H N O
General structure of dimeric peptide
CH3 O
H3C H 3C H3CO O
CH3 O
H 3C H N
N H CH3 CH3
O H3CO H 3C
H N O CH3
O CH3
OH O
H3CO O
N H
O
H3C H N
N H H 3C
O
N H H3C
CH3 O
H N
O H3CO
O OH
H 3C H N O CH3
H3C
O N H H3C
OH
H N
O
O CH3
37 O OH
NH-Thr-Ile-Val-OMe
O i, ii
O
N CH3 O
O
N
N H
CH3
36
OH
CH3 O
O iii
N O
N
36
O OH O
NH-Thr-Ile-Val-OMe O
reagents and conditions: i) Ethyl 4-bromobutanoate, K2CO3, DMF; ii) KOH, MeOH; iii) H2N-peptide-OMe, isobutyl chloroformate
Figure 2.28 Synthesis of divalent peptides designed on conformationally constrained sca¤old.
tive synthesis (Figure 2.30). These heterodivalent molecules (39 to 41) can inhibit HIV-1 multiplication in infected cells at micromolar concentrations, although their activities, as reflected in e¤ective concentration (EC50 ) values, are up to about 100-fold lower than those of NRTI or an NNRTI monomer control, such as AZT, ddC, or 38. Such undesired activity can be attributed to several factors, including unfavorable physicochemical and metabolic properties of the dimers, such as high molecular weight, low cell permeability, and a low degree of phosphorylation of the nucleoside. Other factors may lower the a‰nity of the heterodimers to RT, such as inappropriate covalent attachment of, and nonoptimal spacer length between, the NRTI and NNRTI units. The impact of these factors on activity is illustrated by the dimer 41 which has
HUMAN IMMUNODEFICIENCY VIRUS NRTI
NNRTI
O
HO
O N O
CH3
HN
N
N
O
O N O
HO
O
O
NH2 CH3
HN
53
O
S
N
H3CO
O
HO
C2H5
HN
CH3
S CH3
O N3 38
HEPT
ddC
AZT
NRTI
NNRTI
Linker
O C2H5
HN O
O
HN
N (CH2)n H
C-5
O N HO O
CH3
O 39 (n = 4, 10) O
N3
C2H5
HN O N-3 H 3C HO
CH3
S
N
O
H N
O
N N
N (CH2)10 H O
H N
N
CH3
S CH3
O
40
O
O
O N3 N-4 HN (CH2)12 N HO
Figure 2.29
C2H5
HN
41
O
H N
N
CH3
S
O
CH3
O N O
Structure of divalent inhibitors of HIV-1 reverse transcriptase.
linkage at the N4 position rather than at the N3 or CS position. It is about fiveto 10-fold more active than 39 or 40. 2.2.3
Glycoprotein 120 (gp120) on Viral Surfaces
Infection of T-cells by HIV-1 virus is initiated by the interaction of gp120 on the surface of the virus with the CD4 protein on a T-cell membrane (Figure 2.31) [142]. Infection also relies on a T-cell coreceptor, either CCR5 or CXCR4, in the viral attachment stage. Such initial adhesion depends on the interaction of multiple receptor–ligand pairs and is a prerequisite to the adsorption of a second viral protein gp41 to the T-cell surface. This process initiates membrane fusion, which is a critical step in the cell entry mechanism (not shown). This initial virus–cell recognition is believed to involve very tight
54
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS O
O C2H5
HN O
CH3 i, ii
N H
C2 H 5
HN
S
N
O HO
CH3
CH3
S CH3
O
iv NH-(CH 2)12-NH2
O HN
N iii
O N HO O
O N HO O O C2H5
HN N
S CH3
O
N HO
O
H N
HN
CH3
N
O O
41
reagents and conditions: i) Br(CH2)4CO2Me, K2CO3, DMF, 60oC (19%); ii) 1 M NaOH, acetone (94%); iii) (2,4,6-triisopropylphenyl)sulfonyl chloride, Et3N, DMAP, CH2Cl2; then H2N(CH2)12NH2 (33%); iv) 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), N-Methylmorpholine (NMM), DMF (69%).
Figure 2.30 Synthesis of NRTI-NNRTI heterodimer.
HIV viral core viral RNA
gp120/41 trimer gp41 gp120 CD4
CD4
T cell membrane Co-receptor (CCR5 or CXCR4)
Figure 2.31
Specific adhesion of HIV to T-cells.
HUMAN IMMUNODEFICIENCY VIRUS O
O O
N
55
O
O
i S
S
N
+
N
HS ovalbumin
O
O
S
S
O
O
ii CD4 peptide
N H
S
S n (= 3-5)
CD4 (41-84)-ovalbumin CD4 (40-57)-ovalbumin CD4 (81-92)-ovalbumin
reagents and conditions: i) N-succinimidyl 3-(2-pyridyldithio)propionate (24 eq), phosphate buffer, 25oC, 1 h; then gel filtration chromatography; ii) CD4 peptide (5-20 eq), phosphate buffer, 25oC, 2h: CD4 peptide (41-84): GSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYIC
Figure 2.32 Synthesis of CD4 peptide-based multivalent ligand presented on the surface of ovalbumin.
binding, based on the requisite multivalent interaction between an epitope on the C3 region of gp120 and a CD4 domain encompassing amino acid residues 40 to 57 [143,144]. 2.2.3.1 Neoglycoprotein-Displaying CD4 Peptide. Considering the specific nature of the HIV-cell interaction based on multiple pairing of the gp120–CD4 association, a multivalent molecule presenting ligands derived from the CD4 domain is predicted to bind to a viral surface presenting gpl20. Ghetie et al. [145] reported CD4-derived multivalent ligands prepared via the covalent tethering of three to five copies of CD4 peptide (sequence 40 to 57, 41 to 84, or 81 to 92) to an ovalbumin protein sca¤old (Figure 2.32). The CD4 peptide– ovalbumin conjugates can prevent recombinant CD4 protein from binding gp 120 with an avidity 10- to 20-fold greater than the a‰nity of monovalent peptide. For example, the inhibitory activity displayed by CD4 (41–84)– ovalbumin (IC50 ¼ 30 nM ) is about 20-fold more active than that of the CD4 (41–84) peptide, which translates to an increase of four- to sevenfold per peptide. The activity of the multivalent CD4 peptide depends on using the specific peptide sequence of the CD4 domain, supporting the supposition that residues 40 to 57 are required for CD4 to bind to gp120 [143,144]. 2.2.3.2 Galactosyl Ceramide Immobilized on Viral Surfaces. As discussed above, the CD4 surface receptor is a principal mediator of cellular attachment to HIV, although several lines of CD4-negative cells are nonetheless susceptible to infection by certain HIV strains. These conflicting observations suggest that more than one type of cellular receptor may play a role in viral invasion, thus providing an alternative mechanism for viral entry [146,147]. Galactosyl ceramide (Gal cer; Figure 2.33), expressed on the membranes of CD4-negative neural cell lines, binds to gp120 and probably provides an alternative route for virus attachment [148]. Harouse et al. [149] devised a binding assay based on high-performance thin-layer chromatography (HPTLC) using immobilized
56
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS Galactosyl ceramide OH HO
OH
OH OH
O
O
O
HO
O
OH
OH OH
HO
O
HN OH
O
O
OH OH
O
HN OH
O
HN OH
lipid bilayer
HO OH O HO OH
O N H
O O
O
S
O O
n
42 (n = 1, 2, 3)
O
Figure 2.33 Structure of galactosylceramide (Gal cer) presented as glycolipid in membrane and synthetic analogs of Gal cer.
glycolipids (Gal cer, GM1 , GD1a ) and measured the a‰nity of such multivalent glycolipids to gp120. The gp120 binds selectively to Gal cer (and galactosyl sulfatide), but not to glucosyl ceramide or other glycolipids. The value of the dissociation constant of Gal cer, 11.6 nM, is two- to threefold higher than that of gp120 to the CD4 receptor, which has a Kd value of 2 to 5 nM. Gal cer binding is confirmed further by studies using the anti-Gal cer antibody, which blocks the internalization and infection of HIV in CD4-negative cells [150]. The strength and specificity of the interaction implicate Gal cer as a specific cell surface ligand involved in viral entry to CD4-negative cells. In a di¤erent approach to identify the alternative mode of HIV infection via a non-CD4-dependent route, Conboy et al. [151] investigated the binding a‰nity of recombinant gp120 to naturally occurring glycosphingolipids (GSLs) displayed on the surface of planar lipid bilayers. Among the GSLs studied, galactosyl ceramide binds gp120 tightly; in contrast, lactosyl ceramide and glucosyl ceramide bind weakly. Synthetic analogs of galactosyl ceramide can recognize gp120, provided that they are presented on a planar membrane surface (Figure 2.33) [152]. These analogs consist of a galactosyl moiety that is tethered to the polar end of dioleoyl maleate through a spacer arm consisting of ˚ per ethylene mono-, di-, or triethylene glycol (supplying approximately 3 A
HUMAN IMMUNODEFICIENCY VIRUS
57
glycol). When Gal cer (42) is converted to a multivalent form by reconstitution at 5 mol% density in a planar membrane composed of 1,2-dioleoylphosphatidyl choline (DOPC), it binds to recombinant gp120 with a K a value in the range 2 to 5 10 6 for the spacer lengths tested. However, the amount of bound gp120 on the surface of the membrane is a¤ected by the spacer length as a consequence of di¤erent degrees of steric accessibility at the interface. For example, the Gal-presenting membrane that displays 42 (n ¼ 1) shows low surface coverage of gp120 at a level only twofold higher than that of nonspecific binding. Increasing the spacer length from n ¼ 1 to n ¼ 3 leads to a four- to sixfold increase in surface protein coverage compared to that of nonspecific binding. These data suggest a threshold spacer length that enables the galactosyl ligand to get into the carbohydrate-recognition region within gpl20. The binding to gp120 of Gal cer expressed in planar lipid bilayers is positively cooperative, with a cooperativity coe‰cient of about 1.5, and thus is much tighter than that of monomeric Gal cer [152]. 2.2.3.3 Multivalent Anions. The third variable region (V3) of gp120 has been implicated as a specific binding motif to the Gal cer ligand. This hypothesis is supported by several studies, including one in which monoclonal antibodies raised against the V3 region were able to block the binding of gp120 to multivalent Gal cer [153]. Thus, ligands that bind selectively to the V3 region should be e¤ective in blocking interactions between gp120 and Gal cer. For instance, suramin, a sulfonylated dimeric naphthalene derivative (Figure 2.34), can bind to gp120 (V3 ) as assessed by binding studies with tritium-labeled suramin. It inhibits the infection of colonic epithelial cells by HIV-1 at an IC50 value of 54 mg/mL [154]. NF036, a monovalent analog of suramin, is 100-fold less active in preventing viral infection, thus suggesting that the inhibitory activity of suramin derives from its divalent nature. A number of suraminlike polyanionic molecules can inhibit gpl20/CD4mediated adhesion of HIV to T-cells. Polyvalent anions 43 prepared from ‘‘telomerization’’—a type of chain reaction that produces a limited length of polymer (‘‘telomer’’)—of N-alkylated acrylamide monomers (Figure 2.35) [155] show defined molecular weights and present multiple negative charges in a ratio of 6 to 50 per polymer molecule. They block HIV-induced cytopathicity in CEM-4 cells. For example, 43 (n ¼ 23) shows an IC50 value of 1 mg/mL, an O
O
NaO3S HN
NaO3S
N NH SO3Na
HN
CH3 O
SO3Na
H 3C O
N H
SO3Na
NaO3S SO3Na
N H
Suramin
Figure 2.34
Cl NH SO3Na
O
NaO3S HN
NF036
Structure of suramin and its monomer NF036.
58
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS -O2C -O2C NH
O
O
N
Et "Telomerization" i) CH3(CH2)11SH (5 to 110 eq) AIBN, MeCN, reflux
Et C12H25
N
O
S
n O
N
Et
O
N
Et
43 (n = 1, 8, 15, 23)
ii) 2 M NaOH
HN
O CO2Me
CO2Me HN
O HN CO2-
CO2-
O CO2-
CO2-
Figure 2.35 Structure of polyvalent anionic surfactant prepared by telomerization of acryl amide monomer.
activity that is 20- to 40-fold higher than that of 43 (n ¼ 1, 8, or 15). This indicates that the inhibitory activities of the multivalent anions are influenced by the valency number, with higher valencies leading to greater activity. A di¤erent type of sca¤old, the polymerized micelle, enables the polyvalent display of anions (Figure 2.36). As illustrated by 45, polymerized micelles are prepared by g-polymerization of an aqueous micellar solution derived from undec-10-enoic acid (44) [156,157]. The advantage of this type of polymerization lies in the generation of polymers that have relatively small molecular weight (6 to 10 kDa) as a result of a low degree of polymerization. Such a beneficial result is possible since the number of monomers aggregated in the micelle is relatively small and the micelle stays intact during the progress of polymerization. The synthetic polyanion 45 can inhibit the replication of HIV in a cell culture assay with an IC50 value in the range 0.1 to 3.6 mg/mL. Multivalent anions are also designed on the basis of other sca¤olds, such as carbohydrate-derived oligomers (Figure 2.37). For example, molecules 46 and 47 are prepared by tethering multiple copies of monomer to multiple hydroxy groups present in cellobiose and g-cyclodextrin, respectively (Figure 2.38). This synthetic approach enables Leydet et al. and Schols et al. to prepare multivalent anions that present negative charges in the range 16 to 48 charges per molecule and are structurally better defined than polymer-based multivalent anions [158–160]. The multivalent anions 46 and 47 show strong inhibitory
59
HUMAN IMMUNODEFICIENCY VIRUS
-O2C
-O2C CO2-
-O2C CO2-
-O2C
-O2C 44
CO2-
-O2C CO2CO2CO2CO2-
-O2C
-O2C CO2-
-O2C CO2-
γ-Polymerization
-O2C CO2-
45
-O2C CO2CO2CO2CO2-
Figure 2.36 Polymerized micelle as a sca¤old for presentation of polyvalent anion.
activity against HIV-induced cytopathicity in MT-4 cells with IC50 values of 0.04 and 0.1 mM, respectively. Such activity is specific against HIV and relatively inactive against other viruses, including influenza, respiratory syncytial, and herpes simplex viruses. 2.2.3.4 Bivalent Antagonists of CXCR4. The chemokine receptors are another class of cellular surface proteins that play an essential role in HIV–cell adhesion. The class includes CCR5 and CXCR4, which are G-protein-coupled receptors (GPCRs) variably expressed on the surface of T-cells (Figure 2.31). Both are capable of interacting with HIV gp120 as coreceptors with CD4. Bicyclams, a family of bivalent azacrown molecules, are specific antagonists of
60
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS -O2C
S
S O
CO2-O2C
O O
O O
S
O
O O
O
CO2-O2C
S
S CO2-
O
S
O
S -O2C
CO2-
-O2C
cellobiose
-O2C
CO2- S
CO2CO2-
CO2CO2-
CO246
OR O
O
RO
OR
ORO
RO
O
NaO2C
CO2Na
O RO
R
O RO
γ-cyclodextrin
O O
S
O RO
OR
RO
OR
O RO
O OR
RO
OR OR O OR
RO ORO
O RO
RO O
O
S
CO2Na CO2Na
O
O OR
47
Figure 2.37 Multivalent anions derived from carbohydrate sca¤olds.
CXCR4. They include AMD-3100 and AMD-7049, both of which are composed of two identical cyclam units linked with a xylyl group (Figure 2.39). Bivalent molecules such as these protect cells from HIV infection [161], presumably by interfering with the interaction of gp120 and CXCR4. 2.2.4
Surface Carbohydrates on HIV
2.2.4.1 Oligomannose Sugars Present on gp120. The HIV surface presents a plethora of carbohydrates that are expressed in multiple copies. These sugars serve as viral surface ligands that are probably targeted by multivalent receptors. This notion is illustrated by cyanovirin-N (CVN), a mannose-binding natural protein of 11 kDa that is isolated from a cyanobacterium [162]. It is a potent inhibitor of all strains of both HIV and simian immunodeficiency virus (SIV) and is involved at the stage of gpl20-mediated virus–cell fusion [163]. The antiviral activity of CVN is attributed to its strong association to gp120 through its interaction with N-linked oligomannose sugars present on gp120 (Figure 2.40). Bewley et al. [164] suggested that each CVN molecule presents two distinct mannose-recognition sites that are located on opposite sides along the long axis of CVN. Each of the sites selectively recognizes a Man-al,2-linked
61
HUMAN IMMUNODEFICIENCY VIRUS OR O O OR OR RO RO O RO O OR O RO OR O O
RO
O RO
S
O S
O S
O
S CO2Na
CO2Na CO2Na
S
S
O
ii,iii CO2Na CO2Na
O
O RO
RO RO ORO
O
NaO2C
γ-Cyclodextrin (O-allyl): R = -CH2CH=CH2
O
OR O OR O OR O O OR
CO2Na
NaO2C
O O RO RO O OR RO O OR RO OR O
CO2Na
NaO2C
i
RO OR γ -CD OR O RO OR O O O OR RO RO O OR RO ORO OR O O RO
R = (CH2)3SCH(CO2Na)CH2CO2Na NaO2C
γ-Cyclodextrin: R = H
RO O
O
S
CO2Na CO2Na
47
O
O O
S
CO2Na CO2Na
O
CO2Na reagents and conditions: i) allyl iodide, NaH, DMF; ii) mercaptosuccinic acid, AIBN, THF, hν (254 nm); iii) NaOH, size exclusion chromatography (Sephadex gel G25)
Figure 2.38 Synthesis of multivalent anion tethered to cyclodextrin.
Man residue. The binding of each mannose-recognition site to the Man-a1,2Man disaccharide is not identical: The first binding leads to a high-a‰nity association, with a Ka value of 7:2 10 6 M 1 , while the second shows a lower Ka value of 6:8 10 5 M 1 [164]. Such sequential interaction indicates negative cooperativity. Nevertheless, with its two mannose-binding sites, CVN can bind gp120 with a nanomolar a‰nity constant, which probably results from association with multiple mannose ligands expressed on the gp120 trimer. While the structural details of bivalent binding remain to be established, two modes of
NH N
N HN
NHHN
NHHN AMD-3100
NH NH
N
N
HN HN
AMD-7049
Figure 2.39 Structure of AMD-3100 and AMD-7049 as a class of CXCR4 inhibitors.
62
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS Cyanovirin-N (CVN) high affinity site
low affinity site
intra-trimer inter-trimer
Man GlcNAc
gp120 trimer
enveloped virus (HIV)
Figure 2.40 Modes of binding of cyanovirin-N to oligomannose ligand present on HIV gp120.
bivalent association, between two gp120 trimers or within one gp120 trimer, have been suggested, as shown in Figure 2.40. 2.2.4.2 Modes of CVN Recognition. CVN shows unique structural and binding features distinct from those of most plant lectins, which exist as homodimers or homotetramers displaying a single carbohydrate recognition site per monomer [165]. Shenoy et al. [166] provided a thermodynamic basis for interaction between CVN and two di¤erent classes of al,2-linked oligovalent mannosides in water (Figure 2.41). First, a linear mannose ligand (48) binds to CVN in a 2:1 complex. In this model, the first binding is tighter than the second; the first dissociation constant, K d1 , of 3.48 mM is about 13-fold lower than the K d2 value from the second association. This di¤erence is not due to the di¤erence in enthalpic contribution because binding of 48 at either the first or second site leads to similar values of binding enthalpy. The di¤erent a‰nity at the two sites is due, rather, to the relatively unfavorable entropy change for the second binding event. Second, the binding of a trivalent antennary mannose ligand (49) to CVN leads to the formation of an overall 1:1 complex model in which one copy of branched 49 occupies two sites of the CVN molecule. Such binding generates two dissociation constants that di¤er approximately 10-fold: K d1 ¼ 0:27 mM; K d2 ¼ 2:70 mM. The overall binding a‰nity of 49 is about 10fold greater than that of 48 to CVN. The enhanced a‰nity of 49 can be attributed to a greater enthalpic contribution from the first binding event and to the gain in entropic contribution from the second. CVN binds the mannose-presenting gp120 with an equilibrium Ka value of 2:4 10 7 M 1 and an average stoichiometry of two molecules of CVN to one molecule of gp120. A similar binding feature is observed with respect to a‰nity
ROTAVIRUS HO OH O HO HO HO OO HO HO HO OO HO HO O
63
HO HO OH OH HO OH O O HO O HO HO HO HO HO HO HO HO OO OO OO HO HO HO HO HO HO HO HO OO OO O HO HO HO HO O OO HO
48
O
49
CVN
2:1 complex
CVN
1:1 complex CVN
CVN
n
Kd1 = 3.48 µM; Kd2 = 46.10 µM
Kd1 = 0.27 µM; Kd2 = 2.70 µM
∆H1 = -8.07 kcal/mol; ∆H2 = -8.76 kcal/mol T∆S1 = -0.51 kcal/mole; T∆S2 = -2.75 kcal/mol
∆H1 = -22.80 kcal/mol; ∆H2 = -0.38 kcal/mol T∆S1 = -13.71 kcal/mole; T∆S2 = 7.33 kcal/mol
Figure 2.41
Interaction between oligomannosides and cyanovirin-N.
and stoichiometry when CVN binds to a synthetic Man8 GlcNAc2 (51), a branched antennary mannose ligand with two CVN recognition sites (Figure 2.42): K a ¼ 5:4 10 1 M 1 . Another multivalent ligand, Man9 GlcNAc2 (50), binds CVN more tightly, with a Ka value of 1:3 10 8 M 1 and three CVN binding sites. The high specificity of CVN binding to Man8 GlcNAc2 and Man9 GlcNAc2 is associated with a multivalent binding feature: the presence of multiple copies of Man-a1,2-Man-a residues presented as terminal sugars on a dendritic sca¤old. By contrast, a lower-valency ligand such as Man6 GlcNAc2 (52), which displays only one terminal Man-a1,2-Man residue, shows a lower a‰nity to CVN.
2.3
ROTAVIRUS
Adhesion of the animal rotavirus to epithelial cells is mediated by the binding of a rotavirus receptor to a cell surface ligand comprised of sialyl-containing oligosaccharides expressed as various forms of glycoconjugates [167–169]. Like the influenza hemagglutinin–sialic acid interaction, such viral adsorption is based on tight binding driven by multivalency. Thus, monovalent sialoside serves as a selective ligand but binds rotavirus only weakly, with inhibition constant values larger than the millimolar concentration. Koketsu et al. [170] reported tighter binding of an inhibitor displayed on a liposome (Figure 2.43). This liposomal preparation is derived from 53, a phospholipid containing sialic
64
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
Man-α1,2-Man
HO HO HO HO HO HO
Man-α1,2-Man
Man-α1,2-Man
OH O OO
O HO O OH OO Man9GlcNAc2 (50) O HO HO O HOOHHO HOOH O HOO O OH OO O HO O O HO O O O O HO O HO HO OH NH O AcHN H HO HO OHHO NHAc HO HOOH
Man-α1,2-Man
HO HO HO HO HO HO
OH O OO O OH O
HOO HO O
HO HOOH HOO OO
O OH O HO O HO
OO HO O Man-α1,2-Man HO HOOHHO OHHO HO OH HO
HO HO HO
Man8GlcNAc2 (51)
O HO OO AcHN H
O O
NH NHAc
OH O O
HO O HO O HO HO OH HOO
OH O
OO HO O
Man-α1,2-Man HO HOOHHO OH HO
Man6GlcNAc2 (52)
O OH O HO O HO
O HO OO AcHN
O O
NH NHAc
Figure 2.42 Structure of N-linked multivalent oligomannosides (Man9 GlcNAc2 , Man8 GlcNAc2 , Man6 GlcNAc2 ).
acid on its end, and its mean diameter is estimated to be about 200 nm. It prevents cellular infection by human and simian rotaviruses with IC50 values of 4.35 and 16.1 mM, respectively, while those of a-methyl sialoside are 4.28 and 142 mM, respectively. Therefore, the inhibition of rotaviruses by a multivalent sialyllipid is about 103 - to 10 4 -fold more e¤ective than that of a monovalent ligand.
2.4
POLYOMA VIRUS
Polyoma virus is known to adhere to cell surfaces by recognizing a sialic acid ligand [81]. This interaction is inhibited competitively by a bivalent sialoside ˚ . This bivalent molecule linked with an oligo(glycine) spacer of roughly 57 A
PICORNA VIRUS O
O O
C15H31
O
O
OO P O
O
i
O + (H3C)3N
C7H14CH=CHC8H17
O
HO
OO P O
C7H14CH=CHC8H17
O
O Cl
AcHN
C15H31 O
OAc
AcO
65
O
O CO2Bn OAc OAc
AcO AcHN
ii
OAc
C15H31 O
CO2Bn O O OAc OAc
O
OO P O
O
C7H14CH=CHC8H17
O C15H31
O iii,iv
HO AcHN
OH
O CO2H O
OH OH
O
O
OO P O
O
C7H14CH=CHC8H17
53 reagents and conditions: i) 1,8-Octanediol, phospholipase D, H2O, EtOH; ii) AgOTf, CHCl3, iii) KOMe, MeOH; iv) H2, Pd/C
Figure 2.43 Synthesis of sialic acid–presenting phospholipid.
inhibits the agglutination of erythrocytes caused by polyoma virus with an activity about 500-fold greater than that displayed by a monomeric a-O-methyl sialoside [86].
2.5
PICORNA VIRUS
Picornavirus belongs to a family of nonenveloped RNA viruses encased in capsid proteins (VP1 to VP4) [171]. Other members of this virus family, such as poliovirus and coxsackievirus, include rhinovirus, hepatovirus, and enterovirus. A certain domain on the surface of this family of viruses contains broad depressions or canyons that play a major role as the adhesion of the virus to the cellular ligand [172,173]. The base of the canyon has an opening leading to a hydrophobic pocket made of the VP1 protein, which is occupied by a long, thin molecule, such as sphingosine, palmitate, and myristate, called a pocket factor (Figure 2.44). Tsang et al. [174] reported heteroaromatic ligands that resemble heterobivalent molecules and that are designed to bind a hydrophobic core of the VP1 capsid protein. Each of the molecules, such as 54 and 55, is composed of two heteroaromatic rings tethered by a short, nonflexible, 2-butene or pyridylmethyl linker such that each aryl domain occupies a subsite within the hydrophobic pocket [175]. Thus, 54 and 55 can e¤ectively inhibit picornavirus with minimal inhibition concentration (MIC) values of 3.2 and 0.26 mM, respectively, in a cell-based cytopathic assay. An analogous ligand, R-78206, is far more active, with an MIC value of 8 nM. It is also active against rhinovirus,
66
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS sphingosine (pocket factor)
Tethered
CH3 N S
S
N
N S
binding pocket of viral capsid
Cl
aromatic domain I aromatic domain II
CH3 N N
S
S
H3C N
N S
S
N
N
Cl
S
N S
55
54 O O
N
N
N
O R-78206
Figure 2.44 Hydrophobic pocket within picorna VP1 capsid protein and its complex with a pocket factor (hydrophobic linear alkane) or heterodimeric inhibitor.
with an IC50 value of 0.55 mM. Divalent linkage clearly enables the inhibitory activity of these molecules since untethered aromatic moieties comprising the inhibitors are inactive.
2.6
RESPIRATORY SYNCYTIAL VIRUS
Human respiratory syncytial virus (RSV) is a member of the paramyxovirus group of enveloped viruses [176]. Viral replication is inhibited by molecules that can interfere with cell-virus adsorption. Inhibitors of this type include heparinlike polysulfates and polysulfonates [177]. Viral replication is also inhibited by a di¤erent class of molecules known to interfere with virus–cell fusion mediated by a viral fusion protein. Examples of these are represented by 56 and 57, shown in Figure 2.45 [178–180]. These molecules are composed of a dianionic sca¤old domain and four benzenesulfonamides appended by eight arms that terminate in a primary carboxamide. They are active against human RSV with IC50 values of 0.05 mM (56) and 0.15 mM (57). Studies of both the structure–activity relationships and the biophysical measurements of these molecules attribute their activity to multiple structural and functional features. These include their ability to form multiple pairs of hydrogen bonds (due to the amide functionality), as well as electrostatic interactions (from anionic spacers) and hydrophobic interactions that facilitate the strong association with the
67
DENGUE VIRUS H2NOC(H2C) O N S H2NOC(H2C) O
NaO3S
NH
HN N
N N
NH
N H
N NH
HN O (CH2)CONH2 S N (CH2)CONH2 O
56
H2NOC(H2C)3 O N S H2NOC(H2C)3 O
NaO3S
NH
HN NH
N
N H
N
HN
NH
H2N
O (CH2)CONH2 S N O (CH2)CONH2
N N
SO3Na
H2NOC(H2C)3 O N S H2NOC(H2C)3 O
i
O (CH2)3CONH2 S N O (CH2)3CONH2
N
N
O (CH2)3CONH2 S N O (CH2)3CONH2
57
i O (CH2)CONH2 S NH O
O2N
O S Cl O
N N
SO3Na
H2NOC(H2C) O N S H2NOC(H2C) O
O 2N
O (CH2)CONH2 S N O (CH2)CONH2
HN
iv
i
O2N
N N
iii
O (CH2)CONH2 S N O (CH2)CONH2 NaO3S
N Cl
O (CH2)CONH2 S N O (CH2)CONH2
+
HN O (CH2)CONH2 S N O (CH2)CONH2
NH2
H 2N
v
SO3Na
reagents and conditions: i) Glycinamide, NaHCO3 (78%); ii) bromoacetamide, NaH, DMF (77%); iii) Fe, AcOH (76%); iv) 2,4,6-trichlorotriazine, buffer, pH 7, 0oC to 60oC (80%); v) DMSO, phosphate buffer, NaOH, microwave, 105oC, 1 h (10%)
Figure 2.45 Synthesis of fusion inhibitors of respiratory syncytial virus.
fusion protein. To bind the fusion protein as well as to show antiviral activity, molecules of this class must present at least three benzenesulfonamide appendages [181].
2.7
DENGUE VIRUS
The pathogenic dengue virus utilizes multiple copies of its envelope protein when attaching to the surfaces of target cells [182]. The viral surface protein binds with high a‰nity and specificity to a highly sulfated form of glycosaminoglycan, such as heparan sulfate, on the cell surface. This adhesion mechanism suggests the use of soluble, sulfated glycosaminoglycans and other polyanions as potential inhibitors against viral infection. Examples of poly-
56
68
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS OSO3O -O3SO O O OSO3O SO -O 3 -O3SO -O3SO OSO3O -O3SO OOSO3O OSO3O OSO3OSO3-O SO 3 -O3SO OSO3O O OSO3- OSO - O 3 OSO3OSO3O O O OSO3-O3SO Cyclodextrin sulfate (58)
-O3SO -
O3SO
OSO3OSO3OSO3NH O -O3SO -O SO O OSO3-3
OSO3-
OSO3OSO3O OSO3OSO3O OSO3OSO3Lactobionic acid sulfate (59) -O3SO NH
-O3SO O O O -O3SO RO RO O O O -O2C OSO3- R'HN O RO RO n -O2C OSO3- R'HN O R = H: Heparin R = SO3-; R' = SO3- (86%) & Ac (24%): Sulfated Heparin (60)
Figure 2.46 Structure of polyanions as an inhibitor of dengue virus.
anionic inhibitors (Figure 2.46) include suramin, sulfated b-cyclodextrin (58), sulfated lactobionic acid (59), and natural polyanionic polysaccharides such as heparin sulfate (60). Highly sulfated heparin decasaccharide e¤ectively blocks the binding of dengue virus envelope protein to the cell surface with a Kd value of 15 nM [183]. In a competition plate assay, O-sulfated heparin (60) shows a strong avidity to the viral envelope protein, with an IC50 value of 7.6 nM, which indicates a tighter association than that of densely sulfated heparin (760 nM) and suramin (700 nM) [184]. Therefore, inhibition of the dengue virus by polyanionic molecules is probably based on multivalent interaction, whose strength is controlled by three molecular parameters: the size of inhibitor, ˚ in length, a high density of anionic charge, which must be greater than 39 A and the structural flexibility of the inhibitor.
2.8 NUCLEIC ACIDS OF VIRUSES 2.8.1
RNA–Protein Interactions
Replication of HIV-1 is regulated by two types of RNA–protein interactions (Figure 2.47). The first interaction occurs between the transactivator protein
NUCLEIC ACIDS OF VIRUSES Rev recognition sequence ( C U U CU G GGCCAGA GAGC G CCGGUCU CUCG G A
GGCUGGU CCGACCG
A
UG
69
)
GG
AC G A
CGCAGCGUCA U
GCGUCGCAGU G A
A
TAR (HIV RNA) RRE domain II (HIV RNA)
Tat49-57
Ala-Ala-Ala-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Ala-Ala-Ala-Cys
Rev34-50
Thr-Arg-Gln-Ala-Arg-Arg-Asn-Arg-Arg-Arg-Arg-Trp-Arg-Glu-Arg-Gln-Arg
Figure 2.47 Secondary structure of TAR and RRE fragments of HIV RNA and RNAbinding peptide sequences from Tat and Rev protein.
(Tat) and the transactivator-response RNA element (TAR) in RNA. A second type of regulatory interaction is formed when a Rev regulatory protein (Rev) binds to a Rev response element (RRE). RRE belongs to a short nucleotide domain located within the HIV-1 RNA. Serving as a recognition domain for regulatory Rev protein, RRE is responsible for controlling the active export of the HIV genomic RNA [185]. 2.8.1.1 Neomycin B Linked to Acridine. Known inhibitors of the HIV RNA site include the aminoglycoside class of molecules, such as neomycin. These competitive inhibitors block the association of Rev protein to the RRE domain [186]. Kirk et al. [187] demonstrated that a synthetic, divalent molecule composed of an aminoglycoside and a nucleic acid intercalator is a potent inhibitor of Rev–RRE association. Molecules of this type are represented by a heterodivalent conjugate (61) composed of neomycin B covalently linked to 9-aminoacridine through a short spacer (Figure 2.48). In a gel shift assay, neomycin–acridine conjugate 61 can displace a portion of the Rev protein (peptide Rev34 –50 ) from the Rev–RRE complex with an IC50 value of 0.65 mM and is more e¤ective than neomycin (IC50 ¼ 5:9 mM ). Its binding a‰nity to the RRE is estimated at 15 nM, which is comparable to the a‰nity of 12 nM displayed by the Rev peptide (Rev34 –50 ). This high a‰nity is greater than that of the monomer components such as 9-aminoacridine and neomycin B, which have inhibition constants of 24,000 and 800 nM, respectively. This divalent molecule binds to the same region of the RRE as that targeted by the Rev peptide and thus competitively inhibits the formation of the Rev–RRE complex. This example illustrates the design and enhanced a‰nity of a synthetic bivalent ligand to a viral RNA site. 2.8.1.2 Neamine Linked to Pyrene–Carboxylic Acid. A second example of intercalator-linked aminoglycosides was reported by Hamasaki and Ueno
70
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
HO HO HO
NH2 O NH2
H2N O O O H
NH2 i,ii
OH
i-Pr
OH NH2
O H2N O OH HO
NHBoc O HO HO NHBoc i-Pr BocHN O NHBoc O O O S O H OH O i-Pr OH O NHBoc BocHN O OH HO
Neomycin B RNA binding molecule intercalator
HO HO H N
iii,iv,v
S
NH2 O NH2 H 2N O NH2 O O H OH
61
N OH O NH2 H 2N O OH HO reagents and conditions: i) (Boc)2O, DMF, H2O, Et3N, 60oC, 2 h (72%); ii) 2,4,6-triisopropylbenzenesulfonyl chloride, pyridine, rt, 20 h (75%); iii) H2NCH2CH2SH, NaOEt, EtOH, rt, 4.5 h (80%); iv) 9-phenoxyacridine, phenol, 60-75oC, 1 h (84%); v) 4 M HCl, dioxane, HSCH2CH2SH, rt, 5 min (80%).
Figure 2.48 Synthesis of neomycin–acridine heterodimer.
[188], in which neamine is tethered to pyrene-l-carboxylic acid with an argininecontaining spacer (Figure 2.49). A tethered molecule (62) inhibits the formation of the HIV RRE–Rev complex with an IC50 value of 0.35 mM which indicates tighter binding than that of neamine (21 mM ) or 63 (0.46 mM ). It can also inhibit the formation of the TAR–Tat complex with an IC50 value of 0.028 mM, an activity much greater than that of neamine (28 mM ) or 63 (0.6 mM ). The potent inhibitory activity displayed by 62 is attributed to its strong a‰nity to TAR and RRE, with dissociation constants of 30 and 8.5 nM, respectively. 2.8.2
RNA–Enzyme Interactions
Some molecules not only bind to RNA in a sequence-specific manner but also interfere with RNA–protein interactions occurring at the same sequence. Futaki et al. [189] reported the synthesis and activity of a bivalent molecule that not only binds to specific RNA sequences but, most remarkably, enables an otherwise nonselective ribonuclease (RNase) to cleave at specific RNA sequences. The concept of this artificial RNase is shown in Figure 2.50. First, a natural RNase is assembled in situ as a consequence of the noncovalent association of two proenzyme components, S peptide and S protein, which are derived from two proteolytic fragments from bovine pancreatic RNase A. This complex behaves like a functionally active enzyme, but it lacks the RNA sequence selectivity. However, this nonselective enzyme can be converted to a
71
NUCLEIC ACIDS OF VIRUSES intercalator NHMtr
O
HN H 2N HO HO
NH2 O H2N O HO
NH2 NH2
NH O
HO HO
iv,iii
H2N O HO
OH
NH
O
O i,ii
NH2
HN NH
NH
NH2 NH2 OH
Neamine
HO HO
NH O H2N O HO
62 NH2 NH2 OH
minor groove binder iii NH2
HN H 2N
NH
O HO HO
NH O H2N O HO
63 NH2 NH2 OH
reagents and conditions: i) Fmoc-Arg(Mtr)OH, EDC, DMF, water, rt, 16 h; ii) Piperidine, DMF; iii) TMSBr, TFA, 0oC, 2 h; iv) PyOSu, DMF, water, rt, 20 h.
Figure 2.49 Synthesis of neamine-based aminoglycoside–intercalator conjugate.
selective enzyme by using a tailored S peptide. The design of such an S peptide is based on covalent linkage of an intact S-peptide component to a specific peptide which is capable of binding an RNA sequence selectively. An example is an S-peptide derivative (64), which is composed of a Rev peptide (which recognizes the RRE) attached to an S peptide (which recognizes S protein). The complex made of 64 and an S protein is an artificial RNase S, which cleaves a nucleotide strand of RNA at a loop site between G55 and C56, located close to the RRE domain (Figure 2.50). The single cleavage site is proximal to a major cleavage site (C56 and A57) displayed by natural RNase T1. This artificial RNase S functions even at 10 nM of 64, a concentration that is 10 times lower than that required for an unmodified S peptide. That di¤erence is attributed to the higher binding a‰nity of the modified RNase S to RNA. 2.8.3
Binders to the Minor Groove of Viral DNA
2.8.3.1 Hairpin-Shaped Polyamide Dimers. A hairpin-shaped polyamide comprises two units of polyamide that are tethered at each end with a short spacer such as g-aminobutyric acid. Each polyamide consists of multiple copies of pyrrole (Py) and imidazole (Im). The resulting composite molecule binds a minor groove of double-stranded DNA with high sequence selectivity [190– 193]. Such sequence-specific recognition has been explored extensively by Dickinson et al. at the California Institute of Technology [194] using polyamide
72
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS natural RNase S
+ S-peptide S-protein (inactive enzyme)
active but nonselective enzyme
RNase S (targeted active enzyme)
64
S-protein RNA S-peptide
GG 54 G 41 C GGUCUG CGCAGC CCGGAC GCGUCG A A G A A 79 U
Rev-peptide (RRE recognition)
a major cleavage site by natural RNase S
RRE-containing RNA (Rev peptide)
H2NCO-R-Q-R-E-R-W-R-R-R-R-N-R-R-A-Q-R-T
O N H
O S
(S-peptide) N K-E-T-A-A-K-F-E-R-Q-H-NIe-D-S-CONH2 H
64
Figure 2.50 Generation of active ribonuclease S (RNase S) via noncovalent association of S peptide and the assembly of sequence-selective RNase S by use of S peptide tethered covalently to RRE-recognition peptide (Rev peptide).
dimers such as 65 and 66 (Figure 2.51). Their observed sequence selectivity is rationalized according to empirical rules based on side-by-side heterocycle pairings, which state that a pyrrole opposite an imidazole (i.e., a Py/Im pair) targets a C–G base pair, whereas Im/Py targets a G–C pair and Py/Py binds both T–A and A–T pairs. The polyamide 65 binds very tightly, with a Kd value of 0.05 nM, to a specific DNA sequence that is immediately adjacent to the binding site for TATAbox binding protein (TBP), a transcription factor. The tight binding is attributed to eight pairs of hydrogen-bond interactions between the polyamide and the DNA sequence. When mismatched interactions occur between the polyamide and nucleotide sequence, as observed from 66 (which yields four pairs of matched interactions), the binding avidity becomes weaker, with a Kd value of 5.0 nM. The DNA sites targeted by 65 lie immediately next to a TATA-box sequence with a Kd range of 1 to 3 nM. In fact, its association with the polyamide influences the binding of TBP, as demonstrated by a gel mobility shift assay, in which 65 inhibits the binding of TBP at the TATA sequence. This in vitro functional activity is further translated in vivo such that 65 blocks HIV-1 transcription with an IC50 value of 60 nM. One micromolar concentration of
NUCLEIC ACIDS OF VIRUSES
73
ImPy-β-ImPy-γ-ImPy-β-ImPy-β-Dp (65)
CH3 O N
CH3 O N N H
N
(H3C)2N
H N
H N
H N O
O
N H
N H N
O
O N CH3
N CH3
H N
H N
N H
N H H N
O
O
N H
N
O
N CH3
CH3 O N
CH3 O N
NH
N H N
H N O N CH3
NH
H N
N
O N CH3
O
O
H N
H N
H N O
N
N H
N
N H
O
N CH3
CH3 O N
CH3 O N
(H3C)2N
H N
N
O N CH3
O N H
CH3 O N
CH3 O N
N CH3
O
ImIm-β-ImIm-γ-PyPy-β-PyPy-β-Dp (66)
Match
TATA box
5'-A G A T G C T G C A T A T A A G C A-3' Kd = 0.05 nM
65 3'-T C T A C G A C G T A T A T T
Mismatch
C G T-5'
TATA box
5'-A G A T G C T G C A T A T A A G C A-3' Kd = 5.0 nM
66 3'-T C
T A C G A C G T A T A T T
C G T-5'
Figure 2.51 Structure of dimeric polyamides (hairpin-shaped) and a schematic of an HIV-1 promoter region showing recognition sites by polyamides and transcription factor TBP (TATA box).
65 also induces an 80% reduction of HIV-1 replication. This example with polyamide demonstrates that multivalent recognition on DNA confers a highly specific binding a‰nity and associated functional activity. 2.8.3.2 H-Shaped Polyamide Dimers. An H-shaped polyamide dimer allows dsDNA and the polyamide to make multiple contacts in a 2:1 binding mode. This unique design is achieved by connecting the centers of two polyamide strands through a lateral bridge (Figure 2.52). Sharma et al. [195] reported such H-shaped polyamides designed with a flexible alkane linker (67, n ¼ 5; 7). These serve as minor groove binders, and consequently inhibit the action of
74
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
N N N H
N (CH2)n N
i,ii (90%)
iii,iv Cl3C
N O (CH2)n
H C O3 N Me2N
N H
O N H
N N
N (CH2)O n N
CCl3
NO2
H N N O CH3
O
(70%) Cl3C
N
N NMe2 ix,x
H2N
S
CH3 H N O
(38%) Me2N
N N (CH2)O n N
v-vii
N H N
N
O
(60%)
N O 2N
O2N
N
H C O3 N N H
H N
N
H N N O CH3
N
O
N
N H H3C
67 (n = 5, 7)
viii (62%)
NO2
N O (CH2)n O
N H
CCl3
S
NH2
N
reagents and conditions: i) K (metal); ii) Br(CH2)nBr; iii) CCl3COCl; iv) Et3N; v) Ac2O; vi) HNO3; vii) H2SO4; viii) N-Methyl-3-amino-5-[(3-dimethylaminopropyl-1-amino)carboxyl]pyrrole, DMF; ix) H2, Pd/C; x) 2-Amino-4-methyl-thiazole-5-carboxylic acid, DCC, HOBT.
Figure 2.52 Synthesis of H-shaped polyamide linked through a lateral bridge.
DNA gyrase in supercoiling DNA at micromolar concentrations. The level of activity by 67 is about 10-fold higher than that of natural distamycin, a member of natural polyamides. 2.8.3.3 Naturally Occurring Dimers. There are numerous examples in nature of molecules that exist as dimers or oligomers and exhibit unique biological activities not possible with the corresponding monomers (Figure 2.53). Such oligomeric molecules are represented by a family of over 70 forms of natural quinones that include dimers, trimers, cyclotrimers, and higher oligomers [196]. Conocurvone (69) is a deoxytrimeric quinone molecule that is probably derived from teretifolin B (68) [197,198]. This trimeric quinone strongly inhibits HIV-1 replication. At a concentration below the EC50 value of 20 nM, it averts completely the death of HIV-1-infected human lymphoblastoid cells by inhibiting replication of the virus. Such potent anti-HIV activity [81] is associated uniquely with trimeric presentation of quinone because the monomer 68 lacks such activity completely. Little is known regarding the mode of action of 69, but it may be related to its ability to form a helix, which is not possible with a monomer. The resulting helical molecule then binds the groove of DNA strand and interferes with the replication and transcription of virus-derived nucleic acid. Examples of dimeric quinones that interact with DNA possibly by such a mechanism include viomellein (70) [199] and michellamine (71), which belongs to the family of dimeric naphthylisoquinoline alkaloids that also includes jozimine C and korundamine [200]. Michellamine is highly active against HIV-1 and HIV-2 [201].
NMe2
NUCLEIC ACIDS OF VIRUSES
75
CH3 O O O
O OH H3C
O
H 3C
O
O O
O O
O O H 3C
CH3
CH3
H3C
CH3
CH3 CH3
CH3
CH3 69 (conocurvone)
68 (teretifolin B)
HO H3C O
CH3
OH O O
O OH OH O
H 3C
HN H3C H 3C
O 70 (viomellein)
OH H3CO HO CH3 CH3 NH
OH OCH3 HO 71 (michellamine B)
OH
CH3
Figure 2.53 Structure of naturally occurring oligomeric molecules that display antiHIV activity.
antigenic epitopes
membrane
pathogen (virus, bacterium)
antigenic epitopes
antigenic epitopes
Protein scaffold
Protein scaffold
synthetic multivalent vaccine
Figure 2.54 Surface of pathogen carrying multiple copies of antigenic epitopes, and synthetic multivalent molecules presenting multiple antigenic determinants.
76
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS Dde-HN
O
O HN
NH-Dde
HN
NH2
i,ii,iii
iv O
O
O
O
O
NH-Fmoc
O O
NH v NH
HN NH
NH-Fmoc Solid support
M2
O
O
M2
HN
S1 S1 S2
NH
HN
O O
O
O
O
O NH-Fmoc
HN vi
O
O O
O O
HN
NH
O
HN NH
HN
H N
HN
H N
N H
HN RS
H N
NH
H N
HN HN
NH
S2
O
O O
72
O NH-Fmoc
HS
H N
N H
O O
NH NH
HN
M2
M2
O
O
HO
O
HN
HN
S1 HN H N H N HN vii,viii HN
O O
N H
O
NH
S2
H N
O
HN
NH O
O
NH
HN
NH
HN
O
NH
HN
NH
O O
S
O
O
H N
N H
O O
HN
O O
NH NH
NH2
NH2
M2
O O
O
S
H N
H N
73 O NH
OH
HO M2 = SLLTEVETPIRNEWGSRSNDSSDP S1 = SFERFEIFPKE S2 = HNTNGVTAASSHE
O HN
reagents and conditions: i) 20% piperidine, DMF; ii) standard F-Moc solid-phase peptide coupling with M2 peptide (to terminal Boc-protected serine); iii) 2% hydrazine, DMF; iv) F-Moc standard coupling of Fmoc-Gly-OH, and Dde-Lys(Fmoc)-OH; v) standard peptide addition of M2, S1, S2, and final coupling of Fmoc-Gly-OH, and Fmoc-Cys(Trt)-OH; vi) peptide cleavage from resin; vii) 2,2'-dithiodipyridine; isolation of a disulfide product, and its reaction with free thiol 72; viii) 20% piperidine, DMF.
Figure 2.55 Synthesis of an octavalent peptide construct carrying three types of antigenic determinants.
SYNTHETIC MULTIVALENT VACCINES
2.9
77
SYNTHETIC MULTIVALENT VACCINES
Synthetic vaccines include multivalent molecules that present multiple copies of antigenic determinants tethered to a sca¤old. They are designed to mimic the critical parts of antigenic sites and ectodomains found on the surface of pathogenic viruses and bacteria (Figure 2.54). With multiple determinants on its surface, a multivalent molecule is likely to cross-link antigen-specific immunoglobulin receptors on a B-cell and thus stimulate immune responses against specific antigens [3]. 2.9.1
Peptide-Based Anti-influenza Vaccines
Kragol et al. [202] reported a peptide-based multivalent vaccine designed to stimulate immune responses against influenza virus (Figure 2.55). This molecule (73) presents four copies of an ectodomain derived from the viral M2 protein, a membrane-bound ion channel, as a B-cell epitope, and two copies of S1 and S2 fragments as T-helper cell epitopes. Targeting B- and T-cells with three such distinct types of cross-linked epitopes makes the synthetic vaccine more likely to be a potent B-cell immunogen.
N
O
NH2
O
O
O N H2N
i) DMF, 3h
O
O
O
O
N
N O
O
n ii) Ac-CGSGVRGDFGSLAPRVARQL (FMDV peptide), H2O, 6h
water soluble carbon nanotube Ac-Cys-FMDV peptide S
O N
O
N O
Ac-Cys-FMDV peptide S
O
H N
O
O H N
N O
O
O
O
N n
Figure 2.56 Structure of foot-and-mouth VP1 peptide displayed on the surface of a single-walled carbon nanotube.
78
2.9.2
MULTIVALENT MOLECULES APPLIED TO VIRAL TARGETS
Gp41-Based Anti-HIV Vaccine
Wang and Singh [203] described the synthesis of multivalent peptides that present four copies of gp41 epitope incorporating the T20 domain, a sequence responsible for potent HIV inhibition. The design of this synthetic vaccine is based on the use of a carbohydrate-centered maleimide cluster, which is readily derivatized with a thiol-containing peptide. 2.9.3
Peptide-Based Anti-FMDV Vaccines
Synthetic vaccines targeting the foot-and-mouth disease virus (FMDV) are designed with a lipidated, lysine-cored dendrimer that displays four copies of a cyclic disulfide epitope derived from the virus [204]. This multivalent peptide is immunogenic and has been used for a vaccination trial. In another example, a unique framework based on single-walled carbon nanotubes (SWNTs) is used for displaying antigenic determinants. Pantarotto et al. [205] investigated the use of such material in the preparation of multivalent antigens derived from FMDV. This conjugate is composed of water-soluble amine-terminated SWNT (about 0.3 to 0.5 mmol/g) that is derivatized to present on its outer surface multiple copies of viral envelope peptide VPl of FMDV (Figure 2.56). The peptide on the surface retains its original conformation as well as its original activity and is readily recognized by anti-VP1 antibodies. This nanotube-based antigen induces a strong antibody response in mice.
3 MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
3.1 3.1.1
TARGETS IN BACTERIAL CELL MEMBRANES d-Ala-d-Ala Peptide Precursors
3.1.1.1 Mode of Action by Antibiotics of the Vancomycin Class. Chlororemomycin, a member of the vancomycin group of antibiotics, exerts its antibacterial activity by binding a d-Ala-d-Ala terminus—a cell wall precursor presented on the surface of gram-positive bacteria [206]. Such binding interferes with the biosynthesis of bacterial cell walls (Figure 3.1), thus leading to the death of the bacterial cells. Mackay et al. at Cambridge [207] studied the association of chloroeremomycin in solution using a peptide ligand presenting d-Ala-d-Ala, which shows a strong association and a Ka value of 1.3 10 6 M 1 This tight binding stems primarily from the formation of multiple pairs of hydrogen bonds established between the antibiotic and the divalent ligand (Figure 3.2). In a peptide cell wall model of vancomycin-resistant bacteria where a terminal d-Ala residue is replaced by d-lactate (d-Lac), the association constant of chloroeremomycin with such a modified dipeptide terminus decreases about 1000-fold, to 920 M 1 [65,208]. This weak association is not only attributed to a reduction in the number of attractive hydrogen bonds but importantly, to the generation of a repulsive dipole–dipole interaction between the ester oxygen of
Synthetic Multivalent Molecules: Concepts and Biomedical Applications, By Seok-Ki Choi ISBN 0-471-56347-1 Copyright 6 2004 John Wiley & Sons, Inc.
79
80
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS D-Ala D-Ala L-Lys D-Glu L-Ala HO O HO AcHN
N H
CH3OH O HO OO O O O HO AcHN AcHN
O O O
H3C
D-Ala D-Ala L-Lys D-Glu L-Ala
Transpeptidase-mediated transpeptidation
Inhibited by
HO HO HO AcHN
Vancomycin β-Lactam
D-Ala D-Ala L-Lys D-Glu L-Ala
OH O HO O NHAcHO AcHN O
O O O H3C
L-Ala D-Glu L-Lys D-Ala NH
CH3 O OH HO O O O O O HO AcHN AcHN
HN D-Ala L-Lys D-Glu L-Ala
N H
OH CH3 OH HO O O O O O O HO O NHAc NHAc O AcHN
L-Ala D-Glu L-Lys D-Ala D-Ala
Cross-linked peptidoglycan layer
CH3 O OH O O O O AcHN O O OP P O O-O
Bacterial inner membrane Immature peptidoglycan D-Ala D-Ala L-Lys D-Glu L-Ala HO HO HO AcHN
NH2
CH3 O OH HO O O O O O HO AcHN AcHN
D-Ala D-Ala L-Lys D-Glu L-Ala CH3 O OH O O O O AcHN O O OP P O O-O
Lipid II intermediate
Transglycosylase-mediated transglycosylation Inhibited by Moenomycin Teicoplanin Chlorobiphenyl vancomycin
D-Ala D-Ala L-Lys D-Glu L-Ala HO HO HO AcHN
CH3 O OH O O O O AcHN O O OP P O O-O
Figure 3.1 Biosynthetic pathway of a peptidoglycan layer in a bacterial cell wall and selected inhibitors that block it at di¤erent stages.
d-Lac and an amide oxygen (Figure 3.2) [209]. This model demonstrates that chloroeremomycin relies on the well-ordered receptor–ligand interaction with d-Ala-d-Ala as a primary mechanism of action. When studying the binding a‰nity of the vancomycin group of antibiotics, planar lipid bilayers or liposomes (see Section 1.1.3) that present multiple copies of precursor peptide ligands such as d-Ala-d-Ala or d-Ala-d-Lac on their surface are commonly used as models of bacterial cell membranes. For example, liposomes presenting multiple copies of d-Ala-d-Ala ligand on their surface, such as N a -docosanoyl-N e -acetyl-lysyl-d-alanyl-d-alanine, recognize chloroeremomycin with a Ka value of 2 10 7 M 1 as determined by surface plasmon resonance [210]. That association constant is 15-fold tighter than when performed with a free ligand in solution. Although the enhancement is
TARGETS IN BACTERIAL CELL MEMBRANES H2N HO OH O H3C CH3 HO O
(a)
O N H N H
O HO
Chloroeremomycin OH O O
H 2N HO O H3C CH3 O
O
O
Cl H N
O
Cl
N O
OH O
O N
H CONH2
H
N H
OH OH
N H
O
CH3 H N O
H 2N HO OH O H 3C CH3 HO O
O O HO
N H N H
O OCH3
OH H-bond
O O
H2N HO O H 3C CH3 O
O
O
Cl H N
O N O
H
Cl
dipole repulsion OH O
O
N H CONH2
N H
OH OH H N
H3C O
O H 3C N H
NHAc
CH3 NH CH3 CH3
O HO
H-bond
Nα,Nε-(Ac)2-Lys-(D)-Ala-(D)-Ala (VSE ligand)
NHAc
(b)
CH3
Ka = 1.3 x 106 M-1 O
H N
H3C
CH3 NH CH3
O HO
81
Ka = 920 M-1
O O O
OCH3
Nα,Nε-(Ac)2-Lys-(D)-Ala-(D)-Lac (VRE ligand)
Figure 3.2 Chloroeremomycin and its association to divalent ligand in solution: (a) tight association via multiple pairs of hydrogen bonds (dotted lines) with d-Ala-d-Ala ligand; (b) weak binding to d-Ala-d-Lac ligand as a result of a reduced number of hydrogen bonds and dipole–dipole repulsion (double-arrowed line).
somewhat modest, the observed binding a‰nity on the model surface is indeed close to a value observed with the surface of a bacterial cell (K a @10 8 M 1 ) [211]. This type of enhanced a‰nity from a vancomycin-sensitive cell wall model is also found to a greater extent in a model for a vancomycin-resistant cell wall. For example, the association constant of chloroeremomycin to a liposome presenting multiple d-Ala-d-Lac termini (N a -docosanoyl-glycyl-alanyld-g-glutamyl-N e -acetyl-lysyl-d-alanyl-d-alanine) is 2.5 10 5 M 1 , which is 250-fold higher than that obtained with free d-Ala-d-Lac ligand.
82
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
Figure 3.3 Dimerization of glycopeptide antibiotic and its implication in its multivalent binding to d-Ala-d-Ala (or d-Lac) ligand present on cell membrane.
3.1.1.2 Dimerization of Glycopeptide Antibiotics. The examples described in the preceding section show that chloroeremomycin binds more tightly to a model membrane of a bacterial cell wall than it binds to free ligand. Williams [80] attributed this property to the greatly enhanced ability of the glycopeptide to form dimers on the cellular surface. For example, chloroeremomycin undergoes noncovalent dimerization, in the absence of any ligands, with a dimerization constant K dim value of 1.8 10 5 M 1 . In the presence of d-Ala-d-Ala ligand, K dim increases to 1.1 10 7 M 1 (Figure 3.3). This observation suggests that the enhanced a‰nity on a surface is probably attributed to enhanced chloroeremomycin dimerization, since receptor dimerization helps to reduce the loss of overall entropy generated upon receptor–ligand association. This example is considered as a cooperative system where ligand–receptor association enhances receptor dimerization as well as lowers the energy of divalent complexation. Glycopeptide antibiotics of the vancomycin class show varying degrees of self-dimerization with K dim ranging from about 500 to 10 8 M 1 (Figure 3.4) [212,213]. This ability to self-associate varies from a strong tendency, such as that of eremomycin, to the weak dimerization ability of vancomycin. As described earlier, antibiotic dimerization increases in the presence of bound ligand. For example, the dimerization constant of eremomycin increases about 100-fold, from K dim ¼ 3 10 6 M 1 in the absence of ligand to 3 10 8 M 1 upon incubation with N a, e -di-Ac-Lys-d-Ala-d-Ala [212,213]. With a K dim of 700 M 1 , vancomycin dimerizes relatively weakly in solution although it is highly active against gram-positive bacteria presenting d-Ala-dAla peptide precursors on their peptidoglycan layer. The drug shows potent
TARGETS IN BACTERIAL CELL MEMBRANES OHNH2 OH Glucose O HO OH H3C CH3O O Vancosamine O Cl O O HO O N H N H
O HO
Cl H N
O N O
OH O
O
N H
N H CONH2
H
83
Vancomycin Kdim (M-1) = 700 CH3 NH CH3 CH3
O OH OH HO HO OH Rhamnose HO Me O
HO OH Mannose OH OH O OH Arabinose O O OOH
O Glucose O Ristosamine HO H 3C
O O
O NH2 O O O
HO
N H N H
OHO
H N
N O
H
NH2
Ristocetin A Kdim (M-1) = 500
O OH
O HO HO OH HO
H 2N HO OH O H 3C CH3 HO O Epivancosamine H 2N HO O H 3C CH3 O O O
N H
CH3
O OH HO
HO OH O
N H
HO
O
HO
OH
O
N H N H
Glucose OH O O
O
O
X H N
O N O
O
H
X
O
N H CONH2
OH O N H
Eremomycin (X = H) Kdim (M-1) = 3 x106; Kdim (M-1) = 3 x108 (with ligand) CH3 NH CH3 CH3
Chloroeremomycin (X = Cl) Kdim (M-1) = 1.8 x105; Kdim (M-1) = 1.1 x107 (with ligand)
OH OH HO
Figure 3.4 Dimerization constant of glycopeptide antibiotics of the vancomycin class.
84
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
antibacterial activity against numerous strains of Staphylococcus aureus and vancomycin-susceptible enterococcus (VSE) with a minimal inhibition concetration (MIC) a 1 mM. However, the activity of vancomycin decreases about 700-fold against strains of vancomycin-resistant enterococcus (VRE), which present d-Ala-d-Lac on its surface, with an MIC of about 700 mM [214]. Such reduced activity of vancomycin is associated with its decreased binding a‰nity to the VRE ligand as reflected in the millimolar dissociation constant to Ac2 Lys-d-Ala-d-Lac (Kd = 1.8 mM), which is roughly 1600-fold weaker than when binding to Ac 2 -Lys-d-Ala-d-Ala (K d ¼ 1.1 mM ). The dimerization of glycopeptide antibiotics also occurs in the solid state. For example, vancomycin forms a dimeric complex with acetate or N-Ac-d-Ala [215–217]. The x-ray crystal structure reveals two di¤erent types of dimeric interaction, as shown in Figure 3.5. Ligand-independent association yields a back-to-back dimer, while ligand-mediated association yields a face-to-face dimer. This structural information provides a rationale for designing synthetic covalent dimers of vancomycin though the structure is based on solid state rather than solution phase. It is of particular relevance that vancomycin dimerization leads to increased a‰nity to its target, which can be translated to increased antimicrobial activity. 3.1.1.3 Di- and Trivalent Vancomycin. Gri‰n et al. at Stanford and Eli Lilly [218] reported that a covalent dimer derived from vancomycin enhanced antibacterial activity, possibly through a mechanism of divalent association, as shown in Figure 3.6. As summarized in Figure 3.7, the dimer is composed of two vancomycin carboxamides tethered with a hydrophobic linker at the carboxylic acid terminus of vancomcyin. The MIC of dimers 1, 2, and 3 against VRE in vitro are 32, 11, and 15 mM, respectively. Thus, dimer 2 shows an increase in antibacterial activity over the parent vancomycin by a factor of 60. The antibacterial activity of dimers 1, 2, and 3 against VSE strains is enhanced as well, but to a lower degree, with MIC values of 0.51, 0.50, and 0.29 mM, respectively. Such dimer activity represents only a two- to threefold enhancement relative to vancomycin. These vancomcyin dimers can bind a nonclustered form of the VRE model peptide ligand (Ac2 -Lys-d-Ala-d-Lac) in solution with dissociation constants of 180 mM (1), 440 mM (2), and 660 mM (3). Such dissociation strength indicates 3- to 10-fold tighter complex formation than that of the vancomycin monomer, which shows a Kd value of 1800 mM. The moderate decrease in Kd for dimer-ligand binding in solution does not appear to account fully for the 60-fold enhancement of the dimers’ in vitro antibacterial activity. The enhanced antibacterial activity may be accounted for by considering the additional contribution derived from the intrinsic ability of a covalent dimer to bind a cluster of d-Ala-d-Lac ligands present on a bacterial surface. The stability of the divalent vancomycin–ligand complex would be much greater than that achieved with monovalent ligand. The multivalent nature of vancomycin’s interaction with the d-Ala-d-Ala peptide ligand has prompted further biochemical studies. Using a di¤erent set
TARGETS IN BACTERIAL CELL MEMBRANES CH3 O
(a) -O
N H
O
OH
CH3 HO
OH O
CH3
H2NOC H N
H 3C
H N HN CH3 O HO
O
H
H N HO 2 H3C
O
OH3C O
OH OH
OH O O
O CH3O
N H N H
HO
OH
O
HO HO
O
OH O
O
O O HO
HO O
N H Cl
O
Cl
H N H N
O
N
Vancomycin (back-to-back dimer)
O
O
Cl H N
O
OH O
O
N H
N
H CONH2
H
NHOH 2
Cl
N O
CH3
OH OH
H N
H3C
HO
O H N HO 2 H3C
HO HO O CH3O
HO O O HO
N H N H
OH O O O
O
Cl H N
O H
OH O
O
N H
N
H CONH2
HO
-O2C -O2C O
N H NH
CH3 H N
NH O CH3
N-Ac-D-Glu-L-Dap-D-Ala-D-Ala
O OCH3
O
CH + 3 NH2 CH3 CH3
O OH OH O H 2N
CH3
Cl
N O
CH3 NH CH3
O
(b)
85
Vancomycin (face-to-face dimer)
O OH
OCH3
HO
CH3 CONH2 CH3 H O H H N N N H2N+ N CH3 O H O O HO Cl Cl
O
OH O H N H N
OH O
O OH
O O O HO
OH3C O
OH OH
CH3 NHOH 2
Figure 3.5 Structure of noncovalent vancomycin dimers formed in the presence of ligand: (a) back-to-back dimer with N-Ac-d-Ala; (b) face-to-face dimer with N-Ac-d-Glul-Dap-d-Ala-d-Ala.
86
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
D-Ala-D-Ala L-Lys D-Glu Immature peptidoglycan L-Ala CH3 O OH HO OH HO HO O O O O HO O OO O HO AcHN O AcHN AcHN AcHN O O OP P O H3C O O-O L-Ala D-Ala-D-Ala D-Glu L-Lys bacterial membrane CH3 O H ON N O OH O H CH3 OH HO O CH3 H2NOC Linker HN N H H O H 3C H H H O N N N N HN N CH3 O H O O O HO OH Cl Cl
O
O O O
HO
OH3C CH3 OH O HO H2N OH
HO HO HO AcHN
OHNH2 OH O HO H3C CH3O
OH O O
HO O O NH
N H N H
O
O
Cl H N
O N O
Cl OH O
O N
H CONH2
H
N H
O OH OH HO
D-Ala-D-Ala L-Lys D-Glu L-Ala CH3 O OH HO O O O O O HO AcHN AcHN
O N H L-Lys D-Glu L-Ala
CH3 H N O
CH3 NH CH3 CH3
O OCH3
D-Ala-D-Ala
CH3 O OH O O O O AcHN O O OP P O O-O
Figure 3.6 Proposed multivalent binding of a covalent vancomycin dimer to multiple d-Ala-d-Ala residues present on a bacterial cell surface.
of synthetic glycopeptide contructs, Rao and Whitesides [219] investigated the association of a divalent system derived from vancomycin and the d-Ala-d-Ala peptide ligand (Figure 3.8). A vancomycin dimer (4) presents two vancomycin units tethered at the C-terminus through a rigid linker, p-xylylenediamine, readily prepared by amide coupling. A Kd value of the divalent complex formed between 4 and 5 is about 1.1 nM when measured using a competitive binding assay based on a‰nity capillary electrophoresis (ACE). This bivalent interaction thus demonstrates about a 600-fold enhanced a‰nity relative to the corresponding interaction between vancomycin alone and diacetyl-l-Lys-dAla-d-Ala (Kd of 4.8 mM ). The free energy of association involved in such a divalent complex is 11.9 kcal/mol, while the monovalent complex generates 8 kcal/mol [220,221]. The di¤erence between the two G values—3.9 kcal/mol— might indicate a contribution from a second binding event driving the divalent complex formation. Indeed, the di¤erence in G values is equivalent to a high e¤ective molarity of about 20 mM for the second ligand unit in this particular association.
87
TARGETS IN BACTERIAL CELL MEMBRANES OHNH2 OH O HO O H3C CH3
OH O O
HO O O HO
N H N H
O
O
Cl H N
O
Cl
N O
H
OH O
O N
H CONH2
O OH OH
N H
CH3 NH
H2N-Linker-NH2 (0.5 eq) HBTU* (2.2 eq) DMSO, DMF
CH3 CH3
Vancomycin
OHNH2 OH O HO H3C CH3O
HO
OH O O
OH HO
O O
CH3 H 3C
HO
OH
H N
HN CH3 O HO
H2NOC H N O
Cl
H N O
O
H N H N
O N H Cl
HN O
N H N H
O
Cl H N
O N O
H
O
Cl
O N
H CONH2
OH O N H
CH3 NH CH3 CH3
OH OH
O OH
HO
O 1: Linker = (CH2)6
O O HO
Linker
O NH
O
OH3C CH3 OH O HO H2N OH
2: Linker = (CH2)2-S-S-(CH2)2 3: Linker = (CH2)3-S-S-(CH2)3
HBTU*: 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
Figure 3.7 Synthesis of divalent vancomycin carboxamide (linked from C-terminus to C-terminus).
Using surface plasmon resonance (SPR) spectroscopy, Rao et al. [222] further studied the binding a‰nity of 4 to peptides presented on the surface of selfassembled monolayers (SAMs). The dimer 4 binds to the SAM, presenting 5% of d-Ala-d-Ala ( wL ¼ 0.05) with a calculated Kd value of about 0.5 nM. Such tight surface adhesion is ligand-specific, as demonstrated by the competitive displacement by free N-Ac-d-Ala-d-Ala, the addition of which reduces the amount of dimer bound on a surface. In comparison, vancomycin, with a Kd value of 1.1 mM, is less e¤ective in blocking binding of the vancomycin dimer to the SAM surface. The results from an SPR study indicate that 4 binds multivalent d-Ala-d-Ala displayed on the surface with an a‰nity >1000-fold enhanced relative to the parent molecule, vancomycin. As shown in Figure 3.9, Rao et al. [50] extended their investigation to include the association properties of a trivalent system derived from vancomycin and d-Ala-d-Ala. A tris-vancomycin carboxamide (6) is composed of three vancomycin units linked to the sca¤old of benzene–tricarboxylic acid through
88
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS OHNH2 OH O HO H3C CH3O
OH O O
OH HO CH3 H 3C
H N HN CH3 O HO
OH
HO O
O H2NOC H N O
Cl
H
O
N
N H Cl
O O
H O N
N O H
H N H N
N H N H
O
O
Cl H N
O N O
H
O N
H CONH2
O
O
Cl OH O N H
CH3 NH CH3 CH3
OH OH
OH HO
O O O
HO
OH3C CH3 OH O HO H2N OH
4
O CH3 O -O O
N H
H HN N CH3 O
CH3 NH O O
O
HN
N NH H
H3C
CH3 H N O
O OCH3
O 5 [CH2CONεH(Nα-Ac)-L-Lys-D-Ala-D-Ala-CO2-]2
Figure 3.8 Divalent system of receptor–ligand pair derived from vancomycin and d-Ala-d-Ala.
an amide bond at the C-terminus of vancomycin (Figure 3.10). Similarly, a trivalent ligand (7) is made of three copies of d-Ala-d-Ala ligand tethered to benzenetricarboxylic acid. The trivalent vancomycin 6 makes a complex with the analogous trivalent ligand 7 at an extremely low dissociation constant of about 4 1017 M. This observed avidity of the trivalent vancomycin-d-Ala-dAla system is, in fact, 25 times greater than the a‰nity of the biotin–avidin system (K d A 1015 M ) [223], which belongs to one of the tightest naturally occurring systems. In contrast, 6 binds to a monovalent ligand, N a, e diacetyl-l-Lys-d-Ala-d-Ala, with a K d value of 2.7 106 M. This value is close to the dissociation constant of 1.6 106 M shown by the monovalent complex formed by vancomycin and N a, e -diacetyl-l-Lys-d-Ala-d-Ala. The thermodynamics of the multivalent interactions involved in the complex formation of 6 7 are introduced in Chapter 1, where the interactions are evaluated using isothermal titration calorimetry (ITC). This measurement makes it possible to quantify the contribution from an enthalpy change, DH . Since the enthalpy term is associated with the free-energy equation, DG ¼ DH T DS (DG calculated from a dissociation constant), it is also possible to calculate the
89
TARGETS IN BACTERIAL CELL MEMBRANES
H3C
CH3
H3C H N
H N
O HO
H N
CONH2
O
N H O
O
Cl O
HO OH
HN HO
OO
H NH N
O
HO OHO O
OH
Cl O
OH
O
OHNH2 OH O HO O CH3
O HN
CH3
H 2N HO
OH
H 3C
O O
CH3
O HN
O
Cl H N
HO O
H N
O
N H N H
H O N
O
NH
O O N O
H
Cl OH O
O
N H
N
H CONH2
CH3 CH3
O O
HO
CH3 NH
OH OH
NH
HO
6 O N H HN
HO HO
OH O-
O O
Cl
H
H
O
N
H2NOC
CH3 OH H3C O NH2 O OH OH
NH
O
N O
O
O O
CH3
O HN
O
H3C O
NH H N
OH H N H 3C
O CH3
Cl HO O
CHHN 3
HN
CH3
O
O
NH O
HN H C -O
3
N NH H
H 3C
CH3 H N O
O OCH3
O
CH3 7
HN
O
O
H N
O
O CH3
NH O
Figure 3.9 Trivalent system derived from vancomycin receptor and d-Ala-d-Ala ligand.
90
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS H2N
HN H 2N
H2N
i
O
ii,iii
H N
O NH2
NH-Boc
O
NH
NH2
NH2
Vancomycin HN
OH NH2 OH O HO H3C CH3O
OH O O
HN
O HO
iv H N
O O
NH
O H O N
N H N H
O
O
Cl H N
O N O
Cl
O
N H CONH2
H
O
N H
CH3 NH CH3 CH3
OH OH
Vancomycin NH
6
HO
D-Ala-D-Ala-Lys-L-(Nα-Ac)-HN α
OH O
t
O
v,iii
N -Ac-L-Lys-D-Ala-D-Ala-O- Bu D-Ala-D-Ala-Lys-L-(Nα-Ac)-HN
NH-(Na-Ac)-L-Lys-D-Ala-D-Ala O
O 7
reagents and conditions: i) (Boc)2O, TEA, rt; ii) 1,3,5-benzene tris(carbonyl chloride), CH2Cl2, 2 h; iii) TFA, CH2Cl2, 1 h; iv) vancomycin hydrochloride, HBTU, DIPEA, rt, overnight; v) 1,3,5-benzene tris(carbonyl chloride), DMF, rt
Figure 3.10 Synthesis of a trivalent vancomycin carboxamide and a trivalent ligand.
entropy of binding DS (Figure 3.11). For example, a high association constant of 6 7 yields a DG tri value of 94 kJ/mol, which is split into two components: an experimental value of DH tri (167 kJ/mol) and a calculated value of T DS tri (73 kJ/mol). Such binding parameters are compared with those generated from the association of monovalent vancomycin and d-Ala-d-Ala, which consist of DG mono (33 kJ/mol), DH mono (50.2 kJ/mol), and T DS mono (17.2 kJ/mol). This comparison indicates approximately an additive gain in enthalpy for the trivalent system relative to the monovalent system. On the other hand, the entropy change for a trivalent system represents a greater loss than the monovalent system by 56 kJ/mol. This entropic loss in the trivalent system is possibly related to conformational restriction of the linker during formation of the trivalent complex. Thus, the favorable enthalpy contribution is responsible for the very tight association of the trivalent system (Kdtri ¼ 4 1017 M ).
TARGETS IN BACTERIAL CELL MEMBRANES
91
Monovalent receptor-ligand interaction
+ Ac2-L-Lys-D-Ala-D-Ala
Vancomycin
Kd = 1.6 x 10-6 M Vancomycin-D-Ala-D-Ala
∆GO = -33 kJ/mol, ∆HO = -50.2 kJ/mol, T∆SO = -17.2 kJ/mol
Trivalent receptor-ligand interaction
+ Kd = 4 x 10-17 M
Tris-vancomycin (6)
6•7 Tris-D-Ala-D-Ala (7)
∆GO = -94 kJ/mol, ∆HO = -167 kJ/mol, T∆SO = -73 kJ/mol
Figure 3.11 Thermodynamic parameters involved in monovalent and trivalent interaction of vancomycin and d-Ala-d-Ala ligand.
The structure of vancomycin contains at least three functionally distinct sites that can be derivatized to permit covalent dimerization. These functional sites include a carboxylic acid at the C-terminus, a secondary amino group at the Nterminus (N-Me-Leu), and a primary amino group located at a vancosamine residue. Tethering two of these sites with a linker in a combinatorial manner leads to six possible classes of orientational dimers, including a C-terminus to C-terminus linkage (head-to-head homodimers) as discussed already. Five additional types of linkage remain, including N-terminus to N-terminus (tail to tail), vancosamine to vancosamine (back to back), C-terminus to N-terminus, C-terminus to vancosamine, and N-terminus to vancosamine. Each linkage plays a unique role in presenting the binding pocket of vancomycin to the d-Ala-d-Ala ligand in a way that influences the binding a‰nity and antibacterial potency of the dimer. Staroske and Williams [224] reported vancomycin dimers produced by linking through an N-terminus to a C-terminus. These dimers show enhanced cooperativity in receptor–ligand interactions as well as better antibacterial activity (Figure 3.12). When they bind to multivalent ligands displayed on a bacterial cell surface, head-to-tail dimers such as 8 and 9 tend to undergo oligomerization more readily than do head-to-head dimers and generate highorder complexes, such as dimers of dimers. Synthesis of the N-terminus-to-Cterminus dimers requires several steps, including a key amide coupling between an Fmoc-protected linker acid and vancomycin. Such coupling requires regioselectivity at an N-Me-Leu residue of the antibiotic, which is controlled by use of certain coupling reagents. For example, when PyBOP [(benzotriazol-1-
92
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
OHNH2 OH O HO H3C CH3O
OH NH2 OH O HO O CH3
OH
O O
O O O
O
Cl H N
O
Cl
i,ii HO
HO O N H N H
O HO
N O
H
OH
H3C
O
OH O
O
CH3 NH
N H
N H CONH2
O
CH3
O
Cl H N
O N O
H
O
CH3
O
HO
N H N H
O
Cl OH O
O
CH3 N (CH2)n-NH2 N H H O CONH2H3C CH3 N
OH OH
OH OH
n = 2, 5
HO
HO OH NH2 OH O HO H3C CH O
OH NH2 OH O HO O CH3
H3C
3
O O O HO O
iii O HO
N H N H
O O N O
O OH OH HO
Cl HO O
Cl H N
H
OH O O
OH
O
OH O
O CH3 N (CH2)n NH
N H H O C H 3 CONH2 CH3 N
N H N H
O
O
Cl H N
O N O
O
H
Cl
O N
H CONH2
OH O N H
CH3 NH CH3 CH3
OH OH HO 8 (n = 2) 9 (n = 5)
reagents and conditions: i) HO2C-(CH2)n-NHFmoc, PyBrOP (bromo-tris-pyrrolidino-phosphonium hexafluorophosphate), i-Pr2NEt, DMF (60%); ii) 10% piperidine, DMF; iii) vancomycin, HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), i-Pr2NEt, DMF, DMSO.
Figure 3.12 C- to N-terminus covalent (head-to-tail) dimers of vancomycin.
yloxy)tripyrrolidinophosphonium hexafluorophosphate) is used as a coupling agent, amide coupling occurs to a greater extent at the primary amine of the vancosamine sugar than at the secondary amine. In contrast, use of a close analog, PyBroP (bromotripyrrolidinophosphonium hexafluorophosphate], enables the acylation reaction to take place predominantly at the secondary amine from the N-terminus. Adamczyk et al. [225] and Stack and Thompson [226] at Abbott compared the self-association of back-to-back and head-to-head vancomycin dimers using surface plasmon resonance (SPR) technology (Figure 3.13). Each of the backto-back dimers, represented by 10 and 11, is composed of two vancomycin molecules tethered through a bisamide linkage at the vancosamine moiety. These dimers lack a basic nitrogen at the vancosamine moiety. Based on SPR binding studies, they adhere to a surface that presents an array of N e -Ac-Lysd-Ala-d-Ala ligands, and the association occurs in a bivalent manner. The surface adhesion does not, however, proceed to the higher-order self-association of dimers, which can build multiple layers of dimers at certain concentrations
93
TARGETS IN BACTERIAL CELL MEMBRANES O Vancomycin•HCl
+
N
O
O
O
O
O O
Et3N
N
n (n = 3, 6)
DMF O
back-to-back dimer O
OHO N H3C O H H 3C
O
OO
HO O O HO
N H N H
(CH2)n
OH OH
O
OH Cl O
Cl H N
O
NH OH OH O HO H3C CH3O
HO
N O
H
O
N H CONH2
OH O N H
O CH3 NH CH3 HO O CH
O
N H N H
3
O OH OH HO
OH O O
10 (n = 3) 11 (n = 6)
O
O
Cl H N
O N O
H
Cl
O N
H CONH2
OH O N H
CH3 NH CH3 CH3
OH OH HO
Figure 3.13 Vancosamine-to-vancosamine (back-to-back) dimers of vancomycin.
tested (<10 mM). Such binding behavior of back-to-back dimers is quite distinct from that of the head-to-head dimer 1, which can self-associate into highorder complexes of dimer even at lower test concentrations (1 mM ). As discussed above, self-oligomerization of dimer 1 is believed to play an important role in enhancing its in vitro antibacterial activity against vancomycin-resistant enterococcus (VRE). In a continuing study, Gri‰n et al. at Theravance [227] studied extensively the e¤ect of dimer orientation and linker length on antibacterial activity by testing an array of 40 unique vancomycin dimers subdivided into 10 classes of orientational dimers (Figure 3.14). Synthons required for synthesis of the dimers include four types of vancomycin derivatives, each of which contains an amine-terminated handle at either the C-terminus, N-terminus, vancosamine (V) residue, or resorcinol (R) ring. The synthesis of a dimer library results from cross-amide coupling among the four synthons performed in 10 distinct combinations (C–C, C–N, C–V, C–R, N–N, N–V, N–R, V–V, V–R, and R–R) and using 11- to 43-atom alkane- and peptide-based linkers. The linker orientation influences the antimicrobial activity as illustrated by the V–V series, which in general display good potency against certain bacterial strains, including VSE, VRE, methicillin-resistant S. aureus (MRSA), and glycopeptideintermediate S. aureus (GISA) strains. It is also apparent that other series, such as C–C, C–V, and C–R dimers, with a short, 11-atom linker, show broadspectrum activity, including anti-VRE activity. Overall results suggest that the linkage orientation plays an important role in influencing in vitro potency but
94
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS H 3C H 3C O O vancomycin OO O HO O amide coupling
H N
H2N
N H N H
O HO
O
Cl H N
O OH OH
V-linkage synthon
O H
OH O
O N
H CONH2
reductive CH3 alkylation NH
N H
CH3 N CH3
CH3
NH2
CH3
CH3
O OH OH
C-linkage synthon
NH2
OH Cl O
N O
H3C OH N H3C O H
reductive alkylation
OH NH2
N-linkage synthon
HO Mannich reaction OH OH
R-linkage synthon
HO HN
NH2
11-atom spacer OH N (CH2)2NHCO(CH2)3CONH(CH2)2 N H 3C O H H O
OO O Cl H N
HO O H O N
Me2N
N H N H
OH OH
O
H
N H HN
HO HO O
V-R orientational dimer OH O
N H CONH2
OH
CH3 NH
N H
CH3 CH3
O
O O
O O O HO Cl O HO OH
O
H N O OH
H3C HN
OH OH
Cl N
N
H H 3C
NH
H H2NOC
O
NMe2
O
O
OH Cl O O
N
H N
O
HO
H3C
CH3
CH3 O CH3
H2NHO
HO H3C OH N (CH2)2NHCO(CH2)3CONH(CH2)2 H3C O H O
OO O HO O
Me2N
H O N
N H N H
Cl H N
N
O OH OH
H
O
OH OH
N HN H
O
O
O O
Cl
NH
O N
H CONH2
O OH Cl
HO
OH Cl O O
O
HO NH O
O HO OH OH O N H
H2NOC
CH3 NH CH3 CH3
H
N
O
CH3 H 3C OH O O NH2 OH OH
O N H
N H
V-C orientational dimer H3C
OH O CH3 N H CH3
HO
Figure 3.14 Representative examples of vancomycin dimers linked at 10 combinatorial orientations.
TARGETS IN BACTERIAL CELL MEMBRANES H3C OH N H3C O H O
OO
HO O N H N H
O HO
OH Cl O
Cl H N
O N H
SAc n
O
OH OH
O
O
95
OH O
O N
H CONH2
N H
NaOH, air (O2) CH3 NH
H 2O (50-90%)
CH3 CH3
O OH OH HO H3C OH N H3C O H O
OO O HO O O HO
N H N H
Cl H N
N
O
H
O
NH OH OH O HO O H3C CH3
O n
OH OH n = 2 to 9
HO OH O
O N
H CONH2
N H
O CH3 NH CH3
OH O O
OH Cl O O
O
S S n
O HO
N H N H
O
O
Cl H N
O N O
H
Cl
O N
H CONH2
OH O N H
O
CH3
OH OH
CH3 NH CH3 CH3
OH OH HO
HO 12 vancosamine-to-vancosamine dimer
Figure 3.15 Structure of disulfide-linked (back-to-back) vancomycin dimers.
is dependent on test strains. For example, there is no single class of orientational dimers that are more active against all tested organisms than other classes of orientational dimers. Similarly, the e¤ect of linker length varies with tested strains. Covalent dimerization of vancomycin is achieved not only by an amide linkage but also via a disulfide or olefinic bond. Nicolaou et al. at Scripps [228] reported the synthesis and antibacterial activity of disulfide-linked vancomycin dimers (12) designed on the basis of vancosamine-to-vancosamine tethering (Figure 3.15). In this dimer class, each vancosamine moiety is linked to a second vancosamine through a disulfide bond that is formed by spontaneous aerial oxidation of a thiol generated in situ. Such dimers show potent antibacterial activity, depending on spacer length, particularly against vancomycin-resistant enterococci (VRE) strains. For example, the dimer 12 (n ¼ 2) shows an MIC value of 2 mg/mL against VRE compared to vancomycin, which is nearly inactive, with an MIC > 16 mg/mL. The optimum activity occurs at a specific length of disulfide tether, with about 20 to 22 atoms in the linker (n ¼ 2; 3).
96
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS H3C OH N H3C O H O
OO
HO O O HO
N H N H
O
OH Cl O
Cl H N
O N O
H
O
n
OH OH [(PCy3)2Ru(CHPh)Cl2] C12H25NMe3Br OH O
O
N H CONH2
N H
H2O, CH2Cl2 (>95:5) (30-80%)
CH3 NH CH3 CH3
O OH OH HO H3C OH N H3C O H O
OO O HO O O HO
N H N H
Cl H N
N
O OH OH HO
H
n
OH OH n = 3, 4, 8
O N
H CONH2
OH O O
OH Cl O O
O
O
NH OH OH O HO H3C CH3O
O n
HO OH O N H
O CH3 NH CH3
O HO
N H N H
O
O
Cl H N
O N O
H
Cl
O N
H CONH2
OH O N H
O
CH3
CH3 NH CH3 CH3
OH OH HO
13 vancosamine-to-vancosamine dimer
Figure 3.16 Structure of olefin-linked (back-to-back) vancomycin dimers.
Therefore, proper positioning of two vancomycin receptor pockets is of importance for tight binding to d-Ala-d-Lac precursors expressed on the surface of resistant bacterial cells. In another series of vancosamine-to-vancosamine homodimers, the olefin metathesis method allows the introduction of an olefinic linkage in the middle of a linker (Figure 3.16). This olefinic bond is structurally rigid; it is locked in either a trans or cis configuration and is chemically stable relative to the disulfide bridge, which is readily cleavable by reducing agents. Vancomycin dimers of this class display improved activity against VRE (n ¼ 4: MIC ¼ 2 mg/mL), and the activity is dependent on the length of the olefinic linker (n ¼ 4 > 3 > 8). 3.1.1.4 Cyclic Dimers of Eremomycin. Eremomycin is another member of the glycopeptide antibiotic class. As reported by Sztaricskai et al. (Figure 3.17) [229], its cyclic dimer is linked with bisphenylisocyanate at the sites of N-methyl leucine and aminosugar. This dimer is, however, inactive against S. aureus, in
TARGETS IN BACTERIAL CELL MEMBRANES
97
OH CH3 CH3 H 2N O O OH OH OO
OH CH3 CH3 H 2N O O
O O
O HO
N H N H
OH Cl O O
H N
N O
OH O
O
H CONH2
H
CH3 NH
N H
N
+ O
CH3
C
N
N
C
O
CH3
O OH OH HO
Eremomycin O
OH CH3 CH3 O O OH OH
H N
HN
OO
OH CH3 CH3 H 2N O O
O
NH
O
O
H N
N H N H
O HO
O
OH Cl O
N O
H
O
N H CONH2
OH CH3 CH3 O N H N
CH3
O OH HO CH3 CH3 HN O O OH OH OO
OH CH3 CH3 H 2N O O
O O
O HO
N H N H
N O
O OH OH HO
OH Cl O O
H N
H
O
N H CONH2
O
OH OH
HN
HN OH O N H
O N CH 3 CH3 CH3
Eremomycin cyclic dimer
Figure 3.17 Structure of eremomycin and its cyclic dimer.
contrast to a highly potent vancomycin monomer. Such a result possibly derives from an unfavorable conformation of cyclic dimers and, importantly, to the lack of basic amino groups at both the N-terminus and the aminosugar domain. 3.1.1.5 Polyvalent Vancomycin Constructs. Considering the high surface density of d-Ala-d-Ala peptide precursors in bacterial cell walls, it would be interesting to examine the antibacterial activity displayed by multivalent vancomy-
98
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS H3C OH N H3C O H O
OO
HO
i Vancomycin
reductive alkylation
O O HO
N H N H
OH Cl O
Cl H N
O N H
H
N
OH OH
O
O
O O
O H R OH O
O
N H CONH2
ii CH3 NH
N H
CH3
olefin metathesis
CH3
O OH OH HO
14
H3 C
OH N H3C O H O
OO O HO O O HO
N H N H
Cl H N O
O
H
O H
O N
H CONH2
OH O N H
NH HO O O OH OH CH3 H 3C
O
OH OH
OH Cl O O
N
O
N
O H
O H H O
CH3 NH
N
N
OO O H
H O
n
Ph HO
CH3 CH3
O
O
O Cl H N O N N O H H H N
HO
OH OH
Cl OH O
O
OH H3C O NH N CH3 H N H CH3 CONH2 O
OH OH
O
HO HO Vancomycin-HN 15 reagents and conditions: i) R-CH=O, NaCNBH3, i-Pr2NEt, MeOH-DMF (1:1), 70oC (80%); ii) Cl2Ru(PCy3)2=CHPh (10-16 mol%), MeOH, 36 h, rt (60%)
Figure 3.18 Synthesis of polyvalent vancomycin molecule via olefin-ring-opening metathesis polymerization.
cin molecules, particularly at high valency. Arimoto et al. [230] reported the synthesis and activity of a polyvalent vancomycin construct (15), presenting glycopeptide side chains on a polymer framework (Figure 3.18). The key synthetic approach to 15 is the olefin-ring-opening metathesis polymerization (ROMP) of 14, which contains a norbornene moiety-linked to the primary amino group of vancosamine. The reaction conditions for ROMP employ methanol as solvent and the Grubb’s ruthenium catalyst [231], which tolerates multiple types of normally reactive functional groups such as amine, acid, and alcohol present in vancomycin. Like vancomycin, the norbornene-derivatized monomer 14 is active against vancomycin-sensitive, gram-positive strains with MIC values below 0.5 mg/mL. However, the same molecule is inactive against vancomycin-resistant strains, with MIC values above 125 mg/mL. The polyvalent construct 15 is approximately 4- to 10-fold less active against vancomycin-sensitive species than the monomer 14, but it is more potent, by 8- to 60-
TARGETS IN BACTERIAL CELL MEMBRANES
99
Heterodivalent vancomycin (b)
(a) Lipid II intermediate
(c)
Transglycosylase inhibitor
D-Ala D-Ala L-Lys D-Glu L-Ala
D-Ala D-Ala L-Lys D-Glu L-Ala HO HO HO AcHN
CH3 O OH O O O O AcHN O O OP P O O-O
HO HO HO AcHN Vancomycin
CH3 O OH HO O O O O O HO AcHN AcHN
D-Ala D-Ala L-Lys D-Glu L-Ala CH3 O OH O O O O AcHN O O OP P O O-O
Transglycosylase Bacterial inner membrane
Figure 3.19 Possible mechanisms of action displayed by covalent vancomycin conjugate as a bifunctional inhibitor of bacterial cell wall biosynthesis: (a) inhibition of transglycosylation; (b) simultaneous inhibition of transpeptidation and transglycosylation; (c) inhibition of transpeptidation.
fold, against VRE. It is unclear why the polymeric vancomycin becomes less active than vancomycin against vancomycin-sensitive strains. However, the observation raises several possibilities, indicating fundamental di¤erences in cell wall structure between VRE and VSE strains with regard to surface density and spatial distribution of peptide precursors, as well as the ability of giant polymers to penetrate bacterial targets located in the peptidoglycan layer. This specific example demonstrates the e¤ectiveness of applying the multivalency concept to the discovery of a novel class of antibiotics active against emergent vancomycin-resistant strains. 3.1.1.6 Heterobivalent Vancomycin Constructs. Heterobivalent molecules derived from glycopeptide antibiotics are intended to bind two distinct but proximal targets, including a d-Ala-d-Ala cell wall precursor. Such binding probably occurs in either monovalent or divalent manner, as depicted in Figure 3.19. Sun et al. at Princeton [232] reported the synthesis and activity of a vancomycin-based hybrid molecule that is designed to block two separate but spatially related steps responsible for cell wall biosynthesis, such as transpeptidation and transglycosylation. A heterodimer (18) is composed of vancomycin aglycone tethered covalently to 16, a truncated analog of moenomycin [233], which is a phospholipid-anchored inhibitor of transglycosylase (Figure 3.20). Like moenomycin, the disaccharide analog 16 shows antibacterial activity arising from its ability to inhibit the transglycosylation step [234,235]. With an MIC of 0.1 mg/mL, 18 is active against S. aureus and vancomycin-sensitive strains and is more potent than monovalent components such as 16 and 17 (which have similar MICs of 250 mg/mL), and the vancomycin aglycone (MIC of 2 mg/mL). The dimer 18 also shows anti-VRE activity, although it is fourfold less active
100
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS Cl H2N HO HO HO OH HO
HO OH HN O
O HOO O AcHN
O OHO
O O HO
F3C HO HO HO O NH
CONH2 O
O OO
O P OH NHAc O O
HO2C
OH
Cl
O C25H41
NH
F3 C HO HO HO O NH
O HN O O O
O O OCONH2 HO P O C12H25
F 3C
NH O HN O O O
F3C
O H3CO
16
Moenomycin
OCONH2
O
OCH3
17 Cl F3C HO HO HO O NH
Cl
NH O HN O O O OCONH2
O AcO AcO AcO O NH
N3 O O O
F3C HO HO HO O NH
i,ii,iii
NH O HN O O O
OCONH2 SPh F 3C
O F3C
F 3C iv,v HO
OCONH2
O O
I HO
N H N H
O O
O
Cl H N
O N O
H
Cl
O N
H CONH2
OH O N H
O
CH3 NH CH3 CH3
OH OH HO
18
reagents and conditions: i) (CF3CO2)2Hg, BF3•ether. 2-chloroethanol, 83%; ii) PMe3, H2O, THF, EtOH, then 4-chloro-3-trifluoromethylphenyl isocyanate, CH2Cl2, DMF, 72%; iii) NaI, acetone, then NaOMe, MeOH, 86%; iv) O-allyl protected vancomycin algycone, Cs2CO3, DMF, 84%; v) PdCl2(PPh3)2, Bu3SnH, DMF, AcOH, 66%.
Figure 3.20 Structure of moenomycin analogs and a heterodimer composed of moenomycin disaccharide analog attached to vancomycin algycon.
than 16 (MIC ¼ 4 mg/mL), whose high anti-VRE activity is due to its inhibition of transglycosylation reaction and is not influenced by a vancomycin resistance mechanism. Nonetheless, the anti-VRE activity of 18 is far better than that of 17 or the vancomycin aglycone, tested either alone or in combination. This example illustrates the e¤ective application of covalent heterodimerization targeting receptors and enzymes located proximally on the surface of bacterial cells. A number of semisynthetic glycopeptides might be considered as functionally bivalent, including a vancomycin derivative displaying a hydrophobic substituent attached to the vancosamine sugar (Figure 3.21). Such examples include a chlorobiphenyl derivative (19) [236] that exhibits about an 80- to 160fold increase in antibacterial potency against both vancomycin-sensitive and vancomycin-resistant strains. Ge et al. [237] and Eggert et al. [238] attribute this enhanced activity to a bivalent mode of action by such vancomycin de-
TARGETS IN BACTERIAL CELL MEMBRANES
101
H3C OH N H 3C O H O
OO
HO O O HO
N H N H
OH OH
O
OH Cl O
Cl H N
O N O
H
O N
H CONH2
Cl
OH O N H
CH3 NH CH3 CH3
O OH OH HO
19
H3C
OH N H 3C O H O
OO
HO O
H2N
H O N
N H N H
Cl
O
OH Cl O
Cl H N
O N O
H
O
OH OH
O
N H CONH2
O
Cl
OH O N H
CH3 NH CH3 CH3
OH OH HO
20
Figure 3.21 Semisynthetic vancomycin derivatives presenting hydrophobic aromatic substituent attached at a sugar moiety.
rivatives. Like the vancomycin–moenomycin heterodimer (18), the aglycone pocket of 19 binds the d-Ala-d-Ala peptide, while its hydrophobically modified disaccharide binds certain bacterial surface proteins involved in transglycosylation reaction. Such a mechanism is supported by a desleucyl analog derived from 19. This derivative lacks the ability to bind d-Ala-d-Ala but is still active against bacterial cells through its inhibition ability at the transglycosylation stage [237]. The anti-VRE activity displayed by this type of bivalent molecule is probably mediated primarily by the latter mechanism. Later, Eggert et al. [238] discovered a gene responsible for the susceptibility of Escherichia coli cells to 19. This gene encodes a protein, YfgL, that is identified as a lipoprotein located on the inner surface of the outer membrane of the bacterial cell wall, where it is normally involved in up-regulation of lytic transglycosylases (also known as autolysins). A second example of a heterobivalent glycopeptide acting at both the transglycosylation and transpeptidation stages was reported by Roy et al. at Merck
102
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
[239]. An inhibitor (20) is derived from vancomycin by attaching a bulky aromatic group to vancosamine sugar (Figure 3.21). It is active against both vancomycin-susceptible and vancomycin-resistant strains at an MIC value of about 0.25 to 2 mg/mL. As identified by a‰nity chromatography, the cellular targets of 20 in E. coli cells include a group of membrane proteins involved in cell wall biosynthesis. The group consists of five penicillin-binding proteins (PBP-1B, PBP-2, PBP-3, PBP-5, and PBP-6) and lytic murein transglycosylase A. This finding supports the fact that 20 interacts rather nonselectively with multiple bacterial proteins involved in peptidoglycan synthesis (PBP-1B, a dual transglycosylase–transpeptidase), cell wall remodeling (lytic transglycosylase A), cell growth (PBP-2), and division (PBP-3). However, such protein-binding ability itself is not enough to explain the potent and broad-spectrum antibacte-
Dansyl NH O NH2 HN AA3 AA2 O AA1 X
NH2 AA3 AA2 AA1
HN
NH2 Val Lys Phe
NH2 AA3 AA2 AA1
O -O N
HN
NH2 Val Lys Phe
HN
N
HN
NH
N
NH2 Val Lys Phe
(X = NH; O)
NH
N
N
N
21 O
22
NH
O
O R
OH O NH O
N H 2N
O
O
N H
H N O NH2
O N H
O
O
CH3 NH
N H
N H CONH2
CH3 CH3
Vancomycin mimic OH O NH O
N CH3 H3C HN CH3 O
H N
H2NOC H N O
H
H 2N O
N
N H
O
H N O
O
O
N H
O
O
H N O NH2
O N H
O
O
N H CONH2
N H
CH3 NH CH3 CH3
N HN
O
H N (CH2)nCH(OH)(CH2)n
N H
Mimic dimer (n = 1, 2, 3)
OH
Figure 3.22 Synthetic vancomycin mimics and their dimer that binds d-Ala-d-Ala (Lac) ligand.
103
TARGETS IN BACTERIAL CELL MEMBRANES
rial activity by 20 because a hydrophobic substituent such as N-Ac-N 0 -(3,4dichlorobenzyloxyphenyl)putrescine is equally capable of binding PBP-1B, although it is 100-fold less active than 20. Therefore, 20 probably engages a heterobivalent mode of action in which it sequesters peptide precursors, such as d-Ala-d-Ala (and d-Ala-d-Lac), and interferes with transglycosylation assembly by binding to transglycosylase proteins. 3.1.1.7 Multivalent Vancomycin Mimics. Some synthetic molecules mimic vancomycin as a receptor in their ability to recognize d-Ala-d-Ala peptide residues. Such artificial peptide-binding receptors are less complex in structure and are easier to synthesize than natural glycopeptides of the vancomycin class. Monnee et al. [240] reported a library with 512 members composed of trimeric tripeptides. The library was prepared by a solid-phase method, where each peptide unit is linked to a triazacyclophane sca¤old such as 21, as shown in Figure 3.22. This library includes a selective receptor such as 22, which recognizes the d-Ala-d-Ala peptide ligand in solution, with a K a value of 2.66 10 4 M 1 . It is noteworthy that this receptor also recognizes the N-dansyl-Glyd-Ala-d-Lac—a vancomycin-resistant ligand—with a twofold lower binding constant of 1.01 10 4 M 1 . Ahrendt et al. [241] and Xu et al. [242] reported a novel class of vancomycin-mimicking receptors (Figure 3.22). They are designed on the basis of a monovalent mimic that is composed of a tripeptide attached to half of the vancomycin aglycon. As one of the active receptors identified among the 27,000-member library, the monomer mimic is slightly active in vitro against vancomycin-resistant enterococci, with an activity only fourfold greater than that of vancomycin. Dimers derived from this mimic tethered with a three- to seven-atom spacer show improved activity. For example, mimic dimers (n ¼ 1, 2, 3) show 16-, 8-, and 4-fold greater anti-VRE activity, respectively, than the monomer mimic.
HO O
H N
N H
N O
O
NH2
23
OH O
O N H
CH3
N CH3
NH2
N 24
O2N O N
O-
O O
O2N
O H H H N+
O H O N
Noncovalent complex
O
O-
HO O
O
+H3N
N O
O
- D-Lac N
H2O
O2N
H N
-24
O OH
O
Covalent intermediate
Figure 3.23 Proposed mode of action for catalytic vancomycin mimics that recognize d-Ala-d-Lac peptide as a substrate.
104
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
3.1.1.8 Catalytic Vancomycin Mimics. Recent advances in the design of small vancomycin mimics include receptors displaying catalytic activity to cleave the peptidoglycan precursor. Chiosis and Boneca [243] demonstrated that prolinebased di- and tripeptides display such activity (Figure 3.23). A tripeptide (23) e¤ectively cleaves the ester bond present in d-Ala-d-Lac under physiologically relevant conditions (23 o peptide ¼ @8; phosphate-bu¤ered solution, pH 7), in which 20% of the depsipeptide is cleaved within 24 hours. A dipeptide (24) is more e¤ective and cleaves 50% of the depsipeptide peptide within 24 hours. Selective cleavage of the d-Ala-d-Lac substrate results from complementary peptide binding in combination with a properly oriented nucleophile–electrophile assembly. The resulting serine-d-Ala ester intermediate is subsequently hydrolyzed to regenerate the original peptide. The catalytic activity of 24 shows a synergistic e¤ect when used in combination with vancomycin. For example,
Ph
HO
O O O AcHN
O
i,ii,iii
OBn
O
AcO AcO AcO AcHN
v,vi,vii
O AcO O O AcHN
HN O
HO HO HO AcHN
O
HO O O AcHN
HN O L-Ala γ-D-Glu L-Lys D-Ala D-Ala
O
O
viii,ix
O O P BnO OBn
O
xiii
O O P -O O O P -O O
HO HO HO AcHN
O AcO O O O AcHN BnO HN O
AcO AcO AcO ThPhHN O O
Br
AcO AcO AcO AcHN
O AcO O O AcHN
HN O L-Ala γ-D-Glu(OTMSE) L-Lys(NTEOC) D-Ala D-Ala(OTMSE)
CH3 OTMSE
7
Lipid II (25)
AcO HO O iv O AcHN BnO AcO HN O AcO AcO O ThPhHN CH3 OTMSE
O
HO O O AcHN
HN O L-Ala γ-D-Glu L-Lys D-Ala D-Ala
HO O O HO AcHN
O
HO O O AcHN
HN O L-Ala γ-D-Glu L-Lys D-Ala D-Ala
CH3 OTMSE
x,xi,xii
O O O P BnO OBn
HO O O HO AcHN
O
HO O O AcHN
O
HN O L-Ala γ-D-Glu L-Lys D-Ala D-Ala
3
reagents and conditions: i) Ala(OTMSE), DIPEA, HOBt, PyBOP, THF, CH2Cl2, rt, 2 h (81%); ii) TsOH, MeOH, 75oC, 30 min (89%); iii) pyridine, AcCl, -30oC, 15 min, then rt (80%); iv) AgOTf, 4 Å mol. sieves, CH2Cl2, -40oC, 3 h (60%); v) Amino-modified resin, 4 Å mol. sieves, butanol, 85oC, 24 h, then pyridine, Ac2O, rt (53%); vi) 10% Pd/C, H2, MeOH, 1 h (93%); vii) tetrazole, (BnO)2PN(i-Pr)2, CH2Cl2, -30oC to rt, 1 h, then m-CPBA, -40oC to rt, 1 h (55%); viii) TBAF, THF, rt, 45 min (87%); ix) H-γ-D-Glu(OTMSE)-Lys(TEOC)-D-Ala-D-Ala(OTMSE), DIPEA, HOBT, PyBOP, THF, CH2Cl2, rt, 2 h (61%); x) 10% Pd/C, H2, MeOH, 1 h (100%); xi) CDI, DMF, rt, 4 h, then undecaprenyl phosphate, rt, 48 h (39%); xii) TBAF, DMF, rt, 24 h, then 3% NaOMe, MeOH, 0oC, 1 h (35%); xiii) PBP1b, HEPES buffer (pH 7.5).
Figure 3.24 Synthesis of lipid II bacterial cell wall precursor (method A).
105
TARGETS IN BACTERIAL CELL MEMBRANES
in the presence of 24 (50 mM ), vancomycin shows enhanced activity against vancomycin-resistant Enterococcus faecium by a factor of 8 over vancomycin alone. The synergistic e¤ect of 24 is attributed to its selective hydrolytic action against the d-Ala-d-Lac precursor present in the peptidoglycan layer of vancomycin-resistant cells. This example illustrates a potential benefit that can be achieved when the catalytic unit is linked covalently to vancomycin. Indeed, it was reported earlier by Shi and Gri‰n [243] that semisynthetic vancomycin molecules bearing an imidazole or amine at the C-terminus catalyze the hydrolysis of an activated carbamate attached to a Lys-d-Ala-d-Ala ligand. Such catalysis leads to a rate acceleration of several thousandfold compared to the uncatalyzed reaction. 3.1.1.9 Presentation of Glycopeptide Molecules on Bacterial Surfaces. Lipid II (25) is a transient species serving as an essential building block for cell wall biosynthesis (Figure 3.24). It is a substrate of the penicillin-binding proteins
O AcO O O O AcHN BnO HN O
AcO AcO AcO ThPhHN O
HN O
CH3 O
O
O AcO O O AcHN
AcO AcO AcO AcHN HN O
O
O HO
HN O
AcO AcO AcO AcHN
O i
HN O
CH3 NH
H N
H2NOC O
O AcO O O AcHN O
NH H N
O
O AcO AcO AcO AcHN HN
vi,vii O
O AcO O O AcHN O
O O O O P O P O O- O-
H2NOC O
O
NHCOCF3 NH H N
CO2Me
7 viii 3
H N
O O P HO OH
O
CH3 NH
O
H N O
CO2Me
SO2Ph
CH3 NH
NHCOCF3 H2NOC
O
O
O O O P BnO OBn
CH3 O
SO2Ph
O O P BnO OBn
O AcO O O AcHN
AcO AcO AcO AcHN
ii,iii
CH3 O
SO2Ph
iv,v
O AcO O O AcHN
AcO AcO AcO ThPhHN
i
Lipid II
NHCOCF3 NH H N
CO2Me
O reagents and conditions: i) H2, 10% Pd/C, MeOH, THF (94%); ii) dibenzyl-N,N-diethyl phosphoramidite, 1H-tetrazole, CH2Cl2, iii) 30% H2O2, THF, -78oC to rt (78%); iv) DBU, CH2Cl2; v) EDCI, NHS, DMF, then H2N-γ-D-Glu(CONH2)- Lys(NHCOCF3)-D-Ala-D-Ala(OMe), i-Pr2NEt (46%); vi) CDI, DMF, THF; vii) undecaprenyl monophosphate; viii) NaOH, H2O, 1,4-dioxane (24%)
Figure 3.25 Synthesis of lipid II bacterial cell wall precursor (method B).
106
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS D-Ala D-Ala L-Lys D-Glu L-Ala HO HO HO AcHN
Lipid II intermediate
CH3 O OH O O O O AcHN O O OP P O O-O
+
D-Ala D-Ala L-Lys D-Glu L-Ala CH3
O
O HO AcHN
Bacterial inner membrane (Lactic acid bacterium)
HO HO HO AcHN
CH3 O OH HO O O O O O HO AcHN AcHN
O
OOO POPO O- O
NH ON O
HO OH
D-Ala D-Ala L-Lys D-Glu L-Ala
Alexa 488 hydrazide
CH3 O OH O O O O n AcHN O O OP P O O-O
O D-Ala D-Ala L-Lys D-Glu L-Ala HO HO HO AcHN
OH O
reactive ketone epitope
O
NH
O Transglycosylase-mediated transglycosylation
26
O D-Ala D-Ala L-Lys D-Glu L-Ala
O N H
N NH-Alexa 488
NH
CH3 O OH HO O O O O O HO AcHN AcHN
D-Ala D-Ala L-Lys D-Glu L-Ala CH3 O OH O O O O n AcHN O O OP P O O-O
Figure 3.26 Multivalent presentation on the surface of bacterial cell of nonnatural glycopeptide.
(PBPs)—a class of bifunctional enzymes that catalyze transglycosyalation (glycosyl transfer of lipid II)—as well as the transpeptidation (peptide cross-linking of lipid II) reaction. Due to the biologically unstable nature of the lipid II intermediate, it is extremely di‰cult to procure from natural sources. Schwartz et al. at Dupont [244] reported the total synthesis of lipid II (Figure 3.24). This synthetic lipid II serves as a substrate in polymerization reactions mediated by PBP-lb-catalyzed transglycosylation and transpeptidation. Shortly thereafter, VanNieuwenhze et al. at Lilly [245] reported a di¤erent method for the total
TARGETS IN BACTERIAL CELL MEMBRANES
107
synthesis of lipid II. It is based on a convergent approach using a muramyl dipeptide intermediate (Figure 3.25). The surfaces of bacterial cell walls can be modified chemoenzymatically to present nonnatural ligands in a controlled manner. Sadamoto et al. [246] described such a method in a report in which a ketone-containing group is incorporated into a cell wall precursor (Figure 3.26). For example, a synthetic analog of a lipid I precursor (26) is expressed through the catalytic action of transglycosylase in multiple copies on the surface of gram-positive bacteria, such as lactic acid bacteria. The attached ketone functionality is then used as a handle for further derivatization of the modified peptidoglycan layers, as illustrated by the use of Alexa 488 hydrazide, a fluorescent probe that reacts selectively with ketone groups. The combination of such sequential reactions enables the display of multiple copies of artificial peptidoglycan residues on the outer surfaces of bacteria. These residues can then be visualized by fluorescence microscopy. This strategy applies equally for gram-negative bacteria when performed in the presence of EDTA, an agent added to increase passive permeability through the outer membrane. This technique opens a potential route for the modification of bacterial surfaces with diverse, nonnatural molecules that are otherwise not incorporated through normal biosynthetic pathways.
O
O
H N
N H
Polymyxin B2
NH3+
OH H N
O
NH3+ HN O HO
Lipid A
O
H N
N H
O
NH3+
NH3+ O -O O P HO HO O O
O NH
O O
H N O +H
3N
N H
O O
NH NH
NH3+
OH O
O O O O HO NH O P P O HN O O O O O O- OO HO O OH O O O O O
NH3+
Figure 3.27 Interaction of antibiotic polymyxin B2 and lipid A in gram-negative bacteria.
108
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
3.1.2
Lipid A
The outer membrane of a gram-negative bacterial cell wall provides a protective barrier against destructive action by various enzymes and chemicals generated by host cells. In particular, lipid A plays an essential role in maintaining cell wall integrity. Certain molecules associate tightly with lipid A and disrupt the organization of outer membranes, thus making bacterial cells more permeable and therefore susceptible to antibiotics. This class of molecules is represented by polymyxin B, a macrocyclic peptide possessing five positively charged ammonium cations derived from multiple diaminobutyric acid residues (Figure 3.27) [247]. The domain on polymyxin B that is involved directly in binding lipid A consists of a peptide-based macrocyclic sca¤old that presents on a single face, three of these ammonium cations. The key groups of lipid A involved in the interaction with the polymyxin include the sugar moieties and multiple phosphate anions. 3.1.2.1 Cholate-Based Polymyxin Mimics. Li et al. [248] reported polymyxin mimics that retain the minimal structural features displayed by polymyxin B that are required for biological activity (Figure 3.28). These mimics are designed using cholic acid as a sca¤old and present three amino groups oriented in a locked conformation similar to that predicted for polymyxin. Polymyxin mimics 27 and 28 inhibit the growth of E. coli with MIC values of 7.0 and 2.0 mg/mL, respectively. Such molecules can induce synergistic e¤ects when tested in combination with other antibiotics, such as erythromycin, which, with
CH3
CH3
CH3 i-iii
O
OH OH
CH3
CH3
OCH3
OTr iv-vi
O O O
OH
CH3
CH3
CH3 OTr
CH3 12
CH3
CH3
CH3 N
17
vii-x
O
7
3
O O
O O
O N3 N3
N3
CH3
R
NH
R
NH
R
NH
27: R = H xi 28: R = C(=NH)NH2
reagents and conditions. i) LiAlH4, THF (98%); ii) tritylchloride, Et3N, DMF (70%); iii) allylbromide, NaH, THF (96%); iv) 9-BBN, THF; H2O2, NaOH (80%); v) MsCl, CH2Cl2, Et3N (99%); vi) NaN3, DMSO (95%); vii) TsOH, MeOH (95%); viii) MsCl, CH2Cl2, Et3N (97%); ix) N-benzylamine (96%); x) LiAlH4, THF (99%); xi) H2NC(NH)SO3H, MeOH (89%).
Figure 3.28 Synthesis of cholate-based multivalent amines as polymyxin mimics.
TARGETS IN BACTERIAL CELL MEMBRANES
109
an MIC of 70 mg/mL, is unable to penetrate through the outer membrane and is thus not very active against gram-negative bacteria. The antibacterial activity of erythromycin against E. coli is increased 70-fold, to 1 mg/mL, when measured in the presence of 27 or 28. A comparable synergism is also observed with novobiocin, which is nearly inactive against E. coli. When tested in combination with 28, the MIC value of novobiocin is reduced to 1 mg/mL. The enhanced susceptibility of gram-negative bacteria to those antibiotics that are inactive as single agents is attributed to the binding of multivalent mimics to lipid A. This association probably leads to disruption of the integrity of outer membrane, and thus increases its permeability to these antibiotics. 3.1.2.2 ter-Cyclopentane–Based Polymyxin Mimics. Hubbard et al. [249] reported a unique class of multivalent amines presented on a rigid sca¤old (Figure 3.29). The system is designed on a ter-cyclopentane trimer locked in a defined conformation with the required functionality for chemical derivatization. Such molecules present six copies of phenylalanine (29) or tryptophan (30) tethered to a ter-cyclopentane framework. They bind lipid A tightly under physiological conditions with K d values of 587 nM (29) and 592 nM (30). This binding strength is comparable to the K d value displayed by polymyxin [250]. Therefore, such molecules constitute a new class of synthetic polymyxin mimics, which are structurally unique but less complex than polymyxin. They are
O O i,ii
Ph
H
H
Ph
O
H
iii
O
H H
O
O
H
Ph
O
H
iv
O
O
O
O
v,vi
vii H
H
H 2N
O
O
O H 2N R
H
H
OH H OH
Ph O
O
O
NH2
O H
H
O
HO
O R
O
H
H
Ph O
O
HO
H
H
Ph
Ph
Ph
Ph O
H
viii,ix
O
H
Ph O
O
R
H H
O NH2 R
29: R = CH2Ph 30: R = N H
reagents and conditions: i) K3Fe(CN)6, K2OsO4, quinuclidine, K2CO3, t-BuOH, H2O (1:1); ii) NaIO4, THF, H2O (3:1), 0oC to rt (63%); iii) (i-PrO)2P(O)CH2C(O)CH2CH2Ph, t-BuOK, THF, 0oC to rt, 2h; then bis-aldehyde, -78oC to 4oC (90%); iv) AlMe3, 10 min; then AlCl3, CH2Cl2, 0oC, 10 min; then cyclopentadiene (10 eq), 4oC (87%), v) LiAlH4, THF, rt; vi) Bz-Cl, Et3N, CH2Cl2, rt; vii) O3, CH3OH, CH2Cl2 (1:1), -78oC; then NaBH4, 0oC to rt; viii) Boc-Phe or Boc-Trp, DCC, DMAP, CH2Cl2, DMF (7:3), rt, 18h; ix) TFA, Et3SiH, CH2Cl2, 12 h.
Figure 3.29 Synthesis of ter-cyclopentane-based multivalent amines as polymyxin mimics.
110
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS Ph
Ph O H2N
O
O
O
O
O
H O
O
H
H
N H 2N H
porous silicon
NH2
O
O
O
H
O
n
O 10 eq
N H
N H
Si(O)3
NH2 N H
NH2
O
6% DMSO in water
30 (O)3Si
Si(O)3
O
O Ph
Ph O H 2N
O
O O O
HO
OH
O
O O
H N H2N H
O
O HN
NH
O
o
H
H
H
O NH2 N H
m
(m/o ~0.1)
N H
N H 31
Figure 3.30 Multivalent display of lipid A–recognition molecule through covalent attachment to silicon microcavity.
potentially active in neutralizing endotoxin, a liposaccharide, by associating tightly with lipid A. The structure of lipid A is highly conserved with that of several lipopolysaccharide (LPS) subtypes found from various gram-negative bacterial species. Because of its low structural variability, lipid A is often considered as a target of choice when designing a biological sensor to enable the selective detection of gram-negative pathogens. Chan et al. [251] reported an optical device called a silicon microcavity resonator, which utilizes the high a‰nity of 30 to lipid A. The silicon microcavity is derivatized with multiple copies of 30 at a surface density of 10% calculated on the basis of available attachment sites (Figure 3.30). When bound to lipid A, this functionalized resonator (31) shows a specific optical response seen as a red shift by 3 to 4 nm in the photoluminescence spectra of the biosensor. Indeed, the device responds selectively to lipid A–containing cell lysates prepared from gram-negative bacterial species, but not to lysates from gram-positive bacteria. This example illustrates the e‰cient application of multivalent organic receptors when coupled with a silicon microcavity resonator. 3.1.2.3 Natural Multivalent Molecules Bound to Lipid A. During the humoral immune response to bacterial pathogens, the outer membrane of the bacterial
TARGETS IN BACTERIAL CELL MEMBRANES
111
cell wall presents common antigenic structures targeted by a complementary cascade system that kills bacterial cells by generating hydrophilic pores through cell membrane. The complement cascade involves the sequential and coordinated activation of 11 distinct complement proteins [252]. The classic complement pathway is initiated by the multivalent binding of IgG or IgM antibodies to antigens presented on outer membranes. This binding triggers the adsorption of C1 complement proteins C1q, C1r, or C1s to a complement-binding site exposed on the Fc region of the immunoglobulins. The C1q is a complex has a molecular weight of 410 kDa and is composed of six collagenlike helixes that are assembled together at one end (Figure 3.31) [253]. At another end, six free globular head groups function as a recognition site. In a study measuring the surface pressure relative to the area per molecule, Ringsdorf et al. [254] reported that the globular head of C1q binds multiple lipid A molecules presented on the surface. This type of recognition is specific to lipid A, as supported by the use of fluorescein-labeled anti-C1q antibody.
C1q
Lipid A
Lipid monolayer
Lipid A HO
NH3+ O HO
-O O P O O O
O O
OH O
O O O O NHHO O HN O P P O O O O O O- OO HO O OH O O O
NH3+
Figure 3.31 Complement component C1q and its multivalent binding to lipid monolayer composed of lipid A and DPPC.
112
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
3.1.3
Helicobacter pylori Adhesin Receptor
H. pylori is a human-specific gram-negative pathogen that causes gastritis and gastric ulcers [255]. This causative action occurs through bacterial colonization on epithelial cell surfaces, where pathogen–cell adhesion plays a critical role. Multiple pairs of bacterial receptor–cellular ligands are involved in such attachment [255]. First, BabA is 78-kDa adhesin located on the bacterial surface which selectively binds Lewis b (Fuc-a1,2-Gal-b1,3(Fuc-a1,4)GlcNAc-a1,3Gal-b1,4-Glc) glycoconjugates expressed on the cell surface. The surface of one H. pylori bacterium presents about 500 copies of BabA per Lewis b (Le b ) molecule, a density close to the number of fimbriae organelles on the surface of E. coli. Using multiple pairs of BabA–Le b molecules, the bacterium adheres tightly to the surface of epithelial cells with a high-a‰nity Ka value of 8 10 9 M 1 [256]. Other adhesin receptors on the surface of H. pylori include SabA, which recognizes sialyl-dimeric Lewis x glycosphingolipid; hemagglutinin– HpaA, which recognizes sialyl lactose (NeuAc-a2,3-(6)Gal-a1,4-Glc); a 65-kDa protein, which binds phosphatidyl ethanolamine; and Hsp 70, which recognizes neutrophil activating protein (NAP) and sulfated carbohydrates such as 30 -SO3 Gal-b1,R and 6 0 -SO3 -GlcNAc-bR. 3.1.3.1 Synthetic Multivalent Inhibitors of H. pylori. Multivalent interactions implicated in the adsorption of H. pylori to epithelial cells are inhibited by synthetic multivalent molecules. Bore´n et al. [257] reported that a neoglycoconjugate composed of the Le b ligand in multiple copies on the surface of human serum albumin is an e¤ective inhibitor of such bacterial attachment (Figure 3.32). For example, a neoglycoconjugate (32) reduces the binding of H. pylori p466 to gastric mucosa by 93% at a concentration of 20 mg/mL, while a second glycoconjugate (33), displaying the H-1 oligosaccharide epitope (Figure 3.32), reduces it only by 48%. The inhibition of such pathogen–cell adsorption is achieved specifically by multivalent molecules presenting Le b ligand. Those presenting non-Le b ligands, such as H-2, Lea , Le x , and Le y , are all inactive at concentrations up to 100 mg/mL. The implication of BabA as a Le b -binding receptor is strongly supported by receptor activity-directed a‰nity tagging, developed by Bore´n et al. (Figure 3.33). This photoa‰nity method, coupled with the use of a multivalent Le b glycoconjugate (34) that can be photo-cross-linked, makes it possible to isolate and purify BabA (75 kDa) from virulent strains of H. pylori. Localization of this adhesin protein on the bacterial surface is visualized by electron microscopy in H. pylori cells that were treated with biotinylated Le b glycoconjugate and then with an antibiotin antibody covalently linked to gold nanoparticles. It is often di‰cult to avoid lengthy processes in the chemical synthesis of complex branched oligosaccharides such as the Le b determinant. However, Randolph and Danishefsky [258] developed an e‰cient glycal methodology performed on solid support which enables the synthesis of a form of Le b that
TARGETS IN BACTERIAL CELL MEMBRANES
113
Inhibition of cell-bacterium adhesion by Leb neoglycoconjugate
Adhesin (BabA)
H. pylori 32 or 33
Leb
Epithelial cells OH HO
Leb
human serum albumin
O 32
OH HO OH HO O HO O OAcHN HO O O HO HO O O O OH OH O OH HO
33
OH
N H n (=32)
human serum albumin
H-1
OH OH HO HO HO O OAcHN HO O O HO HO O O O OH OH O OH HO
O O N OH
O O N OH
N H n (=35)
OH
Figure 3.32 Multivalent Le b glycoconjugates constructed on human serum albumin protein and its proposed inhibition in the adhesion of H. pylori to epithelial cells.
supports bioconjugation (Figure 3.34). This approach makes it possible to generate Le b -O-allyl glycoside 35, whose terminal allyl group is oxidatively cleaved to an aldehyde functionality, which in turn is used as a handle for tethering the Le b molecule to human serum albumin through reductive amination [259]. The neoglycoconjugate 36 prepared in this way yields approximately 33 copies of Leb saccharide per albumin protein, conjugated to lysine residues. In a special environment where epithelial cells are subject to persistent infection and chronic inflammation, H. pylori exploits a second type of surface adhesion receptor, which is referred to as the sialic acid–binding adhesin (SabA). It selectively recognizes the sialyl-Le x ligand expressed as a form of glycosphingolipids in gastric epithelium [260]. The interaction between multiple pairs of SabA–sLe x thus becomes more significant during certain diseased states, such as chronic inflammation, because sLe x antigens are expressed at a higher level when stimulated by bacterial colonization. Such a secondary type of pathogen–cell adhesion is shown in Figure 3.35.
114
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS OH HO
Leb
albumin
O OH HO OH HO O HO O OAcHN HO O O HO O HO O O OH OH O OH HO
Sulfo-SBED
N H n
NH2
OH 34 multivalent Leb-cross-linker glycoconjugate
OH HO
O OH HO OH HO O HO O OAcHN HO O O HO O HO O O OH OH O OH HO
O O N OH
OH
O O N OH
N H n
BabA adhesin binding;
NH
then UV irradiation
O S S
disulfide bond O
N3 aryl azide photocross-linker
H HN N
NH
HN O
O
biotin
H N
S O
OH HO O OH HO OH HO O HO O OAcHN HO O O HO HO O O O OH OH O OH HO
O O N OH
N H n
NH O
S S
OH
O
N
H HN N
BabA adhesin
NH
HN O
H N
O
S O
photocross-linking BabA adhesin SH Reducing disulfide (DTT);
O
N
H HN N
then avidin affinity purification O
HN O
H N
NH S
O
Figure 3.33 Multifunctional Le b neoglycoconjugate and a receptor activity-directed a‰nity tagging method used for characterization of BabA as Le b -binding receptor.
115
TARGETS IN BACTERIAL CELL MEMBRANES Glycal 1 OTIPS
O
OSi(iPr)2- S O O O
O
HO HO i
BnO F O OBn OSi(iPr)2-S OTIPS O BnO OBn O O OHOO O ii OH
O
OBn O OBn OR'
O OR O OO O O
BnO
O
O OBn OBn
R = Si(iPr)2- S
; R' = TIPS
iii R = R' = H
Glycal 2 BnO OBn HO OTIPS O O OBn Bu SnO O 3 OTIPS HO O OTIPS OH I O O O OO O vi O NHSO2Ph
v
R = R' = TIPS
OTIPS O
O OBn BnO OBn
iv
R3O OR 3 O OR3 OR R1O OR R4O OR O O O OO O O R 4O NHR2 OR R1O O 1
OR O
O OR 3
R3O OR3 Leb-O-allyl glycoside (35)
OH OH
viii
O OH OH HO OH HO OH O O O OO O O HO NHAc OH HO O
OH O
ix
O
OH
O OH HO OH OH OH O OH HO OH O OO HO O
Leb neoglycoconjugate (36) OH
HO OH O O O NHAc OH HO
O
HSA
OH O OH
O
N n = 33 H
O OH HO OH
reagents and conditions: S = solid support; i) (a) 3,3-dimethyldioxirane, CH2Cl2, (b) glycal 1, ZnCl2, THF; ii) Sn(OTf)2, di-tert-butyl-pyridine, THF; iii) TBAF, AcOH, THF; iv) TIPSCl, imidazole, DMF; v) I(coll)2ClO4, PhSO2NH2, CH2Cl2; vi) glycal 2, 4 Å mol. sieves, THF; vii) (a) TBAF, AcOH, THF, (b) Na, NH3, (c) Ac2O, pyridine; viii) (a) 3,3-dimethyldioxirane, CH2Cl2, (b) allyl alcohol, ZnCl2, (c) NaOMe, MeOH; ix) (a) O3, (b) human serum albumin (HSA), NaCNBH3.
Figure 3.34 Synthesis of Le b -presenting neoglycoconjugate.
An additional surface receptor of H. pylori implicated in cell attachment includes HpaA, a 20-kDa hemagglutinin. It recognizes sialyllactose ligands on cell surfaces. Simon et al. [261] report that 3 0 -sialyllactoside inhibits the attachment of H. pylori to gastrointestinal cells. A multivalent molecule composed of 3 0 -sialyllactose displayed on serum albumin blocks such adhesion 100to 1000-fold more potently than does a monovalent 3 0 -sialyllactose.
116
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS BabA
SabA
H. pylori
A
sLe
Leb
x
chronic infection Epithelial cells (disease state)
Epithelial cells (normal state)
Figure 3.35 Simplified mode of adhesion of H. pylori to the surface of gastric epithelial cell in normal and disease states. OH
OH O
HO
OH
OH O
HO HO O
OH O O
HO
HO O
O N H
HO
OH O S
HO
S
OH
HO
37 OH
HO O HO
O OH
38
O HO
OH O
HO
OH
S O HO
OH O O
O N H
HO
H N
S
S
O
OH
O
O OH O HO
OH
HO
OH
O O HO
39
HO OH O
O
OH OH
OH OH
OH OH
OH
O
OH HO
HN
OH O
HO O HO HO
O OH O O
O
S
N H
H N
S
S S
O
40 O NH
OH O O HO
OH O OH O HO
OH OH
O HO HO HO
O
O
OH
O HO OH
HO
Figure 3.36 Structure of di- to tetravalent galabiosides as inhibitors of S. suis– mediated hemagglutination of erythrocytes.
TARGETS IN BACTERIAL CELL MEMBRANES OAc AcO
OAc
OAc O
AcO O AcO
AcO OAc O O
HO
OAc O O
AcO
Br
AcO OH
OAc O
AcO O
i
117
AcO
ii N3
OH O
HO O HO HO
OH O O
O NH2
+
HO
S
C
S
OH 3
iii,iv
40
O
reagents and conditions: i) NaN3, 15-crown-5, 75 oC, 24 h (97%); ii) NaOMe, MeOH; then H2, Pd/C (87%); iii) F5C6OH, DIC, DMF, 0oC to 22oC, 16 h; iv) HOBT, Et3N, DMF, 22oC, 16 h (55% over two steps).
Figure 3.37 Synthesis of tetravalent galabioside.
3.1.4
Streptococcus suis Hemagglutinin
Many bacterial species utilize cell oligosaccharide ligands displayed on the cell surface for bacterium-cell adhesion. Galabiose (Gal-a1,4-Gal) is one of the epitopes recognized by uropathogenic E. coli [262] and Streptococcus suis (gram-positive) [263]. In principle, this ligand is tailored to inhibit cell attachment by such bacteria. Hansen et al. [264] demonstrated that multivalent galabiosides are much more e¤ective than a monovalent galabioside in blocking the cell adhesion induced by S. suis hemagglutinin. Representative examples of bi- and tetravalent galabiosides are shown in Figures 3.36 and 3.37, which summarize the synthesis of a dendrimerlike tetravalent galabioside (40). In an assay that measures the inhibitory activity of agglutination of human erythrocytes mediated by S. suis bacteria, a divalent galabioside (39) a¤ords complete inhibition at 10 nM. This bivalent activity is enhanced 30-fold over a relevant monovalent galabioside (37). A second bivalent molecule (38), which is tethered through a shorter linker, has a lower activity reflected in an IC50 of 130 nM, representing only a twofold higher potency than that of 37. When the valency number is raised to 4, as in 40, the activity is enhanced 300-fold. This is the first example where bacterium–cell adhesion is inhibited completely by soluble saccharides of relatively low valency at nanomolar concentrations. 3.1.5
Escherichia coli FimH Adhesin
E. coli is a primary cause of urinary tract infections. Its pathogenicity correlates with its ability to adhere to the surface of host cells [265]. Pathogen–cell adsorption occurs through multiple specific interactions between the FimH adhesin located on the tips of the pili of E. coli type 1 and mannoside-containing oligosaccharide ligands present on the surface of bladder epithelial cells [266– 268]. Due to its multivalent nature, such surface–surface adhesion is strong
118
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
enough that microorganisms remain attached tightly to host cells under dynamic physiological conditions, including exposure to shear forces from flowing liquid. 3.1.5.1 Physical Forces Involved in Bacterium–Cell Adhesion. Liang et al. [269] investigated the adhesion forces involved in the interaction of uropathogenic E. coli with a model cellular surface (Figure 3.38). This study uses mannoside-terminated self-assembled monolayers (SAMs) as mimics of epithelial cells in combination with optical tweezers—also known as a gradient force
End-on attachment
Side-on attachment ~0.9 µm
Mannoside
~0.4 µm
mannoside-presenting model surface
HO HO HO
Mannoside
HO HO HO
OH O
OH O
S
S
HN
HN O
O
O
O
O
O
O
O
HO
HO
O
HO
HO
HO
HO
O
HO
HO
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
(CH2)9(CH2)9 (CH2)9(CH2)9(CH2)9(CH2)9(CH2)9 (CH2)9 (CH2)9(CH2)9
S
S
S
S
S
S
S
S
S
S
Self-assembled monolayers (SAM) on Au (gold)
Figure 3.38 Adhesion of E. coli to a mannoside-presenting SAM surface through two modes of attachment (side-on and end-on).
TARGETS IN BACTERIAL CELL MEMBRANES
119
optical trap. Using this method it is possible to manipulate submicrometersized bioparticles freely. The E. coli bacterium can attach to the SAM surface that presents a-C-mannoside ligands with variable surface densities ( wman ¼ 101 , 103 , or 106 ). The surface density (wman ) is calculated on the basis of the background of a tri(ethylene glycol) group: wman ¼ mannoside o [mannoside þ (EG)3 ]. The optical tweezers are then used to detach bacteria adhering to the well-defined model surface. The physical force required to detach a bacterium adhered in a side-on orientation is measured in the range 3.5 to b18 pN from SAMs of mannoside density 10% ( wman ¼ 0.1). On the other hand, the force required to detach a bacterium adhering to a SAM surface with a lower density of mannoside at 105 % (A4 mannosides/mm 2 ) is smaller (3.8 to 7.8 pN ). Bacteria also attach to surfaces through an end-on orientation, where the estimated number of attachment points is one or two, even on a SAM with 10% mannoside density. The force needed to detach a bacterium in the end-on mode of attachment is much lower, around 1.7 pN. This force is interpreted as that required to break the monovalent interaction between a pilus and a mannoside molecule on a surface. It is apparent that uropathogenic E. coli bacteria rely on multiple specific interactions to attain tight binding to a model surface. Such multivalent binding as exhibited during side-on adhesion is much stronger than the monovalent binding that occurs during end-on adhesion. 3.1.5.2 Polyvalent Inhibitors of E. coli Adhesin. Li et al. [270] reported the synthesis and activity of poly(acrylamide)-based terpolymers presenting multiple copies of carbohydrate residues such as a-mannoside and lactoside as their side chains. This type of polyvalent mannoside inhibits the adhesion of E. coli to yeast cells. Such inhibitory activity can be attributed to the competitive binding of the polyvalent ligand to the surfaces of E. coli. Other synthetic examples include dendrimer-based sca¤olds used to display mannosides in an array. These may be synthesized using a one-pot reaction that includes monoand dimannose and an amine-terminated dendrimer, as reported by Hayes et al. [270]. 3.1.5.3 Presentation of Mannosides on Gold Nanoparticles. Using self-assembled thiolates on a gold surface, Lin et al. [271] reported the synthesis and biological characterization of multivalent mannosides presented on gold nanoparticles (Figure 3.39). The nanoparticle 41 (diameter ¼ 6 G 1 nm) is manipulated to present approximately 200 copies of covalently attached mannosides, with the synthesis shown in Figure 3.40. The bacterial receptor, adhesin FimH, interacts specfically with surface mannosides, causing the particles to adhere to E. coli type 1 pili. This adsorption is adhesin-specific, such that a mutant E. coli bacterium that lacks adhesin FimH on its pili cannot bind the sugar-coated nanoparticle. The adhesion is very tight, due to the multivalent nature of the binding, and the addition of monovalent mannose is insu‰cient to detach the particles from the pili, even at 20-fold higher mannose concentrations than that
120
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS Wild-type E. coli
~6 nm
mannoside-presenting gold nanoparticle (41)
mutant
wild-type
E. coli mutated in type 1 pili
Figure 3.39 Selective adhesion of mannoside-presenting gold nanoparticles to the surface of E. coli type 1 pili.
presented on the surface of the nanoparticles. Detachment is observed when free mannose concentrations are much higher, such as 100-fold (10% detachment) and 2000-fold (roughly 90% detachment). This example illustrates that gold nanospheres presenting multivalent mannoside can serve as an e¤ective probe, capable of binding selectively and tightly to adhesin FimH on the surface of type 1 pili. 3.1.6
E. coli Chemoreceptors
Bacterial chemotaxis is a process whereby bacteria respond physically to specific chemicals [272,273]. It occurs through complex signal transduction events based on receptor-mediated molecular recognition. The E. coli chemotaxis is triggered by the binding of small molecules, such as sugars and amino acids to specific receptors located as clusters on the bacterial plasma membrane [274,275]. The small molecules act as chemoattractants or chemorepellents. For example, galactose binds to a soluble glucose–galactose binding protein HO HO HO
HO HO HO
OH O
AcO AcO AcO
i,ii OH
iii
AcO AcO AcO
Br
OH O
vi
O
OAc O
HO HO HO
2
iv,v
O
OH O O
S
OAc O
~200 mannoside per particle S
S
41 multivalent mannoside presented on gold nanoparticle
O O HO
OH OH OH
reagents and conditions: i) Ac2O, pyridine, DMAP, 90%; ii) HBr, AcOH, 80%; iii) 4-pentenyl alcohol, Hg(CN)2, 88%; iv) AcSH, AIBN, dioxane, 80%; v) cat. NaOMe, MeOH, 97%; vi) AuHCl4, NaBH4.
Figure 3.40 Synthesis of mannoside-presenting gold nanoparticle.
TARGETS IN BACTERIAL CELL MEMBRANES (a)
121
Galactose GGBP Out Membrane In
~90 Å (b)
(c)
Trg (dimeric chemoreceptor)
multivalent galactoside (short)
multivalent galactoside (long)
receptor clustering
Figure 3.41 E. coli chemotactic response via clustering of bacterial chemoreceptors (Trg) by polyvalent molecules: (a) monovalent galactose (Gal), which binds to GGBP and then to a dimeric form of Trg; (b) short polyvalent Gal, where its tethered ligands are unable to span the distance necessary to cluster dimeric Trg; (c) long polyvalent Gal, composed of su‰cient spacer length to make it possible to reorganize dimeric receptors into discrete clusters at a plasma membrane.
(GGBP) (Figure 3.41). Following formation of the galactose–GGBP complex, the complex is able to interact with a galactose-specific chemoreceptor (Trg), which initiates a signaling pathway that eventually guides bacteria to swim toward the galactose nutrient [276]. 3.1.6.1 Polyvalent Galactosides as an E. coli Chemoattractant. Gestwicki et al. at the University of Wisconsin [277] studied chemotactic responses in E. coli to polyvalent ligands such as 43, a neoglycopolymer bearing galactoside ligands at various valencies (Figure 3.42). These ligands cause chemotactic activity such as the tumbling behavior of bacteria, which can be measured as
122
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS HO O HN
O HN
O
Ph
i) [Cy3P]2Cl2Ru=CHPh C10H21N(CH3)3Br water, 1,2-dichloroethane
n-2 O
ii) ethyl vinyl ether
HO HO HO
OH OH OH
O
O
HN
O O
HO HO HO
OH
O
HN HO HO HO
O
OH
O
42 HO HO HO
O
43 (n = 10, 25, 50)
O
O
O
OH
O
OH HN
O
Ph 44 m O
O
HN
HN HO
HO HO HO
O
O
O
O
O
OH HO O HN
23
OH
O N H
O
N H
O
S F F BN N
O
HN O
OH OH OH
O O
O
O
OH OH OH
O
Ph
HO HO HO
O
O
HN HO HO HO
45 O
O
OH
Figure 3.42 Structure of polyvalent galactoside of varying valences that are synthesized through ROMP-mediated polymerization of galactose monomer.
tumbling frequency or mean angular velocity in a bacterial path. The polyvalent galactoside 43 (n ¼ 25) is about 100 times more active than monovalent 42 or galactose. This polymer induces low mean angular velocity even at very low concentrations (e.g., 1 mM per galactoside) and starts to trigger a significant response at 10 mM. Such a significant response can be displayed by a monovalent galactoside (42) but at a higher concentration, 1 mM. The enhanced activity of 43 is attributed to its ability to cluster the chemotactic Trg receptors through multivalent binding (Figure 3.41). This is an example of the important role of ligand valency in bacterial chemotaxis. To further evaluate the relationship between ligand valency and chemotactic activity, Gestwicki et al. [277] devised a capillary accumulation assay that
TARGETS IN BACTERIAL CELL MEMBRANES
123
measures the number of bacteria accumulated as a function of the concentration gradient of attractants. The monovalent galactoside 42 and a short oligomer (43; n ¼ 10) show similar activities by eliciting a maximum chemotactic response at 1 mM. Higher-valency polymers (43; n ¼ 25, 50) generate more potent activity, with maximum responses observed at 0.25 mM (n ¼ 25) and 0.1 mM (n ¼ 50). A second generation of multivalent galactoside (44) containing a longer spacer between the attached ligand and polymer backbone is more active than 43 [278,279]. The degree of chemotactic activity is rationalized by considering the length of the glycopolymer molecule and its ability to induce receptor clustering. For ˚ , which is example, 43 (n ¼ 10) has an extended polymer length of roughly 50 A shorter than the spacing between Trg chemotactic receptors (approximately ˚ ) [280]. Therefore, it is unlikely that the polymer is able to cluster Trg re90 A ceptors (Figure 3.41b). Clustering of Trg receptors by polyvalent galactoside molecules is supported by fluorescence microscopic imaging performed using a galactose-bearing fluorescent polymer 45, in which the polyvalent ligand binds specifically to chemotactic receptors and causes receptor clustering on cell surfaces. The clustering of one class of chemoreceptors by a polyvalent ligand influences the response of a second class of chemoreceptors to a di¤erent chemoattractant. Kiessling et al. [277] reported one example using the polyvalent galactoside 43 (n ¼ 25) in E. coli, which not only presents galactose-sensing Trg receptors but also serine-recognition (Tsr) chemoreceptors. Both receptors respond to specific amino acids, such as serine and aspartic acid, as chemoattractants (Figure 3.43). Serine causes a maximum bacterial response at a (a) Serine
Galactose Out Membrane In
Tsr (dimeric)
(b)
Trg (dimeric)
multivalent galactoside
receptor clustering
Figure 3.43 Chemoreceptor clustering involved in potentiation of serine response.
124
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
concentration of about 100 mM. Pretreatment with 43 (10 mM per galactoside basis) lowers to 1 mM the concentration of serine required for a maximum response. This amplified response is attributed to clustering among the arrays of di¤erent bacterial chemoreceptors. This example illustrates the use of polyvalent ligands as a molecular probe in the study of receptor clustering and signal amplification. 3.1.6.2 Polyvalent Glucosides in the Chemotaxis of Gram-Positive Bacteria. Chemotactic responses are also observed in gram-positive bacteria. Gestwicki et al. [277] reported the correlation between ligand valency and glucose-induced chemotaxis of Bacillus subtilis. This bacterium, unlike E. coli, responds to glucose but not to galactose and galactoside-presenting polymers. In a capillary accumulation assay, a glucose-presenting polymer (47; n ¼ 10) elicited a maximum chemotactic response at 0.1 mM glucose concentration, which is 10-fold greater than 46 and fivefold greater than glucose (Figure 3.44). A highervalency polymer (47; n ¼ 25) at 10 mM generates a response that is 100-fold greater than that of 46. It is clear that ligand valency is strongly associated with chemotactic response. 3.1.7
Nonbacterial Lectins
Entamoeba histolytica is a causative parasite of amebiasis which colonizes in the large bowel. As an essential step toward infection, the colonization is ini-
HO O
HO O
HN O
Ph
HN
HO HO
n-2
OH O O
O
O
HN
OH 46
OH OH
O
HO HO
OH O
HN
O HO HO
OH
OH O
O
OH
47 (n = 10, 25)
BSA OH HO O HO OH n = 40 48
BSA OH HO O HO NHAc n = 39 49
Figure 3.44 Structure of Glu-bearing neoglycopolymer as a ligand of B. subtilis and GalNAc-presenting neoglycoproteins that bind to E. histolytica lectin.
TARGETS IN BACTERIAL CELL MEMBRANES
125
tiated by parasitic adherence to the surface of host cells in the colon wall [281]. The pathogen–cell attachment involves specific interactions between lectin receptors on amebic surfaces and N-acetylgalactoside residues linked to epithelial glycoconjugates and colonic mucin. Lectins refer to a family of proteins that recognize specific carbohydrate moieties (for more details, see Section 4.1.16). The adhesion lectin is a 170-kDa heterodimer, whose adherence to target cells is inhibited selectively by N-acetylgalactosides only at 5 to 10 mM. Adler et al. [281] evaluated a series of multivalent glycoconjugates for their a‰nity to E. histolytica lectin. In a lectin-induced hemagglutination assay, natural glycoproteins such as fetuin and asialo-fetuin show inhibitory activity with a MIC value of 0.31 mM. Synthetic neoglycoconjugates that display multiple galactoside residues on protein surfaces show much greater activity (Figure 3.44). For example, the MIC value of 48 (Gal 40 BSA: 40 Gal residues linked to bovine serum albumin) and 49 (GalNAc39 BSA) are 0.15 mM and 5 nM, respectively. Compared to monovalent sugars such as galactoside, with an MIC of 0.71 mM, and N-acetylgalactosamine, with an MIC of 2.5 mM, the activity of 49 is enhanced about 140,000- and 500,000-fold, respectively. Radioligand binding studies with 49, using the displacement of [ 121 I]GalNAc39 BSA from E. histolytica membranes, provide a Kd value of 10 nM, indicating a 200,000-fold tighter binding for 49 over monovalent GalNAc. Therefore, a multivalent Ga1NAc presented on a serum protein shows much a higher avidity to E. histolytica lectin than do natural ligands. 3.1.8
Staphylococcus aureus E¿ux Pumps
QacR belongs to a member of multidrug-binding repressor proteins expressed in S. aureus and regulates the expression of multidrug resistance (MDR) e¿ux pumps [282]. QacA, another MDR pump, is involved in the transport of monoand bivalent cationic lipophilic antiseptics, such as quaternary ammonium ions, outside the cell. The structure of QacR comprises a DNA-binding domain and a drug-binding domain. It initiates the transcription of QacA gene when bound by structurally diverse lipophilic drugs, many of which also are substrates of QacA. Crystal structures of QacR–drug complexes reported by Schumacher et al. [283] suggest that drug binding induces the formation of an extended multidrug binding pocket which presents separate but linked drug-binding sites within a single protein. The complex with a divalent drug, dequalinium, is shown in Figure 3.45. Binding domain 1 creates an environment where a quinolinium group binds through p-interactions between Trp-61 and Tyr-93, and domain 2 interacts with a second quinolinium group sandwiched between Phe162 and Tyr-103. The decamethylene linker is stabilized through multiple van der Waals contacts with multiple hydrophobic side chains contributed from Leu-54, lle-99, Met-116, and Leu-119. Monovalent quaternary cations, including antimicrobial alkaloids, bind to either site 1 (berberine, rhodamine 6G) or site 2 (ethidium). Thus, divalent sites in the binding pocket appear to play a crucial role in the recognition of multiple drugs by bacterial cells. Such a
126
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS Phe-162 Trp-61
N H
CH3 N+
Thr-89
OH
H3C
NH2 N +
H2 N Tyr-103 OH
HO
Tyr-93
Binding domain 1
Binding domain 2
Figure 3.45 Structure of dequalinium and its proposed divalent recognition by multidrug-binding repressor protein QacR from S. aureus.
divalent-recognition site is also observed in multidrug transporters, including bacterial QacA and QacB [284,285].
3.2 3.2.1
BACTERIAL TOXINS Heat-Labile Enterotoxins
LT is a heat-labile enterotoxin isolated from E. coli. It is a member of the AB5 family of bacterial toxins, which include Shiga toxin, Shigalike toxin, and pertussis toxin [286–289]. Structurally, LT is a heteromeric complex composed of one enzymatic A subunit as a lethal factor and five B subunits, which play an essential role in adsorption of the toxin to the target cell membrane. As shown in Figure 3.46, the five B-subunits are organized symmetrically, such that each
Galactoside binding site 1 Galactoside
45 Å
Pentavalent ligand
B5-ligand complex
B5 (LT)
Figure 3.46 Model for 1:1 complex between heat-labile enterotoxin (LT) B5 and a pentavalent galactoside.
BACTERIAL TOXINS
127
subunit contains an identical carbohydrate-binding site located in the same face. This pentameric face selectively recognizes galactoside-presenting sugar ligands such as natural ganglioside GM1 [290,291]. The enterotoxin initiates its intracellular invasion process by attachment to cell surfaces, a process attributed to specific, tight interactions between multiple galactoside-recognition sites on a B pentamer and multiple ligands derived from cell surfaces. 3.2.1.1 Pentavalent Galactosides. Fan et al. [292] reported high-a‰nity, multivalent inhibitors of LT-B5 designed through a modular approach. As in conventional rational drug design, this design relies heavily on known structural information of the target. Based on the distance and position of carbohydratebinding sites on B5 complex, a series of pentavalent ligands that are structurally complementary to the pentavalent receptor sites are designed (Figure 3.46). For example, a simple derivative of galactoside is tethered to an azacrown sca¤old through a flexible linker of varying lengths. Each pentavalent molecule presents ˚ , the estimated distance between tethered ligands separated by more than 45 A sugar-binding sites present on two nonadjacent B-subunits (Figures 3.47 and 3.48). As calculated in an extended conformation, the distance between non˚ (50) to 180 A ˚ (53). Howadjacent ligands is approximately in the range 60 A ever, the e¤ective length, calculated on the basis of a polymer model, is in the ˚ (50) to 45 A ˚ (53). In the latter model, the efsmaller approximate range 30 A fective length is proportional to the square root of the molecular weights of two tethered galactosides [52,293]. Such a linker distance suggests that some pentameric ligands bind the pentameric target in a multivalent way because of similarity in their molecular dimensions and shapes. In an ELISA assay [292], which evaluates the ability of various molecules to inhibit the binding of LT-B5 to ganglioside, pentavalent galactosides show greatly enhanced activity compared to that of a monovalent galactoside, as shown by the IC50 values of 242 mM (50), 16 mM (51), 6 mM (52), 0.56 mM (53), 5 mM (monomer 54), and 58 mM (galactose). This binding result provides a positive correlation between linker distance and a‰nity. For instance, ˚ (53), which the highest a‰nity is achieved at an e¤ective distance of 45 A matches the estimated distance required for a pentavalent association. This specific inhibitor shows a binding strength 105 -fold greater than that of monovalent galactose and 10 4 -fold (or 2000-fold on a valency-corrected basis) greater than that of a monomer control (54). However, 53 is still less active than is LT’s natural ligand, GM1 -OS, which shows an IC50 of 0.01 mM. In place of a plain galactoside, a more active ligand monomer such as GM1 -OS can be attached to a multivalent sca¤old to prepare a more potent pentavalent ligand. Indeed, a pentameric GM1 -OS equivalent to 53 leads to an inhibitory activity about 100 times higher per GM1 -OS ligand than that of the GM1 -OS monomer. By comparison, multivalent presentation of a weakly binding galactoside enhances the avidity of a multivalent ligand by four or five orders of magnitude, whereas a similar multivalent molecule presenting the more tightly binding GM1 -OS exhibits a less dramatic improvement.
128
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS HO HO OH O
HO
NH L = distance (at extended dimension)
O
HO OH
HO HO
Linker
O H N OH O
Linker
O
NH
O
OH OH OH
N N Linker
N N
N
Linker
Linker
O HN O
O OH HO OH
OH
HO HO OH O Linker =
N H
O N H
OH
HN
O
(CH2)2[CH2OCH2]3(CH2)2
O
O
N H n
N H
Azacrown O
50 (n = 1): L = ~60 Å (effective length = ~30 Å) 51 (n = 2): L = ~100 Å (effective length = ~35 Å) 52 (n = 3): L = ~140 Å (effective length = ~40 Å) 53 (n = 4): L = ~180 Å (effective length = ~45 Å)
HO HO HO
O H N OH
O
O
O
N H
N H
(CH2)2[CH2OCH2]3(CH2)2-NH2
54
Figure 3.47
Structure of pentavalent galactosides presented on 15-azacrown-5 sca¤old.
3.2.1.2 Multivalent Inhibitors Displayed on a Solid Support. Multivalent sugars immobilized on a solid support are e¤ective agents capable of neutralizing toxins. They act by tightly binding B5 units. Nilsson et al. [294] reported the synthesis of such glycopolymeric material presenting multiple sialyllactose or lactose immobilized on silylaminated Chromosorb P (Figure 3.49). In a cytotoxicity assay, sialyllactose-presenting Chromosorb polymers, represented by 57 and 58, show antibacterial activity by protecting cells from heat-labile enterotoxin of E. coli. Approximately 95% of toxic activity is blocked. These polymers also neutralize cholera toxin by blocking about 98% (57) and 95% (58) of toxin activity, while the nonderivatized Chromosorb P shows no block-
BACTERIAL TOXINS
129
R1 N
R1 N
R1 i,ii,iii
N CO(CH2)3NH2 N
N R1
R1
R2
R2 N
R2 N
N CO(CH2)3 N
O
O
N H
N H
N R2
R2
R3
R3 N
R3 N
N CO(CH2)3 N
N R3
R3
O MeO
iv
(CH2)2[CH2OCH2]3(CH2)2 -NH2 n
O
O
N H
N H
(CH2)2[CH2OCH2]3(CH2)2 NH n
50 (n = 1) 51 (n = 2) 52 (n = 3) 53 (n = 4)
O N H
(CH2)2[CH2OCH2]3(CH2)2-NHBoc
HO HO HO
HN
O
O H N OH
HO HO HO
O
O H N OH
55
O
O
O
O
N H
OMe
56
reagents and conditions: i) 55, MeOH, NaHCO3, H2O; ii) TFA; iii) repeat steps i and ii; iv) 56, NaHCO3, H2O
Figure 3.48 Synthesis of 15-azacrown-5-based pentavalent galactosides.
ing ability. This study illustrates the potential of sugar-containing solid supports as potential therapeutics in the treatment of bacterial toxin–mediated diarrheal disease. 3.2.2
Cholera Toxin
Cholera toxin, a member of the AB5 enterotoxin family, comprises one Asubunit—a 27-kDa enzyme that catalyzes ADP ribosylation of Gs-a protein— and five copies of an 11.6-kDa B-subunit—a lectin that recognizes galactoside ligand such as that found at the termini of GM1 molecules [295]. The distance between adjacent galactoside-recognition sites in the cholera toxin B-pentamer ˚ . Cholera toxin adheres tightly to cells through specific is estimated to be 31 A interactions between the five B-units and multiple GM1 gangliosides expressed on cell surfaces, with a Kd value ranging from 4.6 1010 to 5 108 M for
130
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS OH OH AcHN HO
CO2O HO HO O HO
Chromosorb P
O HO O OH
OH O N
H N
H N n (2.1 µmol incorporated/g)
O
OH O 57
-O2C HO HO
O
HO OH O HO O O OH
HO
O HO O OH Sialyllactose
H N n (2.4 µmol incorporated/g)
O
OH O
AcHN OH
CO2O HO HO O
H N
OH 58
OH OH AcHN HO
Chromosorb P OH O N
Chromosorb P OH OH
O OH
+
H2N
H N
H N O
i,ii
57
m
reagents and conditions: i) MeOH, AcOH, 60oC; ii) Ac2O
Figure 3.49 Multivalent sialyllactose immobilized on solid support as a bacterial toxin –binding agent.
the B-pentamer and GM1 ganglioside in solution [295–297]. The association of free GM1 gangliosides to the cholera toxin B-pentamer occurs in a cooperative manner as a result of enhanced intersubunit interaction upon sequential binding [298]. 3.2.2.1 Galactoside-Presenting Pentavalent Inhibitors. In a subsequent application of rational design, Zhang et al. [299] (see also Williams and Davies [300]) reported the synthesis of azacrown-cored multivalent ligands ending with branched galactosides. These multivalent molecules are designed to target two pairs of cholera toxin B-pentamer simultaneously (Figure 3.50). By virtue of a variable linker length, it is possible to optimize the binding of galactoside ligands, presented on the branched arms of a decavalent molecule, to a Bpentamer. These ligands are highly e¤ective inhibitors of cholera toxin B binding to ganglioside. When assessed by ELISA, the decavalent ligands show IC50 values of 191 mM (59; n ¼ 1), 5.3 mM (59; n ¼ 2), 1.4 mM (59; n ¼ 3), and 40 nM (59; n ¼ 4). The activities observed improve with increasing linker length in the range tested, and are 200- to about 1,000,000-fold greater than that of a monovalent galactoside, which yields an IC50 of 38.5 mM. In ELISA, 59 (n ¼ 4) makes a 1:1 complex with the cholera toxin B-pentamer with an apparent Kd value of about 40 nM. This value is supported by dynamic light scattering (DLS), which measures the hydrodynamic radius of the B-pentamer. The study indicates that a linker length of four iterations in 59 yields the
BACTERIAL TOXINS
131
OH OH OH HO OH OH OH HO
O O
HN HO HO
O
HO HN
OH NH
O
O
O O HN
O
O
N N
O Linker
NH O
O
O
NH HN
HN O HO HOHO
OH OH OH
O
O
H N
N H O
NH
O
OH
OH HO OH
O
OH
O
O NH
HN
O HO HOHO
O Linker =
O
O O
O
HO N H
N Linker
O
H N
O N Linker
O O
O
O
N
HN OH
NH
O
Linker
O Linker
HO
O
O
NH
OH OH OH
O
HN O
HO
HO HO
O NH
N H
O
OH
OH HO OH
O
O
HN (CH2)2[CH2OCH2]3(CH2)2 N nH
N H
O
OH
Azacrown O
59 (n = 1, 2, 3, 4)
Figure 3.50 Structure of branched galactosides presented on pentavalent arms of azacrown sca¤old.
greatest binding enhancement. At su‰ciently high concentrations of cholera toxin, a single molecule of 59 can associate with two cholera toxin B-pentamers by forming a sandwich complex (Figure 3.51). This arrangement is confirmed by crystal structure determination and DLS in solution [299]. Based on the DLS study, this sandwich complex, although less stable than 1:1 complex, appears considerably stable, with a Kd value estimated to be in the submicromolar range. Merritt et al. [301] reported the next generation of multivalent molecules composed of symmetric pentacyclen-based multivalent galactoside as an inhib-
132
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
+
B5 (cholera toxin)
decavalent ligand
sandwich complex
Figure 3.51 Formation of a 2:1 sandwich complex between cholera toxin B pentamer and a branched decavalent ligand.
itor of cholera toxin and E. coli heat-labile enterotoxin (Figure 3.52). A pentavalent inhibitor (62) is composed of five copies of m-nitrophenyl-a-d-galactoside (61), a monomer that has IC50 of 195 mM, reflecting a binding activity to cholera toxin B-receptor that is about 100 times higher than that of alkyl-a-dgalactoside. The pentamer 62 displays much greater activity, with an IC50 value
OH O HO HO OHO
OH O HO HO OHO
O
BocHN H 2N
O
O
O
OH
O
NO2 O
O MeO
OMe
NO2 OH O HO HO OHO
O
O
N H
i,ii
O
60 O
O
N H
OMe
O O
O
N H
iii NO2
iv O
61 HO
O OH HO HO
O OHO
Spacer
O N H
O
O
O
O
N H
HN
O HN Spacer
O
NO2
O
O N
O
O
N N
O O
H N Spacer
O
O
O
N H
O
HO
O OH
N H
NO2
N
N
O
O O
O N H
OH OH
O OH
N H
2
NO2
OH O HO HO OHO
NH2
O
N H 2
N Spacer H
NO2
N H
HO
O OH
OH OH
NO2 62
reagents and conditions: i) cyanuryl chloride; ii) TFA, CH2Cl2; iii) dimethyl squarate, NaHCO3, pH 8, H2O, rt , overnight; iv) squarate derivative of 15-azacrown-5, NaHCO3, pH 9, H2O, MeOH, rt, 36 h.
Figure 3.52 Synthesis of pentavalent m-nitrophenyl-a-d-Gal constructed on 15azacrown-5 core as an inhibitor of cholera toxin and E. coli heat-labile enterotoxin.
OH OH
BACTERIAL TOXINS
133
of 0.9 mM, which represents a 263-fold gain in inhibition activity compared to that of a single-finger ligand (60). Compared to the pentavalent galactoside 51 ˚ , 62 shows about an 18-fold encontaining an identical spacer length of 35 A hancement in activity. This example demonstrates that multivalent molecules derived from a high-a‰nity monomer can provide much better activity than a low-a‰nity monomer, although it depends on the system and is probably limited to relatively low valency molecules. 3.2.2.2 Mode of Action of Pentavalent Galactosides. With DLS analysis in solution along with crystal structure determination, Merritt et al. [301] demonstrated that the potent antitoxin inhibitory activity exhibited by 62 derives from a tight 1:1 association between a pentavalent ligand and a toxin pentamer. For example, the hydrodynamic radius (Rh ) of enterotoxin B-pentamer remains unchanged when bound by 62, even at high concentrations of the multivalent ligand, supporting the fact that toxin–ligand interaction leads to the formation of a 1:1 complex rather than multiple aggregation (>2:1) complexes. A crystal ˚ resolution provides further structure of the cholera toxin–62 complex at 1.46-A details about such interactions, by showing that each of five m-nitrophenyl-a-dgalactosides binds to each of five ligand sites present on the toxin with a fivefold axis (C5 ) of symmetry. 3.2.2.3 Dendrimer-Based Multivalent Lactosides. Although lactose binds weakly to the cholera toxin B (CTB)-subunit in the millimolar concentration range [302], the multivalent presentation of lactosides enhances the binding a‰nity to CTB. Vrasidas et al. [303] reported the synthesis of multivalent lactosides constructed on a dendrimer sca¤old (Figure 3.53). When evaluated for binding to CTB using a fluorescence quenching assay, the lactoside-displaying dendrimers show reduced K d values, such as 235 mM (63), 99 mM (64), and 33 mM (65). These values represent tighter binding by 38-, 46-, and 68-fold, respectively, than that of free lactose, which has a K d value of 18 mM. This binding result suggests a correlation between increasing ligand valency and increased binding a‰nity. The Hill coe‰cient (n) derived from three multivalent molecules binding to CTB pentamer lies in the range 1.4 to 1.5. An n value greater than 1 involves positive cooperation, possibly through a bridging mechanism. Thus, a dendritic molecule such as 65 is likely to bridge two gal˚ apart on the cholera toxin B-pentamer, actoside-recognition sites about 31 A provided that there is appropriate interligand spacing close to such a distance. 3.2.2.4 Polymerized Liposomes Incorporating GM1 . Taking advantage of the specific interaction between ganglioside and cholera toxin, Charych et al. [304] designed an artificial membrane-based sensor sensitive for detecting cholera toxin. The design of the biosensor incorporates GM1 (66) into a matrix of polymerized diacetylenic lipid (10,12-pentacosadiynoic acid) (Figure 3.54). As introduced in Chapter 2, polymerized liposomes presenting GM1 show a characteristic blue coloration, with a l max of about 630 nm that arises from the
134
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
OH OH
HO OH OH
HO HO HO
O OH OH HO O OH HO O
HO
HO
O
HO
O HO
NH
S
NH
S
O
O
O
NH
O
HN
O
O
NH
NH
O
NH S
NH
NH
NH S S NH
O
HO
O
HO
NH
NH S
O
O OH HO
O
O OH HO HO
O OH OH HO O OH HO O
HO
OH OH OH OH OH OH HO O HO O O OH OH O OH OH
O
HN O
O
O
OMe 63
64
O
OMe
OH OH OH OH OH OH OH OH OH OH HO O OH OH OH HO HO O HO O OH OH O HO O HO OH OH O O O HO OH OH OH HO O OH HO O OH OH HO OH OH OH HO O O OH HO O HO OH O HO O OH HO O HO NH HO HO O O OH S NH O O OH NH HO O NH HO S HO NH HO O S NH S OH NH NH S NH NH O HO S NH NH HO O O NH O S NH O O S NH O O NH O HN
O
HN
O
O
O HN
HN
O O O
O
O
O
NH
HN
O
O
O
65 MeO
O
Figure 3.53 Structure of lactose-presenting dendrimers.
BACTERIAL TOXINS OH GM1 (66) OH OH HO O O HO O O OH OH AcHN H OH O HO N O -O2C O O O OH O O HO H C 3 OH HO OH AcHN OH O
CH3 i) sonication (liposome);
CH3 +
ii) hν, 254 nm (cross-linking)
HO
OH OH OH HO O O HO O O OH OH AcHN OH O HO O -O2C O O O OH O HO n OH HO OH AcHN OH
135
GM1 Cholera toxin CO2-
Polymerized liposome (χ ~ 5%) blue color
OH OH OH HO O O HO O O OH OH AcHN OH O HO O -O2C O O O OH O HO n OH HO OH AcHN OH
CO2-
red color
Figure 3.54 Preparation and use of cross-linked poly(diacetylene) liposome presenting multiple copies of GM1 on its surface.
absorption of the conjugated poly(diacetylene) chromophore. When exposed to cholera toxin at 40 ppm, the liposome solution immediately undergoes color transition to red, with a l max value of about 550 nm. This red-to-blue color transition occurs because multiple toxin–GM1 recognition events that occur on the surface of the liposomes perturb the poly(diacetylene) framework. The lower limit of detection by such a method is about 0.1 nM of cholera toxin. The Ka value of cholera toxin to the GM1 ligand present on a poly(diacetylene) membrane is about 3 10 10 M 1 when studied by surface plasma resonance (SPR) spectroscopy [304]. This value is in good agreement with binding a‰nity of the toxin to GM1 on the natural surface of living cells. Such tight interaction is also supported by a separate SPR study reported by Kuziemko et
136
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
al. [305], where cholera toxin binds to GM1 displayed on the surface of biosensor membranes with a Kd value of 4.6 1012 M. The toxin also recognizes asialo-GM1 presented on the same biosurface but with 50-fold lower avidity, as reflected by the Kd value of 1.88 1010 M. 3.2.2.5 Liposomes Presenting Fluorescent GM1 . The sensitivity of bacterial detection can be improved to 0.05 nM of cholera toxin according to a technique developed by Song and Swanson [306]. This approach is based on an optical technique called fluorescence resonant energy transfer that is performed on biomimetic membranes. For example, cholera toxin is allowed to interact with fluorophore-labeled GM1 expressed on lipid bilayers in which the multivalent toxin–ligand interaction causes a dramatic change in fluorescence of the labeled GM1 . 3.2.3
Shigalike Toxin
Like other toxins in the AB5 family, Shigalike toxin (SLT) also comprises pentavalent B-subunits that serve as a sugar-binding lectin [307,308]. Each Bsubunit contains two nonidentical sugar-binding sites that recognize Gal-a1,4Glc-b1,4-Glc carbohydrate, or Pk trisaccharide, linked to glycolipid Gb3 or CD77 [309,310]. The distance between these two sites on a single unit is pro˚ , while the distance between two neighboring sites posed to be about 20 A ˚ [311]. Using SPR spectroscopy, located on two adjacent subunits is 18.5 A Nakjima et al. [312] studied the kinetics of Shiga toxin in the binding of isoforms 1 and 2 to cell-mimicking surfaces, including derivatized dextran surfaces that present multiple copies of Gb3 ceramide glycolipid. The interaction probably involves bivalent binding of the glycolipid with each Shiga toxin unit. This type of interaction is specific to Gb3 Cer surfaces since Shiga toxins 1 and 2 do not recognize GM3 -presenting surfaces and bind only weakly to GB4 Cer surfaces. 3.2.3.1 Bivalent Pk Trisaccharides. Lundquist et al. at Duke [313] reported the synthesis of bivalent ligands derived from C-linked Pk trisaccharide, a natural ligand recognized by pentavalent SLT-1B (Figure 3.55). For example, 68 and 69 are composed of two Pk ligands attached to a pentapeptide framework. The divalent ligand 68 inhibits SLT-1B in a competitive ELISA assay with an IC50 value of 20 mM, which represents about a 100-fold enhancement over the a‰nity of the monovalent Pk ligand (67). The thermodynamic parameters of binding of the divalent Pk ligand to SLT-1B were assessed by isothermal titration microcalorimetry. In these studies, the K a value of 68 is 11,000 M 1 . The binding stoichiometry (n), defined as the ratio of ligands to toxin units, is approximately 1. The association constant indicates about 20-fold stronger binding than that of the monomer 67, which has a K a value of 500 to 1000 M 1 and a binding stoichiometry of 1. A second ligand (69) composed of a hydrophilic spacer shows about 10-fold enhancement in binding, with a K a value of 68001
BACTERIAL TOXINS O H2N
CH3 O
H N
N H
O
CH3 O
H N
CH3 CH3
N H HN
O
O HO
NH2
HO
Pk trisaccharide
HO
O NH2
67
O HO
OH OH O HO O OH O HO O OHHO
H2N
CH3 O
H N O
OH O OH
N H
CH3 HO
O
NH2 NH
NH2
HO
O HO
68
O
OH HO O O
O HO
HO O OH O HO O OHHO
H2N OH O OH
H N
O N O H HO2C
HO H N
OH O OH HO
O NH2
N H HN
O
HO
O
NH2
NH2
NH O
OH
HO O OH
HO
OH OH O
OH
HO O OH
CH3
N H HN
O
OH HO O O
OH O HO OH
CH3 O
H N
137
69
O HO
OH HO O O
OH
HO O OH OH O HO OH
Figure 3.55 Monovalent and bivalent Pk trisaccharides displayed on a peptide sca¤old.
but with a distinct binding stoichiometry (n ¼ 2). It appears that these two dimers bind SLT-1B in di¤erent modes, depending on the nature of linker. The hydrophobic, bivalent ligand 68 binds a B-subunit with 1:1 stoichiometry (i.e., two Pk units bound per B-monomer), while a hydrophilic bivalent ligand (69) binds with a ratio of 2:1 (i.e., four Pk units bound per B-monomer). Based on the crystal structure of SLT-1B, Lundquist et al. suggested that 68 would bind within a subunit in which two Pk units of a bivalent ligand span two distinct ˚ apart, on a single B-subunit. Clearly, the sugar-recognition sites, roughly 20 A linker length is an important parameter that a¤ects both binding a‰nity and stoichiometry, possibly through little-studied e¤ects, such as contact interaction with a protein surface and dimer orientation. Another class of divalent ligands that bind to the Shigalike toxin has been reported by Kitov et al. [314]. A representative dimer from this class is composed of two Pk trisaccharides or galabiosides tethered with a bisamide linker at the O-2 0 atom. This dimer binds bivalently by occupying two sites present on a single B-subunit. The a‰nity of the dimer is enhanced 8- to 47-fold over that of the monomeric galabioside and is influenced by the length of the spacer. 3.2.3.2 Decavalent Pk Ligands. Kitov et al. at the University of Alberta [315] reported that a Pk-based multivalent carbohydrate ligand is a potent inhibitor of Shigalike toxins I and II (SLT-I and SLT-II). The structures of a divalent Pk
138
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
HO HO
OH O
HO HO
HO O OH O HO O OHHO
HO
HO O OH O HO O O HO
OH O OCH 3 OH
OH O
HO
OH O
O
HO O OH OH O O O OCH HO 3 O HO O O OH N H
N H
OH O OCH 3 OH
O
Pk trisaccharide methyl glycoside 70 HO HO
OH O
HO
OH O
HO
HO O OH O HO O O HO O
HO O OH OH O O O OCH HO 3 O HO O O OH N H O
O
N H
OH O OCH 3 OH
O
NH (CH2)7 HN O
R
O O
R
O
H N
S O O
R
O
O
N H
O
=R
R 71
Figure 3.56 Structure of multivalent Pk inhibitors of Shigalike toxin.
ligand (70) and a decavalent Pk ligand (71)—so-called ‘‘starfish’’ molecules— are shown in Figure 3.56. The dimer 70 can block the binding of a Pk-based glycoconjugate to SLT-I or SLT-II with an IC50 value of 55 mM and a K a value of about 105 M, which represent 40-fold higher activity than a monovalent Pk trisaccharide. However, 70 is far less active than the decavalent 71, which displays an IC50 value of 0.24 nM. This subnanomolar activity of the starfish molecule represents more than a 106 -fold increase in inhibitory activity over the Pk trisaccharide. It correlates well with the estimated dissociation constant ((K d @ 109 M ) of a B-subunit pentamer binding to the surface of a cell that expresses glycolipid Gb3 (Gal-a1,4-Gal-b1,4-Glc-b1-O-ceramide). In a cytotoxicity assay, the decavalent molecule protects cells from SLT I and II at micromolar concentrations. Kitov et al. determined the crystal structure of the decavalent Pk ligand 71 to the SLT-1B pentamer (Figure 3.57). The crystal structure shows that one molecule of 71 interacts with two pairs of B-subunit pentamers in the pseudotwofold symmetry of a 2:1 sandwich complex. The complex forms in a unique fashion such that the two ligands at the end of a single arm of 71 cannot bind adjacent sites on a single B-subunit. Rather, the two terminal ligands bind to di¤erent subunits in separate pentamers. Ultimately, five copies of the Pk li-
BACTERIAL TOXINS Starfish molecule (71)
139
Top view: bottom half of B5-ligand sandwich
Pk trisaccharide
Figure 3.57
Mode of binding of a ‘‘starfish’’ molecule to Shigalike toxin I.
gand interact with the second B-subunit pentamer, thus creating the sandwich complex illustrated in Figure 3.51. 3.2.3.3 Polyvalent Polymeric Pk Ligands. The use of a polymer framework makes it possible to increase the valency of Shiga toxin inhibitors. Gargano et al. at Syracuse [51] reported that such a polyvalent polymer is a potent inhibitor of the SLT-1B pentamer. Its design concept is shown in Figure 3.58. The polyvalent inhibitor is synthesized via the copolymerization reaction of an acrylamide, derived from Pk ligand 72, with unsubstituted acrylamide monomer. During the reaction, the ratios of the two acrylamides are varied to produce molecules with varying degrees of substitution. In a cell-based assay that measures the ability of the polymers to inhibit Shiga toxin 1, three variants of poly(72-co-acrylamide), with ligand densities (wPk ) of 0.1, 0.2, and 0.3, show IC50 values in the range 800 to 900 nM per Pk trisaccharide. These activities represent a 5000-fold enhancement in the inhibition of Shiga toxin 1 relative to a monovalent ligand such as methyl- or octyl-Pk trisaccharide, which have IC50 values greater than 5 mM. The potent activity of the polyvalent molecules is specific: Incorporation of lactose instead of the Pk saccharide in the polymer chain leads to inactive polymers. In a model of the AB5 toxins, Gargano et al. [51] proposed a theoretical equation useful for calculating the binding enhancement contributed from multivalency. The term binding enhancement (b) reflects the strength of a multivalent association relative to the monovalent association (for a detailed discussion, see Section 1.2). It is based on several limited conditions that define multivalent receptor–ligand interactions, such as equivalent binding sites, no cooperative interaction, a flexible linker with optimal length, and no linker– receptor interaction. The general equation for multivalent binding enhancement is expressed as F ½sK a ð102 Þ n1 where K a is the association constant of the monovalent ligand–receptor complex, n is the valency number (smaller than either the number of sites on a receptor or the number of tethered ligands on a multivalent molecule), F is a statistical factor defined by the system (b1), and s is a factor that adjusts the distance between receptor sites and is defined as 30
140
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS Pk trisaccharide SLT-1 B subunit
Polyvalent Pk polymer
OH OH O
HO
HO O OH O HO O OHHO
OH O O OH
O
O +
N H
copolymerization
H2N acrylamide
Pk monomer 72 OH OH O
HO
HO O OH O HO O OHHO
OH O
O
OH
NH2 O HN OH OH O
HO
HO O OH O HO O OHHO
OH O OH
O
HN O
O O O O NH2 NH2 NH2 NH2 OH OH O HO HO O OH HO
O
NH2 O
O
O O O HN NH2 NH2 NH2
O OHHO
OH O
O
n O O NH2 NH2
O
OH
poly(72-co-acrylamide) (χPk = [72]/{[72] + [acrylamide]} = 0.1, 0.2, 0.3)
Figure 3.58 Inhibition of Shiga toxin 1 by polyvalent Pk polymer and its synthesis.
divided by the distance between receptor sites in angstroms. For example, the binding enhancement contributed by a polyvalent Pk molecule binding to Shiga toxin 1 is calculated as follows: b A 1½1 10 3 ð102 Þ ð51Þ ¼ 10 4 per ligand, where K a ¼ 10 3 M 1 , s A 1, F ¼ 1, and n ¼ 5. Thus, the calculated value of binding enhancement is comparable to the value of (5 10 3 ) obtained experimentally. 3.2.3.4 Multivalent Presentation of P1 on a Solid Support. The application of a‰nity chromatography makes it possible to isolate and purify the B-subunit of
141
BACTERIAL TOXINS
HO
OH OH O
P1 antigen (73)
HO O OH O HO O OHHO
HO
agarose matrix OH H O O O (CH2)n NHAc
+
reductive amination H2N N H
NHNH2 m
OH OH O HO O OH O HO O OHHO
OH O O (CH2)n NHAc
H H N N
N N H H 74
AcHN (CH2)n O O HO
OHHO O O
OH
m
HO O OH OH O HO OH
Figure 3.59 Immobilization of P1 trisaccharide on agarose solid support used as an affinity matrix.
Shiga toxin. This technique is based on the tight and specific receptor–ligand interaction mediated by multivalency on the surface of a solid support. Pozsgay et al. [316] reported the preparation of an a‰nity matrix derived from the P1 trisaccharide ligand (73) (Figure 3.59). This a‰nity matrix (74) proves to be a useful tool that enables the isolation of subunit B on a preparative scale (100 mg). 3.2.4
Verotoxin
Another AB5 class of bacterial toxins is VT-1, produced by enterohemorrhagic E. coli. In the solution structure, its B pentamer is symmetric, with each Bsubunit presenting a site for binding globotriaosylceramide (Gb3 ) with a K d value of 1 10 3 M [317]. Due to this structural feature and low a‰nity displayed by a monomer, the toxin pentamer is targeted by multivalent Gb3 molecules or equivalents. For example, SAMs on a gold surface presenting multiple copies of a disaccharide ligand (Gal-a1,4-Gal, a truncated version of Pk trisaccahride) serve as a sensor to detect verotoxin (National Institute of Advanced Industrial Science and Technology, Japan). 3.2.5
Bacillus anthracis Anthrax Toxin
B. anthracis produces anthrax toxin, a causative agent responsible for severe life-threatening symptoms [318,319]. The adverse e¤ects of the toxin are initiated when bacterial protective antigen (PA) binds to a surface receptor on a mammalian cell. This surface binding initiates a series of events that includes proteolytic activation of PA to PA63 and self-association of the PA63 monomer into a heptameric complex (Figure 3.60). This complex is then utilized as a receptor capable of binding two bacterial enzymes, edema factor (EF, adenylate cyclase) and lethal factor (LF, a protease), with a high a‰nity (K d @1
142
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS self-association to heptamer PA 63
binding of EF/LF
receptor to PA63
Cytoplasm Endocytosis
polyvalent P1 (75) inhibition of EF/LF binding
Cytoplasm
75: poly(acrylamide)(P1) (χP1 = [P1]/ [acrylamide] = ~22/900 = 0.02)
poly(NAS)
O R
O R
O R
n O
O R
R
i,ii O O O O O O O O O O O O NH2 NH NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH2 NH NH2
n ~180 P1 peptide
(R = NHS) AcNH-HTSTYWWLDGAPK-CONH 2
AcNH-HTSTYWWLDGAPK-CONH 2
reagents and conditions: i) P1 peptide, Et3N, DMF, rt, 24 h; ii) NH4OH; then dialysis
Figure 3.60 Entry of anthrax toxin complex (PA 63 heptamer-EF/LF) into a cell via receptor-mediated endocytosis (top) and prevention of the cell entry by binding of polyvalent inhibitor to heptameric PA 63 (bottom).
nM ) to EF/LF. Formation of this high-a‰nity complex enables intracellular tra‰cking via endocytosis of the enzymes, which are lethal to macrophages and phagocytes. 3.2.5.1 Polyvalent Peptide Inhibitors. Mourez et al. at Harvard [320] demonstrated that a tailored multivalent molecule is e¤ective in preventing the harmful action of the toxin through interference at the stage of EF/LF binding to the heptamer complex (Figure 3.60). This multivalent molecule is designed on a sca¤old of poly(acrylamide), which presents through its side chains multiple
BACTERIAL ENZYMES
143
copies of P1 peptide, with about 22 peptides and 900 acrylamide units per molecule, thus yielding a ligand density of approximately 0.02 (Figure 3.60). The P1 peptide was discovered from a phage display library raised against PA63 heptamer. P1 binds to the heptamer with only low a‰nity, as reflected by the IC50 value of about 150 mM. A polyvalent inhibitor (75) inhibits the binding of a radiolabeled LF to PA63 on CHO cells with an IC50 value of 20 nM. This binding activity represents about a 7500-fold increase on a per peptide basis relative to a monomeric P1 peptide. In a cell culture assay that measures the cytotoxicity of PA63 , 75 blocks the toxicity with an IC50 value of 6 nM on a per peptide basis. Such activity is of significance since neither monomeric P1 nor the underivatized poly(acrylamide) control displays inhibitory activity.
3.3 3.3.1
BACTERIAL ENZYMES Transpeptidases
The bacterial cell wall is made up of multiple layers of polymeric cross-linked peptidoglycans in the inner and outer membranes of the bacterial cell [321,322]. The cross-linking of peptidoglycan precursors is catalyzed by transpeptidase, the enzyme that belongs to a family of penicillin-binding proteins and is the target inhibited by b-lactam antibiotics. During catalysis of the cross-linking reaction, this enzyme recognizes two separate Lys-d-Ala-d-Ala strands from two closely located, growing peptidoglycan strands, as depicted in Figure 3.61. One strand supplies a nucleophilic component and the second supplies an electrophilic component [323]. 3.3.1.1 Divalent Substrates. To understand precisely the mechanism of the transpeptidase-mediated cross-linking reaction, Lee et al. [324] designed a hybrid molecule (76) composed of cephalosporin and d-Ala-d-Ala. This hybrid molecule, which mimics those produced by transpeptidase-mediated cross-linking, is designed to bind bivalently to two nonidentical substrate-recognition sites present in the transpeptidase enzyme. An x-ray structure that is solved at ˚ resolution supports such a design principle, where, through bivalency, 76 1.2 A occupies an active site of a bifunctional d-Ala-d-Ala carboxypeptidase/transpeptidase. This structure serves as a snapshot of the enzyme bound with the cell wall components positioned to undergo the cross-linking reaction. 3.3.1.2 Multivalent b-Lactams. Divalent b-lactams are expected to target two separate penicillin-binding proteins (PBPs) and show higher a‰nity than the corresponding monomeric b-lactam. Rodriguez-Tebar et al. [325] reported improved activity from covalently linked penicillin dimers as shown in Figure 3.62. For instance, 77 is a dimer derivative of penicillin V, and 78 belongs to a divalent penicillin linked with a lengthy glycine–azobenzene spacer attached to the amino group at the C6 position. These dimers can cross-link two molecules
144
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS NH3+ CO2MurNAc
N H
Me H N O
O
H N
N H
CO2-
O
GluNAc
PBP acylation
Me H N Me
O
-(D)-Ala
CO2PBP enzyme
NH3+ site 1 for peptidoglycan strand 1
CO2MurNAc
N H
O
Me H N
N H
CO2-
O
GluNAc
O
H N
Me
O
O
Acyl enzyme intermediate
B
O
+H3N CO2-O H N
MurNAc
Me H N
N NH H
O
CO2Me
O N Me H
CO2-
site 2 for peptidoglycan strand 2
GluNAc
NH3+ CO2Cross-linking of peptidoglycan strands
MurNAc
N H
O
Me H N O
CO2-
GluNAc
N H
H N O
O
Me H N
O CO2-O
MurNAc
H N
N NH H
Me H N O
CO2Me
O N Me H
CO2-
GluNAc H N O
O
S
O
N
N NH H
CO2-O 76
Me H N O
CO2Me
O N H
CO2-
Figure 3.61 Transpeptidation that is catalyzed by a class of penicillin-binding proteins (PBP) and an example of its bivalent inhibitor.
BACTERIAL ENZYMES HO
O
O O O
N H
S
O
OH
O
O O
N
145
N N H
S OAc
OH 77 O HO
O
O O
N N H
S
O
H N O
N
H N
N H
O
N H N
H N
H 2N O
H
H2N
CO2K N S
O
OH
OAc
O
O
H N S
Cl
O
O
O
Cl
O O
N
i-iii
+ O
O
O KO2C
O OAc
CO2tBu
N H
H
O
Cl
S
N
O
AcO
S N
O
78
OAc CO2H
H N O
O
S
N
N H
O
OAc H
O
NH O
H
S OAc
N CO2K
H O 79
reagents and conditions: i) pyridine, CH2Cl2, 0oC to rt; ii) trifluoroacetic anhydride, CH2Cl2; iii) potassium α-caproate
Figure 3.62 Structure of penicillin dimers and cephalosporin trimer.
of penicillin-binding protein per penicillin dimer, such as PBP1b, 1c, or 3 isolated from E. coli. Kova´cs-Kulyassa et al. [326] reported the in vitro activity of trivalent blactam molecules composed of cephalopsorin linked to a trihydroxybenzne sca¤old (Figure 3.62). This class of trimeric b-lactams shows variable antibacterial activity and is sensitive to specific bacterial strains. For example, 79 is as active as cefuroxime against Streptococcus faecalis, with an MIC value of 3 mg/mL. However, it is 10-fold less active against Staphylococcus aureus than the cefuroxime monomer, which has an MIC value of 1.5 mg/mL. Polyvalent, polymeric b-lactam antibiotics have been designed on a copolymer sca¤old made of vinyl alcohol and vinyl amine or vinyl carboxhydrazide (Figure 3.63). Such polyvalent penicillins (80 and 81) present multiple copies of benzylpenicillin and phenoxymethylpenicillin as polymer side chains, as reported by Usakov et al. [327] and Panarin et al. [328]. Like the parent b-
146
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
HO HN
n
O
OH O
O O
N
n NH HN O
N H
S
O O
N N H
S
X
81 X = CH2: 57 mol% Penicillin G X = CH2O: 1.5 mol% Penicillin V
80 (2.5 mol% Penicillin G)
Figure 3.63 Structure of polyvalent polymeric b-lactams.
lactams, these macromolecules are water-soluble, stable, and active in antibacterial assays. 3.3.2
E. coli Pyrophosphokinase
Transfer of a pyrophosphate group from ATP to 6-hydroxymethyl-7,8-dihydropterin (HP) is catalyzed by HP pyrophosphokinase (HPPK), a microorganism-specific enzyme that is absent in humans. This reaction constitutes a first step in the biosynthesis of folate cofactors (Figure 3.64) [329]. The active site of this enzyme presents two proximal sites: one site for dihydropterin and a second site for ATP. These sites are arranged to bring two di¤erent substrates close together. Based on this structural knowledge, Shi et al. [330] designed bi-
6-Hydroxymethyl-7,8-dihydropterin (HP) ATP NH2 O N
HN H2N
N
OH
+
N H
O O O -O P O P O P O- O- O-
N O
O
N
N
Mg
N
H2 N AMP
HO OH
N
HN
2+
N
N H
O O O P O P OO- O-
HP pyrophosphate
HPPK (6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase)
Monomer
Divalent inhibitor O
O N
HN H2 N
N
N
OH
N
HN H2 N
N
N
O O P O n O-
NH2 N O
N
N N
HO OH Petrin (82)
83 (n = 2, 3, 4)
Figure 3.64 Structure of bivalent inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase.
BACTERIAL ENZYMES
147
valent inhibitors (83) of HPPK, each of which is composed of a pterin moiety tethered to an adenosine moiety through varying numbers of phosphoryl groups. Binding and inhibition studies with E. coli HPPK show that 83 (n ¼ 4) has the highest a‰nity, and inhibition activity with a Kd value of 0.47 mM and an IC50 value of 0.44 mM. The activities of dimers tethered with shorter linker lengths are lower. Compared to unlinked monomers, a divalent inhibitor 83 (n ¼ 4) shows an a‰nity that is enhanced about 116 times over that of MgADP and is 76 times higher than that of 6-hydroxymethylpterin (82). Shi et al. ˚ resolution. determined the crystal structure of an 83: HPPK complex at 1.85-A The structure shows that the dimer indeed simultaneously occupies both dihydropterin and ATP-binding sites, thus supporting the notion of divalent recognition. 3.3.3
Protein Tyrosine Phosphatase
Certain members of the protein tyrosine phosphatase (PTPase) family are believed to be involved in various forms of diseases caused by Yersinia and Salmonella bacteria [331]. Since these bacteria do not possess phosphorylated tyrosines in their cellular system, they exploit PTPase to target the host. One class of PTPase inhibitors, the aryl-a-keto acids, bind to a PTPase catalytic site through interactions involving multiple contacts [332]. Chen and Seto [333] reported a multivalent approach in their design of aryl-a-keto acid–based PTPase inhibitors (Figure 3.65). For example, divalent inhibitors are constructed by linking two units of aryl-a-keto acid to a benzene sca¤old at three di¤erent orientations (ortho, meta, and para). In an enzyme assay against Yersinia PTPase, a dimer (85) in the meta orientation shows the best activity, with an IC50 value of 0.7 mM. This activity represents about a 214-fold increase relative to a monomer (84). The ortho and para orientational isomers of 85 are also active inhibitors of PTPase but are less e¤ective than the meta isomer by a factor of 12 and 6, respectively. The activity of a trimer (86) is enhanced as well. It is noteworthy that the orientation of divalent ligands substantially influences the molecule’s activity, perhaps by controlling interligand distance and the direction of ligand units. 3.3.4
DNA Gyrase
Psammaplin A (85) is a natural product isolated from Psammaplysilla sponge [334,335]. It is a symmetric dimer composed of two units of a bromotyrosine analog that are connected through a disulfide linkage. Its biological action includes antibacterial and antitumor activity, although its cellular target and mechanism of action have yet to be unveiled. Multiple enzyme targets, including DNA gyrase, topoisomerase II, farnesyl protein transferase, and leucine amino peptidase, are thought to be inhibited by this antibiotic [336,337]. Nicolaou et al. [338] reported a total syntheis of psammaplin A, starting from l-tyrosine (Figure 3.66).
148
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS O
O CO2H
O
HO2C
O
CO2H O
O
84 O
O
HO2C
O O
O
OH HO2C
85 (ortho, meta, para)
NH2
86
NH-Boc
i,ii
CO2H
CO2Me
iii
CO2Me O
HO
O
iv,v
CO2Me O
O
O
O
MeO2C O
NH-Boc
Boc-HN
CO2Me
HO
O
vi
O
HO2C
CO2H O
O 85 (meta)
reagents and conditions: i) SOCl2, MeOH (100%); ii) (Boc)2O, NaHCO3, H2O-dioxane (95%); iii) 1,3-bis(bromomethyl) benzene, Na, EtOH (49%); iv) TFA, CH2Cl2 (91%); v) HO2CCHO, CuSO4, AcOH, pyridine (19%), vi) NaOH, H2O (69%).
Figure 3.65 Synthesis of bivalent and trivalent aryl-a-ketocarboxylic acid.
The fluoroquinolone class of antibiotics, represented by ciprofloxacin, target bacterial type II topoisomerase enzymes, including DNA gyrase and topoisomerase IV [339]. Dimers derived from fluoroquinolone were reported by Kerns et al. [340,341] as potent antibacterial agents (Figure 3.67). The dimers are composed of either ciprofloxacin or norfloxacin linked with an unsaturated alkene or aryl spacer at a piperidine moiety. For instance, dimers 1 and 2 are more active than ciprofloxacin against S. aureus, including methicillin-sensitive and methicillin-resistant strains as well as glycopeptide-intermediate-resistant S. aureus strains. The activity of dimer 1 is much greater than that of dimer 2, and it is strongly influenced by the nature of the linker. This class of quinolone dimers underscores the validity of divalent design as a strategy for overcoming bacterial drug resistance. 3.3.5
Dihydrofolate Reductase
Dihydrofolate reductase (DHFR) is an NADPH-dependent enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate [342]. Because of its unique existence in E. coli, DHFR serves as a drug target for treating bacterial infections. There are a variety of ligands to DHFR, including methotrexate
BACTERIAL ENZYMES OH
OH
Br
Br O
O S S
N H
HO N
N H
N
OH
Psammaplin A (85) OH
OH
OH i
O
OH
Br
Br
Br
ii
O OH
OH
O OH
O
N
NH2
NH2
iii
OH
O
CF3 OH
OH
Br iv
Br
v
vi
O
Psammaplin A
O OH
THPO N
THPO N O
O N
O
reagents and conditions: i) KBr, KBrO3; ii) TFAA, heat; iii) aq. TFA; iv) THPO-NH2; v) EDC, NHS; vi) cystamine, Et3N.
Figure 3.66 Syntheis of psammaplin A.
O
O F
HO
N
N R
NH
Ciprofloxacin (R = cyclopropyl) Norfloxacin (R = ethyl) O
O F
HO N R1
N
N N
N
R2 N OH
F O
O
Fluoroquinolone dimer-1: R1 = R2 = cyclopropyl Fluoroquinolone dimer-2: R1 = cyclopropyl; R2 = ethyl
Figure 3.67 Structure of symmetric fluoroquinolone dimers.
149
150
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS O NH2 N
N N
H 2N
CO2H OH
N H
O
N CH3
N
Methotrexate (MTX) O
O NH2 N
N H 2N
N
N
i
N CH3
N
H 2N
N
N
CO2H N H
N CH3
H N
N
CO2Bn OH
N H
N
N H2N
O NH2 N
NH2
OH
O
N CH3
N
O
O
O O
N H
CH3 N
H N HO2 C
ii,iii
N N
N
NH2 N
NH2 O
86 reagents and conditions: i) α-benzyl glutamate, PyBOP, DMSO; ii) 4,9-dioxa-1,12-diaminononane, PyBOP, NMP; iii) LiOH•H2O, MeOH.
Figure 3.68 Synthesis of methotrexate dimer.
(MTX), a folate analog that displays a high a‰nity (IC50 ¼ 0.6 nM). Although this enzyme exists as a monomer, it undergoes dimerization in the presence of a synthetic, divalent ligand. Kopytek et al. [342] reported such a molecule (86) based on MTX (Figure 3.68). The bis-MTX binds simultaneously to two DHFR enzymes, thus forming a ternary complex. According to gel filtration analysis, the binding is tight, with a K a value of 1.69 10 9 M 1 . The o¤-rate of the complex is about 100 times lower than that of MTX–DHFR complex. Thus, the divalent ligand ensures a longer half-life for the ternary complex. The enhanced strength of the ternary complex is attributed to the additional contribution from favorable protein–protein contacts. 3.3.6
Sialidase (Neuraminidase)
Bacterial sialidase or neuraminidase catalyzes the hydrolytic cleavage of Olinked sialic acid expressed as a form of terminal sugar in glycoproteins and glycolipids on cellular surfaces [343,344]. It belongs to a modular enzyme that presents two adjacent interacting domains located near an active site, one for catalytic action and another for the recognition of one or more lectin domains. Thobhani et al. [345] reported a multivalent mode of action displayed by bacterial sialidase in the hydrolysis of a sialic acid–presenting synthetic glycopolymer (Figure 3.69). Two sialidases from Clostridium perfringens and Vibrio clolerae can cleave O-silaloside with terminal galactosides presented in multi-
BACTERIAL ENZYMES
151
cleavage site HO
HO
AcHN
-O2C O O OH OH HO
OH
OH O O HO OH
O O NHAc
NHAc
Monovalent sialyllactoside
HO
HO CO2O
AcHN
O
OH OH HO
OH O O HO OH
OH O O NHAc
NH2 O
HO
NH
HO
AcHN
CO2O
O
OH OH HO
OH O O HO OH
HN O
O O O O NH2 NH2 NH2 NH2
NH2 O
O
O O O HN NH2 NH2 NH2
O
n O O NH2 NH2
OH O O NHAc
HO HO
-O2C
AcHN
OH OH
O
OH
O O HO OH OH
O
OH O O NHAc
Polyvalent sialyllactoside poly(NeuAc-co-acrylamide); χSA = 0.18
Figure 3.69 Polyvalent 3 0 -sialyl N-acetyllactosamine presented as a side chain of poly(acrylamide).
ple copies on poly(acrylamide). The catalytic e‰ciencies (Vmax /Km ) of the two sialidases are, respectively, 46- and 32-fold greater when cleaving the poly(acrylamide) derivative than when cleaving the monovalent sialyllactoside. The enhanced enzymatic activity results from tighter binding of the polyvalent substrate, since the value of Km is lowered 55- to 142-fold compared to that of the monovalent substrate. This increased association is attributed to the occupation of the lectin domains by terminal galactosides generated by catalytic action of the sialidase [346]. Therefore, the partially hydrolyzed silalylglycopolymer binds in a multivalent manner using its generated galactosides (to the lectin site) as well as O-sialoside (substrate site). Thobhani et al. showed further that the polyvalent, galactoside-presenting polymer was 100-fold more e¤ective than the galactoside monomer for inhibiting the action of bacterial sialidase. 3.3.7
NAD Synthetase
Nicotinamide adenine dinucleotide (NAD) synthetase is a homodimeric enzyme responsible for the synthesis of NAD, which occurs via the catalytic conversion of deamido-NAD. The active site of this enzyme, as resolved by crystal structure, shows that two distinct but proximal sites are involved in the recognition of substrates such as ATP and nicotinic acid adenine dinucleotide (NaAD) [347,348]. On the basis of such structural information, Garcia et al.
152
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
[349] invoked rational design to synthesize dimeric inhibitors composed of N-methylnicotine tethered to an indole (or indolylaromatic group or structure) through (un)saturated spacers of varying length. The indole moiety serves as an adenine mimic of ATP. The resulting dimers show micromolar inhibitory activity against NAD synthetase from B. subtilis and are e¤ective inhibitors of gram-positive bacteria.
3.4 3.4.1
BACTERIAL NUCLEIC ACIDS Ribosomal RNA
3.4.1.1 Divalent Aminoglycosides. Aminoglycosides belong to a class of antibiotics displaying a broad spectrum of antibacterial activities. Their mode of action involves the inhibition of translation during bacterial protein synthesis, where they interact with A-site rRNA on the 16S domain of the ribosome [350]. For example, neamine interacts with the A-site by recognizing G–C base pairs selectively and forming a 2:1 complex (two drugs per rRNA) with a Kd value of 10 mM for each binding site (Figure 3.70). Therefore, connecting two identical copies of the drug with a spacer would be an e¤ective approach to enhancing the binding a‰nity to the targeted nucleic acid as proposed by Hendrix et al. and Sucheck et al. at Scripps [351]. This hypothesis was tested using a set of divalent neamine molecules with amine or amide linker functionalities and linker lengths that varied from 2 to 12 atoms. For example, a dimer (88) binds tightly to an immobilized rRNA sequence mimicking the A-site with a Kd value 1495
C CGCUG
AA
5'- G G C G U C A
1490
GUGG
G
CACC U
H 2N HO HO
C
O NHO2 HO
U
NH2 NH2 OH
Neamine covalent linking
N3 BnO BnO
H2N HO HO
O N3O O
N3
O
N3 OBn
i-iii
H2N HO HO
O NHO2 O HO
NH2
O NHO2 O
NH2 NH2 OH
NH2 OH
OH N
N H3C
CH3 12-atom spacer
87
88
reagents and conditions: i) N,N'-dimethyl-1,4-diaminobutane, EtOH, 95oC, 16 h; ii) P(CH3)3, THF, H2O; iii) 20% Pd(OH)2/C, H2, H2O, AcOH.
Figure 3.70 Recognition sites of neamine in an E. coli 16S ribosomal RNA A-site and synthesis of neamine dimer.
BACTERIAL NUCLEIC ACIDS
153
of 40 nM and in 1:1 stoichiometry. Such binding represents a 250-fold enhancement over neamine. This dimer also shows improved antibacterial activity, with an MIC value of 6.25 mM, which is about eightfold lower than that of neamine. 3.4.1.2 Divalent Aminoglycoside Bound to a Dimerized A-Site. Kirk and Tor [352] and Tok and Hu¤man [353] reported a series of homo- and heterodivalent aminoglycosides (89 to 91) designed by combining neomycin and tobramycin (Figure 3.71). Each monomeric aminoglycoside binds to a 16S E. coli ribosomal A-site with K d values of 0.44 mM for neomycin and 2.11 mM
16S A-site rRNA
CC GCUG 5'- G G C G U C
AA
16S A-site rRNA
GGCGUC A
CA
A
AA
C CGCUG
GU
GUGG
G
CACC U
C U
aminoglycoside covalent linking OH O
OH O
NH2 OH
HO H2N
89
NH2
NH2
O O NH 2
Neomycin
S OH OH NH2
S
O
S
H2 N O HO HO
Neomycin
HO
90
HO
HO H2N O O NH2
S
OH NH2 O O H 2N OH
NH2 OH S
O
O
NH2 NH2
O
S
Tobramycin
S
O
NH2
H 2N O O
NH2 OH
OH
Tobramycin
O
NH2 H 2N
OH O HO H2N 91
O O NH 2 NH2
OH O
H 2N O NH2 OH
S O HO O OH H2N
OH
NH2
NH2 OH S OH OH NH2
Neomycin
Tobramycin O
S S
O NH2 H 2N
S O HO O OH H 2N
H 2N O
O NH2 OH
OH
Figure 3.71 Structure of divalent aminoglycoside and its binding to a dimerized A-site in E. coli 16S ribosomal RNA.
154
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
for tobramycin. Divalent molecules can, in principle, bridge two recognition sites present on RNA structures. RNA models bearing such dimeric RNA binding sites are constructed artificially by grafting two A-sites into a dimerized RNA 16S A-site [353]. The K d value of a neomycin–neomycin homodimer (89) to a dimerized A-site (46-nucleotide construct) is lowered to 20 nM, thus representing about a 19-fold stronger association than that of monovalent neomycin. Such enhancement is attributed to divalent binding since the a‰nity of 89 to a monomeric 16S A-site of 27 nucleotides is not enhanced but is similar to monovalent recognition by neomycin. The binding a‰nities of other classes of dimers (90 and 91) to a dimerized A-site are not enhanced, but rather, resemble that of the monomer. This indicates that the binding activity of these divalent aminoglycosides is strongly influenced by the nature of the aminoglycosides. 3.4.1.3 Polyvalent Polymeric Amikacin Derivatives. Amikacin—a derivative of kanamycin with a 4-amino-2-hydroxybutanoyl group—belongs to a family of aminoglycoside antibiotics that act similarly to neomycin and kanamycin. Tanaka et al. [354] reported the synthesis of a polymeric, polyvalent amikacin. This aminoglycoside contains an amine moiety as its side chain, which provides a handle for derivatization (Figure 3.72). Thus, a 4-vinylbenzolyl monomer (92) is prepared and polymerized in the absence or presence of 9 equivalents of Kanamycin: R = H Amikacin: R = H2N
HO HO H2N
O OH
HO HO H 2N
OH
O HO
HO O
HO O HN
H 2N
O NH2
OH NH2
O
O
HO O
HO
HO O RHN
HO HO H2N
i
OH
O
OH
O HO
HO O HN H N
OH
OH NH2
ONH 2
HO O O NH2
OH NH2
ii or iii
O
OH
Amikacin
92
HO HO H 2N O
HO HO H2N
OH
O HO
HO O HN H N
HO O O NH2
OH NH2
O
O
HO
HO O HN H N
R
93 (Homopolymer)
HO O O NH2
OH NH2
O
OH
OH
n
OH
O
R
R
R
(R = CONH2) m
94 (Copolymer: [amikacin]/[acrylamide] = 0.1)
reagenst and conditions: i) 4-vinylbenzoic acid succinimidyl ester, MeCN, H2O, rt (51%); ii) 2,2'azobis- (2-amidinopropane) dihydrochloride (1 mol%), H2O, 60oC, 8 h (52%); iii) acrylamide (9 eq), 2,2'-azobis- (2-amidinopropane) dihydrochloride (3 mol%), H2O, 60oC, 4 h (70%).
Figure 3.72 Synthesis of polyvalent polymeric amikacin.
MULTIVALENT MOLECULES AS SYNTHETIC VACCINES
155
acrylamide to produce amikacin-presenting polymers such as homopolymer 93 and copolymer 94. In an assay that measures the ability of drugs to inhibit protein biosynthesis, a monovalent amikacin derivative (92) shows an IC50 value of 5 mM, which is 50-fold less active than amikacin itself. Some of this loss may stem from the conversion of the basic amine in amikacin to the neutral amide, as the protonated amine probably plays an essential role in amikacin’s binding. However, the polymeric amikacins 93 and 94 do not show reasonable activity. A nonoptimized spacer distance in these polymers is likely to fail to allow the amikacin side chains to bridge multiple rRNA sites. In a standard antibacterial growth assay, which assesses the ability of drugs to penetrate bacterial cell walls and to reach rRNA targets, both of the amikacin polymers are not active at 100 mg/mL, while the monovalent 92 shows only modest activity, with an MIC value of 40 to 60 mg/mL.
3.5 3.5.1
MULTIVALENT MOLECULES AS SYNTHETIC VACCINES Synthetic Shigella Vaccines
Carbohydrates expressed on the surface of pathogenic bacteria, such as capsular polysaccharides (CP) and O-specific polysaccharides (O-SP), constitute essential virulence factors. They serve as antigens for raising human antibodies in order to initiate immune reactions [355]. Several commercial CP-based vaccines, including Pneumovax 23 and Pnuimmune, target pneumococci and gram-positive bacteria [356]. Pozsgay [357] reported a chemical approach for preparing a synthetic vaccine against Shigella dysenteriae type 1. This bacterial strain presents on its surface an O-SP complex that consists of repeating tetrasaccharide units of composition Rha-Gal-G1cNAc-Rha. The synthetic vaccine encompasses multiple copies of the O-SP hexadecasaccharide fragment displayed on human serum albumin (Figure 3.73). Varying the ratio of saccharide to protein in the reaction leads to a series of multivalent glycoconjugates (95) with tetra to hexadeca valencies. 3.5.2
Synthetic Mycobacterium Vaccines
The microorganism Mycobacterium avium intracellularae (MAI) poses serious threats to immune-compromised persons. Its outer membrane surface presents species-specific oilgosaccharide haptens in the form of glycopeptide lipids [358]. Tri-, tetra-, and pentasaccharides are attached through O-glycosidic linkages to the threonine unit of a tetrapeptide (Figure 3.74). Representative examples of such glycopeptide antigens include Serovar 8 and 21, both of which contain immunodominant 4,6-pyruvylated b-d-Glc-Tal(6-deoxy)-Rha. Ziegler [358] reported the synthesis of a Serovar 21 analog, a trisaccharide neoantigen of MAI, and its glycoconjugate form, which is built on bovine serum albumin. This multivalent conjugate (96) presents 12 copies of the trisaccharide per albumin molecule.
156
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS Hexadecasaccharide fragment of O-specific polysaccharide HO HO H C HO 3
O N
OH O
O
O
HO H 3C O OAcHN O HO
OH O HO HO HO O H 3C O HO O OAcHN O HO HO H 3C O O HO HO OH OH OH HO O HO
O OH
O
O 3
HO O H3C O O OAcHN O H3C HO O HO HO 3 OH O O HO HO HO O H C OH O 3 HO O OAcHN O HO HO H 3C O O HO HO OH OH HO HO
OMe OMe
(17 eq)
O HO
O
O
HN NH 2
i,ii
O O HN N H
iii H O
OH
O HO O H3C O O OAcHN O H C HO 3 O HO 3 HO OH O O HO HO HO O H3C OH O HO AcHN O O O HO HO H 3C O O 95 (n = 4 to 16) HO HO OH OH
O O HN N H
H N n
HSA
reagents and conditions: i) DMF, rt, 4 h; ii) AcOH, H2O, rt, 6 h; iii) human serum albumin, pH 7 borate-phosphate buffer, NaCNBH3, rt, 4 days.
Figure 3.73 Synthesis of neoglycoprotein displaying O-specific polysaccharide antigen as a synthetic vaccine against Shigella dysenteriae.
3.5.3
Carbohydrate Vaccines against Leishmaniasis
Leishmaniasis is a tropical disease caused by infection from a parasite species, Leishmania. On its cell surface, this parasite expresses multiple copies of unique lipophosphoglycans (LPGs) which are composed of a glycoylphosphatidylinositol (GPI) anchor, a repeating unit of phosphorylated disaccharide, and a cap oligosaccharide (Figure 3.75) [359]. Because of its abundance and the strong antigenicity of the phosphoglycan saccharide, LPG has attracted conceptual interest as a vaccine candidate. Synthetic vaccines based on natural LPGs are likely to be heterogeneous, due to the diversity of LPGs. Hewitt and Seeberger at MIT [360] developed a synthetic approach that enabled them to prepare a Leishmania carbohydrate vaccine. In this solution-phase method, the aminepresenting derivative of the cap tetrasaccharide is converted to a multivalent
MULTIVALENT MOLECULES AS SYNTHETIC VACCINES
Me O
H N
O MeO O H 3C MeO OH
Me O
N H
H3C
O
O
H N O Me
157
Ph O N H
Bacterial Cell
Alkyl
HO OHO HO H3C
Serovar 8: R = Me HO2C
Serovar 21: R = H
O H3C O RO
MeO2C O H3 C O BzO
OH
OH
O
NH-Cbz
O H3C
O O
H3C
O OBnO
i,ii,iii
BnO BzO O H3C O OAc
HO2C O H 3C O HO
OBz
NH2
O
HO OHO HO O H 3C O OH OH
trisaccharide unit of Serovar
O H3C
N H
O
HO2C O H 3C O HO
HO H 3C
BSA n (n = 12)
HO OHO
iv,v
H N
O O
OH
96
OH
reagents and conditions: i) cat. NaOMe, MeOH, rt, 24 h; ii) NaOH, H2O, rt, 48 h; iii) H2, 10% Pd/C, H2O, rt, 24 h; iv) bovine serum albumin (0.3 eq), glutardialdehyde solution (28%), pH 7.2 phosphate buffer, 4oC, 1 h; then NaBH4, 1 h; v) dialysis, then lyophilization.
Figure 3.74 Synthesis of neoglycoprotein displaying Serovar antigen as a synthetic vaccine against Mycobacterium avium.
form (97) by attaching multiple copies of the saccharide to keyhole limpet hemocyanin (KLH) as a protein sca¤old. This neoglycoprotein presents over 50 copies of the cap saccharide per hemocyanin molecule. 3.5.4
Capsular Polysialic Acid Presented on Liposomes
A polysaccharide, K1, found on the outer membrane of E. coli consists of 100 to 200 repeating units of a-2,8-linked sialic acid, with the terminal sialic acid connected to a lipid residue [361]. This type of multivalent carbohydrate cluster belongs to a class of acidic capsular polysaccharides [362]. To study the multivalent ligand–receptor recognition involving this type of polysialic acid, Frosch et al. [363] and Ringsdorf et al. [364] designed giant liposomes. The liposomes were composed of a lipid derivative of a2,8-linked polysialic acid incorporated into model membranes derived from phosphatidyl choline (Figure 3.76). The membrane display of the polysialic acid was verified by observing the binding
158
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS
HO OH O HO HO HO OO HO OH HO HO HO OO O O HO HO HO O Cap tetrasaccharide
OHOPO32- OH OH O O O HO HO O
Phosphoglycan
HO OH O HO HO HO OO HO OH HO HO HO OO O O HO HO HO O
Glycosylphosphatidylinositol (GPI) anchor HO O O P O OH HOO HO OO O HO -O P O HO O OHO OH O O HOO HO HO O O HO O OH OH OH
n
i
NH2
Leishmania OH OH O
OH
HO
HO HO H2N O O HO
O-lipid
O OH
HO OH O HO HO HO OO HO OH HO HO HO OO O O HO HO HO O
O S
N H
O
O Br O
Br
HN H N
N H NH
Br O
ii,iii
O Br
HO OH O HO HO HO OO HO OH HO HO HO OO O O HO HO HO O
97 KLH O
O N H
S
N H n = 55
reagents and conditions : i) S-acetylmercaptoacetate pentafluorophenyl ester, DMF; ii) 0.2 M NH2OH, bromoacetyl derivative of keyhole limpet hemocyanin (KLH); iii) 2-aminoethanethiol.
Figure 3.75 Synthesis of multivalent Cap tetrasaccharide presented on keyhole limpet hemocyanin as a carbohydrate vaccine against leishmaniasis.
of a fluorescently labeled anti-K1 antibody to the membranes. The antibody– liposome interaction leads characteristically to nonhomogeneous distribution, or patching, of fluorescence images, which is caused by lateral di¤usion of the antigen–antibody complex in the membrane and by clustering of multiple K1 antigens by the bivalent antibody. 3.5.5
Multivalent Carbohydrate Antigens from Streptococcus
The cell walls of members of the b-homolytic Streptococcus group A contain a well-defined polysaccharide composed of multiple repeats of rhamnopyranoside with N-acetylglucosamine (GlcNAc) attached as a branched sugar. Targeting such carbohydrate antigens is of importance in the application of immuno-
MULTIVALENT MOLECULES AS SYNTHETIC VACCINES
AcHN
H OH
-O2C
HO HO
O OH
159
OH
O AcHN
CO2O OH OH
O OP nO O
O O
n = 100 - 200
O
(CH2)14CH3
liposome
(CH2)14CH3
phosphatidylcholine DMPC
O
-O2C
HO HO
O
AcHN
OH
OH
H OH O AcHN
O OH OH
HO -O2C H HO OH O O n CO2n AcHN AcHN O O OH OH HO O -O P O HO O -O P O O
CO2-
Liposome
Capsular polysaccharide mimetic of outer bacterial membrane
Figure 3.76 Multivalent capsular polysaccharide K1 displayed in a model membrane.
HO HO OH HO O O OH HO NHAc O O O HO HO O HO O O AcHN O HO HO HO OH
ii,iii
O
i
HO HO OH HO O O OH HO NHAc O O O HO HO O HO O O AcHN O HO HO HO OH HO HO OH HO O O OH HO NHAc O O O HO HO O HO O O AcHN HO HO
HO HO OH HO O O OH HO NHAc O O O HO HO O HO O O AcHN O HO HO HO OH
O
S
O
O
N H
N H 16
O
O
N H
N H 9
O
S
NH2
Bovine serum albumin
98
O
S
Ovalbumin
99
reagents and conditions: i) cysteamine, UV; ii) diethyl aquarate; iii) bovine serum albumin.
Figure 3.77 Structure of neoglycoconjugate presenting either penta- or hexasaccharide corresponding to Streptococcus group A polysaccharide.
160
MULTIVALENT MOLECULES APPLIED TO BACTERIAL TARGETS Ion channel
lipid bilayer
divalent AmB
AmB OH Me HO
O Me
OH OH
OH
OH
Me
OH OH O
HO
i,ii
CO2H
Me O
O Amphotericin B (AmB)
O Me
OH OH
Me
O 100
NH2
OH Me iii
HO
O Me
OH OH
CO2H
Me
OH OH O
CO2H
O Me
OH
OH
Me HO
Me
NH
OH
OH
O
HO H2 N
OH OH
Me
OH OH O
CO2H
Me
Me O Divalent AmB
Me
OH OH O
Me
OH
HO
OH
Me
O
O
Me OH
HO HN
O
O N H
R
O
OH
HO N H
Me
NH
101: R = (CH2)6 102: R = (CH2)2C(=O)O(CH2)2OC(=O)(CH2)2 reagents and conditions: i) FmocNH(CH2)5CHO, NaCNBH3; ii) piperidine; iii) bis-succinimidyl ester of 1,8-octanedioic acid (or ethylene glycol diacid), Et3N.
Figure 3.78 Proposed mode of action by amphotericin B (AmB) and synthesis of AmB dimer.
stimulation agents and in immunodiagnosis [365]. Auzanneau and Pinto [366] (see also Hu et al. [367]) reported the synthesis of neoglycoproteins 98 and 99. These molecules present multiple copies of hexa- and pentasaccharides whose sequences are identical with Streptococcus group A polysaccharides (Figure 3.77). 3.6 3.6.1
FUNGAL CELLS Covalent Dimer of Amphotericin B
Fungal infections are treated by amphotericin B (AmB), which is a member of the class of polyene antibiotics. The activity of AmB is attributed to its ability
FUNGAL CELLS
161
to undergo self-assembly into AmB octamer-ergosterol, an oligomeric complex, thus forming ion-permeable channels across lipid bilayers (Figure 3.78) [368]. Tethering two neighboring monomeric AmBs through a spacer provides a possible route for preorganizing dimeric constructs and stabilizing the functional complex. Matsumori et al. [369] tested this design strategy by constructing AmB dimers. The model for this complex suggests that the optimal spacer between AmB units would extend outside the fungal membrane. Therefore, a chemical handle was installed on the glycoside domain of AmB to allow dimerization with a linker. Reductive amination of an N-Fmoc-protected aminoaldehyde with AmB a¤ords such a derivative (100), after deprotection of the Fmoc group. To generate dimeric AmB, the primary amine of 100 is coupled with an activated bisester with a variable linker length (101 and 102). In a hemolytic assay using human red blood cells, both of the dimers are highly active, with an e¤ective dose (ED50 ) value of 0.3 mM, which is fivefold higher than that of AmB. Despite such in vitro activity, the two dimers are less active in inhibiting the growth of Candida albicans, where their activities are about 26 (101) to 13 (102) times lower than that by free AmB, which has an ED50 value of 0.3 mM.
4 MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
4.1 CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES 4.1.1 Hepatic Mannose/N-Acetylgalactosamine-4-SO4 Receptors Mannose (Man)/N-acetylgalactosamine-4-SO4 (GalNAc-4-SO4 ) receptors are expressed on the surface of hepatic endothelial cells and macrophages [370]. These receptors recognize physiological glycoprotein molecules, such as the hormones lutropin and thyrotropin, that bear carbohydrate moieties terminating in Man and GalNAc-4-SO4 . Depending on the site of expression, this receptor exists as either a dimer, as in hepatic cells, or as a monomer, as in macrophages. The hepatic Man/GalNAc-4-SO4 receptor has the important role of regulating physiological levels of lutropin. It does so by selective binding of the GalNAc-4-SO4 moieties presented by lutropin, thus mediating the clearance of lutropin from the circulation (Figure 4.1). 4.1.1.1 Glycoprotein-Based Multivalent Ligands. Lutropin hormone interacts multivalently with a dimeric Man/GalNAc-4-SO4 receptor. The hormone– receptor binding is tight. Depending on the number of GalNAc-4-SO4 moieties involved in the association, the K d value varies from 8.3 nM, with three to four GalNAc-4-SO4 moieties, to 267 nM, with two GalNAc-4-SO4 moieties [371].
Synthetic Multivalent Molecules: Concepts and Biomedical Applications, By Seok-Ki Choi ISBN 0-471-56347-1 Copyright 6 2004 John Wiley & Sons, Inc.
162
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES OH OH O O O HO HO AcHN AcHN HO HO HO
163
-O3SO
O O
Lutropin (LH) n n~4
GalNAc-4-SO4 Man receptor
GalNAc-4-SO4 receptor LH
membrane
Man-specific Man/GalNAc-4-SO4 receptor (Monomeric)
GalNAc-4-SO4-specific Man/GalNAc-4-SO4 receptor (Dimeric)
Macrophage
Hepatic endothelial cell
Figure 4.1 Man-specific (macrophage) and GalNAc-4-SO4 -specific (hepatic endothelial) form of Man/GalNAc-4-SO4 receptor. The dimeric receptor interacts selectively with lutropin, which presents multiple copies of terminal GalNAc-4-SO4 moieties.
Lutropin binds much more tightly to the receptor than does a monovalent GalNAc-4-SO4 ligand (inhibition constant Ki ¼ 16.8 mM ). Roseman and Baenziger [372] further elucidated the role of multivalent binding of Man/ GaINAc-4-SO4 receptors in hepatocytes. Although Man/GalNAc-4-SO4 receptors can recognize the GalNAc-4-SO4 ligand selectively in a multivalent environment, the receptors do not display high ligand-binding specificity during monovalent interaction. For example, this receptor shows similar binding activity toward two trisaccharides, with Ki values of 25.8 mM (1) and 16.2 mM (2) (Figure 4.2). These molecules di¤er only with respect to location of the sulfate in position 3 or 4. However, multivalent presentation of the ligands on a sca¤old of serum albumin substantially increases the binding a‰nity displayed by the resulting molecules, with Ki values of 13 nM for 3 and 170 nM for 4. This study shows that ligand specificity is achieved through multivalent association. Moreover, the rate of clearance from the blood circulation di¤ers between the two molecules such that 3 is cleared about 12-fold faster than 4. This 12-fold di¤erence in clearance rate is comparable to the about a 13-fold di¤erence in a‰nities.
164 -O3SO
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OH O
HO AcHN
HO
OH O O HO AcHN HO HO HO
-
OH O
O3SO AcHN
O O O
OH O
HO AcHN
OH O
O HO AcHN HO HO HO
O O
OCO2Me
2 (GalNAc-3-SO4)
HO -O
O
3SO
OH O
AcHN
O O
O
OCO2Me
1 (GalNAc-4-SO4)
-O3SO
OH O O HO AcHN HO HO HO
BSA
OH O O HO AcHN HO HO HO
O O O
O ~7
3
4
BSA O ~7
Figure 4.2 Structure of GalNAc-SO4 -presenting ligands.
4.1.2
Hepatic Asialoglycoprotein Receptors
Mammalian liver cells express on their surfaces multiple copies of the asialoglycoprotein receptor (ASGP-R), which recognizes b-d-galactoside (Gal) or 2-acetamido-2-deoxy-b-d-galactoside (GalNAc) displayed on soluble glycoproteins [373]. This hepatic receptor plays a role in the uptake of such glycoproteins and in regulating their cellular level. For instance, it is involved in the rapid clearance of desialylated glycoproteins from the blood circulation, provided that prior to desialylation, such asialoglycoproteins present on their surface multiple galactoside residues attached to sialic acid. 4.1.2.1 Triantennary Galactosides. A series of trivalent b-d-galactosides were designed in the form of antennary clusters [374]. Although structurally homologous, these ligands di¤er in the distance between neighboring galactosides (Figure 4.3). Such trivalent galactosides bind asialoglycoprotein receptors located in parenchymal liver cells, in competition with [ 125 I]asialoorosomucoid ligand. Relative to the weakly binding monomeric GalNAc, which has a Ki value of 870 mM, the binding a‰nities of the trivalent ligands are enhanced up to 4000-fold in manner, which depends on the spacer length, with Ki values of >390 mM (5), 19 mM (6), 11 mM (7), and 0.2 mM (8). Thus, if presented at optimum length, vicinal galactosides within a cluster are bound more tightly by asialoglycoprotein receptors than are those with shorter spacing. 4.1.2.2 Lysine-Based Multivalent N-Acetylgalactosides. Valentijin et al. [375] developed a solid-phase methodology for preparing lysine-based di- and tri-
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES OH OH O O OH
HO
OH OH O O HO OH
OH OH O O OH
HO
OH OH O O HO OH
O C N 3 H
O O
O
C N 3 H
O O
O
O
C N 3 H
O O
O
O
O
HO
O
C N 3 H
H N
OMe O
O
O
O
O
O
O
O
H N
OMe
H N
OMe
H N
OMe
165
5 (4 Å)
6 (9 Å)
7 (13 Å)
8 (20 Å)
OH OH O
HO
9Å
O O
OH OH O O HO OH
O O
O
O C
O
N H
H N
OMe O
O
O 9Å O OHO OH HO HO
6 (9 Å)
Figure 4.3 Structure of glycoclusters composed of triantennary galactoside.
antennary galactosides (Figure 4.4). These multivalent ligands are composed of Gal or GalNAc ligands displayed on a sca¤old derived from a lysine peptide. They bind asialoglycoproteins on the surface of parenchymal liver cells more tightly than monovalent ligands, with Ki values of 95,000 nM (9), 30 nM (10), 650 nM (11), and 4 nM (12). The results indicate that GalNAc-presenting molecules are more active than the corresponding Gal-presenting molecules. Trimers show higher a‰nity than do dimers constructed on comparable scaffolds. The highest a‰nity exhibited by 12 indicates >200,000-fold enhancement over monovalent GalNAc. 4.1.2.3 Trivalent Galactoside–Cholesterol Conjugates. Multivalent antennary galactosides that bind selectively to liver cells play unique roles of biological
166
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OH OH O O R
HO OH OH O O R
OH OH O O R
H N
HO
O
OH OH O O HO R
O
O
NH O 9: R = OH 10: R = NHAc
BzO BzO
NH
O
OH OH O O HO R
OH
O
H N
HO
N NH H
OH O
O 11: R = OH 12: R = NHAc
OBz O O
BzO BzO
OBz O O R
R O
i,ii
NH
O
i,iii,iv
NH
Alloc-HN
O
O O
O
Fmoc-HN O R = OBz; R = NHAc
N H
Fmoc-HN
solid support
BzO BzO
O O
OBz O O R
BzO BzO
OBz O O R BzO BzO
O
H N
11, 12 O
O
O
OBz O O R
v
NH
N NH H
O O
O
reagents and conditions: i) piperidine, DMA; ii) Fmoc-Lys(Alloc)-OH, BOP, DIEA; iii) Pd(PPh)3, AcOH, NMM, CHCl3; iv) carboxylic acid derivative of β-D-galactoside, BOP, DIEA; v) 1 M NaOH.
Figure 4.4 Solid-phase synthesis of lysine-based cluster galactoside.
significance. Biessen et al. [376] reported the functional activity of a triantennary galactoside conjugate (13) which presents a cholesterol derivative on one end of the conjugate (Figure 4.5). This bifunctional hybrid is designed on the assumption that its cholesterol moiety would associate with cholesterol-recognizing receptors such as lipoproteins, while its multivalent sugar ligand guides
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
167
LDL
13 LDL
ASGP-R
Gal
membrane (liver cell)
intracellular uptake
OH OH O O OH
O
HO
O
O
O
O
O
H N
C N 3 H
OH O
O
BOP DMAP
O H2 N
OH OH O O HO OH
O
O O
O
ligand for ASGP-R
O
O
O
C N 3 H 13
H N
H N O
O O
O LDL-binding domain
Figure 4.5 Simplified model for targeted delivery of low-density lipoprotein into hepatic cells by a cholesterol-presenting multivalent galactoside.
the hybrid to hepatic cells through selective interaction with hepatic asialoglycoprotein receptors [377]. Like nonhybrid galactoside clusters, the conjugate 13 shows high a‰nity to asiologlycoprotein receptors, with a Ki value of 200 nM. Due to its amphiphilic nature, this ligand forms micelles in aqueous solution with an average radius of about 5 nm, at a surface density of about 20 molecules per micelle. It is also incorporated into lipoproteins, such as the lowdensity lipoprotein (LDL) present in human serum. Indeed, 13 is associated with LDL at a ratio of about 210 molecules per LDL. Upon intravenous injection into rats, this hybrid ligand causes a decrease in the level of cholesterol present in serum. Such cholesterol-lowering activity is attributed to the targeted
168
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
delivery of LDL to hepatic cells, which results from the multivalent, tight interaction of the LDL–glycolipid complex with asialoglycoprotein on liver cells (Figure 4.5). 4.1.2.4 Trivalent Galactosides for Cell-Specific DNA Delivery. The specific a‰nity of multivalent galactoside molecules to hepatocytes is utilized further for the selective delivery of DNA to mammalian cells. In a study reported by Ren et al. [378], mono-, di-, and trivalent galactosides are covalently conjugated with a molecular construct comprising seven primary amines that serve to form a complex with DNA (Figure 4.6). In a gene transfection assay mea-
NH2 O TBDMSO
O
9
AcO AcO AcO AcO
O
i N
TBDMSO
N
9
OAc O O
O
N H
ii
N
NH2
O O
OAc OAc O O
NH
O O
OAc
iii-vi
O N
N H
N H
OTBDMS
O
9
NH2
NH2 OH OH O O HO OH OH OH O O HO OH
O O O O
N
N H
N
NH2
N
N
N
NH2
O
O N H
H N
O
NH
N
O
R=
H 2N
9
ASGP-R recognition
14
NH2
N
H 2N DNA association domain
OH OH O O HO OH OH OH O O HO OH
OH OH O O HO OH O O
O HN
NH
N
O O
O
N
O
H N
O O
N H
9
O
NH-R
15
reagents and conditions: i) N(CH2CH2NH2)3, DMAP, MeCN, 88oC; ii) acetylated galactosyl derivative, Et3N, THF, 69oC; iii) Bu4NF, THF, 82oC; iv) CDI, DMAP, CH2Cl2, 87oC; v) DAB-dendrimer (NH2)8, THF, reflux; vi) NaOMe, rt.
Figure 4.6 Synthesis of multivalent galactoside–polyamine conjugate.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
169
suring DNA transfer to hepatocarcinoma cells, these galactoside–amine conjugates increase the level of DNA transferred into cells, as assessed by subsequent expression of the transfected genes. For example, the levels of gene expression observed in the presence of 14 and 15 are 300- to 500-fold higher than that displayed by a monovalent galactoside–polyamine conjugate. Such a large enhancement is obtained specifically in hepatocytes and is inhibited competitively by the addition of galactoside-presenting asialofetuin. The enhanced gene transfer is explained by asialoglycoprotein-mediated endocytosis to hepatic cells [379]. Another use of cell-specific targeting is based on peptide nucleic acid (PNA) conjugates that present multivalent lactoside residues [380]. This macromolecule e‰ciently enters liver cells through asialoglycoprotein–lactoside recognition. It also blocks telomerase activity, provided that the PNA provides an antisense telomerase sequence. A similar example is a cholate-based, trivalent galactoside linked covalently to an antisense oligonucleotide [381]. Similarly, the goal of designing this molecule is to enable the carrier-mediated delivery of a therapeutic nucleic acid. 4.1.2.5 Multivalent Binding and Intracellular Tra‰cking. Polyvalent galactosides presented on the side chains of an HMPA [N-(2-hydroxypropyl)methacrylamide] copolymer can attach to the surface of human HepG2 cells (Figure 4.7) [382]. The polymers containing lactoside (16, with galactoside densities of 20 and 30%) and trivalent galactoside (17, with galactoside densities of 20 and 30%) bind more strongly than does galactoside-free HMPA, a polymer control. Furthermore, its binding is selectively inhibited by a large excess of free lactoside. There is a correlation between binding capability and the density of galactoside on HMPA such that polymers with higher galactoside densities show higher adsorption rates, as observed from 16 and 17. After receptor– ligand-mediated multivalent binding to hepatic cells, 16 and 17 are internalized and transported into lysosomal compartments of the cell. The extent of the resulting receptor-mediated endocytosis is determined specifically by galactosidepresenting polymers and is dependent on the nature of the polyvalent ligand (17 is greater than 16). The extent of receptor-mediated endocytosis is also related to the carbohydrate density: Molecules with 30%, 20%, and 10% carbohydrate density experience successively lower rates of endocytosis. In a separate study, a radiolabeled multiantennary GalNAcLe x enabled the discovery that the multivalent ligand predominantly targets hepatic cells [383]. Such ASGP-mediated specific cell recognition is also achieved by using polymers presenting a nongalactoside ligand, such as a modified glucose at the C6 position [384]. 4.1.3
Mannose-Binding Proteins
Mannose-binding proteins (MBPs) are calcium-dependent lectins that bind to mannose and N-acetylglucosamine as specific ligands [385,386]. These man-
170
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS 17 (χgal = 10, 20, or 30%)
16 (χgal = 10, 20, or 30%)
O
NH O OH
NH O
OH
HN
Fluorescein-HN
NH O
NH
OH O HO
HO O OH
O
NH O OH
OH
S
HO
NH O
O
O
NH O OH
HN
Fluorescein-HN
OH
NH O
S
HO HO
OH HO HO HO
NH O
NH
OH
OH O O OH O O OH
O NH O O
OH
HO HO OH
fluorescence-labeled HMPA copolymer
ASGP-R
Gal
membrane (liver cell)
internalization
Figure 4.7 Structure of HMPA copolymer–based polyvalent galactoside and its role in intracellular uptake.
nose-binding lectins are expressed as two closely related forms and are classified according to the site of expression, such as serum (MBP-A) and liver (MBP-C). An important role played by MBPs includes triggering the immune response by binding to mannose ligands present at or above a threshold density on the surface of pathogenic bacteria and fungi. This binding subsequently activates the complement pathway, which is targeted to kill foreign organisms. Although their function relies on their ability to recognize mannose with high specificity, MBPs show only weak a‰nity to monovalent sugar ligands, with Kd values in the millimolar range [387]. However, with multiple carbohydrate-recognition domains (CRDs) displayed per protein subunit on the membrane surface,
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
171
MBPs bind very tightly to target cells, such as bacterial and fungal cells, that present dense and repetitive arrays of Man-type ligands. 4.1.3.1 Bivalent Mannosides. Quesenberry et al. at Johns Hopkins [388] proposed that MBPs display two distinct modes of binding, as shown in Figure 4.8. A subunit in MBP-A, from serum, contains a CRD with dual a‰nity to
GlcNAc or Man site Multivalent antennary glycosides Man site Man GlcNAc
MBP-A (rat serum)
MBP-C (rat liver)
Multivalent glycoprotein
MBP-A
MBP-C
OH
18 (GlcNAc)2
O
H N
AcHN
N H
O O
N H
H N
AcHN
H N
AcHN
O
O
OH OH OH
O
OH OH OH
O
O
O
O
O
OH
19 (Man)2
O
H N
AcHN
N H
O O
N H
H N
OH
O H N
O
O OH
O
OH OH OH OH OH OH
OH
20 (GlcNAc)(Man)
O
H N
AcHN
N H
O O
N H
H N
AcHN O
O
O
O
OH OH OH
O H N O
OH
OH OH OH
Figure 4.8 Model for interaction of mannose-binding protein with its multivalent ligands, which include divalent glycosides presenting either GlcNAc or mannoside.
172
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
Man or GlcNAc, while MBP-C, from liver, presents two CRDs, with one site selective to Man and another to Man or GlcNAc. This di¤erence in ligand specificity and the valency of CRDs distinguishes the monovalent nature of the MBP-A subunit from the bivalent nature of the MBP-C subunit, and this is reflected in the binding a‰nities ofmannoside- and GlcNAc-based divalent glycosides (Figure 4.8). For example, MBP-A is inhibited by the galactoside ligands 18, 19, and 20, with IC50 values of 0.5, 0.56, and 0.44 mM, respectively, which suggests no substantial benefit from divalent glycosides relative to monovalent sugars such as Man (1.5 mM) and G1cNAc (0.9 mM). However. the binding profile to MBP-C is notably improved, with IC50 values of 0.35 mM (18), 0.05 mM (19), and 0.14 mM (20). Thus, bivalent glycosides 19 and 20 exhibit a 22- and 8-fold increase in their a‰nity to MBP-C, respectively, over monomer. 4.1.3.2 Mannose-Presenting Neoglycoproteins. Multivalent mannosides presented on the surface of a glycoprotein such as bovine serum albumin have increased a‰nity to MBPs. For example, a tetravalent mannoside, BSA(Man)4 , shows IC50 values of 0.2 mM to MBP-A and 0.7 mM to MBP-C. These values represent about 10 4 - and 103 -fold enhancements over free mannoside [389]. When the valency of the glycoprotein increases to 20, as with BSA(Man)20 , its a‰nities to MBPs are much higher, with IC50 values of 2 nM (MBP-A) and 5 nM (MBP-C). This example suggests a mechanism that enables the human body to distinguish membrane surfaces derived from the self from those of pathogens. ‘‘Self ’’ membrane surfaces probably contain less dense mannose clusters, and MBP clusters are likely to bind only weakly to such surfaces. In contrast, MBP clusters will probably bind tightly to the dense mannose arrays present on pathogenic surfaces, thus facilitating the discovery and demise of pathogens by the immune system. 4.1.3.3 GlcNAc-Presenting Polymer. Multivalent presentation of mannoside not only increases avidity to MBP, but also modulates selectivity to MBPs derived from various tissues. Fan et al. [390] reported the synthesis of the neoglycopolymer 21, in which poly(acrylamide) is used to present multiple copies of synthetic Man9 GlcNAc as side chains. The multivalent molecule is prepared by copolymerizing acrylamide and a Man9 GlcNAc-terminated-acrylamide derivative in aqueous solution (Figure 4.9). This synthetic glycopolymer inhibits the binding of MBP-CRD coated on a solid surface to BSA(Man)30 ligand, with IC50 values of 3.5 mM for MBP-A and 74.5 nM for MBP-C. The a‰nity of 21 to MBP-C is enhanced about 180 times relative to that of a nonpolymeric ligand control, Man9 GlcNAc, and is also higher than that of natural soybean agglutinin, which has an IC50 value of 13.2 mM. The a‰nity of 21 to MBP-A is relatively low compared to MBP-C, yet it is still of great interest because there are few high-a‰nity ligands to MBP-A, and neither Man9 GlcNAc nor soybean agglutinin shows significant activity.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES HO OH O HO HO HO OO HO HO HOO
173
O H 2N
O
OH OO O HO Man9GlcNAc2 HO O HOOH OH HOOH O HOO OH OO O HO O HO OO O O O HO O HO HO OH OH O O H AcHN HO NHAc HOOH OHOH HO
HO OH O HO HO HO OO HO HO
ammonium persulfate TEMED, H2O O N H
21 [Man9GlcNAc2]/[CONH2] = 1/44
O HOO OH OO n O HO HO O HOOH OH O O O O O O HOOH NH NH NH NH NH 2 2 NH 2 2 2 O HOO OH OO O HO HO O OO O O O HO O HO HO OH OH O O H AcHN HO NHAc HOOH OHOH HO
Figure 4.9 Structure of neoglycopolymer presenting Man9 GlcNAc2 as a side chain.
4.1.3.4 Mannoside Mimics. Grandjean et al. [391] and Angyalosi et al. [392] designed multivalent mannoside analogs using d-quinic and shikimic acid as ligands. These carbocyclic acids are likely to serve as mannoside mimics because their structures possess a vicinal diol at the C4 and C5 positions (Figure 4.10), as displayed by a mannoside ligand bound at the calcium site of MBP. The acids are incorporated into fluorescence-labeled multivalent molecules constructed on a lysine–peptide sca¤old with a valency of 2 to 8. Glycomimetics such as octavalent 22 and 23 undergo internalization as a result of MBP-mediated uptake in human dendritic cells, although the level of internalization is about twofold (22) and fourfold (23) lower than that of an equivalent octavalent mannoside. Such internalization is achieved only if mannoside or its mimic is presented as the ligand; a similar multivalent construct made of galactonoyl ligand is not internalized. Tetravalent mimics (24 and 25) show a twofold higher level of mannose-receptor-specific internalization than that of a tetravalent mannoside. Thus, multivalent constructs derived from quinic and shikimic acids are recognized by human mannose receptors. In a separate study, Schuster et al. [393] reported the solid-phase synthesis of mannose mimics derived from shikimic acid as ligands to a C-type lectin and a mannose-binding protein.
174
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OH 5 OH O OR HO HO 4
5 O HO HO OH OH 4 OH
D-Mannose
5 HO HO 4 OH
(D)-Quinic acid
CO2H
Shikimic acid
R-HN
O
H N
R-HN O
S
OH N H
CO2H O
O CO2H O 22: R =
HO HO
OH
OH
NH
NH
HN
O S
HN
O
O
O
CO2H NH2
O NH
O
NH O
N H
O
HN
O
NH-R
HO HO
N H
H N
O 23: R =
S
OH
R-HN R-HN
NH-R
O
O
NH
S
N H
O HN
HN
HO2C
O H N
HO2C
S
O
O
R-HN O
S
N H
24: R =
CO2H OH
OH O
25: R =
HO HO
OH
CO2H O
O HO HO
NH-R
O
H N
R-HN
NH-R
N H
NH
NH O HN O
OH
NH-R
HN
H N
S O
O
N H
O S N H
H N O
CO2H
O
NH2 O
NH-R
Figure 4.10 Structure of multivalent mannoside mimics.
4.1.4
Mannose 6-Phosphate Receptor (Insulinlike Growth Factor II)
Mannose-6-phosphate/insulinlike growth factor II receptor (Man-6-P/IGF-R) contains two Man-6-P-binding domains located in the extracytoplasmic region of the receptor [394]. The receptor recognizes Man-6-P as a specific ligand, although its a‰nity to various Man-6-P ligands varies with ligand valency. For instance, it binds to monovalent Man-6-P with a relatively low a‰nity, re-
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
175
flected by a Kd value of 6 to 8 mM. However, the receptor binds with high a‰nity to glycoproteins presenting divalent Man-6-P groups, as reflected by a Kd value of 1 to 2 nM [395]. 4.1.4.1 Neoglycoprotein-Based Mannose-6-Phosphate. Byrd and MacDonald [396] and Byrd et al. [397] studied the mechanisms responsible for the higha‰nity association of Man-6-P receptors with multivalent ligands, with particular emphasis on intrareceptor bridging and interreceptor dimerization (Figure 4.11). This receptor displays two Man-6-P sites and binds to a pentavalent ligand present on bovine serum albumin, (Man-6-P)5 , with a K d value of 0.54 nM and a stoichiometry of 1:1 (Figure 4.11a). In comparison, nonnatural Man-6-P receptors that contain only one Man-6-P recognition site, such as truncated receptor or mutated receptors that lack a second Man-6-P site, are also able to bind the pentavalent ligand (Man-6-P)5 in the nanomolar a‰nity range but with a 2:1 stoichiometry, resulting in the receptor dimerization (Figure 4.11b). Therefore, it is likely that the interaction between Man-6-P/IGF-R and multivalent ligands involves multivalency, leading to a high-a‰nity association as well as receptor oligomerization on cell surfaces.
(a) Man-6-P site Man-6-P/IGF-II
Man-6-P BSA(Man-6-P)5
membrane Dimerization of receptor (1:1 stoichiometry) (b) mutated Man-6-P/IGF-II
truncated Man-6-P/IGF-II
Dimerization of receptor (2:1 stoichiometry)
Figure 4.11 Hypothetical model for interaction of Man-6-P/IGF-R with multivalent ligand presenting Man-6-P: (a) dimerization of natural receptors via divalent bridging; (b) dimerization of mutated or truncated receptors that presents one Man-6-P binding domain per receptor.
176
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
4.1.4.2 Biotin/Avidin-Based Tetravalent Mannose-6-Phospate. Biotin and avidin display a noncovalent but very tight interaction, with a K d value of 1015 M. Such a strong association provides a system that makes it possible to design a novel type of multivalent ligand. Rothenberg et al. [398] reported the preparation of a pentamannose phosphate that is linked to biotin through a 2,6-diaminopyridine spacer (Figure 4.12). This mannose phosphate–biotin conjugate (26) is converted to a noncovalent form of multivalent construct when its terminal biotin unit associates to tetravalent avidin. The resulting tetravalent complex binds to a mannose-6-phosphate receptor immobilized on the surface, whereas a monovalent mannose phosphate shows only poor a‰nity.
O
O HN HO
NH
H2 N
N
NH2
HN
H2 N
S
N
i
O
H N
NH +
S
OPO32OH O O HO
HO HO
O
PO32OH O OH 4
pentamannose phosphate
O 2-
iii
HO HO
OPO3 OH O O HO
2-
OPO3 OH O O HO 3
HN
2-
PO3 OH H OH N
N
NH iii
H N
S O
26 fluorescent mannose-phosphate biotin conjugate
HO HO
HO HO
OPO32OH O O HO
OPO32OH O O HO OPO32OH O O HO 3
OPO32OH O O HO 3
PO32OH H OH N Avidin
2-
PO3 OH H OH N
biotin (Kd = 10-15 M to avidin)
N HO H HO 2O3P
N HO H HO 2O3P
OH O O HO 2O3PO
OH O 2-
O HO O3PO
OH O3 O HO 2O3PO
OH O3 O HO 2O3PO
OH OH
OH OH
reagents and conditions: i) EDC, NHS; ii)Schiff base formation, and reductive amination; iii) avidin
Figure 4.12 Tetravalent presentation of mannose phosphate through biotin–avidin interaction.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES CD45
177
CD45 Galectin
Galactoside
CD3
CD3
Figure 4.13 Cross-linked complexes formed among galactin-1, CD45, and CD3.
4.1.5
Galectins
Galectins, a class of mammalian lectins, consist structurally of homodimers that recognize N-linked complex carbohydrates terminating in Gal residues such as N-acetyllactosamine [399]. The CRDs of galectins are presented bivalently, where each site is located in the opposite face. Galectins are involved in cell–cell adhesion, cell migration, and growth regulation through a mechanism based on multivalent interaction [400–402]. For example, galectin-1 isolated from calf spleen can induce apoptosis in susceptible T-cells [403]. Its proposed mechanism of action includes a cross-linking of specific T-cell receptors on cell surfaces, followed by the segregation of T-cell receptors (Figure 4.13) [404]. Evidence for this mechanism is further based on galectin-induced spatial segregation of the CD45–CD3 complex on human T-cell surfaces caused by the formation of an extended lectin–carbohydrate lattice [405]. 4.1.5.1 Glycodendrimer. Andre´ et al. [406] reported galectin inhibitors that are designed to target CRDs of galectins. The opposite orientation of the two galectin CRDs makes it di‰cult to design multivalent ligands capable of binding simultaneously. Disubstituted benzoic acid can be used to attach two, four, and eight copies of lactoside moieties, thus creating multiple generations of wedgelike glycodendrimers (Figure 4.14). These glycodendrimeric molecules are potent inhibitors against homodimeric galectin-1. For example, a tetravalent, second-generation glycodendrimer (27) shows inhibitory activity, with an IC50 value of 27 mM. The activity of the second-generation glycodendrimer is enhanced 1667-fold per lactoside relative to free lactose. In addition, 28 blocks hemagglutination mediated by galectin-3 at micromolar concentrations in an assay that is commonly used as a cell adhesion model. The hemagglutination blocking activity is 144 times greater per lactoside than that of a monovalent lactoside. A separate study by Andre´ et al. [407] showed that the binding activity of a lactose-presenting, polyamidoamine starburst dendrimer to
178
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OH OH OH
OH OH OH HO
HO
O O
OH OH
OH HO
OH HO
O
HO
O
HO
O
NH
NH S
HO
O HO OH
O HO OH HO
O
HO
O
OH
HO
NH
S NH
S
S
NH
NH
O O
OH OH
OH
O NH NH
O
O
O
O HN
HN
O
O
O
O 27 O
MeO
OH OH HO OH OH OH OH OH OH HO O OH OH OH O HO HO HO OH OH O O HO O HO OH OH O O O HO OH OH OH HO O OH HO O OH OH HO OH OH OH HO O O OH HO O HO OH O HO O OH HO O HO NH HO HO O O OH S HO NH O O OH NH O O NH HO S HO NH OH S NH S OH NH NH S NH NH O HO S NH NH HO O O NH O S NH O O S NH O O NH HO
O HN
O
HN
O
O
O HN
HN
O O O
O
O
O
NH
HN
O
O
O
28 MeO
O
Figure 4.14 Structure of wedgelike glycodendrimers as inhibitors of mammalian galectins.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
179
galectin-1 is influenced by the method of dendrimer generation, and is therefore influenced by the molecule’s shape and ligand density. 4.1.6
Sialoadhesin CD22
CD22 belongs to a class of cell adhesin glycoproteins that are expressed uniquely on the surface of B-cells and B-cell-derived tumor cells [408,409]. It recognizes glycans terminated with sialic acid residues. As one of two isoforms of CD22 (a and b), CD22b binds to endogenous ligands presenting a NeuAc(a2,6)Lac trisaccharide unit (29) as a binding motif (Figure 4.15). Van Rossenberg et al. [410] and Sliedregt et al. [411] found that some disaccharides, and even monovalent sialic acids, show comparable or higher a‰nity than that of a natural trisaccharide in an assay that measures their ability to bind to CD22b. For example, the N-nitrobenzoyl derivative of NeuAc(a2,6)glucosamine (30)
OHOH 29
AcHN
CO2H OH O O OH O OH HO OH HO O
OHOH CO2H
OH O OMe OH
AcHN
O OH
OH
O HO HO
O
OMe 30
NH O
O 2N
OHOH CO2H AcHN
O OH
OH
O HO HO
O
O
NH O
O O2N
HN
OHOH AcHN O
O
OH
O OH HO HO
O
O
CO2H AcHN
NO2
O
O
O
NH
N H
O HN
H N
O
O
OH OH HO
O
O
O n
N H
O CO2H
OH NHAc OH OH
31 (n = 0, 1, 2)
O
NO2
O2N O HN O
O OHOH
CbzHN
CO2H AcHN
O
OH
O OH HO HO
O O
O
NH
O
N H
O
O2N
OHOH NO2
O O
O
32
CO2H
HN NH
O
O
OH OH OH HO O NHAc O
O
O O N H
O
HN O
O
OH OH OH HO O NHAc O CO2H
OHOH
Figure 4.15 Structure of Neu5Ac(a2,6)Lac-displaying multivalent ligands to CD22.
180
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
exhibits an IC50 value of 26 mM, an activity about ninefold greater than that of 29, which has an IC50 value of 244 mM. Tethering this glucosamine-derived disaccharide unit to a Tris- or glutamate-based sca¤olding creates a multivalent molecule. The resulting di-, tri-, and tetravalent ligands (31; n ¼ 0; 1; 2) inhibit CD22b with about 10-fold higher activity than that of 30. A second type of trivalent ligand constructed on a Tris sca¤old (32) binds potently to CD22b with about 30-fold higher a‰nity than 30, and about 270-fold higher activity than that of the natural binding unit, 29. This example demonstrates the utility of multivalency in designing ligands that target dimeric CD22 receptors. 4.1.7
Dendritic Cell–Specific ICAM-3–Grabbing Nonintegrin
The dendritic cell–specific ICAM-3-grabbing nonintegrin (DC-SIGN) is a Ctype (calcium-dependent) lectin present on the surface of dendritic cells. This molecule mediates intercellular communication between dendritic cells and Tcells by binding to the intercellular adhesion molecule-3 (ICAM-3) molecules present on T-cells. It also binds to the gp120 envelope glycoprotein on the surface of human immunodeficiency virus (HIV). The crystal structure of oligosaccharides bound to the DC-SIGN CRD show that this receptor recognizes mannoside-containing high densities of oligosaccharides displayed on protein surfaces of ICAM-3 and gp120 [412]. The DC-SIGN receptor is believed to form tetramers on cell surfaces [413]. 4.1.7.1 Mannoside Clusters on Peptide and Protein Sca¤olds. Feinberg et al. [412] studied the mechanism of carbohydrate recognition by DC-SIGN receptors using ligands based on mannosides (Figure 4.16). Free mannose shows weak inhibition activity, with a Ki value of 13.1 mM, while Man9 GlcNAc2 (33), a high-a‰nity mannoside cluster, shows enhanced activity, with a Ki value of 0.016 mM. The significant di¤erence in a‰nity between the two ligands is HO OH O HO HO HO O O HO HO
HOO HO HO OH
O O
O HOO
OH O O HOO
OH OHOH
O O O O
O HO
OH HO O O O HO AcHN
HO O OR O HO AcHN
HO O HO HO OH
BSA
O 30
OH OHOH
OH OHOH
Man9GlcNAc2 (33)
Man30BSA (34)
OH OHOH
Figure 4.16 Structure of a triantennary mannoside cluster and a mannoside-presenting neoglycoprotein.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
181
attributed to the manner of presentation of multiple mannosides. When the binding is tested for Man30 BSA (34), DC-SIGN shows a much higher a‰nity, with a K d value of 169 nM. Multivalent ligands probably enhance the binding a‰nity because multiple CRDs from an oligomeric cluster of DC-SIGN receptors are involved in the binding. 4.1.7.2 Lewis Saccharide–Presenting Dendrimers. Frison et al. [414] reported oligolysine-based dendrimers displaying four or five copies of Lewis saccharides, such as Le a , Le b , and Le x . These glycodendrimers show a higher a‰nity to DC-SIGN receptors than do mannoside-presenting dendrimers of the same type. Upon binding, the Le glycodendrimers undergo multivalency-mediated endocytosis into cells expressing DC-SIGN receptors. A separate study by Van Die et al. [415] suggested that human DC-SIGN binds to Le x determinants displayed multivalently on a neoglycoconjugate by using a region within the CRD that di¤ers from the site for high-mannose ligands. 4.1.8
Spermatogenesis
Male germ cells interact closely with Sertoli cells in testes through direct cell– cell adhesion. This is a first step that leads to multiple stages that are essential to germ cell maturation. This maturation process, spermatogenesis, enables germ cells to undergo di¤erentiation into mature spermatozoa [416]. This type of intercellular communication is based on a specific interaction between a lectin receptor present on Sertoli cells and certain N-glycans displayed on germ cells (Figure 4.17) [417]. Akama et al. [418] reported that carbohydrate ligands involved in such interactions comprise triantennary carbohydrates terminated with multiple copies of GlcNAc residues. Their involvement is supported by an observation that the adhesion of mouse germ cells to Sertoli cells is blocked by an N-glycan oligosaccharide which presents three copies of terminal GlcNAc and a fucose residue attached to the core of the glycan chain. Thus, it is likely
GlcNAc Mannose Fucose lectin
Sertoli cell
Germ cell tri-antennary N-glycan
Figure 4.17 Proposed model describing intercellular communication between Sertoli cell and germ cell mediated by lectin–carbohydrate interaction.
182
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
that this type of rare carbohydrate cluster is involved in mouse spermatogenesis. 4.1.9
Sperm–Egg Interactions
4.1.9.1 Bindin. During fertilization, molecules on the surface of egg cells play a direct role in species-specific interactions with sperm [419]. In the sea urchin, the receptor on sperm is bindin, a cell surface component of acrosome granules (Figure 4.18). The complementary ligands on egg surfaces, known as O-linked glycans, are attached to cell surface glycoproteins [420]. Kitazume-Kawaguchi et al. [421] reported that the basic structure of the glycan ligand is a polysialic acid that terminates in a sulfated sialic acid, 9-(SO4 )Neu5Gc-a2,5-Neu5Gc. When sperm bind to the outer coat of the eggs, formation of the acrosomal process ensues. The sperm adheres to the plasma surface of the egg by means of the sperm bindin receptor binding to 9-(SO4 )-Neu5Gc-terminated polysialic acid molecules on the egg surface. This association is specific, as supported by identification of a free oligosaccharide composed of a sulfated sialic acid (such as 35), which can bind to sperm that have undergone the acrosomal reaction and can prevent the fertilization of eggs [422,423]. Beads that display on the surface multiple copies of a neoglycoprotein containing sulfated sialic acid can elicit sperm binding, which leads to the formation of stable aggregates of sperm and beads.
acrosomal process
actin polymerization; cell adhesion
Bindin receptor
Sperm acrosomal vesicle nucleus
carbohydrate (35)
jelly coat/vitelline layer Egg O OHOH -O S OH HO OH OHOH OO H H O CO2H O CO2- N O H CO2O CO2- N O N N O HO O OR O HO O HO HO HO O HO HO O HO HO 35
Figure 4.18 Sperm–egg interaction in a sea urchin and an oligosaccharide ligand on the egg surface involved in the process.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES (a)
183
(b) acrosomal process
GalTase GlcNAc
cell adhesion integrin α6β1
Sperm
acrosomal vesicle
nucleus
fertilin β
zona pellucida and perivitelline layer
Egg
Figure 4.19 Mammalian gamete recognition: (a) adhesion of sperm to the outer surface (zona pellucida) of egg through GalTase-GlcNAc binding; (b) binding of acrosomereacted sperm at the side face of its head to the plasma surface of the egg through fertilin b–integrin a6 b1 interaction.
4.1.9.2 b-1,4-Galactosyltransferase. In the mouse, sperm–egg interaction initiates when multiple copies of b-1,4-galactosyltransferase (GalTase) present on the surface of the sperm heads bind to oligosaccharide ligands displayed in the egg coat, or zona pellulcida (ZP) [66,67]. The GalTase selectively recognizes GlcNAc presented on ZP3 glycoprotein (Figure 4.19). This surface-to-surface interaction involves multivalency-mediated clustering of GalTase, followed by intracellular signaling events, leading to acrosomal reactions in the sperm. The sperm-ZP3 adhesion is blocked by the addition of multivalent molecules presenting GlcNAc, including natural ZP3 or other glycoproteins. 4.1.9.3 Fertilin b. Expressed as an integral membrane protein on the extracellular surface of sperm, fertilin b is involved in sperm–egg adhesion at a stage that requires its binding to a6 b1 intergrin, which is present on the egg plasma membrane (Figure 4.19) [424]. Since the fertilin b-integrin interaction takes place at the cellular interface, it can be modulated by multivalent molecules that present ligands binding to either fertilin b or integrin. This notion is tested by Gupta and Sampson [425] and Gupta et al. [426], who designed a POPCbased liposome that presents a fertilin b peptide sequence at a density of 1 mol% on its surface. The resulting liposome inhibits sperm–egg binding with an IC50 value of 5.2 mM and is 100-fold more active than a monomeric fertilin b peptide. Moreover, this multivalent mimic of fertilin b blocks sperm–egg association completely. This degree of blocking cannot be achieved with monomeric peptides. 4.1.9.4 XL35 Lectin. An animal lectin present on Xenopus laevis oocytes, XL35 binds galactoside moieties displayed in the jelly coat glycoprotein (JCP)
184
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OH OH O
NH2
HO
HO O HO HO
O O OH
+
O O O O OR OR OR O O N R O
Et3N, DMF; then NH4OH
36
OH OH O HO HO O HO HO
O O O O NH NH2 NH2 NH2
37 (χsuagr = 8, 17 mol%)
O O OH
Figure 4.20 Structure of multivalent galactosylglucoside presented on the side chain of poly(acrylamide).
that surrounds the frog egg [427]. The interaction of XL35 with JCP plays an essential role in blocking polyspermy, the adhesion of multiple sperm cells to a single egg. XL35 is an oligomeric glycoprotein that presents collectively 9 to 12 carbohydrate-binding units. In an e¤ort to understand the mechanism of XL35 binding to jelly coat mucin, Arranz-Alex et al. [427] studied poly(acrylamide) presenting multiple side chains of melibiose (Gal-a1,6-Glu) as mimics for natural JCP (Figure 4.20). One such example is a glycopolymer (37), which was modified to contain 8 or 17 mol% melibiose (36) as side chains of the polymer. The derivitized glycopolymers block the binding of XL35 to JCP with IC50 values of 16 mM (8 mol%) or 7 mM (17 mol%). These activities, which are close to the activity of natural JCP (Ki ¼ 4.3 mM ), represent a marked enhancement over the binding of the monovalent ligand 36, which shows an IC50 value of 14 mM. In a SPR study, 37 (17 mol%) binds to immobilized XL35 with a K d value of 1.67 mM, while a monovalent melibiose binds weakly, with a K d value of 1.57 mM. Thus, the XL35 lectin helps protect the egg by binding tightly to multiple sugar ligands present on JCP in frog oocytes. 4.1.10
Fucose-Binding Receptor on Cancer Cells
4.1.10.1 Fucose–Batracylin Conjugate Based on Neoglycoprotein. Certain cancer cells present lectin-binding surface receptors that recognize particular carbohydrate epitopes. For example, the colon cancer cell line SW480 contains fucose binding receptors [428]. Lerchen et al. [429] developed multivalent molecules as a molecular tool for delivering anticancer drugs to specific cancer targets (Figure 4.21). The molecular drug delivery system is based on a neoglycoprotein composed of multiple copies of batracylin, BAY H204, an anti-
185
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES O O H2N
OHO
OHOR
N
lysine
O
H N
H N
i,ii
N
S
N
BSA
Batracylin
NH2
N m = 15-30
iii
38
O HO OR 39: R = OH (fucose); n = 9 40: R = OCH2CO2H; n = 22
O OH N N
tyrosine
n HO
O
H N
H N S
N
m
N
reagents and conditions: i) CSCl2, ii) bovine serum albumin (BSA), iii) NaNO2, HCl (diazotization).
Figure 4.21 Synthesis of neoglycoconjugates presenting multiple copies of anticancer drug (batracylin) along with fucose as cancer cell–targeting ligand.
cancer drug. In addition, the molecule contains multiple copies of a fucose derivative; these serve as ligands that target the surface receptors of cancer cells. A drug-carrying glycoconjugate (39) undergoes intracellular uptake via endocytosis into SW480 tumor cells, although only weakly. However, it is taken up e‰ciently by hepatocytes that present fucose-binding receptors. A second glycoconjugate (40), carrying modified fucose residues as the ligand, shows selective and improved cellular uptake by SW480 cells but little uptake by control cells. This uptake inhibits cell growth and induces cytotoxicity against SW480, while a carbohydrate-free drug conjugate (38) lacks any activity against SW480, presumably due to an inability to permeate the cell. 4.1.10.2 Liposomes That Display GM3 –Lac Ceramide. Certain tumor cells express elevated levels of specific types of glycosphingolipid (GSL) on their surface. These cell adhesion molecules contribute to metastasis and the invasion of tumor cells into other cells and tissues [430]. For example, melanoma cells express a high number of the gangliosphingolipid (GM3 ), molecules on their surface, and the surface density of GM3 is associated directly with the metastasic competency of the melanoma cells. This type of cancer-specific expression provides an opportunity to develop multivalent GSL molecules as antimetastasis agents in cancer therapy. Otsuji et al. [431] reported the construction of liposomes that present multiple copies of GM3 –Lac ceramide or GM3 –Gg3 ceramide. The multivalent ligands block the adhesion of B16 melanoma cells to endothelial cells in vitro and furthermore, inhibit melanoma metastasis in vivo.
186
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OSO3O
O HO -O3SHN
OSO3O -O C 2 O O HO HO O HO AcHN OH -O2C O
Heparin
OSO3O O -O3SO OH -O3SHN O n
O
~40 Å Heparin FGF receptor
membrane Fibroblast growth factor (FGF)
Dimerization of FGF receptor
Figure 4.22 Dimerization of fibroblast growth factor (FGF) receptors mediated by binding of heparin-linked FGF dimer.
4.1.11
Fibroblast Growth Factors
Fibroblast growth factors (FGFs) comprise a family of multifunctional proteins that mediate cellular functions by binding to membrane-bound FGF receptors [432]. Activation of the protein kinase activity of an FGF receptor requires oligomerization of the receptor, which occurs when the extracellular domains bind to a dimeric form of FGF [433]. The FGF dimer is formed by the creation of a complex with heparinlike multivalent molecules. DiGabriele et al. [434] reported the crystal structure of a heparin-linked, biologically active form of FGF dimer (Figure 4.22). This heparin decasaccharide ligand binds to two FGF molecules through five or six contacts made by monosaccharide units with the protein. 4.1.12
Carbohydrate–Carbohydrate Interactions on Cell Surfaces
4.1.12.1 Gg3 –GM3 Interaction. Oligosaccharides present on cell membranes are in certain cases involved in carbohydrate–carbohydrate interactions that mediate cellular recognition events. Among various studies investigating carbohydrate–carbohydrate interactions, Hakomori’s works describe the role of Le x –Le x in embryogenesis, the Gg3 (gangliotriaosyl ceramide)–GM3 interaction between lymphoma and melanoma cells, and the Gg3 –GM3 interaction in signal transduction [435–438]. Using SPR spectroscopy, Matsuura et al. [439] provided quantitative estimates of the binding of polyvalent glycosides to
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
187
n
OH HO OH HO O O HO O O HO OH AcHN
OH O
NH O RHN
O RHN
O
OH 41 (R = Gg3)
Gg3
n
OH O HO
HO HO
O
OH O
NH O RHN
O RHN
O
OH
OH Lac
42 (R = Lac)
n
HO HO
OH O HO
O
OH O
NH O RHN
O RHN
O
OH
OH Cel
43 (R = Cel)
Figure 4.23 Structure of polyvalent glycocopolymer presenting either Gg3, Lac, or Cel as side chain.
glycolipid monolayers. The polyvalent molecules are based on polystyrene, which presents multiple copies of Gg3 , Lac, or Cel on its side chains (Figure 4.23). For example, 41 binds to GM3 monolayers with a Ka value of 2.5 10 6 M 1 , whereas a monovalent Gg3 does not adhere to the monolayer. Two other glycopolymers (42 and 43) bind with a 30- to 60-fold lower a‰nity, suggesting carbohydrate specificity. Similarly, 41 shows ligand selectivity when bound to glycolipid monolayers, with relative a‰nities of GM3 > LacCer > GlcCer. This type of homophilic carbohydrate interaction is also reported to play an important role in rainbow trout fertilization, where (KDN)GM3 on sperm heads binds to Gg3 -like epitopes present on the surface of the egg [440]. 4.1.12.2 Aggregation Factors of Marine Sponges. Cell–cell adhesion in marine sponges occurs via two events. First, in a calcium-independent process, extracellular proteoglycan-like molecules known as aggregation factors (AFs) bind on the cell surface. Second, in a calcium-dependent process, AFs selfassociate. These cell–cell adhesion events are responsible for cell aggregation and sorting [441]. A sulfated disaccharide (44) isolated from the sponge M. prolifera is identified as a surface epitope acting as an AF [442]. To study selfinteractions of the sponge, Haseley et al. [443] developed a model surface com-
188
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS BSA OH O HO HO NaO3SO
O OHO
S
O
OH
NHAc
O HO HO NaO3SO
O OHO
H N
H N
O
O
n
OH
n = 7.8
NHAc 45
44
2+ 2+ Ca2+ Ca Ca
45
Ca2+
2+ 2+ Ca2+ Ca Ca Ca2+
Ca2+ CMC sensor
Figure 4.24 Structure of neoglycoprotein presenting multiple copies of sulfated disaccharide epitope and a schematic for calcium-induced self association.
posed of a neoglycoprotein (45) attached to the surface of a carboxylmethylated dextran sensor used for SPR measurement (Figure 4.24). In the absence of Ca 2þ , 45 undergoes no observable self-interactions. However, upon addition of Ca 2þ , 45 undergoes self-aggregation to form multiple layers. Such aggregation is specific to Ca 2þ ; other divalent cations, such as Mg 2þ and Mn 2þ , do not induce such self-association. The binding strength of 45 in self-aggregates is estimated to have a K a value of about 10 5 M 1 (ka ¼ 100 M 1 /s; kd ¼ 0:001 s1 ). 4.1.12.3 Le x –Le x Interaction. Homophilic carbohydrate interactions between Le x antigens [444] are implicated in molecular compaction. De la Fuente et al. [445] reported a model surface that presents Le x carbohydrates through an alkanethiolate linkage on gold nanoparticles. Nanoparticles at a mean diameter of about 20 nm become aggregated in an aqueous solution containing Ca 2þ but remain dispersed in the absence of such divalent ions. This calcium-dependent aggregation is attributed to specific self-recognition between Le x –Le x molecules mediated by Ca 2þ . 4.1.13
E-Selectin
The recruitment of white blood cells to injured tissues involves specific interactions between the glycoprotein E-selectin [endothelial leukocyte adhesion molecule-1 (ELAM-1)] present on the surface of activated endothelial cells and a cell surface carbohydrate ligand displayed on neutrophils (Figure 4.25) [446– 448]. The basic structural motif recognized by E-selectin includes a branched
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
189
Leukocyte
rolling
Sialyl Lewis x E-selectin
Endothelial cell
Figure 4.25 E-selectin-mediated adhesion of leukocyte to endothelial cell.
tetrasaccharide terminated with a sulfated trisaccharide, such as 3 0 -O-SO3 Lewis x, or with a sialic acid, such as sialyl Lewis x (SLe x ) or sialyl Lewis a (SLe a ). The a‰nity of the monovalent ligands, including SLe x , to E-selectin is relatively weak, with an IC50 value of 1 to 2 mM [449,450]. However, the cell– leukocyte adhesion mediated by E-selectin is very tight, suggesting the involvement of multiple specific interactions at the cell interfaces [451,452]. 4.1.13.1 Divalent Sialyl Lewis x. To identify E-selectin antagonists that are more active than sialyl Lewis x, DeFrees et al. at Scripps [453] designed a series of bivalent sialyl Lewis x ligands composed of two copies of sialyl Lewis x linked to a galactoside template (Figure 4.26). These ligands thus represent positional isomers which di¤er only in the spacing between adjacent sialyl Lewis x. These dimers block the adhesion of HL-60 cells to immobilized Eselectin more potently than does sialyl Lewis x. For example, the IC50 value of 46 (3,6-orientation) is 0.2 mM, which indicates sixfold more activity than that of sialyl Lewis x alone. Other orientational dimers (47 and 48) are three times more potent than sialyl Lewis x. Thus, the point of attachment on a galactoside sca¤old influences significantly the a‰nities of the resulting dimers in the order 3,6-linked > 4,6-linked > 2,6-linked > monomer. The hierarchy of activities probably stems from di¤erences in distance and orientation between the two presented ligands. In another report, Wittmann et al. [454] studied dimers of sialyl Lewis x linked through oligo(ethylene glycol) spacers of varying lengths (Figure 4.27). Dimers (49) show inhibitory activity against immobilized E-selectin, with IC50 values of 70 mM (n ¼ 3) and 81 mM (n ¼ 6). Such activities represent approximately a five- to sixfold enhancement over the sialyl Le x monomer. ¨ hrlein [455] re4.1.13.2 Trivalent Sialyl Lewis x Constructs. Baisch and O x ported di- and trivalent sialyl Le molecules attached to an oligopeptide
190
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OH OH -O2C HO OH O OH AcHN O NHAc O O O OH OH O 6 OH OH O O O OEt OH OH HO AcHN O O OH OH 3 O OH HO O O O HO -O2C OH O HO OH O AcHN 46 (3,6-linked) OH OH
OH OH OH OH O OH HO -O2C HO NHAc O O O O O AcHN O OR OH OH OH HO
HO OH
Sialyl Lex
OH OH OH OH CO2OHOH OH OH OHOH HO O O -O2C OH OH O OH O OH AcHN O OH NHAc O O O OH OH OO OH HO O NHAc HO O O OH HO O OH O OH 6 HO O HO NHAc O OH O(CH2)5CO2Me -O2C OH 6 O O HO O OH O HO O(CH2)5CO2Me O O 4 O O AcHN OH AcHN O OH HO O OH OH OH 2 OH OH O O HO HO -O2C O O HO O OH O OH AcHN 47 (4,6-linked) OH OH 48 (2,6-linked) AcHN HO
O
OHOH HO HO HO HO HO
NHAc OH O O O OEt NHAcO OH O
HO i
HO OH
HO
O HO O OH HO OH HO O O OH
NHAc OH O O O OEt NHAc O OH O
ii
OH
OHOH -O2C OH OH AcHN O NHAc O O HO OH OH OH O O O OH HO O OEt AcHN O OH O OH HO HO O O HO -O2C OH O HO OH O AcHN
OH
iii 46
OH
reagents and conditions: i) UDP-glucose, uridine 5'-diphosphogalactose 4'-epimerase, β-1,4-galactosyl transferase; ii) CMP-N-acetylneuraminic acid, α-2,3-sialyltransferase, iii) GDP-fucose, fucosyltransferase.
Figure 4.26 Chemoenzymatic synthesis of galactoside-anchored bivalent sialyl Le x .
191
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES OH OH OH O OH OH HO -O2C HO NHAc O O O O O AcHN O O OH OH OH HO
O
H N
N
NH2 +
O
O
O O
O
O
O
O n
O
N
O
n = 2 to 6
Et3N, DMF
OH OH OH OH O OH HO HO -O2C NHAc O O O O O AcHN O O OH OH OH HO OH OH O OH OH HO -O2C HO NHAc O O O O O AcHN O O OH OH OH HO
H N
NH
O
O O
OH
H N O
O N H
n
O
49 (n = 3, 6) x
Figure 4.27 Synthesis of divalent sialyl Le molecules of varying linker length.
framework. These constructs closely mimic the clusters of sialyl Le x moieties presented on natural glycoproteins (Figure 4.28). The synthesis combines both chemical and enzymatic methods. A trivalent sialyl Le x ligand (51; n ¼ 4) shows a‰nity to E-selectin with an IC50 value of 0.14 mM per sialyl Le x , which is fourfold more active than a monovalent sialyl Le x . A second trivalent ligand (51; n ¼ 5) is slightly better than monomer control, with an IC50 value of 0.39 mM. Sprengard et al. [456] reported a trivalent molecule that presents three sialyl Lewis x moieties attached to an oligopeptide sca¤old. The synthesis is based on a cyclic heptapeptide framework prepared by a solid-phase method and includes coupling of a partially protected sialyl Lewis x to the sca¤old in the solution phase (Figure 4.29). This trivalent ligand (52) blocks the binding of E-selectin to sialyl Lewis x–presenting tumor cells, such as cell line HL-60, with an IC50 value of 0.35 to 0.6 mM, thus representing two- to threefold higher activity than the SLe x monomer. 4.1.13.3 Neoglycoproteins Displaying Sialyl Lewis x Ligands. Bovine serum albumin (BSA) is used as a sca¤olding to present SLe x in multiple copies as a ligand for E-selectin, as reported by Welply et al. at Monsanto [457]. For example, a BSA conjugate presenting 16 copies of SLe x per protein shows inhibitory activity against cell adhesion mediated by E-selectin, with an IC50 value of 1 mM. This activity is about three orders of magnitude greater than that of the monomer. The structure of this neoglycoconjugate can be altered to attach biotin. The resulting multivalent ligand provides a way to stain the surface of
192
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS HO HO HO OH AcHN O O
HO HO HO
O +
HO HO HO
O
H N
H N NHAc
O
CO2tBu
NHAc
HN i
HO HO HO
O
NHAc
O (CH2)n NH
NH-CO-(CH2)n-NH2 AcHN
50
O
CO2tBu
O
NH NHAc
H N
O
HO O H HO N HO t CO2 Bu AcHN O
ii,iii
NH NHAc
O
N H HN
NH-CO-(CH2)n
O
O O
HO HO HO
n = 4, 5
O iv,v,vi
(CH2)n NH AcHN
O
O O
HO HO HO
NH NHAc
OHOH AcHN HO
HO
CO2- OH OH O O HO O OH O
O
AcHN OH
OH
OH COHO 2HO O O O O AcHN O OH OH OH HO
O
H N NHAc
HO OH NH-CO-(CH2)n
O
OH
O
H N O
N H HN
tBu
CO2
O
51 (n = 4, 5)
(CH2)n NH
OHOH AcHN OH
OH CO2-OH HO O O O O AcHN O OH OH OH HO
O
O
O O
NH NHAc
OH OHOH reagents and conditions: i) DMF, DCC, HOBt; ii) TFA, 0oC; iii) 50, DCC, HOBt, DMF; iv) UDP-Gal, galactosyl transferase, pH 7.5; v) CMP-sialic acid, α(2,3)-sialyl transferase, pH 6.5; vi) GDP-fucose, fucosyl transferase, pH 6.5.
Figure 4.28 Chemoenzymatic synthesis of trivalent sialyl Le x constructed on a peptide sca¤old.
endothelial cells expressing E-selectin. Such cells are colored in the presence of bound biotin-presenting multivalent SLe x and Texas red-linked avidin. 4.1.13.4 Liposomes Displaying Sialyl Lewis x. Liposomes serve as an e¤ective sca¤old for the multivalent presentation of selectin ligands. DeFrees et al. [458] and Allen et al. [459] reported a phospholipid molecule terminated with sialyl Le x on its distal end. As shown in Figure 4.30, the sialyl Le x moiety is tethered via poly(ethylene glycol) (PEG), which is long and flexible. The incorporation
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
193
O HO HO HO AcHN
O
O OH OH
O
HN O OBn BnO O O O O OH
HN O
Me O
NH2 NHAc
+
O
NH
O
NH
HO
OBn BnO OBn
O O
i-iii
NH
Me NH O
O
OH
HN O
HO HO
OH HO2C OH HO O O O O AcHN O OH OH OH
H O N NHAc O HN OH Me HN OH O OH HO OH O NH HO HO2C OH O NH O HO HO OH O O O O O O AcHN NH N HO O OH OH OH NHAcH HO HO Me NH O HO O AcHN NHAc OH OO O O HN N O O OHOH H H CO OH OH O 2 OH HO OH O
52 reagents and conditions: i) HATU, HOAt, DIPEA; ii) H2, Pd/C, MeOH, dioxane, AcOH; iii) NaOH, H2O, MeOH, pH 10.6.
Figure 4.29 Synthesis of a trivalent sialyl Le x built on cyclic oligopeptide.
of a PEG spacer is intended to minimize potential nonspecific protein–ligand associations. Liposomes averaging 100 nm in diameter are prepared by forced filtration of a mixture of 54, cholesterol, and phospholipid through membrane filters. The liposomes that present 0.5 to 5 mol% of 54 block the binding of HL60 cells to immobilized E-selectin with an IC50 value of 0.2 mM. This activity represents a 5000-fold more potent inhibition than that of the native sialyl Le x oligosaccharide, as well as about a 750-fold greater inhibition than that of a nonlipidated derivative of sialyl Le x (53). This enhancement in inhibitory activity is attributed to multivalent interactions between E-selectin and the multivalent presentation of sialyl Le x . Stahn et al. [460] reported a separate study that shows assay-dependent inhibition of E-selectin activity by liposome-based SLex ligands. For example, in an assay that examines the ability of cells to bind to anti-SLe x antibody in solution, liposomes displaying SLe x ligands inhibit antibody binding more e¤ectively than monovalent SLe x by seven orders of magnitude. The same liposomes inhibit the binding of cells to immobilized E-selectin by five orders of magnitude. In addition to the functional groups required for E-selectin recognition, the conformation of SLe x carbohydrates bound to E-selectin is considered an important factor when designing SLe x mimics [461]. Wong et al. [462] designed a fucosyl-containing glycopeptide (55) as a SLe x mimic (Figure 4.31). It shows a
194
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OHOH NaO2C OH OH OH HO OH AcHN O O O O O OH O OEt OH O O OH OH NH O OH H3 C OHOH
PEG Liposome
SLex
OAc OAc MeO2C OAcOAc AcHN O O OAc OAc O O HO OAc
OAc O
OAcOAc
i,ii,iii
O
O
NH2
OAc
~100 nm
OAc OAc MeO2CAcO AcHN O OAc OAc O
iv,v
OH O
OAcOAc O
O
OAc
OEt
O O O O OH NH O OH H3 C O OHOH
OH OH O OH O
OH O
O O
OH O
OH NH O OH H3 C O OHOH
H N
OEt + HS
O n
O
O Br
N H
vi
OAc O
O O
NH2
OH
OHOH NaO2C HO AcHN O OH OH O
O
OAc NH O OH H3 C O OHOH
OEt 53
OHOH NaO2C HO AcHN O O OH OH
OAc
H N
O
O
O P O O-
O O C17H35 C17H35
O O
n = 42-48
OHOH O
O
OH O N H
OEt
54 H N
S O
O
O n
H N O
O
O P O O-
O O C17H35 C17H35
O O
reagents and conditions: i) p-Nitrobenzoyl chloride, NaHCO3, CH2Cl2; ii) tri-O-benzyl-α/β-L-fucopyranosyl fluoride, AgClO4, SnCl2, TMU, CH2Cl2; iii) H2, Perlman's catalyst, MeOH, H2O; iv) NaOMe, MeOH, H2O; v) bromoacetic anhydride, EtOH, H2O, NaHCO3; vi) Na2HPO4, EDTA, pH 7.2.
Figure 4.30 Liposome presenting multiple copies of sialyl Le x ligand on its surface tethered through PEG linker.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES E-selectin recognition units HO OH O OH HO HO AcHN
-O2C HO OH O
O
OH OH
NHAc
O O OH HO O
-O
O OR
2C
OH OH H3 C O OH OH O CH3 OH O NH CO2Et N H O 55
Sialyl Lewis x
BnO2C
iii
HO2C
iv
HO2C
OBn OBn H3C O OBn OBn O CH3 OH O OH NH N O H O OH OH H3C O OH OH O CH3 OH H O N NH N O H O OH OH H3C O OH OH O CH3 OH H O N NH N O H O 56
195
H2N
O i,ii
O
O
N3 3 HO2C
OH OH H3C O OH OH O CH3 OH H O N NH N O H O
O
NH2 3
H N 3
O
H N 3
O O HO
n reagents and conditions: i) EDC, HOBt, CH2Cl2; ii) H2, Pd(OH)2/C, EtOH, H2O, dioxane, AcOH; iii) di-yne-acid NHS ester, Et3, DMF; iv) di-yne acid, HEPES buffer, sonication; then hν, 0oC.
Figure 4.31 Synthesis of sialyl Le x mimetic and its conversion to polymerized liposome.
binding a‰nity to E-selectin with an IC50 value of 0.5 mM, an activity equipotent to sialyl Le x [462]. When 55 is derivatized as a distal group at the end of di-yne-incorporated lipid, the resulting lipid can be converted to polymerized liposome (56), which displays 55 on its surface. This polymerized liposome shows enhanced inhibitory activity to E-selectin with an IC50 of 30 mM. Its activity represents about a 16-fold enhancement over 55. 4.1.13.5 Polyvalent Polymeric Sialyl Lewis x. A linear polymer can be used as a sca¤old to present multiple copies of sialyl Le x on its side chains, as shown in Figure 4.32. Thoma et al. [463] reported such a synthetic glycopolymer con-
196
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS Cl NH2
H N
O N H
NH2
NH2
O
H N O
N H
60
O
NH2
NH
O
O
H N
O
O
H N
i N H
HN
HN
N H
O
O
O
60
NH
O
Cl
Cl
Cl
HO OH O OH HO AcHN
OH
-O2C HO OH O
OH OH
ii,iii
O
O O OH HO O
O HO
S OH
S
N H
H N
57 SLex-thiol (20 mol%)
OH
O
NHAc O O
NH
HN
O
H N
O
O N H
O
S HN
N H
O
O
OH
O
60
NH S
OH OH
reagents and conditions: i) chloroacetic anhydride, 2,6-dimethylpyridine, DMF, 0oC; ii) sialyl Lewis x thiol (20 mol%), DBU, DMF; iii) excess thioglycerol, DBU, DMF
Figure 4.32 Synthesis of polyvalent poly(lysine) presenting sialyl Le x as a side chain.
sisting of commercially available poly(lysine) containing on average 240 lysine monomers per polymer molecule. Its amine-terminated side chains are derivatized with chloroacetyl groups, which then react with sialyl Le x -terminated alkanethiol groups for covalent attachment. Varying the ratio of sialyl Le x thiol to the pendant chloroacetyl group on the polymer chain controls the sidechain density of sialyl Le x . Such a method leads to synthesis of 57, which contains about 20 mol% of sialyl Le x relative to the total number of side chains composed of glycerol and sialyl Le x . However, this glycopolymer shows little inhibitory activity to E-selectin at 0.1 mM. The E-selectin activity improves on the use of a ligand that binds more tightly than sialyl Le x [464]. For example, sialyl Le x mimic 58 (Figure 4.33) shows a high a‰nity to E-selectin, with an IC50 value of 36 mM. This value represents a 30-fold enhancement over sialyl Le x [465]. When this ligand is converted to a polyvalent polymeric ligand (59, 20 mol %), the polymer shows an IC50 value of 2 mM and an 18-fold higher a‰nity to E-selectin than that of the monomer control (58). The size of such a glycopolymer influences the Eselectin activity. Thus, an analog of 59 (20 mol%; n ¼ 1200), which is composed of a greater number of monomer units, shows an IC50 value of 0.2 mM.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
197
HO OH O OH -O2C HO OH O
O O O OH HO
O
58 HO OH O OH
HO OH O OH
-O2C HO OH
-O2C HO OH O
O
O O
OH
i
O
O
O NH2
ii,iii
O O
O NH
OH
SH
O HO OH O OH -O2C HO OH O
O
O O
O NH
OH
OH S
O
H N
59 SLex mimetic (5 to 100 mol%)
O S
HO OH
NH
HN
O
H N
O
O N H
O
S HN
N H
O
O
OH
O
n = 60 or 300
NH S
OH OH
reagents and conditions: i) thiobutyrolactone, Et3N, MeOH; ii) chloroacetylated poly(lysine), DBU, DMF; iii) thioglycerol, DBU, DMF.
Figure 4.33 side chain.
Synthesis of polyvalent poly(lysine) presenting mimics of sialyl Le x as a
The density of sialyl Le x mimetics also influences the activity such that the density of 59 responsible for the highest activity (IC50 ¼ 0.05 mM ) is observed in the range 35 to 50 mol% (n ¼ 1200). This optimized activity represents roughly a 50,000-fold improvement relative to sialyl Le x . Glycopolymers containing 58 at a density outside the optimum range show lower activity. Sialyl Le a also serves as a ligand that binds to E-selectin. Weitz-Schmidt et al. [466] reported the synthesis of a polyvalent ligand that displays sialyl Le a carbohydrates (Figure 4.34). It is prepared by reacting a derivative of sialyl Le a with the activated ester of poly(acrylic acid), which leads to a poly(acrylamide)based ligand (60). A glycopolymer containing a 20 mol% density of sialyl Le a binds tightly to immobilized E-selectin with an IC50 value of 2.4 mM. The E-
198
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS HO OH O OH OH -O2C HO OH HO O O O O O O AcHN OR OH OH OH AcHN OH
Sialyl Lewis a
HO OH O OH -O2C HO OH HO HO O O O O O AcHN OH OH OH AcHN OH
O
O
O OR
n O OR
+
O O
i) DMF, rt NH2
ii) 2-ethanolamine
R = 4-nitrophenyl NO2 HO OH O OH OH COHO HO HO 2OH O O O O O AcHN OH OH OH AcHN
O O
n NH O HN
O HN
OH
OH
O
60 (χSLea = 2 - 20 mol%)
Figure 4.34 Structure of poly(acrylamide)-based polyvalent sialyl Le a .
selectin a‰nity is a¤ected by the SLe a density in the polymer chains such that a lower density of sialyl Le a , such as 2 or 5 mol%, leads to inactive ligands. 4.1.13.6 Sialyl Le x –Binding Multivalent Receptors. In designing a nonnatural receptor that mimics E-selectin, a multivalent strategy may find success. Using phage display, Kwon et al. [467] that identified a 12-amino acid peptide (AHWIPRYSSPAT) that binds weakly to sialyl Le x -conjugated bovine serum albumin, with a K d value of >1 mM. When this peptide is tethered to a lysinebased sca¤olding and displayed in multimeric form, its a‰nity to BSA-sialyl Le x conjugate increases 14-fold, with a resulting K d value of 70 mM for a dimer, [AHWIPRYSSPAT]2 K. The a‰nity increases 10,000-fold, with a Kd value of 0.1 mM for a tetramer, [[AHWIPRYSSPAT ]2 K]2 K. This example illustrates that the valency of the carbohydrate-binding receptor plays a major role in enhancing the binding a‰nity to its cognate multivalent ligand. 4.1.14
L-Selectin
L-selectin, one of numerous carbohydrate-binding proteins located on the surface of leukocytes, is involved in the binding and rolling of leukocytes on endothelial cells [468] (Figure 4.35). Physiological molecules that bind to Lselectin include mucinlike glycoproteins, such as the glycosylated cell adhesion molecule-1 (GlyCAM-1), PSGL-1, and CD34 [469,470]. These glycoproteins
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
199
Leukocyte
rolling
L-selectin
Sialyl Lewis x E-selectin
Endothelial cell
HO OH OH AcHN HO
HO
NHAc OH OH
O
CO2O OH O HO OH OH OH HO O OH O O OH OH OH O OHO O OH HO O OO NHAc HO HO O NHAc O OH OH O O OH AcHN HO O HO O HO CO2-
OH CO2OH OH OH O O OO OH HO O HO OO HO OH O NHAc HO HO NHAc O O O O HO OH HO HO OH OH O O NHAc O O AcHN O OH O O NHAc O O HO OH OH HO O O OR -O2C O O HO HO O OH HO AcHN O O O O 61 O O OH AcHN OH OH HO O HOHO OH O OH O O HO NHAc OH O OH O O O HO -O2C 62 O O HO HO AcHN O O HO OH O OH AcHN OH O OH OH O HO O HO
HO HO
NHAc O OR
O OH O
-O2C O HO HO
OH
OH NHAc
Figure 4.35 Adhesion and rolling of leukocyte on an endothelial cell mediated by l-selectin and its ligand on a cellular interface, and the structure of branched multivalent sialyl Le x .
200
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
present on their surface multiple copies of anionic saccharide epitopes, including sulfated (sialyl) Le x and Le a . These sialyl carbohydrates serve as ligands to L-selectin. This multivalent display is probably the basis for the high-avidity interaction with L-selectin on leukocytes. For example, a divalent cluster of sialyl Le x (61) blocks selectin-mediated lymphocyte–endothelium adhesion with an IC50 value of 150 nM (Figure 4.35). This activity is considerably more than that of a monovalent sialyl Le x , which has an IC50 value greater than 10 mM [471]. When the valency of sialyl Le x is increased to 4, as in a branched sialyl Le x (62), the molecule blocks selectin-mediated adhesion much more effectively, with an IC50 of 5 nM [472]. As a naturally occurring divalent ligand for L-selectin, 63 is composed of two sialyl Le x saccharides linked in a linear manner (Figure 4.36). The chemical synthesis of this ligand was reported by Nicolaou et al. [473]. 4.1.14.1 Divalent Sulfated Lactoside. The a‰nities of multivalent mimics of natural L-selectin ligands can readily be modulated, first, by controlling distance and orientation between saccharide units, and second, by varying the nature of the sca¤old. Kiessling et al. [474] reported the synthesis of a class of multivalent ligands that binds L-selectin (65). These molecules display 3 0 sulfoallyllactoside (64), a simple analog of sialyl Le x , through asparagines Lex
Lex
HO OH O OH HO
OH
OHOH
-O2C O
AcHN
NHAc OHOH O O
O O OH HO O
O
OH OH
HO OH O OH NHAc O(CH2)6CO2But
O O OH HO
O
O
63
BnO OBn O OBn BnO MeO2C AcO OBn BnO O O O O O AcHN OBn OBn OAc
BnO OBn O OBn NPhth O F
AcHN
O OBn OBn
O
O OAc
O O
i
OHOBn HO
O OH
OBn
BnO OBn O OBn BnO BnO MeO2C AcO OBn
+
O O
NHAc t O O(CH2)6CO2Bu OBn
BnO OBn O OBn NPhth OHOBn O O O
OBn
OH
ii-v O O
NHAc t O O(CH2)6CO2Bu OBn
reagents and conditions: i) AgOTf, HfCp2Cl2, CH2Cl2; ii) LiI, pyridine, 120oC; iii) hydrazine hydrate, MeOH, benzene; iv) Ac2O, MeOH, CH2Cl2; v) H2, Pd/C, MeOH, rt, 2d.
Figure 4.36 Synthesis of sialylated divalent Lewis x.
63
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES HO OH O O HO HO OH
OH O O OH
HO OH O O NaO3SO HO OH
HO OH O
i,ii
OH O O OH
O NH2 +
AcHN
N H O
CH3 H N n O
HO
64
OH O O OH
O HO OH
NaO3SO
O
iii,iv,v
CH3
N H O
201
CONH2
vi
HO n = 1, 3
O AcHN HO OH O
NaO3SO
OH
O HO
OH HN O O OH
N H O
CH3 H N n O HN
O N H O
CH3 CONH2 HO O O HO
OH O
HO O
OSO3Na
HO OH
65 (n = 1, 3) reagents and conditions: i) Bu2SnO, MeOH; ii) SO3•NMe3, THF; iii) O3, MeOH, -77oC, then PPh3; iv) BnNH2, HOAc, BH3•pyr, MeOH, H2O; v) Pd(OH)2, H2; vi) HBTU, HOBt, DMF, rt.
Figure 4.37 Synthesis of sulfated bivalent lactoside as l-selectin ligand.
linkages on the framework of an alanine peptide (Figure 4.37). By varying the size of the peptide sca¤old of 65, the distance between the sulfated ligand units can be adjusted. 4.1.14.2 Neoglycopolymers Presenting Sialyl Lex . The glycoprotein, GlyCAM-1, is a heavily O-glycosylated mucin. GlyCAM-1 displays multiple copies of certain saccharide epitopes, such as 6- or 6 0 -sulfated sialyl Le x , that are recognized by L-selectin. Sanders et al. [475] reported the synthesis of multivalent mimics of natural GlyCAM-1. The mimics are prepared by polymerizing sulfated Le x monomers in aqueous solution via ROMP. The reaction is catalyzed by a ruthenium metal complex (Figure 4.38). The ROMP reaction generates neoglycopolymers such as 66 and 67, which present 15 copies of sulfated Le x ligand per polymer chain. This synthetic method is versatile, since it works well in water, and with substrates containing unprotected polar and charged functionalities. It also enables the synthesis of neoglycopolymers of various size by varying the ratio of initiator to monomer. These glycopolymers actively inhibit the binding of L-selectin to heparin, with IC50 values of 39 mM (580 mM per Le x ; 66) and 35 mM (520 mM per Le x ; 67). They are more active than sialyl Le x monomers, which show an IC50 value of 3 mM. Glycopolymer 66, which displays 3 0 ,6-disulfoLe x , potently blocks L-selectin-mediated cell rolling when evaluated under conditions of physiological shear flow, with an IC50 value of 15 mM per sialyl Le x . It is more potent than monovalent sialyl Le x , which re-
202
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS HO HO AcHN
OHOH
-O2C O
OH OH
O
O
OSO3O OR
OO
OH O OH OHOH
H 3C
NHAc
GlyCAM-1 epitope
Ph O
HO OH -O
O O O OH H3C O OH OHOH
3SO
OSO3HN O O OH
PCy3 Ph Cl Ru Cl PCy3
n = 15
HO OH -O
O O O OH H 3C O OH OHOH
3SO
DTAB, DCE pH 6, 60oC
OSO3HN O O
O
OH 66
Ph HO OSO3 -O
O O OH O H3C O OH OHOH
3SO
O OH HN O O OH
PCy3 Ph Cl Ru Cl PCy3 DTAB, DCE pH 6, 60oC
HO
OSO3-
O O O OH H3C O OH OHOH
-O SO 3
n = 15 OH HN O O OH
O
67 x
Figure 4.38 Synthesis of multivalent disulfo Le neoglycopolymer as l-selectin ligand.
mains weakly active, with an IC50 value of 2.5 mM. In contrast, the second polymeric ligand 67, presenting 3 0 ,6 0 -disulfoLe x , shows no inhibition at all against cell rolling. This example illustrates that under shear flow, the avidity of multivalent, sulfated Le x to L-selectin is a¤ected not only by multivalent ligand presentation but also by the display pattern of sulfate anions along a polymer framework. The neoglycopolymer 66 shows not only tight binding to an L-selectin array but also functional activity of biological significance. When it is incubated with human neutrophils, it induces shedding of the extracellular portion of the Lselectin protein from the cell surface [476,477]. As a result, the neoglycopolymer decreases the density of L-selectin on cell surfaces, which is expected to decrease the leukocytes’ adhesion ability. A neoglycopolymer that contains a fluorescent probe allows the visualization of polyvalent ligands interacting with L-selectin on cell surfaces. In Figure 4.39 is shown as an example of the synthesis of a fluorescence-capped neoglycopolymer (68), which possesses multiple copies of 3,6-disulfogalactoside on its side chains [478]. Upon interacting with Jurkat cells, this neoglycopolymer binds to localized sites on cell surfaces. The resulting patches are visualized by adding a fluorescent, anti-L-selectin antibody. Cells lacking L-selectin do not bind 68. The binding pattern of 68 to
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
203
O HO OH O O HO OH
N3
PCy3 Ph Cl Ru Cl PCy3
HO OSO3Na O O NaO3SO OH
i,ii,iii
Ph HO OSO3Na HN O O NaO3SO OH
v
NH2
O
RuLm n O
n HO OSO3Na HN O O NaO3SO OH
O
O
O
O
MeO
TMS
O
TMS
vi,vii O
O HO2C O
Ph n HO OSO3Na HN O O NaO3SO OH
O
end-capping
O Ph
HO OSO3Na HN O O NaO3SO OH
iv
O
O
O
S N H
N H
N H
OH Fluorescent probe
O 68
reagents and conditions: i) Bu2SnO, MeOH, heat; ii) SO3•Pyr, pyridine; iii) H2, Pd(OH)2/C; iv) (±)-norbornene 5-carboxylic acid NHS ester, N-methylmorpholine, DMF; v) dodecyltrimethyl ammonium bromide (DTAB), bis-tris buffer, pH 5.9, dichloroethane, 40oC; vi) 50 mM NaOH, 60oC; vii) 5-((5-aminopentyl)thioureidyl) fluorescein, EDCI, NHS, H2O.
Figure 4.39 Synthesis of end-capped neoglycopolymer carrying multiple sulfated galactosides and a fluorescent probe attached at its distal end.
L-selectin on leukocyte surfaces is similar to that observed upon adhesion of multivalent sialyl Le x to activated endothelial cells that express E-selectin [479]. 4.1.14.3 Poly(acrylamide) Sca¤olds That Present Sulfated Le x . As a polymer sca¤old, poly(acrylamide) allows the polyvalent display of 3 0 -sulfo-Le x for Lselectin binding. Sasaki et al. [480] reported examples such as a terpolymer that presents both a 3 0 -sulfated Le x mimic (side chain density ¼ 7%) and 6-sulfo-GlcNAc (6%) as side chains. This polymer blocks the binding of Lselectin to SLe x with an IC50 value of 3 mM per glycoside. It is more active than the free ligands, which remain inactive at 50 mM. 4.1.14.4 Poly(lactosamine) Sca¤olds That Present SLe x . A branched poly(lactosamine) is used as a sca¤old by Renkonen et al. [481] in their design of a nanomolar inhibitor of lymphocyte adhesion. This glycopolymer-based ligand, which is readily synthesized with chemoenzymatic methods, comprises four
204
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
P-selectin
+++
+++
Tyr-OSO3-
Tyr-OH
SLex
SLex
PSGL-1 (peptide 9 to 18) Kd = 10-3 M
Kd = 10-8 M
HO
OH CO2-
AcHN HO
O
OH OH OH OH O OH
O
HO
O HO
HO
O - OH CO2OH
HO
AcHN
OO HO
O OH OH
O
NHAc OH O
O OH
O
O NHAc O
Gln-Ala-Glu-Tyr-Glu-Tyr-Leu-Asp-Tyr-Asp-Phe-Leu-Pro-Glu N H OSO3OSO3- OSO3-
H N Glu-Pro-Pro O
P-selectin epitope of PSGL-1
Figure 4.40 Interaction of P-selectin and PSGL-1 (P-selectin glycoprotein ligand-1).
copies of SLe x attached to the backbone of poly(LacNAc) in a b-1,3 0 or b-1,6 0 orientation. 4.1.15
P-Selectin
As a natural ligand to P-selectin present on human neutrophils, P-selectin glycoprotein-1 (PSGL-1) plays a primary role in leukocyte recruitment during inflammation [482,483]. It is an O-glycosylated, mucinlike molecule carrying multiple copies of sialyl Le x residues, which serve as a minimal recognition motif to P-selectin (Figure 4.40). Optimal binding by PSGL-1 occurs in cooperation with several O-sulfated tyrosines that are located proximally to the sialyl Le x , which is attached to threonine. These sulfated tyrosines contribute to the enhanced a‰nity of PSGL-1 to P-selectin by enabling bivalent recognition between the ligand and P-selectin. Indeed, the sulfated glycopeptide binds to Pselectin with a Kd value of about 108 M—approximately 105 more tightly than the unsulfated glycopeptide ligand, which has a Kd value of about 103 M [484]. Koeller et al. [482] reported the synthesis of a PSGL-1 binding determinant by combining chemical solution and solid-phase methods and an enzymatic glycosyltransferase reaction. The method provides a complex sialyl Le x attached heptapeptide (69) (Figure 4.41).
205
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
AcHN OAc AcO AcO O O O AcO AcO AcHN O
Rink amide resin H2 CH3
N-Glu(But)-HN i-iv
OH O O HO AcHN O
NH-Glu(But)-HN O
O AcHN HO AcO O HO
v,vi CH3
Ac-Tyr-Asp(But)-Phe-Leu-Pro-Glu(But-HN )
OH
FmocHN
AcHN OAc AcO AcO O O O AcO AcO AcHN O
vii,viii,ix CH3 NH-Glu-NH2
Ac-Tyr-Asp-Phe-Leu-Pro-Glu-HN O
HO OH OH O OH -O2C HO OH HO NHAc OH O O O O O O O O AcHN HO OH HO OH OH AcHN O 69
CH3 NH-Glu-NH2
Ac-Tyr-Asp-Phe-Leu-Pro-Glu-HN O
reagents and conditions: i) HBTU, HOBt, NMM, DMF; ii) morpholine, DMF; iii) Fmoc-AA-OH, HBTU, HOBt, NMM, DMF; iv) repeat ii and iii, then Ac2O, Pyr; v) TFA, H2O, EDT; vi) NaOH, MeOH; vii) β1,4-galactosyl transferase; viii) α2,3-sialyl transferase; ix) α1,3-fucosyltransferase.
Figure 4.41 Synthesis of sialyl Le x -attached heptapeptide as P-selectin-recognition glycopeptide epitope.
4.1.15.1 Sialyl Lewis x-RGD Conjugates. A heterobivalent glycoconjugate comprised of a sialyl Lewis x moiety attached to a tripeptide, Arg-Gly-Asp (RGD), provides two recognition elements. One element recognizes selectin and the other recognizes the integrin receptor. Depending on the spacer length and interligand orientation, the RGD motif can bind to an accessory site located close to the SLe x binding site in P-selectin. Two typical RGD-sialyl Lewis x ligands (70 and 71) are designed based on such a notion (Figure 4.42). With an IC50 value of 26 mM, the ligand 70, tethered with short alanine spacer, actively inhibits P-selectin-mediated cell adhesion more potently than sialyl Le x [485]. The second ligand, 71 with a longer spacer, binds to immobilized Pselectin with a Ka value of 6.6 10 7 M 1 [486]. This a‰nity represents about a 100- to 1000-fold enhancement over either sialyl Le x (K a ¼ 8.8 10 5 M 1 ) or RGDS (K a ¼ 9.7 10 4 M 1 ) alone. In the presence of both P-selectin and intergrin b1, 71 interacts with the two di¤erent receptors simultaneously, thus forming a ternary complex. 4.1.15.2 Copolymers Presenting Sialyl Le a Residues and Sulfated Tyrosines. Synthetic polymers possessing multiple copies of sialyl Le a and O-sulfated tyrosine in their side chains closely mimic the natural PSGL-1 ligand. Pochechueva et al. [487] reported the synthesis of a molecule in which poly(acrylamide) presents sialyl Le a along with sulfated tyrosine as a secondary recognition motif of P-selectin (Figure 4.43). One such glycopolymer (72) is a potent inhibitor of P-selectin, with an IC50 value of 0.25 mM per carbohydrate. Such an inhibition is 480 times greater than that of 73, which does not carry
206
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OHOH OH O OH -O2C HO OH HO NHAc CH3 O O O NH O O O O N AcHN OH HO H OH OH O O
O
H N O
NH3+
N H
O-
NH
70 (sLex-Ala-Asp-Gly-Arg)
OHOH OH O OH -O2C OHOH HO NHAc O O O O O O O AcHN OH HO OH OH
H2N
O +H
3N
N H
H N O
+
H N
NH2
O
H N
N H
O
H2N
+
N H O
O
NH
OH
O
OO
O-
NH2
71 (sLex-spacer-Lys-Gly-Arg-Gly-Asp-Ser)
Figure 4.42 RGD-linked sialyl Le x glycoconjugates.
sulfated tyrosine residues. With an IC50 value of 1.3 mM, poly(acrylic acid)based polyvalent sialyl Le a (74) is far better than poly(acrylamide)-based ligand 73. The enhanced a‰nity from the anionic polymer is attributed to the involvement of carboxylate side chains in multivalent binding to P-selectin sites, in a role similar to that of sulfated tyrosine. 4.1.15.3 Neoglycopolymers Presenting Sulfated Galactosides. Although sLe a is a P-selectin ligand, its complex structure makes large-scale preparation di‰cult. In contrast, mimics of P-selectin ligand are relatively simple in structure, but bind weakly. However, these can be manipulated into multivalent molecules for tighter binding. Manning et al. [488] reported the synthesis of a polyvalent neoglycopolymer that presents sulfated galactosides as side chains (Figure 4.44). For example, 75, which presents the 3,6-disulfogalactoside ligand, inhibits cell adhesion to immobilized P-selectin with considerable activity, as reflected in an IC50 value of 167 mM per galactoside. In blocking P-selectin-cell adhesion, it is about 20 times more e¤ective than sialyl Le x , which has an IC50 value of 3.4 mM. However, a neoglycopolymer (76) carrying monosulfated galactosides at the 3-position shows only weak inhibitory activity, with an IC50 value of about 1 mM. This example illustrates that high-a‰nity binding to Pselection requires multiple 6-sulfogalactosides, a structural feature consistent with that of the GlyCAM-1 ligand, which displays multiple copies of sulfated sialyl Le x at the 6-position of the galactoside determinant [489]. 4.1.15.4 Polymerized Liposomes Presenting Mimetics of Sialyl Lewis x. The liposome serves as an excellent tool for the multivalent presentation of Pselectin ligands on the outer surface. Spevak et al. [490] (see also Bruehl et al.
207
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES P-selectin
P-selectin
+++
+++
polymer
SLex
Tyr-OSO3-
HO OH O OH OH CO2-OH OH HO O O O O O O AcHN O OH OH OH AcHN
i-iii
OH
+
n O RO
O RO
O
O
NH2
Sialyl Lewis a-O(CH2)3NH2 R = 4-nitrophenyl NO2
HO OH O OH OH CO2-OH OH HO HO O O O O O AcHN OH OH OH AcHN
O
n O
NH O HN
O HN
O
HO2C OH
72 (χSLea = 15 mol%, χsulfo-tyr = 20 mol%) 73 (χSLea = 20 mol%, χsulfo-tyr = 0 mol%)
OSO3HO OH O OH CO2-OH OH HO = 20 mol%) O O O O O AcHN OH OH OH AcHN HO HO
74 (χSLea
O O
n NH O -O
O
-O
O
reagents and conditions: i) Et3N, DMF; ii) tyrosine O-sulfate; iii) 2-ethanolamine, rt
Figure 4.43 Bivalent interaction of P-selectin and synthetic polyvalent sLe a .
Ph
Ph n = 17
HO OSO3Na HN O O NaO3SO OH
75
O
n = 17 HO OH HN O O NaO3SO OH
O
76
Figure 4.44 Sulfated neoglycopolymer as P-selectin ligand.
208
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS P-selectin recognition units HO OH O OH
HO OH O OH HO
HO
-O2C HO OH O
AcHN
O
OH OH
-O2C HO OH
NHAc
O O OH HO O
O
O OR
Sialyl Lewis x
O O OH HO O
OH O OR
O
O O OH HO O
OH O OR
i) di-yne acid, sonication OH Ac O N S
ii) hν (254 nm), 0oC H N O O
HO OH O OH -O2C HO OH O
O HO O OH HO Lactoside
Sialyl Lewis x mimic (77)
HO OH O OH -O2C HO OH
HO OH HO
O O OH HO O
HO O
OH O
N Ac
S
N H O
78 (5 mol%)
HO
n
polymerized liposome
Figure 4.45 Polymerized glycoliposome presenting sialyl Le x -mimics.
[491]) reported the creation of a polymerized liposome presenting 5 mol% of a sialyl Lewis x mimetic, such as 77 and lactoside (Figure 4.45). A glycoliposome (78) potently inhibits P-selectin adhesion to cells, with an IC50 value of 2 nM, and its level of activity decreases by either increasing or decreasing the surface density of the carbohydrate mimetic. Another glycoliposome, 79, presents lactoside on its surface and is also active, with an IC50 value of 15 nM. However, its activity is sevenfold weaker than that of 78. Overall, these polymerized glycoliposomes are far more active than monovalent 77 or polymerized liposomes displaying no carbohydrate, which have IC50 values greater than 5 mM.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
4.1.16
209
Lectins
Lectins are a family of proteins that recognize specific carbohydrate moieties attached to glycoproteins and glycolipids [328]. Being ubiquitous proteins found widely in plant, animal, and bacterial cells, lectins are involved in diverse cellular events, such as cellular recognition, cell–cell adhesion, bacterial colonization, and signal transduction [20,492]. An example of a well-characterized plant lectin includes concanavalin A (Con A), a mannose-binding protein with a molecular weight of 29 kDa. Con A monomers assemble into various highorder aggregates whose dominant species are controlled by pH [493]. For example, Con A exists predominantly as a tetramer at pH 7, with four mannose binding sites per tetramer. These binding sites are separated from each other by ˚ [494]. Similar oligomeric structures are also observed in soybean 65 to 70 A lectin isolated from Glycine max (SBA), which recognizes galactoside ligands and cross-links multiantennary oligosaccharides that terminate in galactoside residues [495]. Isolectins are composed of many di¤erent subunits. For example, Gri¤onia simplicifolia-1 (GS-1) is a tetrameric lectin comprising lectin monomers A and B. The A subunit binds specifically to a-d-GalNAc and the B subunit binds to a-d-Gal [496]. Through various combinations of the two subunits, the isolectins exist as a mixture of five di¤erent tetramers (A4 , A3 B, A2 B2 , AB3 , B4 ), each of which should display unique a‰nity to multivalent carbohydrates present on cell surfaces. 4.1.16.1 Oligovalent Mannosides Binding to Con A. To study the multivalency e¤ects from Con A, Dimick et al. and Corbell et al. [497] synthesized dendritic mannosides whose sugar ligands are displayed through a rigid aromatic sca¤old (Figure 4.46). A divalent ligand (80) inhibits Con A–mediated agglutination of red blood cells with an IC50 value of 380 mM, an activity only twofold greater than that of methyl a-mannoside. Increasing the ligand valency enhances the inhibitory activity, as illustrated by a tetravalent molecule (81) whose activity is 31 times higher than that of methyl a-mannoside. Such enhanced activity is not attributed to a favorable free energy of binding of 81 to Con A, since 81 shows a free energy of binding identical with that of methyl a-mannoside. Rather, the improved binding is driven by a large favorable entropy, with unfavorable enthalpy—conditions that are considered typical of aggregation. Therefore, as observed in an agglutination inhibition assay, the enhanced activity by a given tetravalent ligand is not necessarily related to increased a‰nity but to its ability to inhibit the formation of cross-linked lectins. 4.1.16.2 Trivalent Mannosides on a Rigid Sca¤old. A conformationally rigid sca¤old makes it possible to fix the distance between tethered ligands. A trivalent mannoside, 83 (Figure 4.46), is designed in such a sca¤old. The three mannose residues are appended to a well-defined macrocyclic lactone which ˚ of separation between adjacent mannosides in the extended conprovides 35 A
210
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
HO HO HO
HO HO
OH O
HO HO HO
OH OH O HO
NH
HO HO HO
HN
O
OH O
O
O
O
HO OH HO O HO
HO HO
O
O O
O
HN NH
O
NH
HN
O
N3 80
O
O
OH O O
N3 O 82
H N
OH OH
HN
O
HO HO HO
O
NH O
O
HO
81
O
O
O
OH OH
O OH
O O
HO HO HO
OH O O
O O
NH O
O
O H O
H
H
O
O
O O H
H O
83 HN
NH
O H O 35 Å O O O O
OH OH OH O OH
Figure 4.46 Structure of dendritic mannosides and a trivalent mannoside prepared on a macrocyclic sca¤old.
˚ sepaformation [498]. This interligand distance is smaller than the 65 to 70 A ration required for bridging mannose recognition sites within Con A tetramer. Hence, this trivalent molecule is likely to interact with multiple Con A tetramers rather than with a single tetramer. In an SPR study designed to measure the binding of Con A to a mannose-presenting glycolipid surface, a monovalent ligand (82) shows inhibitory activity, with a Ki value of 99 mM, a value close to that of methyl a-mannoside, which shows a Ki value of 65 mM. In contrast, the trivalent ligand 83 shows di¤erent modes of binding. At concentrations greater than 50 mM, it inhibits lectin binding; however, at concentrations less than 10 mM, it promotes lectin binding. Burke et al. [498] attributed this dual activity to the formation of soluble clusters between 83 and multiple Con A tetramers, a mechanism that allows some unoccupied saccharide sites of the lectin–
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
211
ligand complex to interact with the surface. According to other assays, 83 interacts with Con A at least 10 times more potently than does 82. 4.1.16.3 Bifunctional Multivalent Glycosides Binding to Con A. Fijimoto et al. [499] designed an octavalent glucoside, 84, built on a calix[4]arene scaffold to utilize multivalent interaction in host–guest complex formation. This calixarene-based glycoside acts as a bifunctional molecule: It presents a binding pocket for a guest molecule, such as fluorescent eosin Y, within a calixarene ring system, and it binds multiple glucoside ligands, which enable tight binding to Con A (Figure 4.47). For example, 84 binds to Con A immobilized on Sepharose gel with a K a value of 1 10 6 M 1 , a‰nity about 200-fold higher than that of methyl a-glucopyranoside. Using its hydrophobic cavity, 84 also makes a complex with eosin Y, with a K a value of 7.5 10 5 M 1 . When measured in the presence of eosin Y, 84 binds to Con A on gel with a slightly improved a‰nity, as demonstrated by the K a value of 2 10 6 M 1 . Such improved association is probably linked to the formation of a ternary complex, as shown in Figure 4.47. 4.1.16.4 Heptavalent Mannosides Linked to b-Cyclodextrin. In a separate report, Ortega-Caballero et al. [500] studied the inclusion ability and Con A binding of a dendritic heptavalent mannoside (85) designed with a b-cyclodextrin core (Figure 4.47). Using its cyclodextrin hydrophobic pocket, this multivalent ligand has the ability to form a complex with guest molecules, such as 2-naphthalenesulfonate, with a Ka value of 2.53 10 3 M 1 . In addition, it can inhibit Con A binding to mannan with an IC50 value of 67 nM in an enzyme-linked lectin assay (ELLA). The ability of this multivalent ligand to inhibit Con A binding is 17 times greater than that of methyl a-mannoside, a monovalent ligand. This and other examples [501–503] point to a potential application of bifunctional multivalent molecules as tools for the selective delivery of probes and drugs to clustered targets present on biological surfaces. 4.1.16.5 Mannosides Displayed on a Benzene- or Peptide-Based Dendrimer. Ashton et al. at UCLA [504] developed convergent synthetic routes that allow the synthesis of glycodendrimers based on a 1,3,5-trisubstituted benzenoid core that serves as a sca¤old for the display of 9 to 36 copies of mannoside ligands (Figure 4.48). An example of the dendritic mannosides is the 18-mer 86. These dendrimers are active in inhibiting the binding of Con A to yeast mannan in ELLA. Optimal potency is observed from 9- and 18-mer forms of 86, which are four times more active than methyl a-mannoside or a dendritic wedge. A second example of a mannoside-presenting dendrimer includes the 16-mer 87 (Figure 4.49), as reported by Page´ et al. [505] (see also Woller and Cloninger [506]). This dendritic ligand displays 16 mannosides appended to multiple branches of an oligolysine peptide. This 16-mer is identified as a potent inhibitor of Con A–mannan binding, with an IC50 value of 1.6 mM, representing a 578-fold (66-fold per mannoside) enhancement in a‰nity relative to methyl amannoside.
212
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS Con A tetramer Eosin Y
84 Glucoside
Host-guest complex Ka = 7.5 x 105 M-1
HO HO
84 R = (CH2)10CH3
HO HO
HO HO
OH O
OH O
O OH HO
OH O
O OH HO
HO HO
OH OH HO
O NH
O
OH OH H N HO O OH O
O OH HO
85
HO O
R
R
R
R
O
O
O O
HO
O
O OH OH HO N O HHO O HO HO
O
O
OH OH
OH OH
O OH
S
O OH HO
O HO
O HO
OH O OH O OH S O OH
HO HO HO
OH OH
OH OH OH
OH O
O OH OH
OH OH
O OH OH HO N O HHO O HO HO O OH OH HO NH O HO O HO HO
O
OH OHHN
S OH O S
O
O
HOHO HO
HO HO HO
O OH OH HO NHHO O O HO HO
OH OH H N HO O
O OH HO
O S O HO
HO OH
S O
HO
OOH
OH
HO O HO OH O O
S O HO
OH OH OH
OH OHOH
Figure 4.47 Formation of ternary complex from Con A, bifunctional glucoside, and a guest molecule; and the structure of dendritic glycoside built on calix[4]arene or bcyclodextrin sca¤old.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES AcO AcO AcO AcO AcO AcO
OAc O O
OAc O
AcO AcO OO AcO AcO O
HO O O
NH
N H
O
O N
AcOO AcO AcO O AcO AcO O O AcO AcOOAcAcO O
i,ii
O
NH2
+ HN O HN
O
OH O
NH
O
HO
O HO HO OH
AcO AcOOAc HO HO HO HO OH HO HO HO OH OH OH O O O O O OH O
O
HN
HOOH OH OOH O O OHHO OH OH O O OH O
HO HO HO
HN OH O
O
N HN
HO HO O O HO HO O HO O HO O HO OH
O
N
O O
NH
N H
O
OH O O OH HO OH O OH HO OH OH
O HN
86
O
OH OH O OH O OH
O
NH O
H N O
O
H N
O
NH
O O
HO O HO HO HO
O
NH
N
O
NH O
HO O
HO HOOH
O HO O
HO HO OH
O O HO
O O HO
OH HO OH
OO HO
OH OH OH
OH OHOH
reagents and conditions: i) DCC, HOBt, CH2Cl2, DMF; ii) NaOMe, MeOH.
Figure 4.48 Synthesis of mannopyranoside-containing dendrimer.
213
214
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS HO HO OH OH
HO HO HO OH
HO HO
O
O
OH OH
HOOHOH HN
O O
HN
S
O NH
O
N H
O
NH HN
O
O
HN
HN HO
HO HOOH
O O
S
O
O
NH
O
O
H N
HN NH
S
O
O
O NH HO
O
HN
H N
O N O H
O
N H
O
O
S
HO
O NH
NH
NH
O HO OH HO OH
O HO
OH OH OH OH
H N
S
HN O NH O S O HN
O
O
O
O
HO OH OH
H N
S
O O
O
S
O
OH
N H
HN
HN O
NH
HN
O
O
N NHH NH
O
HOOH OH
OH
O
O
O HO HO HOOH
O
NH
O
O
NH
O
NH
HN S
H N
H NH N O
S
NH
NH
N NHH
O O
O O
O
HN
S
O
NH
O
O
H O N N H O
S
N H
O
NH
OH O
NH
O
O
NH
NH H N
HN
O
O
N H
HOOH OH OH
O
S
O HN
HN O NH
O
O
NH
NH O S O
O
HO HO HO
HN O
O
OH
OH
O
S
HN O S
HO HO HO
O
O HO
OH OH OH
OH HO OH 87
Figure 4.49 Structure of lysine-based dendrimer presenting mannoside.
OH OH OH
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
215
Con A tetramer
~65 Å
glycoside ligand Neoglycopolymer 89
carbohydrate recognition domain
TESO O TESO TESO TESO
+ OH
H O
O
O
H O
i.ii
H O
HO OH HO
O
O HO
H O
H O
n OH
O O
OH
OH O
OH
88
O
HO OH HO
OH OH
OH O
iii
H O
O O
HO
O
OH
89 O
O H O HO OH HO
OHX O
H O
n OH
O O X HO
90 (x = OCH2)
OH O
OH
H O HO OH HO
H O
n OH
O O X
X
HO O
OH O
OH
OH 91 (x = CH2) 92 (x = OCH2)
reagents and conditions: i) N-methyl 2-chloropyridinium iodide, DMAP, Pr3N, CH2Cl2; ii) HF, pyridine; iii) RuCl3, H2O, 55oC.
Figure 4.50 Multivalent neoglycopolymer binding to Con A tetramer and structure of neoglycopolymer presenting carbohydrate ligand to Con A.
4.1.16.6 Poly(oxanorbornene) Presenting Glucosides. Mortell et al. at the University of Wisconsin [507] reported the synthesis of polymeric, polyvalent glucosides derived from a 7-oxanorbornene monomer. Theirs syntheses are based on the polymerization of a 7-oxanorbornene glucoside catalyzed by a ruthenium metal complex in aqueous solution (Figure 4.50). A neoglycopolymer (89) presents multiple glucosides attached to a polymer skeleton in the aconfiguration preferred for Con A–binding. The C-glycosidic linkage o¤ers resistance against the chemical and biological hydrolysis that occurs with natural O-linkages. This neoglycopolymer strongly inhibits Con A–mediated ag-
216
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
glutination of erythrocytes, with an IC50 value of 25 mM, a 2000-fold activity enhancement relative to methyl a-d-glucoside or 88. However, a second neoglycopolymer (90), whose glycoside ligand is attached through an O-linkage with three atoms of distance, shows only weak activity, with an IC50 value of 2 mM (Figure 4.50) [508]. The inhibitory activities of these polyvalent neoglycopolymers are controlled by a combination of several molecular parameters, such as the intrinsic a‰nity of the monovalent ligand, the nature of the polymer–ligand linkage, and the length of the polymer–ligand spacer. For instance, the equivalent polymer possessing fucoside as the side chain is inactive. Additionally, the neoglycopolymer 91 presenting a-mannoside—a better ligand to Con A than a-glucoside—is highly active in the C-linked form, with an IC50 value of 0.5 mM, while the corresponding O-linked mannoside-presenting polymer (92) has an IC50 value of only 13 mM. Provided that tethered epitopes are able to span targeted carbohydrate recognition sites in the Con A tetramer, the size and ligand density of a glycopolymer comprise the major parameters that govern multivalent interactions. Kanai et al. [509], Strong and Kiessling [510], and Mann et al. [511] studied the e¤ect of the length of mannoside-presenting glycopolymers on the ability of Con A to induce hemagglutination (Figure 4.51). Glycopolymers (94) with various mannoside valencies (wmann ¼ 100%; valency ¼ n ¼ 10 to 143) are prepared under living ROMP conditions. This method allows the generation of
Ph H O
H O
Ph
PCy3 Cl Ru Cl PCyPh
N
H O
H O
CH n 3
H O N
ii
i
OH O
H O
N
3
O
n
O
OH
OH OH 93
O
OH O
OH O
OH
OH
OH OH
OH OH
94 (n = 10, 25, 52, 143)
95 (n = 10, 25, 52, 143)
Ph H O
H O
H O
N
H O N
+ O
OH O
OH OH
OH
i
O HO
PCy3 Cl Ru Cl PCyPh 3
OH O
HO
n H H O O
H O
H O
m
N
N O
OH O OHHO O HO OH OH
OH
O
OH
OH
96 reagents and conditions: i) H2O, ClCH2CH2Cl, DTAB, rt; ii) TsNHNH2, H2O, 100oC.
Figure 4.51 Synthesis of mannoside-presenting neoglycopolymers of varying length and density.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES
217
monodisperse polymers of defined length by varying the ratio of monomer to ruthenium catalyst. The inhibitory activity of 94 in Con A–induced hemagglutination increases exponentiallyin relation to the polymer length and the mannoside valency. For example, as the polymer size increases, the potency of 94 relative to monomer 93 is enhanced 100-fold (n ¼ 10), 300-fold (n ¼ 25), 2000-fold (n ¼ 52), and 2500-fold n ¼ 143). A neoglycopolymer (95) whose polymer backbone is made of a saturated chain, and thus is more flexible than the unsaturated backbone in 94, shows a similar trend in the relationship between activity and length. Such an exponential correlation is linked with multivalent binding, where the variation of length of the polymer makes it possible to achieve improved potency. 4.1.16.7 Poly(norbornene) Derivatives Bearing Two Types of Ligands. In a continuing study, Cairo et al. [512] reported a neoglycopolymer (96) prepared by copolymerization of a mixture of two di¤erent glycomonomers (Figure 4.51). This glycopolymer presents both mannoside and galactoside ligands as side chains. The role of the galactoside unit is to control spatial separation between neighboring mannoside ligands. This copolymer promotes the formation of Con A clusters through multivalent associations, as supported by data from a quantitative precipitation assay. The number of Con A tetramers bound per polymer molecule increases with a higher density of mannoside epitopes. For example, 96 (n ¼ 143, m ¼ 0)—a neoglycopolymer whose side chains are composed entirely of mannoside—binds 16 Con A tetramers. However, 96 (n þ m ¼ 116) has a mannoside density of 10% and binds three Con A tetramers. In terms of cluster stoichiometry calculated on the basis of mannoside available per Con A, a glycopolymer (96) with a lower epitope density binds more e‰ciently, by using fewer epitopes, than the equivalent glycopolymer with higher density. This concept is illustrated by calculating the number of mannosides bound per Con A tetramer: The molecule with 100% mannoside density binds nine mannosides per Con A, while the molecule with 10% mannoside density binds only two mannosides per Con A. The clusters of Con A bound by the mannoside-containing glycopolymers can be visualized by transmission electron microscopy (TEM) using biotin-labeled Con A and streptavidin-presenting gold nanoparticles, where the glycopolymer promotes the aggregation of gold particles in dimers and trimers [513]. 4.1.16.8 Glycopolymer-Mediated Cell–Cell Adhesion. Through its multiple sugar-binding units, Con A promotes the aggregation of mammalian cells that display multiple copies of diverse glycans terminating in mannoside (Figure 4.52). Such cell aggregation is also possible in the presence of lectin clusters induced by a neoglycopolymer. Gestwicki et al. [514] demonstrated that a mannoside-presenting glycopolymer, 97, induced Con A clustering with a stoichiometry of four to six Con tetramers per polymer. Thus, upon incubation with Con A and Jurkat cells, this glycopolymer mediates cell–cell aggregation more e¤ectively, with a 60% enhancement over that of Con A alone. The gly-
218
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
cell Neoglycopolymer 97
Glycan Con A tetramer
cell
Ph HO HO HO
OH O O
H O HN
ROMP HO HO HO
H O
OH O
n 97 (n = 142)
HN O
Figure 4.52 Lectin-mediated cell–cell aggregation mediated by neoglycopolymer.
copolymer itself induces such cell aggregation poorly, through a mechanism that involves the mannose-binding receptor. 4.1.16.9 Mannosides Displayed on Self-Assembled Monolayers. Presentation of carbohydrate arrays on self-assembled monolayers (SAMs) on a gold surface serves as a convenient system for mimicking natural cell surfaces that display diverse arrays of complex carbohydrates. Houseman and Mrksich [515] reported a versatile chemical strategy based on specific chemical reactions occurring on the surfaces of SAMs. This approach utilizes a mixed SAM that presents multiple terminal hydroquinones on the background of a SAM containing penta(ethylene glycol). This biologically inert surface inhibits nonspecific protein adsorption (Figure 4.53). The next steps include the oxidation of hydroquinone to quinone and reaction with a cyclopentadiene–mannoside conjugate via a Diels–Alder reaction, which leads to a mannoside-presenting SAM on gold. Mannose ligands on the surface of this chip bind Con A with an IC50 value of 55 mM when assessed by SPR. This strategy may be used to introduce other carbohydrates to the SAMs and to perform enzymatic modification of the exposed carbohydrates. 4.1.16.10 Multivalent Galactosides Binding to Bauhinia purpurea Lectin. TentaGel is a commercial resin made of ethylene glycol–grafted polystyrene. The gel is commonly used as a solid support in the solid-phase synthesis of oligosaccharides. Liang et al. [516] reported that this resin is useful for synthesizing a multivalent carbohydrate library and for on-bead screening where sugars are displayed on the surface of resin in multiple copies. One such example is shown in Figure 4.54, where disaccharide Gal-b1,3-GalNAc-b-SPh residues are synthesized on the surface of TentaGel beads. The disaccharide-displaying resin
219
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES HO HO HO
OH
H N
O O
O O O
HO
O
O OH
HO
HO O
O O
O
O O
S
O
O
O
O O
O O
S
S
O
i oxidation
S
S
O
O O
O O
S
O
O O ii Diels-Alder reaction
S
S
O
O
O O
O
O O
OH O
O
O O
S
HO O
O
O O
HO
O
O
O O
O
O O
OH O
O
O O
S
HO
HO
OH O
O
O
O
O O
O O
O O
O O
O O
S
S
98 reagents and conditions: i) excess 1,4-benzoquinone, H 2O; ii) mannoside-cyclopentadiene conjugate, H2O.
Figure 4.53 Preparation of carbohydrate chip based on self-assembled monolayer.
(99) binds Arachis hypogaea lectin, which recognizes Gal-b1,3-GalNAc as a specific ligand and induces aggregation as a result of multivalent lectin–ligand recognition. The sugar-coated resin also shows a‰nity to Bauhinia purpurea lectin, which recognizes Gal-b1,3-GalNAc-b-SPh. Such recognition is selective to Gal-b1,3-GalNAc-b-SPh present on the bead and thus does not occur with beads that contain altered disaccharides such as Gal-b1,3-GlcNAc-b-SPh and molecules with altered stereochemistry, such as b to a, at the anomeric GalNAc linkage. The avidity between the B. purpurea lectin and Gal-b1,3-GalNAc-bSPh presented on beads is influenced by the surface density of the disaccharide. In a related study, Horan et al. [517] addressed the e¤ect of surface density by using SAMs on gold (100) with SPR analysis. The a‰nity of lectin to sugardisplaying SAMs varies with epitope density, and tighter binding is observed at a low density (wsugar ¼ 0.1) rather than a high density (wsugar ¼ 0.6). This result may point to steric congestion, which is likely to occur at higher surface density. 4.1.16.11 Dendritic Sialosides Binding to Limax flavus Lectin. The L. flavus lectin binds to the human a1 -acid glycoprotein (orosomucoid), which presents sialic acid–terminated carbohydrates as the epitope required for such interac-
220
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
Ph
Ph
O O O
AcO
S
N3
OH
O
PivO
Ph OPiv O
TentaGel
OPiv
S O
HO
OH O OH
HO O
OH
HO O
n
OH O
S NHAc
H N
O
n
O
HO
HO
iv-vi
H N
N3
OH O
iii
H N O
HO O
S O
O O O
O N3
H2 N
O
PivO
HO
i,ii
+
O O
99
O
OH O
n
Au
S NHAc
O
H N
O
N H
O
O
O 6
S
100
reagents and conditions: i) HOBt, HBTU, DIEA, NMP, rt, 12 h; ii) H2NNH2, DMF, rt, 9 h; iii) Gal-(OPiv)4-1-SOPh, (CF3SO2)2O, DTBMP, CH2Cl2, -60oC to 0oC; iv) HSCH2CO2H, rt; v) 20% TFA in CH2Cl2, rt; vi) LiOH, 80% MeOH, THF, rt.
Figure 4.54 Synthesis of multivalent Gal-b1,3-GalNAc-b-SPh presented on either TentaGel resin or a self-assembled monolayer on gold.
tion. Zanini and Roy at the University of Ottawa [518] reported the synthesis of a glycodendrimeric construct that displays multiple copies of a-thiosialic acid tethered to a dendrimer sca¤olding made of a 3,3 0 -iminobis(propylamine) core (Figure 4.55). These glycodendrimers include tetra- to dodecavalent sialosides. A dodecamer (101) is the most e¤ective molecule in inhibiting the binding of L. flavus lectin to orosomucoid, with an IC50 value of 8.2 nM (98.6 nM per sialoside residue). It is 182-fold more potent than monovalent sialic acid, NeuAc-a-N3 . A second type of sialodendrimer is the spherical dendrimer designed on the Starburst PAMAM sca¤old, as exemplified by 102 (Figure 4.56). With an IC50 value of 1.13 nM (36.2 nM per sialoside), this 32-mer shows better inhibitory activity than the 12-mer (101) [519]. Dendrimers analagous to 102, with valencies lower than 32, are less active by one order of magnitude: 16-mer > 8-mer > 4-mer. Other glycodendrimers include starburst dendrimers that present lactosides or galactosides. Their ability to inhibit the activity of plant lectins is a¤ected by the size or generation of the dendrimer and the binding-site orientation of the lectin [407,519]. 4.1.16.12 Dendritic GlcNAc Binding to Wheat Germ Agglutinin. Zanini and Roy, and Baek and Roy [519], reported the synthesis of oligolysine-based dendrimers that display multiple GlcNAc residues (103 and 104). These dendrimers are prepared by a solid-phase synthetic method, using Wang resin (Figure 4.57). The GlcNAc dendrimers show a‰nity to wheat germ agglutinin
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES CbzHN H N
N CbzHN
NH2 O
O H N
+
OH
i-v
N
H 2N
NH2
N
CbzHN
N
O
CbzHN AcHN OH HO OH OH OH AcHN HO O HO CO2HO O CO2 S S O HO OH AcHN CO2HO O HO S HO
OH
CO2-
O H N
HO NHAc OH HO OH O
O NH NH N O NH
NH
O S AcHN O OH OH
N
N O
NH
CO2- HO NHAc HO OH O NH OH O S CO2NH S
O
HN
O
N
N H
O
O N
N
N H
NH
HN N -O
HO HO AcHN
2C
O
O
N
HN
S O HN O O OH -O2C S OH O HO OH HO OH NHAc
O
O
HN
N H
N
O
N HN
N H N H
S
OH NHAc
OH CO2- OH
O S
-O
HO O
2C
OH OH NHAc HO OH O
HN O O S
S O2C O OH O OH OH NHAc HO OH HO OH HO NHAc
-O
2C
101
reagents and conditions: i) DIC, HOBt, DIPEA; ii) H2, 10% Pd/C, MeOH; iii) (ClCH2CO)2O; iv) methyl 1-α-SH-sialic acid (OAc)4, Et3N, DMSO; v) NaOMe, MeOH, rt; then 0.05 M NaOH, rt.
Figure 4.55 Synthesis of tethered a-thiosialic acid–presenting dendrimer.
221
222
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
AcHN OH AcHN OH HO OH OH HO OH HO O AcHN OHHO O HO CO2CO2HO S AcHN OHHO O CO2- S HO - S NH HO OH HO O CO2 NH S AcHN S NH S NH NH HO O CO2 NH S NH HO OHHO HN HN S NH S O O AcHN HN O NH CO2HO O O HN N S NH HO S NH HO OH O N NH HN NH S AcHN CO2O NH O HN O HO NH N S HO O NH O NH S N HO OH HN H H CO2O N N AcHN H O O HN O HO S N N N HO S O N H O N N H NH O O HO OH
CO2-
O S AcHN OH OH
H H N N S H H N N
O N HO N H O
N
O
H N O
N
N
NHAc OH OHHO NHAc OH O OH HO NHAc HO CO2- O OH S -HO OH S CO2 O HO NHAc S CO2HO OH O OH S NH NH S CO NH S HO 2 NHAc NH S NH HO OH HN O NH S OH S NH OHN CO2- HO O HN NH HO NHAc N OHN S O OH NH S N O NH - OH CO2 HN O NH S O NH HO HO N O H NHAc N H N N S O N H O OH S O CO2- OH H NH N N N HN HO HO H N O H O N OH S O NHAc S HN N N -O C N N N OH 2 H O OH O H H HO
HO
HN N
O N
NH
O HN
N
H N
O
H OH S N S OH O N N O NHAc -O C H 2 H NH N S HO OH HN O HN O OH S N HN OH O NH O HN O O2C NHAc S HN HN NH N O HO OH HN S OH N HN S O NH O OH O2C O NH HN NHAc O O S S HN NH NH HO OH OH HN S HN O2 C O OH HN HN HN S S NHAc S HO OH HN -O C HN OH O 2 S OH S O2C O OHHO NHAc S HO O2C O2C OH O OH HO O OH HO NHAc OH HO HO OH HO NHAcHO NHAc
NH O
O O NH
NH
HN HO -O2C S HO O H N N H N O S N AcHN O N H HN O OH OH S NH -O C HN O 2 HN O HO N S HO HN O S NHO N AcHN OH OH -O C HN NH O 2 O HN S HO NH S HN O NH HO HN S HN AcHN OHOHO2C S HN S HN HO O HN S -O C HO OH S 2 AcHN OH O -O C S HO 2 OH S HO O O 2C OH HO OH AcHN O OH HO OHHO NHAcHO OH NHAc
N
N O H
N
102
Figure 4.56 acid.
Structure of 32-valent PAMAM-based dendrimer presenting a-thiosialic
(WGA), which recognizes the GlcNAc ligand. The dendrimers inhibit WGA binding to GlcNAc-containing porcine mucin, with IC50 values of 0.51 mM (103) and 0.088 mM (104). Such activity by GlcNAc dendrimers represents at least a 25- and a 170-fold enhancement, respectively, relative to monovalent allyl a-d-GlcNAc. 4.1.16.13 A Cyclodextrin-Based Multivalent Glucosides Binding to Pisum sativum Lectin. Garcı´a-Lo´pez et al. [520] reported the synthesis of b-cyclodextrin–based heptavalent glycosides, which are prepared by per-glucosylating the primary hydroxymethyl groups of b-cyclodextrin (Figure 4.58). The biological activity of these cyclodextrin-based glycosides is demonstrated by
223
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES HO HO HO
O H O O S N N N NHAc H O H O HO H O O HO N S HO N N NHAc H O H HO HO HO HO HO HO
HO HO HO
O S NHAc
O S NHAc
HO HO HO
O S NHAc
O S NHAc
O N H
O
NH
HN O
O
NH
O
HN
O O
HN O
O
N O NH H
O N H
O OH
H N
NH
O
N NH H
104
Figure 4.57 drimer.
O
O N H
O
O
103
OH
H N
H N O
O
N NH H O
O
O
O
HN
O
O
H N
H N
O N H
N H
N H
O
H N
O
O H O O S N N N NHAc H O H O HO H O O S HO N HO N N NHAc H O H HO HO HO
O
H N
H N
N H
O O
H N O
H N
N H
O
AcHN S O
AcHN S O
H N
N H
OH OH OH
OH OH OH AcHN S O
O O H N
O
OH OH OH AcHN OH S O OH OH
Structure of tetra- and octavalent GlcNAc presented on oligolysine den-
inhibiting P. sativum lectin (pea lectin), which recognizes d-glucoside and dmannoside as ligands. For example, 105 shows an IC50 value of 90 mM, an activity about 105 times greater than that of methyl b-d-glucoside, or 15 times greater per glucoside. The second molecule (106), composed of glucoside tethered to cyclodextrin, with a shorter spacer, shows poor activity, with an IC50 value of 870 mM. Synthesis of a heptavalent sialoside displayed on the rim of bcyclodextrin is also reported [521]. 4.1.16.14 Oligovalent Mannosides Binding to Dioclea grandiflora Lectin (DGL). A lectin from the D. grandiflora seed recognizes a trimannoside epitope presented through an asparagine linkage to a glycoprotein. Brewer et al. at Albert Einstein College of Medicine studied the thermodynamic basis of DGL binding to oligovalent trimannoside by using microcalorimetry [2,41]. The divalent (108) and tetravalent (109) molecules present multiple trimannosides attached to an aromatic core (Figure 4.59). Because of the relatively short distance between neighboring trimannosides, individual epitopes are unlikely to bind simultaneously to multiple CRD sites present on a lectin oligomer. A reference monomer (107) binds DGL in 1:1 stoichiometry, with a K a value of 39 10 4 M 1 . Increasing the ligand valency to two (108) and four (109) leads
224
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS HOOHOH
HO OH HO HO
HO O
O S
S O
HO HO HO
O
H O N
S
NH
O O
NH
O OHHO O OH
O HO
OH
O HO
O
HO
O
HO
OH O 105 HO OH O HO O OH O OH OHHO HN O O HN O O S HN O
O
S
N O H
O OH
S O
S
OH HO HO OH
O
O
OH OH OH
OH OH OH
OH
OH OHOH HOOHOH
HO OH HO HO
HO
O
O S
O OH HO HO HO
O
O S
OH
O
S O OHHO
O HO
O HO
HO
OH O 106 HO O OH O HO O OH HO O OH OH S O O S O O O HO OH S OH HO O OH
S
OH OH OH OH O
OH OH OH OH
OH OHOH
Figure 4.58 Structure of dendritic glucoside based on b-cyclodextrin core.
to 15- and 166-fold increases in binding a‰nity, respectively, with respective K a values of 6 10 6 M 1 and 6.5 10 7 M 1 . Based on thermodynamic parameters, the enhanced binding results mostly from favorable binding enthalpy, such that the DH value observed per multivalent molecule is very close to the sum of DH values contributed from individual epitopes from a multivalent ligand. Unlike binding enthalpy, binding entropy does not contribute favorably to the multivalent association. Therefore, it is likely that the multivalent ligand binds multiple independent CRD sites from separate lectin molecules.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES HO HO HO HO HO HO
HO HO HO
OH O O HOO
HO HO HO
OH O
HO HO HO
OMe
O OH
HO HO HO
107 HO HO HO
HO HO HO HO HO HO
HO HO HO
OH O O HO O
OH O O
O OH OH O O HO O
O OH OH O
NH S
O OH
CO2H
S
OH O
NH NH O
O
O OH
108 OH O O
O
O NH HN
NH
S
S HN
NH
HN
NH O
O HO
S
S OH O
O
HN CONH- (CH2)6 -HNOC
O HO O
O NH
OH O O HOO
225
O
O
O
109 O HO
OH O OOH O
OH OH OH
OH OH O HO OH OH O OH OH OH OOH O OH OH O HO OH
Figure 4.59 Structure of multivalent construct presenting trimannoside.
4.1.16.15 Polymeric Polyvalent Lactosides Binding to Psophocarpus tetragonolobus Lectin. A biotin end-labeled multivalent glycopolymer serves as a tool in the microfabrication and engineering of biosurfaces, especially when designing a device for detecting lectins and antibodies. Sun et al. [522] reported the synthesis of a biotin-terminated poly(acrylamide) with lactoside side chains (110, Figure 4.60). This glycopolymer is selectively immobilized to the portion of the surface that is microfabricated with streptavidin, and the resulting glycopolymer surface recognizes in turn the galactoside-binding lectin of P. tetragonolobus. The lectin adsorption occurs selectively on the region microfabricated with glycopolymer. 4.1.16.16 Resin-Displayed Multivalent Galactosides Binding to RCA Lectin. Micrometer-sized beads that present specific carbohydrates on their surfaces are used in flow cytometry to screen sugar receptors. Vetter et al. [523] reported this method, which is based on synthetic sugar-coated TentaGel beads approximately 10 mm in diameter, which present multiple copies of lactoside (111) (Figure 4.61). The glycoconjugated beads bind the fluorescence-labeled Ricinus communis agglutinin (RCA120), a lectin that presents on its B-subunit three galactoside-binding sites [524]. Fluorescence-activated particle sorting makes it possible to detect the complex of fluorescence-labeled RCA120 with the glyco-
226
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS O HN
O NH
NH2
H N
S
HN
NH
i
N2+
H N
S
O
ii
BF4-
O
O HN
NH
•OCN
H N
S
+
OH HO HO O HO O HO HO
O
O O OH
O
iii
N H
radical initiator O HN 110 (χLac = 10/70 per polymer)
NH H N
S
O O O O O O O NH2 NH2 NH NH2 NH2 NH2 NH
O
HO HO HO
HO O OOH OH
O
O
OH HO HO HO
HO O OOH
O
n
O OH
OH
reagents and conditions: i) NaNO2, HBF4, H2O, THF; ii) NaOCN; iii) acrylamide, H2O, THF, 50oC.
Figure 4.60 Synthesis of polyvalent polymeric lactoside terminated with biotin.
conjugated beads and to isolate the bound beads from the unbound. The lectin–sugar recognition is ligand selective, such that beads presenting nonlactosides, such as sialyllactose and LacNAc, do not associate with the RCA lectin. 4.1.16.17 Liposome-Based Multivalent Galactosides Binding to RCA Lectin. Liposomes are commonly used to present multiple copies of a sugar ligand on a cell-like surface. However, the nature of ligand presentation, either as a cluster or as a simple sugar monomer, influences the biological properties displayed by
OH HO HO O HO O HO HO
iii
O OH OH
i,ii
OH HO HO O HO O HO HO
OH HO HO O HO O HO HO
H O N OH O
H O N OH O
O
O O
N O
O N H n
TentaGel
111 reagents and conditions: i) aq. NH4HCO3, 5 d; ii) disuccinimidyl suberate, HOBt, DMSO; iii) H2N-TentaGel, DMF.
Figure 4.61 Synthesis of lactoside-presenting TentaGel resin.
CARBOHYDRATE-RECOGNITION RECEPTORS ON CELL SURFACES HO HO HO
O
O
O O
CH2
O
HO
C18H37
+
CH3
H m
m = 3, 12
O O O
CH3
CH3
CH3
N C18H37
CH3 CN
CN N
CN
C18H37 N C18H37
N
i
O
O N
OO
O O
OO
O
O
O
O OH
O OH
O OH
O
OH HO HO HO HO HO OHHOHO HO OH OHOH
227
CH3
CH3
CH3
112 (degree of polymerization = n = 6, 15)
Galactoside
ii liposomal membrane
reagents and conditions: i) THF, 70oC; ii) DMPC, sonication.
Figure 4.62 Preparation of liposome presenting oligogalactoside cluster.
liposomes. Liposomes that present sugar clusters more closely mimic a natural cell surface because carbohydrates present on cell surfaces are expressed as clusters. Kitano et al. [525] studied such multivalent liposomes with respect to their ability to bind to the RCA120 lectin. For example, sonication of 1,2dimyristoylphosphatidylcholine (DMPC) lipid with an amphiphile terminated with a block of multiple galactosides (112) induces the formation of liposomes displaying multiple sugar clusters (Figure 4.62). Upon addition of RCA, the solution of liposomes composed of 112 becomes turbid, due to RCA-mediated liposome–liposome cross-linking. The turbidity change increases in exponential fashion upon an increase in galactoside-terminated lipid density on the liposome surface. It also depends on the degree of polymerization of 112. At a low molar ratio of 112 to DMPC, the liposomes show a more rapid turbidity change, with higher degrees of galactoside clusters, on the order of m ¼ 12 > 3. At a high ratio, the liposomes show a gradual decrease in turbidity change. Thus, steric congestion occurs on liposome surfaces that are overloaded with galactosides, which blocks the binding of lectin and cross-linking. 4.1.16.18 Multivalent Display of Saccharides on Microtiter Well Surfaces. Diverse sets of specific carbohydrates can be displayed on the surface of 96-well microtiter plates to enable screening for corresponding carbohydrate receptors. Bryan et al. [526] developed one such method, based on hydrophobic interaction, that allows noncovalent anchorage of simple carbohydrates to microtiter
228
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS OH HO O HO HO
i O
OH HO O HO HO
ii
O
HO HO HO HO OH HO OHHO OH HO OH HO O HO HO
O HO
O HO
O
O
O
O
iii
O
(CH2)8
(CH2)8
(CH2)8
113
surface of microtiter plate reagents and conditions: i) CH2=CH(CH2)10CH3, Cl2Ru(PCy3)2=CHPh; ii) H2, 10% Pd/C; iii) loading on microtiter plate, washing.
Figure 4.63 Multivalent display of saccharides on a microtiter plate.
surfaces. For example, a galactosyl lipid (113), which is synthesized via olefin metathesis, is adsorbed to microtiter surfaces and displayed in a multivalent fashion (Figure 4.63). This glycosurface recognizes the ricin B chain in ELISA. Fazio et al. explored this display strategy further to optimize the presentation of diverse oligosaccharide arrays on microtiter plates [527]. A second example is based on a copper(I)-catalyzed 1,3-dipolar cycloaddition occurring at the interface of a sugar-containing alkyl azide in solution, and alkyne lipid adsorbed on the surfaces of microtiter wells (Figure 4.64). For example, an azide tethered to a trisaccharide (114) reacts with an -alkyne lipid presented on the surface. This reaction leads to regioselective formation of a 1,4-triazole, and as a result, covalent attachment of the trisaccharide sugar to the well surface. The linked carbohydrate is converted further to a sialyl Lewis x residue, through enzymatic fucosylation. This approach makes it possible to display 11 di¤erent sugars, ranging from mono- to tetrasaccharides on microtiter plates.
4.2 PEPTIDE AND HORMONE RECOGNITION RECEPTORS ON CELL SURFACES 4.2.1
CD14 Glycoprotein
4.2.1.1 Poly(acrylamide) Displaying Muramyl Dipeptides. CD14 is a surface receptor present on monocytes and macrophages that induces the production of proinflammatory mediators such as TNF-a and IL-1 [528]. It is anchored to the cell membrane through glycosylphosphatidylinositol (GPI). Exposure of CD14 to bacterial cell wall components initiates the proinflammatory response,
229
PEPTIDE AND HORMONE RECOGNITION RECEPTORS Sialyl Lewis x AcHN HO
OH OH
HO O
CO2O
HO 114
AcHN HO
HO O
OH OH O
AcHN HO
HO
- + N N N
O
NHAc O
1,3-dipolar cycloaddition N
i
O
OH OH OH OH O O HO OH OO HO
O OH HO
O N N
O
NHAc O
enzymatic fucosylation N
ii
N N
O
O NH
CO2O
OH OH O
NHAc
OH OH
HO O
CO2O
O OH HO O
OH OH
NH
NH
microtiter well reagents and conditions: i) CuI (5 eq) , DIPEA (5 eq), MeOH; ii) GDT-fucose, fucosyltransferase, 37 oC, 1 h.
Figure 4.64 1,3-Dipolar cycloaddition-based multivalent display of sialyl Le x on the surface of a microtiter plate well.
which invokes liposaccharides (LPSs), peptidoglycan, and lipoteichoic acid. Siriwardena et al. [528] elucidated the mechanism involved in such CD14 binding and the structural features of the CD14 ligands by using neoglycopeptide polymers composed of multiple cross-linked muramyl dipeptides. These polymers mimic the bacterial peptidoglycan layer. The synthetic polymer is made of a poly(acrylamide) backbone that presents pendant muramyl dipeptides on the side chains at varying densities (Figure 4.65). When allowed to interact with monocytes, the polymer (115) induces the production of TNF-a in a dose-dependent manner, while the monovalent muramyl dipeptide or underivatized poly(acrylamide) fails to induce TNF-a production. TNF-a production is inhibited by an anti-CD14 monoclonal antibody. 4.2.2
Major Histocompatibility Complex
4.2.2.1 MHC Peptides Tethered to a Peptide Sca¤old. MHC proteins are expressed as heterodimeric glycoproteins on the surface of antigen-presenting cells (APCs). An integral part of the immune system, the MHC complex displays peptides derived from foreign antigens in an array of MHC–peptide
230
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS NH2
HO O
OH O O NHAc O H O N N H O
S
n O O OR OR O
O +
NH2
R
O
O N
Et3N, DMF; then NH4OH
CO2H
n O O O NH2 NH NH2
HO O
OH O O NHAc O H O N N H O
S 115 (χpeptide = 4, 8%) NH2 CO2H
Figure 4.65 Synthesis of petidoglycan-derived neoglycopolymer.
complexes on the APC surface [529]. The MHC–peptide complexes are recognized by antigen-specific T-cells in a process that initiates T-cell activation. APC-T-cell recognition occurs through multivalent interactions between an array of T-cell receptors and an array of antigenic peptides presented in the context of the MHC (Figure 4.66) [530]. In a study involving oligomerization of MHC proteins by biomimetics, Cochran and Stern [531] provide insights into the molecular basis of T-cell receptor binding and activation by multivalent MHC–peptide complexes. Multiple copies of the MHC HLA-DR1 protein were attached to a peptide framework, providing dimers (116), trimers, and Cell
MHC Antigenic peptide
T-cell receptor
T Cell
multivalent MHC
T Cell
Figure 4.66 Multivalent association occurring between arrays of MHC and T-cell receptors and that for artificial multivalent MHC.
231
PEPTIDE AND HORMONE RECOGNITION RECEPTORS 45 Å MHC peptide (HLA- DR1) S O N
HO
O
O
O
S O
O O
O
NH
N
NH
CO2H N
HN S
H O H O H O H O N N N N N N N NH2 H O H H O OH O OH O CO2 116 (divalent)
50 Å
S
S O
HO
O
O CO2 H N
HN S
O
N
S
S O
O O
O NH
O
O
N O
O
NH
N
O
O NH
N
NH
-
H O H O H O H N N N N N N N H O H O H O O OH OH CO2-
HO OH H H O H O H H O H O N N N N N N N N N N H O H O H O H O O O OH OH CO2CO2-
O
H O N NH2
117 (tetravalent)
Figure 4.67 Structure of multivalent MHC peptides tethered to a peptide backbone.
tetramers (117) (Figure 4.67). These multivalent MHC proteins bind to the surface of T-cells in a competitive binding assay, with IC50 values of 1.8 mM (116), 0.31 mM (trimer), and 91 nM (117). Thus, the binding a‰nity is valencydependent, as illustrated by about a 41-fold enhancement by the tetrameric MHC–peptide over the monovalent MHC–peptide. The multivalent MHC– peptide molecules are also functionally active since they can induce T-cell activation under conditions not possible with monomeric MHC–peptide complex. 4.2.3
Integrins
4.2.3.1 Poly(norbornene) Presenting RGD and PHSRN Sequences. Extracellular matrix proteins such as fibronectin can attach tightly to cell surfaces. The cell–matrix adhesion is attributed to the specific interaction of integrin receptors on the cell surface with a matrix component, the RGD peptide ligand [532]. This attachment is tight because multiple RGD domains bind simultaneously with multiple integrin receptors. Multivalent synthetic molecules that present the RGD peptide mimic natural RGD-containing proteins by their
232
MULTIVALENT MOLECULES APPLIED TO CELLULAR TARGETS
O
O
H N
N H
N H
O
O
O
H N
OH
N H O
O
n O
i,ii
O
O
HN
HN
H N
O N H
O
HN NH O S O
H N
N H O
O
OH O
OH
HN HN
OH
O
NH2
O 118 poly(norbornene)(GRGDS) H2N
NH H N
HN O HO
O
H N O
O
N H HO
N H N
119 poly(norbornene)(GRGDS, PHSRN)
HN O
N O O
NH2 m
n O
n/m ~ 1
H N
HN O
N H
H N O
OH
O N H O
OH O
OH
HN HN
O
NH2
reagents and conditions: i) Cl2Ru(PCy3)(N,N-di-Mes-2,3-dihydroimidazole)=CHPh, CH2Cl2, MeOH, 55oC; ii) TFA, TIS, H2O.
Figure 4.68 Synthesis of poly(norbornene) presenting RGD-containing peptide.
ability to interfere with cell–matrix protein adhesion [533,534]. Maynard et al. at Caltech [534] reported the synthesis of polyvalent RGD, or RGD and PHSRN pe